var title_f40_8_41088="Mesothelioma MRI I";
var content_f40_8_41088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mesothelioma on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 286px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEeAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxIquB8o/KoxGmfuL+VSU62WJriL7RLJFbFlWWVULFAepAHX6UAV2hTP3F/Kk8lAPur+VdJ4F0WHxN4o0nSJLqWOS8uPLkWNPmSPGd4Y/LnPGPxrc+Lfgq28Ca/pemRX00q3dmLmSW4Ufuzu2kAL1FAHn3lL/dH5UqxLn7q/lWhexWFvq8sNtePqGnJKdtxAhjeSIH7wV/unHY1AiJlhlnZgPLEZB5z/FQAiRJ/cX8qkEa/wB1fyqaBYvMR5JGWAECQb18zpztU9eaPLmB2SYicKG2ynZkEZBGfWgBgRB/CPypGVeRtX8qsMIpJ1itpPlZU+edhGFbA389MBs4PoK07HQ2u/Ew0WG5t7h2dljuLWZZYmUdww4I+lAGDsXH3RTCg9B+Vd03gghMm+AOOdwFQL4MYk4uskegFAHDtEv90flSeSCfurXa/wDCG3TvsgEsrf7CZq7Y+Arp51jujdQMxwMwZ/pQBwCW6jnYv5VIsSj+EflX0BpHwElvbZZH1Z4iwyN0C4/lmuL8ffDr/hFLryn1SK5H+ymD+VAHnKouM7RShV/ur+VbaaMWXcJRz7U19IkTof0oAxWRcfdX8qjKL/dX8q6C30UzH5n2/hmoNa0n+zoopEmjkVuGUnDZ9QOpFAGBJGufur+VM8pcfcX8qsOORyu04GfSr02k3Nt9oFyioY7RrtcHO5Qyr+H3qAMjykz91fyqRIl/uj8q159Hljg88Sx+WsQkbIOQOP8AGnaFot9rV39m0yJZ7gQSXUkZO0xxoMkkn8OPegDLWNf7q/lUgjTI+Rfyq3BaPNJYhP8AV3Ii+fHA8xiB/I0v2VwzkkbVlePP+6cZoAq+XGf+WaflTTDH/wA81/Kt1tGcWwm81SD2CmorfR5ZzgMoHqRQBhtFHj/Vp+VRSQx/881/Kumn0CWJlBkQ57gGr8ngm4+zLKLy3IbouCKAOEMKZ+4v5UeUn9xfyrsrjwdcQweabmEg9hmq9p4XnnfHmIoHU4NAHLrAmf8AVr+VWEgj7xr+VejaT8MbvVZRFp15btMeiSZXP51V8ReANe8OuBqenOkZPEqKXQ/iKAOGEMY/5Zp/3zQYosf6tP8AvkVrXumXUVs1zDH50EalpWRf9WP9qkh0i8uxdizgeeSAoNkaliS3pQBjNFF/zyT/AL5poij7xp+Vathpkl3NYJ0N00y7cElfL65FJqdlDbXTQQS+YIow88qqSEJ4CkdjnA+poAx2ijP/ACzT8qjMMfeNP++a1tR0u4sbPT7meWzYX8XnRRRXCvKinp5iDlCc9DVRICyiWQPFbtuQTFCVaQKSEBHc4/CgCl5Mf/PNPyFKsMX/ADzT8qvSafeR6el5JbypbvP9nR2UgM+0tgevAqKOMeTLK0iqVICIVOZDnBwenHWgCIQRf88k/wC+ad5MXeJP++atx2rTpaCzLXNxNkNFGhLRtuwq+5PWmXULW95PbtjdE5Qk8cg0AQrDD/zyj/75oo3c9aKAFB6Gu98F+LNG0SwT7domr3QRiHmt5YxHyfRq4AdKlaRXCOqwR7FC5GA/A647/WgD6W8L/E3wvrms2+hWthqdskhYQ6g6osbsoz0HzDPoaxPjF8S9W0nUdO0bSJ7PyRELiS9urRbhsN0QIwIwOuRya8n8BJO+v6QFuo5I/MldbXzcmJgvLlP4c+verXxGvZZ9WsrQRwjyIlkR/LG9iw5Ut1KjsvSgDodB8Y3N7erB4lttNu7C/jcW2oW+nJauhUkONqgFlJBUhvrXSXVnoaaZHcafBp63KnKyxwKjL+IGa8z8IRWc3iHSl8uRr1obj7YpXCggnyyvb7m3OO9dBrCNp8iNbEiE/eU9qAOv0i+0PSokurzQtEv3Jy/m2Ubt9ckZznvXoF34y8D+IvKu9d8OWl5OE2CS6tI5mUdcAsCce1fPMt0yXAMTHy37V1GjtttiWZCG7E0Aeh+K9T8I6hZWtpp3h7RUtbcFYjLZR/ugSWIQY+UEknjqSa423uNJ0/UI5tO0ixgnUECeCEKwz1wahPmMn3SU9BzVeVnI+Rfl9xQBb1Ce3cF0iO09cHmsYsqsGt3cLn7tWUcByPLOPWnnynQ+QgL96AGQ6neW1wkttIYWXvmvU/CnxYmgCQ+IoFe3UYE8Y+YfhXkkzAr5aqfM9+lSJGfliuWTaR1FAHr3ib4zWslvJb+HbKeaVwV8+QbVUeoFeQyreavqBnnka5lY52elSuY4A0UB4PfNbfw717T9A1R5NTspb5iMIsK7sH6UAYV/aG2A8222Sf3RVDbHM4RUbf0C13fiq3uvEGpPqH2c6PYZyBONpIrM8PXXhbSNQa71S6+0eXnCqM7jQBh3FmLCNWlVg57VheK7WXy7S+ey8+08owFtzfu3JyGwvPAzx0NdN4s8UW2uXjyaZatHEDxx2qfRNduLe0ZvssgdRw6HBFAHmVtaSXFytnYr9unusRj/AEdotm0g5Ge5ArUbVYdUn1VvEuomzm+wvYW6Q6ezAESIV3bB0wrc9elev+GvHmpBTDqR+2WZ4aGTniui8S+ILHUNAeLR2nspWXBV3O0UAfObTG88MtPesJIYb2GE+XHt3R4bJx9B+tepfCS0t7bw1q+slpLu81aG5tYUaINLEioVjVXPzfNvAIz/AAL6Vq6Fe2WnaVJ5V3bz6oVIGw/NWPceI7yytZ3mcLct03UAeYW+rJZwWcdxF5Mdmbb7TA4/es8DSZ2n+EHzDwfSu/tvCSyeDNPuL2GazvbiSa5aGUYYI7ZTI+lYcPiW9F39pntoppCfvGIE/wAq7ay8QJeQrNfsZB3XOSKAOJgt5Y5WtSfkXpmrNnaXEVw25Q6D0rtrzwvHrMYv/D+q2qyDkwSHBrT8PaLZSca0fLlTgiPkNQB5vekyzYEZQA9q67wjZJqkRjldFxxz1FR+MLP7NMx022xEO7dSK5az1yS1nDRqYnHXB60AafiX/iX6g9mX3rnArHMbqmFJB68Hmupmt18RWBu4gnnxjnPJrBW3kiheZm2mL7wxQBJFqclpbpPFGzPGcllJBr6Y8B65b+K/CdrdmNWBXy5EcbuQO+a+adMb7erz20ZeLo4xXV/Dnxovgm+lgvoZjpFy2WZRkRt6j/CgDY+M/wAH7rWdQ0y78G6bZbFWVbuB5zDvJKlWB7fxdPavO/FHwk8c3V097F4X0+zXaA0Vjf8AmA4HXDc/lX1hYavp9/YpeWl5BJbONwcOMfj6VDceINIt/wDW6jaj6SBv5UAfFep6HrA0i0sD4citZLFpXN2ly7SPuO5gwJ2jGOMVmaDpY1y8htVlE3mD7TeyplXiXpsOeG5wcivs5pPCU8k8rTWbtLy+T1/CuQg8H+CzdzyWgs7ZnOMxRLHn8hQB4BrvhvVbzUdVki0Brv7VMskF3DMVMaAcoEztIPuMjtWcmg+LpdOl0WKw1J7IMJY7JzuCvuyWjXoCeckdRmtT4o6dp2n+L/FW/TkvJE1SOGORpXVYYzGWKkKRliQBz0rkbyCaHTkt7OeS40p4oLy4ghJ8qCaQY8tv9oEhc9eaAL994W8Q6Rp1zfXOk3Nhp9rJG7veoo3SMdgA9fvdPTmu2+FPwwm8ex3nn3Vxa6Npi+RbSxSebBc3J/1rpnoCeTtwM15jcRLDIypCNOkmZYntcO4KYz5hZie+OOvcVqaNPqOk3tw2jai+nXenLLdJcRvIVuGiBOCmdvOO4x60AbPib4deJPDOsahEdG1i4t7WTNvf2sOYnXqrE9vw6VyF75rXsst9FJHJK5dwF2kE+x6V9d+FPjLo2rpbwX0NxbyNAhkkkX5SxHOB6ZrwH42zx6h8SNVa0WL7DbyR20UVuoTcxXJbI689zQB5x9M4opCQRkdKKAHqcEGup0TUfDcFlGuowo9xk5LWRfHPHI61ynauo8J7klScbPM8yeBmdsgw/Z8mMqeME85xQB2Xg/U/DNzr6LaQoNQkDFZxCyHH8XX2qp8RtQs7PWYtM/s6z1FUVZjJeSNHHEHGRhlII988VzfgRLxNY0d2VI4TBcvbyBFDOASHyRycNkDPTtxV3xVqCRa3ri3ENvdvPZ2kSJKWByMHcu0g5FAFzwbqNrLqU9jaaVaWNxJGXWWymeVJFXkgs5PTtjFbXiG2e404jhD2BHU1y3geGD/hJLGa3ljSWa0unmgUk/ZyCVVeefmUBufWu3t5EmuEjuIyyg8GgDz62yA8Ew2uvKtW/wCH5zLmKR42degPGapeL47eDxCiwg4OMrTJLWS0v45ICpJ/gNAHXqHUYZevAAPFSxxFQQ6gKfWsTVdYuLGCMJahpm7YyBUtpb3l3ClzfXCw7uREpwaANSExMzKACRzgVXm8qSYCMCNehNEJtrfIcfMeNwNRuEA/dgkE9SOaANG4sbb7KptiWY9WPasu6t1QoQyEZ5BqcedFCAgyh/DFU7h0i5uZML2A70AN1WxuLkRvZSeSi/eNOsdWl0q4ifTj5t0pHzYzS29jfaghLy/ZNOHV2PJ+lW7fT4LcNJAwtbFP9ZdzHH5UAS+IdU1fX1WbX9SXyVH3OmB9K51J9GjfFvbS3ZH8JHBrN8U6/YSTeTpO+4ReDPKMbj7CuYmvbiTgysq+inAoA9ItdbVlMMVtp9iv91jgmuy8L2Q1OB4pWWPd0eM5FfPmSSc5J963fDniTUdEuFazuXjQHlc5H5UAe0y/DPxNa3QuLKOO6tTyCGw35VX1a1liia0uojbTY2t5nFVPC/x+1PTbuO31Wxhu7FmG6RCVkQdMjtXteunw74u8P295LIrwSgbZEI3rmgD5r/4RCSG7FxDdhGByGXtVbW9WMU3lagounXjdjFdv448Nar4RnS+0GV7zT3PSQZxXnfiG21S4cX15FFFG/OAMUAH2geR5yNti7rjtW74YutIv5PKhDpdnjDthTWTJHbtonmqSSF5GO9Z/hGyvbm/ZtLtVuXUZKGgD0CbQttyWN7FvPSOBua7Lw9ZPDCpkU57ZbcTXmenXmpS6oLSLTBbXDNtZgucV9JeAvC0ek2CXF6nm3jjdvc52j2FAHF6noF/rMXlxQrEDwHk4rldQ8D22h7v7WiFxI3KspyBXYfGHxlaW9t5FncTLMmQxX5VrwbU/iFqFxB5Bfeo/ibrQB2ujaOLG+Y287wJJ2524qLWLC/0+8YK8d7Zy9Qori9F+IM9k6rdQLcRg9DXcaf4h0jxM4FrcDTbr+7I3DGgCjbWzwqyaTqS2yPy8DDFMiKSo9pKCx/i9CavatpEnmhLqMRt1WePowrIjnktrg214oC9pV70ATpJgfZVaSBE6HecH8KdGX3bY28wrTERTMdkZkz6mrbWn2dPNUHcf4M9KAFiE7qTwrd+cUJNKDtV3LKckg9KWCNmG5ZAhP8JanMXR9olA9wOtAHGahcX134i1PTQ2pQrqGsJczSwPtV4whXJ9Tk5BPHFUfGGiQ6bYWH9mQ3rW5Li8uJm3NJKWymVXgADOOK9EeS7WPBkPlegY8/hT7eVVX93K0bkYPzYJoA8bsbW5njePTbFrxbR/tssiwlCEUYIP+z3p1vqDySXEcEAmlvY5beOARsphMp5Ib+Ln1r12S46nzZtsfIJY4Brhte1Zpp5BPLK6k4BLGgDP0G7kTxJawXN7dtIt0YZbbJ8pYgOoPTOe1N8b+fa+JL8XETxfaLj7VDK68OmMDHtW7pesxWlmqsDLM3CIBzU1wl7ckS6hI8MeMpBjmgDzQ9BRUl0MSvj1ooAEGSK7Xw74W0vUtPiluY5Gmbk4kI4BrjIuWHvXsXwyiil0+GO44G07SfXNAFOz8MaZpFwLmwguGutpUtJJkAEYPFVvE+h2l6kFzl4rqNduYiAxHufbtXUyCOG+nUyMT/B3qjcRCVSCVZifukYoA5rw9YWlrLI0CzvdvwZZm3MB3AxXUWsB81ZGJZgeg4xWS1s1ndRsY8RsedtdFaTRw3MUK8pIMAt2oA4zxnbI+oxzru809c9qylt7+6uEi05GmkPUqOld34xgj0qBt3lyyzD5O5FZ3hSKXTLGacMVuZhhR6UAPsNOjsbdUkPnX38RPRajmP7zbjfJ7VclaSKI+ev7+Q5yKhwEIAIjkJ6nmgBsQ2RktH83oad5gKjaGD+opZgyspl+ZvY087sbVVUB7GgCvNO0ceXfJqfRtKk1GcSXChk7ADmpdH02O5utkspINM8U+LbXw3G1npf728xjd2WgDe1lNO0CzW812ZWjQfu7VW+Zj9K8j8YeLbvxLOquiW1hH/qreMYA9z6msXUtRutTumuL6d5pW7sc4+lVOpoAdSGlpDQADrSr1pAKUfrQAE819G/suajb39nqWj3iRyNEBIgfk7Se1fORrsfhRrt3oHiyC5sSN7KUZT3FAH1p400eFNHkkgkCJENxhkbKsPbNeEeOZrLWdPUadbrC8fDrnqak8Va7Lq2oyS3EkkTN1Bc4/Kubt9OjlSVorpi3PA70AZ0TqmmtbheMc5rT+EqLZ+IZZbhzHb7CCQa5e+na3laGctj6Ve0qHUDtNo4RG9T1oA9p8Cadd634ju3tIkWxjbmaTG4fSvVfEOqWnhPwzPcXVwQsaEKznJLYrwHwD4g1DQtZWMTrlvvL2asb44fEK88QXC6WAIreHllXjJoA4bxr4mm17U5piSUZjjrXLk0rHNMJ5oAM0qsynIJB9abQetAHdeFPGlxAsVhqksktnu9cn6Z64ru7vTra4hE9vdh0YZVe4rwsHaRiul8M+KZdKmUXKefB0IPUD2oA9Dtxc2aFwdwB4NWxftOBlg0g7eg71Db3trrFgZtOkG09UB5Wqgt3jGA+fUDrQBqx6hJHIypFBKQPTpUUd05Mkk7xoc9AvAqBbfMTC2yMjD5PNV4N8cYjZyyJ13Dk0AXvPgb5GlUs33QDUOwKCmDJIeQQM1U1O3a82yWCiG5jGRu4Bqzodz4klSaOU2MbIMbpBgkfWgDG8SajJbWjwBlRiRxjtjmuQ3iSHzZirKnQEYya3r7T7m6vJHvZBwTnByDWPeR/bNWhtIEXylP8NAGt4T0xmY6pdhljU4jXGa6a/kj2kuryM4+838NXVmhS0hto1+SJeexBrPuw0kDSXDkJzhO5oA8iu+J3x60Ut2MTuOOtFABF94fWvUfCUoXRLZOQ3PP415fD94fWvS/CW0aREZlbaQQCpoA6QyJuCSn5+zCoCMzhUkzJnvUiCGFAFyVPrzTWSMzBkO0+ooALtvLixK4B9CKjkuLZbWJrhA7Z+XHBrA8S3L2s4aSRpF7A9qd4ZsjqVx9pvLsJHHyFoAn8Ry/abq1V5QRjKp3rRQeY0SxqcqP4q5XUrj7T4hCIcopwCtdfBHMib1Ybsd6ACaQXGVfajqMc1UCM0q4XOPWkkjklmLygZ7CppIpwAMHJ6AUAPlSSV1AAjUetQFPKn3TZb0wam1GT7PbImC10/RetZus3H9jaV9ovAftT8RxntQBV8ReJV0yNodO4nfgt6V53cSyTytLKxd2OSSafczyXErSSnLE81C1AB1xR9aBRnmgB1IfSlppoAB1pwpFzmnLQAlXNJvJ7C+jntjiVTgZFVQpdsKCW9AK6Lwp4avdW1GFTC8cAYFncYoA9W0bwpLf6Suq6xG6hxuBUVcs9PtRCYoVAzwMLzXbRatDZeGRYEq5RNo3VzGkgu0kkh2c8KOlAGHL4GhurkTSjeg54rTOkWFrH++iVIUGM1voqRwM4dt5/umqOqWwvrOOBVHzN8xz1oA5q68NXEVrca5YW0sttGpO9T0rw/VLuW9vpZ5mLMzE8mvpX4seMLLQPh8NC0b93cTRiN8HoO/518vkk0AIaZ3pWzSUABoNB9qKAChaPagUAaWhatcaNfJc2x5B+ZT0YV6jDq1jrEMdykflzY+cKehrxytbw5qjaZqCSMSYScOvYigD0+2/0qQmMMsadWB61I+ZAwDoAOlZTTKmy/wBLkP2Z/vxtV+dluI45bYYBHI9KALFkrbw13Iw2/dC960ZLZvEdjcQTNFaSxKTCcBS/41iTsDCoy28d/SnOJmeC4Qs23jFAHGaNJeyXd1ZTMoePIBc9xWn4esmS6aZyFcHA20upwpY+IkumjGJTyo6CuxgsrexsmlVGYT8gn+GgCnMP3q+eiA9sd6guS8SGR1CpjC9xUkKBJ8ucx9QWrK8R3vySlW3EDAUdqAPMro5mc+9FMmJLEmigCe2A8xfcivVNGgsItLsfLmMjtEGkVP4G9DXlMWdwxwa7zQLo2ul28dmu+4f5pM896AOs82L7OVG4SH7vpTA2xFOwCQeh612vhXw7o93o76nreqR25RctFgZH51zmt6lpa2rnw3ZtJ820zSn9QKAOM8X2xmhWd32MOiVD4ajnksJyIsIg+/W1p9hOZTPeSx3JccRn+GpLmwkFlNGh8sP/AAjigDjdHQz6zg7iM120/DhFkAAHGKzvD+mQ2js8xxJ2z3q/K4eYgBN54yRigBjxJI+5nf5fatG1RmUyjJRR1PeooIyn7uX5y3epJUcSJbDKqT1zQBLoFmdR1SS9kBSGAElm6V5l471l9Y1yZsgwxHYmPQd67Xx9rqaVo66VZSHzph+8ZeMCvJz6nk0ABpD1paQ0AJS4pAaUUAL9KQ9aXPSk+lACrWr4f0e41nUI7aAEAn5mxworKUc+5r274caUNM8Otdtt86UZx3FAFrSPC2maOFjt4kluscyyDJz7VrhJYCCQpX1FQQF1XcQHZj37Vftd8aESAcjoKAM3Xjcz22dPGGA53c1j6P4hu7QGG6025k7GRV+Wulit5W8zjaD0NZ1hqQ0++aK5O+InkUAXoPFNikX7+GRFPquMVn3HjLSoZv8ARQ8jE8jbXQXF5o8qhmgVuPu461Pp3gmDxHp9xcadaxQSAEIzDAJoA8K+JGuprGpKYU2IorizmtvxJpd/p2tXdrqULRTxuQQRislYi2QOooAhNNJpzAjg0lACUhpTzSUAHSlHSmmlFAC0GkzSHigD0bwDPFq1i+lyMVnTmPn71a8Iu7KR7W6hwF6e9ea+GtSbStXguVIAVhkn0r2HUr+11SSC9tsEYBJHQmgCjaxK4JO4H+6ehq/FOEtmD/Ko6YNZwlE1zmV2HoBwKdM8TssY/ebeSc0AVPExjS0gmX52J4zV63nn1G2to5pGVUAwgPX8KwPF94P3IjcKifw4wKmE09tpcN9Btd2GCQelAGje3HmzGONf3icBaxtShLw/vAQ3fHWhdZj80KBsnk+8W61eu4AtuRvDErkgnmgDy24x5jY6UUk+PNYDsaKAJI+Grv8AwVavFZ/2i3zEnaiHvXBwjLj616L4fDxWFjKozGq8rQB2mm2v9rRSR3EZBAyFFVGX7L8vlbREcYxjNLo9+1jei6Vi0R+8p4K1v6nZrfWralbyoLQDL72HFAHPrcQyTBifKdhxtqrd75ZhGFYsOdwPBp8BtpI3lh+dehI6CqIZobn902QeeaALV6xUJ5hDN6KMGq5gUYlbk+/ap7yWdl/dCHzBjbnj9amtXEkg80IZB2x2oAhlMsKo+9dp6DvVzR7a5v7pzIpVEUsGYcU7S4odV19FuWUW8P3gB6V0WoSRX0d+towtbeKIhZD0NAHgXiW7a81i4ZjkK5UfQVk96muAVnlDHLbjz61CelABTGpwzTW680AFA68UCigB3NIOKPanIjPIqICWY4AoAvaLZm71CGNULZboK95s41js4LVY9u0DvXF+D/BOqW89tdSQqgOGGTzivS205RKNp3y98HpQBTeJ0KiNjIAQCAOnvT4Y3MpJZkx3PekZBAz+fITjsO1Rpdwxgu8p8vuWPIoAvbC0LlXYnB61w9+ot7h3ljOSeCDxXa2d/Bekx2ku5TxkriuR1vTnl1Ro4Jyj56P0oAiNx5kIWNwGHI7GvYPhPqsSaVcefMypGuTuPHFeDXlhq9reL50kLqTxg10njw3PhnwNDIJ/LmuxtAjPYjvQByHxj8ZxeJfFFybWCNY4mKCQDlsV515pBzTMnuck/rSc5OQNvagC60ZuoC8MbEr97aM1RII9vrW54S1C40++lktwrAxncrDIrGuZDNPLI2AWYk4oAiNBPGKcOmaQ0ANpQKQ4FHQd6AFHWkNLjik7UANNd38PbuWaKW0RS5T5gOtcIetb/ge9nsvEVq0DYDMFcdiKAPSoXjmilxHtmXgg1XgVwhOOvU4rV8SWtsdXjliDRhlG4KeCazppIYoZN0hx2UcmgDk/GoWWWMR52iorCeaDSiFyI05yTxWj4o0+4Nnbsq/K54LdabBpU6aT5bY8x/figDJ8Owtresl/LysfJPauv1LcIXHlMzhSAR2qnosEWmmGBHjR5D+8ZetdvfeBtVurOTUNMmW9thGWaNG+YcelAHz7P/rG+tFPul2ysCOc0UAWLVN0gr1/4deHNQ8TWNpbWiMqRj5pOgAzXl2hxh7tN3TPNfZ3wcsoLT4daI0Mao01uJHI7k0Acpe/C14LXyraYzOw5bHSuSHh5492kzyFk3fOpOM19GV5x460GddTOoxSkRnnhehoA8+8S6RbaVpscOmRbFA+cnoTXI6dKsUzblG09x0r3KLSE8R+DrlSv79QwTHG4gV5N4Q8PXOofbYo7d3ELEMeuKAMvVzu2GCLKf3s1BbiQEDcNzcAV1GpeHJbO2+0MoWJT0auS1HUIrVw8bFpgcCNVzQB2ukaZZaNpMs8jpJdyj7pPSsPxHdP/wAI7MYwEix82DjNVreRruOM3TN5r9IycHFQfEfUILDQI9OhwHf7y9SKAPI523yse2aiPrTj14prHFAGh/Zjnw6NWSVWQXZtZI8coSm5Gz33Ycf8ANZhrp/CJF7pHiLST9+a0+2Qqf8AnpbneT/36M/51zPGKAGigUo5ox9aAFB5zXSeA7L7b4ktF2bwG3EVgKoC5BGfQ113w31K3sNaRrlAA/yhh2oA92kWRZo9+1QoAApZrmKzikupDhFGWC96Qw74BJLlYnGUc0ydFeweLaoPqx60Aeb6j8QbIXkrJayeXnHPetLwtdR60zXYtZRGPXpW+2h6U9uCLG2eY9SwzW/aaZHbWKpE8Ua4+4gxigCjBHBcwnbtgccKQMVxviC6ls9SWO/2eSTxKDzXoVraSKCXWNo17dDXH+N7Sw10C2Eb20qnAlzx+NAFfTrF7u9ilhLT245B4IrlvjhqUtxeWVo4ZFiXhK6iw8EalZWERsdd3KOdsbE/1rzP4k+f/bIW5mkldF2lnGDQByFFFKFLEBRkngUAd38NNAl1Ox1/UCMQWts3zEfxY6fpXAkkk/WvZdXv4/B3wkt9Ft+L/UvnmIPODXjY4xQAdFxSGpWIKDHSoiD2oAaRS9KQdaXg0ALSHpSmkbgGgBh+lTWkrQ3MUi5BVgcioScUg68cUAfTeq6bZ614X0ufTo2aXYPMdW56d64+fS2gv1UoCq9ec1mfD7Wr6x0GRo4pJLfoxUnitqKSC6Qz2u52Jy4LcigDF10PPeRxrkxr0Un+lWp7gC3QFDvUcGo4ZI7vUZEA8sr03Vl3tw8l08JT5lPBBoA04nEhjn8qN3zjpiuq8KwJa68dQn1SezWOIt5IchZOOnWuFjllgjVwjgD2611ojceGpb6WSNpChAideRQB4rq0onv55VG0MxIAoqvcH9431ooA3dA/4+U+tfaXwoz/AMK48PZGD9kSvi3QsfaEz619o/C0CT4baAATtazUfTigDQ1vxVo+jTJBfXiC4fG2Ffmc/hWhMI9R004BaOVMgd68L1Tw7cWPxDCoRdBpMqGOTjNe+W6FLeNCApCgEL0HFAHIJqlr4Y8K3s16wRo2bCLyWJ6VV+D2iPpvhlry5Ytcai5nIPZT0FZfxA0ifVPFGj6Xas5t3fzJx22g5Oa9PijSKJI4lCogCqo6ADoKAPMfjde2tnolrYxbFu7iTKL04HevLfANpEmvy3mp2vnGBCFBGVNdB8VNRbWPHiwRyJLaWaiPgcBu/P1rUup7XT9BhgsUjkuJT8xzyKAMHS/Dl1qer6j4j1BVjtLcFkjU4FeIeKdS/tLWbmZchC5AGc8V638TteutD8Px2VnKYJLkYdVPbvXhoyATQA0sQDikxgfzpcZFBoA1fCGoJpHibTb6cbreKdfPX+9EeHX8VLD8areINNk0bXNQ02U5e0uHhJ/vbWIyPY4zVPJxiux8aaTqOo2Gn+JorG5exn0+E3VyIm8tJUPkHc3QFiit776AOKU04E9qQDml+lAC4PWrFqZBIpizvzximIgjZTKGAPtXc+DNL0vUJQ8bSPcpyU4AoA6fQ/EGswaTEL2B7i3QD73pW1a+I7XU8BojFjsTnFOa6t49KntUCMwUgq3auS8GThdaaCdVMTHtzigD0OBTuV1dJF7DHStto2gWORgNrelY90Le3uUEEzKp7EVrqYLiEKZg+B0zigB+q3AhiRI2aTf14rh9eWU3kcEOBuPIYV1hiMUTSOrbR0+bNc200lzqTOSqAkcN2+np/wDWoA3bW1sbGyjw7xXJHVTxmvFvilbv/au8yCUnvXrcCxTX6xSHe56ZbArzP4rxiHVRCUCAf3TmgDzVVJ4wc11fw80q3vNfge/dI7eI7z5nQ4rBEasy7TgdzXWF7ez0QKpzIw+9t5oAj+KWopq3iCRrZR5EK7EK9MVwv1rail+0OYpNzAnAxUuq+HLm0sluwn7o9upFAGCM44p6puUgduc0ztVrT9rSMr/d20AUh1xTgO5of5XPpSZoAB1yaGpMmkOT1oAQ8ikbAHSgn0pAdzfSgD1r4I3W6C9s7qF5bZlz8vRTVqGNbDU7yK3IVXY7fas/4FaibTV7q3kKCGReS1dV8R4baNlls4uSclk4zQBgiNImf5vMnPPNYs0wW8aURkyqcFRXSz6DcyaJHqP2aePcOGB61kx6VeWtu1zcR7t3Qg8/jQBZhuPtUcLIGDA/Mp6CtHxjd2sWnwxWhYylTnBz/Kqmn2oh0m5u5yEJHAZuay9E0nUtcjnNqDhQTuxQB5tOf3jZ9aKfeRmOd1b7wYg0UAbmh/69a+0fhR/yTfw9/wBeiV8WaGwFxGTyMjivsr4f3UVh8JtHup2xFDp6uxPpigDntJjt9Z+K11NbzMyWxLMF6ZH/ANevVq8g+A93FqN7r95BGFV5AAc8nk165M4iheQ9FUsfwoAzdH8m4uLu5VAJfMMZJ6gCsf4l+Jk8NeG5pI2Jvpx5Vui9dx/i/CtTwoS+lee3LTSM+fXJrxPxzqMl/wCM715i8iQOY41fhUA44oA4++1eeAQadbQibU7pgW+XJBNdJFod3o9/axXtwGu5lz5HdfrUngSzaXxTLqQsWnuYFzG4Hyqa1bSzllu9Z8T6zOpvIFIijfgUAeJ/E64u5vEksF3JuEPCqOwrkBxWjr93NqGqXF1PzJKxYkUvh/SLrWNUhtbeNzvYbiBnAoAgsdOu71sW1vJIM9VWuhtPAurXMe4W5QDu3FfQGkaDYeHNGgjiSN5sDcW9aneWOcbwqIoHJU0AeBp4B1Neqq49BXtmv6tca38BtVsNSIOqWa28MuTzIonj2v8AiBg+4PrVSW5zd7osxxLwc96g1ZoxFKIii/aFCOBzvAYMP1UGgDwC90m5jfIhKofyp2haYbzVYYZOFzliemK93gtbbyPKubdJCR/drHj0WK3uppIbZMMCBjrQB5d4yura51BYrXbtgGzcoxnFUtAkaC8R4ZXSQnHynFaGteG7+xuZpHtzh3JXI9TXQ+AvCsnmtf6jHthRcruHFADPFmr29lZxW8O83kgy7A9Kg8ETOLyNgnLn77U6/wBAGq6/JIis1sG5K+lbmjwI2swxWMGYocAKRQB6RNawx2qvdyxOzDgirWjWUTxszzIU9AOao3MbXMqCZEQKPu4rTgtytsSBtGOg60AOY20qSQoGRRnluQa5ySO1juH8xSzr0wOK1nlhhj2gsHJ79Kimt5prdpDKFHYhelAGCn+k33mW7EOv8PpXlvxCnmbWZA+Djjr0r0u3lME8vluHPPzLzXlHji5WbVHUAbs8kd6AMCIqJVLHjPOK7LXY8eHrcxJlCPvCuIhDLKCo717Xp/htdS+Gs1/OmXiUkKD7UAeORtKuDAcOOeOtacWraheL5ErMxxjAFZQ1AxBlhjRWz94dais7+W3vFnU/NnnigCO9tpLeZhIpXPTIqBCQcDitvVroahJ8g4PNYki7WI9KAGucsc0mcUE+1HbigBBg0hPHGaXsPWg5PFAEZHTPWgGhvek74zxQB1Hw+zL4ltbUMVM52DnHNem+JF1TRtQk0nV48ofmjNeP+Go5Jddslhk8qXzF2P0wc17x41a+d7SPUYvNvBGNsxHUYoA9O+HGnDU/h4Y71GYHds9eB2rN8D6HBqg1A3cH+j25IViM5PpW18Er+a98KNHKystvKY1I/UU7VJIvDHgrXpoWMcxdxtBztJ44/CgDwPxfi5/teeAxxx2auUjPGSoJrov2cNYv9Ql12w1QWs9vaael5BsjwwL56njPHavOL+9V9Pv9wlkllgmYse3ynmu8/Znura1vvE0lzdWluTplrGhnlVMnYfU9OlAHiuuYbUblhjmRun1opmqsGvJzkHLnkcjrRQBc0xtsqH/aFe3+PvE8+mfBXwvpdqGU3donmODxjGcV4VYsBKmemRXp3xY1GH/hX/gOwjObgWCySDsBjigDo/2WdeWHXtQ0iaQKbqPzI1Pcr1xX0nqClrC5VV3MY2AHqcV8WfBC5e2+KWgMhA3zeWc+h4r7Q1e9TTdMuryVSyQRlyB1OKAOV8M6s1v8Pbi8chZrSOXK9cMucD+VeA6pqa3ml/apfMa5nnJd+neu303U2g8H6zcSTCNr5ziJm/pXndzLJbWy7QA+d2GHFAHpuleLNM0zw9HZ2gZLx1+ZuhNVLd5NRtJhdAtbv1UGub8K6eltoWpeJfEDpJEilYYzxk+1SfD7UJ7rT726nkjgtnbEYdv5UAVbrwjpZkZ0CjJ4UHkV0PhbRbTSUaWDiZum0cipm+zxgCJEefrkc5rGm16K01Mfa90Kg8jsaAOrumnNq+4ncemRWZEZksim8gsegFaOnz2mqMGt5XdcZwpyaI4tssgOVUdn4JoAqi3jkjjXaqnqxOear3kim42IAAncrkVca7iyQX3MOi094xJbl2Gwn2oAzrS4UOzsjO3TdVizhcXXnQLnPJB61MGb7MqeV83QNUjJLZ7JyyBj/CeKAI9TtBqJDTpgqc7cCq8zMLbykgzEBjBGK0Udi7TuYzn+HNVEVrkSMUZE9M0AYP2U2sMsnl+TER/D0NTeEo4EeSYKQxPBFXtTxLpskShl7fN0ql4ajeBBkAAd80AdSuTlp4C+fusOtS2kcssMiWpAlI4DnFJDO0QDeaCT0GKfNBetGZ4YQzdQ2cUAV4fDeo3HE0RyTy2elJ4idbWBdPtZeQMPms3VPGGowxfYbk7G6ZU4rGjM0znzUDq3JYnmgCKwieNbpoIwyqpLHHWvF9ed5tRnkbj5jXuV0z2Wj3SxpiMqfmB5rwXUGxdSkktljyaAKhcgjHUV1+ja/qLeHLuz+0TCALjavQiuPGGJNdh4Osp5rC8eKGSVApyFGQPrQBxJBOT3qaygE06hztUdTS3a7biTjacnj0qO2kMUoY8juKALSh0uXEIMiCqMud5yMe1amn3kccr/AC7QQcYqjeSLPKXHBoArUD86Uk4xime/SgA6UEdcd6Sg+9ADWx045pO4oNAoAs2ztBcRyISGVgRg19Hz61Fq3hazub2ZftEUQVVxz0r5xsFWS/t1Y/KzqP1r2vWbdvDuqWVrcxhre5iBQn3FAHpn7OMwbTtYjV8qZw+0nkdai/aBu4ra1is0Yx/aBvlx3qh8Ah9n8T6rB5wXKbvLH8VYP7Rtw8viyCGKQuFjAZR0FAHnNrCb25fTbUqi3UDwCaTgKWUjJx25rrb34BeKL3T7e4luvCN0tvbLGkgEwZkRcLkhcE4HXA965LSYSmuWhhfcxYZXPFaes/FjxDrcOoNoernw3pWmWyi1sYgJJbzc+1izlSN3OewA4AJ5oA8wvYzDK0TFdyEqdvTI9KKbeytJcSOxBZmJJHQ0UATwN86/UVs+LdVk1GbTomx5dlaR26AegArBjbDL9adKcuSe9AHWfCiYwfEbw/INpIu0+8cDrX178VLmS18Eag0WcsAhx6E18e/DBwnxB0BiFP8Apkf3unWvrP41S+V4GnGcb5UXPtmgDxHWvKi0SxEnBJyG3c/lVGxtX1jU4beM7sfxEV0nip9Kg8H6fHBaebekDdLnIFc/ol21ncpLCxLKMnAwBQB0HiO2tp47bRdUecWyHJWIYzXl3jbUYYdWSw0kyxWNtwFY9T612Wu6+7i4vZD8yrhXIryO5me4uZJZGLM5ySaAO/0nxSsUYkefayLx3rmvEmuTareeYzZx3FYAPUUoNAHU+FPE95o92rxzMF716N/wn6X1myzBTxyx614rDx0qxHKIwQeT7UAdXfeKbyOdvscrMue4rR0H4h3dvKsN4vmI3ykt2FcIrvMdsa4NTRwhfmc5YUAe52WtQ3UyRwEqGweTW5CDcuTOUmRBwuea8X0LVhayxvvXg898V6tomowXgjls/lcj5i4wKANILG8ZZYtp6BSKWzK+aYHby2PY9KsTXKGZY0/eNj5iBxWdf3q6e0sscJ80r8ueRQBDrs9paSCNlGAfmJPFUoJrW7lVrNlZR2WvJ/EWrX91fzfaHwGPRWyBXefDu2mitA7Hcjc/KKAPQrVEW23yLyenBrpLDUrVLKOG5UZb0Brlrl5URVVy6H+DvT1kdogjqF9M9aAKPxIsNPlu4JbO3ZBwS+DishYMhBGybMdmrtEimu9Pljmj85VXjjkVyVlZq1y0cqBUDcYOCKAHeK4fsPhCYzspZl4FfON3IDK2Bjmvov4vMtv4QVQRuA4IOa+bHYliT1oAkiOQeK+nvD2mWXg/4C3eo3caC6uoTIH75bhQDXzBaQtPcxQqMl3C/ma9u+POuXNt4S8N+G45AsCwLJKqnliBgZ/OgDw6RzIzO/VjmkQjcMjimntRnAyKADJ3ZFJz1NL26c0hoAb1NJSnrmmk5NAAQRj1pD+tOyM0jnkYoAjNA6fWlf0oPQCgC1psTTX0KR/fLDFe7a5cnVNEsTf7BdWygKW64FeE2Extb2CZRko4bHrg19IeNJdKvfDmkXVqmyd4gZAtAGV8M717PxzBdB2CFdrbe4qv8U72O+8b3TtymOO3FN8E2bSeJQ1mj5QZLHkVleOCzeJbh5SskqjHyjpQBneHbRrvWIYrTBcyABe/Wsz4o/8ACIJqso8CfY/saabGLw2gfy/tHnAEneOOPTj8a6/4R2pvPG1kMZxJzheg71T+KngG8+FGiKmj+Jbuex1RjDLbNaRqpQfNguck84449aAPHJMnFFEnv1ooAnXhhTmI3U0HmigDoPAgY+MtE2BiftkeNvX71fVnx/cjwlapkjzLlRt9eK+bfgnCs/xR8PK6ggT78H25r6B+P03mXHhuxHO+4Ln6cCgDg/EaPb6dp9s7BUZQSCOawlgk1nU1tLeEwQRDMkid/rXc+NBZPdW0FsG85IwCz9BWBHpN1baddfYpJGaUHzHUcAfWgDznx5ep5y2Nox+zw8HH8RrkO1aOuFPtzxRsW2kgk9zVAjHAOaAGj1pV9KKcKAFXg8U5Tn2oVR1Y49qCozgHFAD/ADnAwny+9PaQCLG4lqhCndtGW+lX7bSLu5ZQImAPegCjFM6NmNirV3Hhqe8MatcyuYO2DitTwx8OJLhRNcfc77hiu9j8IWsVqlrEo3NwGzQBVsLpRbqYvu+u7muf8Y+MRZw/ZrZS0p4LEV1N94TaziEKzkNjO1a848VaXNCHMg4TueaAOMe8luLtSI03McYA9/8A69e9eBrG6t9GUzASFl4XGMV414NgS416BJVyoavoWxY+WUWMhFGMCgDPkf7OGEaHzCe5ziq6XJe5QSSc98DpV262xRySxRnPuKoWAjllJRMTHsaAOt0TxD/ZswgYJL5nAzxW1rmm6XFaefOQ1zKcoijgk/SvPZrUG5EtwxVk5wBXoXhu/jvfIjNq8iIP9YUzigDxL47XN3Z6bb2cyLCr8hQeSK8K717T+0xcK3iaGKM5TZuzXi1AFvSJfJ1O1fG4rIpx68113xd1mbV9etmniWLyoFVQDXJaO4j1O3dgGCuDip/Et0bvV5pSTgnAz2oAyj1ptONIOOtACUZoHrSUAKeRwaZTjzTCBQAuOnpnvSdqD0o+lADSMnOMUg6ignB5NC+uaAJBgSrzj39K9YguZ/7OtFLiYhBtB6ivJVOGUnsa9bk86BNKu4UjWKSIZyc54oA2vBlzdRai5BkUnqB0rN8bj/iZO6QP833m9a2PA1s+qavfGO5VVVSShOM/SsrxCspS4VHxtbHHOaAK/h68vtF8K+JtZ0ydrW8s7UGCWPBZGZtpPPsa84vrC/azvLm6mmure1uRavNNf5YSNyCImO8jnqBj1Ir0y02w/DDxnJdbDbi1jV4/M2M5aUBcHHZiCR3HFeTWwlSaK5lsI7gI2WlmgZwRnksw4xQBUY8kenWihuSSOeaKALAoFIOtLQB6V+z5H5nxV0jIztDt/wCO17Z8Xp1Pj3Q4igJSItkn3rxH9n6fyvito24gb96/XK17P8aLdV8caLcP8itEV3lsAnPSgDAkMF1rUsssmQpxsroPFVzDoPg+S9EqxLIu1UHOTXn+r299ZT3F1vKQnlcd64rxrreoXmn29vcyv5IPCnoaAOUupRPdSytjLsTxTF2kVGvSnAUABGTxS9xTlQs2AK0LLT5ZZAQpKjqQKAM9VLNgCtTR9Inv7jYsbEDkkCum8N+GPtUjTyFREo6tXpHhKXT9ISVbeCOR2GCSuaAOL0vw5ZWqrI6lmHZq6K2mh81FgtUDr3xW5LJDPFKAi726ZXGKbpekRxIZrpUyenzUASS6ss1usbGTcvVQMCtnSZt8ayiNnVfzFV7a3tIxvYxkH+E9TWy8Vt9kRrJXjyeRmgCtczxrm6nYhcgYKFiM/SszW/D0Oo6fNc2uxzg7lBBIrRvp7SKSNVLsx4YMaoNFCblktnkQOOikgGgDwaMPoniMMuRtfo3HFfQWgXavpSSQFSzgEqea8R+JWmPYajuIIVjkE9a7/wCE8rGwhMsrlB2boKAOr12Yi3WFY2Un71UIrmGzhXy8iXHVhXSXM6SXwWdo2hPRqxPEAiVPLwjqT8pAoAltUW5haVpw0h5rrfhrqYYXVvcXMYKfdU4FeW6hBJBbARRyb2HQGuu8I6AbDwfqWs3rBHSF3UOfQZ5oA8Q+P2sw6v8AEa/NpKsltAFiUqeNwHzH8684xnpVi+uDeXk9w2AZXL/marnIGe1AFnS4mlv41VSxz0pNTBN7KMYOcYqzoEz21206HaFU5OM1XEvmTTSt8zNk5NAFMgqcUnepUjeUkqCa2tJ8PSX+AhO49vSgDAHXrShSRnFep23wyRrdC9yN7dq0J/hxa2sccUksSFj1LcsaAPG9pz0pu0k9K9h1LwNYxQqEuEjI9BnNQWfgO2eEN5mPX5etAHkhWolMjbvMUKM/L64r3VPhPY3Fk10ZJY0AzkDqa4LWPBq2iSywTkxp/eFAHEFSTQR2qd7d0kOOcHtUTDLc0AIgBdQehNewWqi50K0tpizeWmUIHWvIMgEEV7fa30F74AsnK7J412jaME4oAPBiRpLdSwSeRKoIOT1qCWI3s848zvksg4rc8I2No/g+/vAxF8M4Vu9cKL7UYTIyFUOTnbQB658DNE07U21u31C3ju7d4vJkjlGVYE85FeKfGjw/oXhXxdJpPhiSf7NCmJla988B88rgfdx3U17F8FLq4j8E+M78P5c8VrK6yDgqwjYg/pXzW8SC5t4nIl+0pHJJM43SbnGWwc8/jQBTbFFBYmigCelzSUd6AO0+EM5tviT4fkViv+lKpIGeDxXv/wAeIpT4i8PSTZNoMgKOpbNfOvw0dE8e6C0knloLuPLfjX0x8f1+zpoGoDJMNwQE7HpQBkeOtGN94ctbwMY1XG2FhjNeD+PL4XF5BbIqKsK4IX1r3fxX4ha88PebMMMsXyxgYxxXzrcW81/fM2MF26mgDMUFjgA1s6ZolzelDHG20nGcV1XhXwRJf3aRuGRT95yvGPavoHwp4DsrKxi2ESQryWxk0AeQaH8L5ZLH7TcISccAV2Wh/CuKO1V5i8Zc/dPFezT28MCwKgVIFwAMc1HqN0YpoyGVYh/eFAHJ23w9t7C3Cx7NhHzZq5p/gnSoI3mijkd/YcGugtNUi1GcxRE4XrkcVfeZoztijDAdcGgDzu+8MxS3aLGAmT9wkAml1Dwo/lhSVCgevNdvOGOZLdYTJ79RU2nlY0YzMqueTk0AeWQ6EbUZeOSQjo2OlVpFkNzh5JGjX+FTivSJdY0+81FrLYeOr44NU9Y0GA280lmVAx/CeaAPPI2gvbl9gIKdAakgt5TeRAho1znGeT/hUMNrdRSyEIAmec9av2VysGMFg3XL85oA4P4lW0TagguVYxg81r+ENWtrmx+x2dv5aIMZIqH4nCKDTWvJt24/3jXG/DjVQ2obC4UMeFPFAHqhwY2DI3HftWFPeme4LzyoltDk7h/jXUSu0dq0bKIlcZJNeQeJ9SkvL5tL0zc0RbDsnegDu/Dk1z4s16O3sT+6RhlwOAB3Nb37Rmtf8I94DtNFtt3mXp2FwcfKuM/nmun+CukWWl+GSLND5jEeYzDkmvCP2l9f/tbx99hikLW+nRCLHbeeW/pQB5CR27U05PfpT8DmkjRpJFSMZdztA96ANexiK6PNI6cOdqkdavabopGntPMpw/StWTSWt47GzcYOAzgHvXQXRjQRxxAbFXGKAMHw1o/nbsxqEHc16no+n2VlpK4t0kf1SuG0ya0jMxmkBbuinpXQ6XqKiELbZCn36UAa15NF58SQptbupNZGpyy3OoqoHyr2JqvJcXEGp+aZAw9z0qvLfTPqR8xUVG/jJoAk1a7WNFWRuR2AqbTruaUo0Uh2f3TUM0cbzgKfNOeuK0EgbcoityJAefSgDbfWbh7f7M8jeT3Cjis65FlNpzwx+WufvZGc1t3tksOlRtje78sqjpWI0QkIhRBCBycjk0Aeb6v4acNJNEQIvTFcFf2j207j0Ne+6afMu5baSEyL0+Y8Vw/j3RY4JpDFsDddo7UAeYZ7H869L8KzS3HhPyIiWERPbp+NebTIUc+le0/AXS4dbSfTDMI3mBYk+ntQBpeF5Lq18J3c0vkhDkAZ5NcRdJGbKa4UspJOVJr1b4geHT4asU057hRHKN8cir1+tebR6ZJfX2n6Ra4knu5QhYe5oA9b+Geliy+A3iW8RA093ZXb5/vARMAP518v/LLcWtyGC20CQxyuWXcCoAOFzk/gK+rfjtrMXgP4TwaFpjqlxeILKPBwQgGZGA+mfzr4/PJzjmgBRRSZooAtdKB9aMmgUAbfg5/L8U6Q+4jbdRnI5/ir6q/aKRn8KafKpYRpdBmI69OK+UPC7bPEGmv/AHbhD+tfWnx9PneCLNdrtvnRvl+lAHlurSPqen2+AY4QnPqfyritLs2fXFijBZA3evQYNbt7fw19ilWFG24DsPmrP8E2AfU1kaNXy3ylqAPWPh1pLofMdCI8d1zXYXt6+nWcghiPkj/loo4WmaTEY4FVHMY2/dTpTpQn2G4imMjRt2A6UALo+qNqVnukXgHAc1pvYRXCgyszjHQms3T4lj0oW9pFuB6nvV+HdHaGPLlgP4uKAEUW2mBxEiKmMnnmqtlLFqccohdoTntWTA04uJXvEHldhnNa2kSWsxcwxiJgeuetAGjHBKkQjBRlxgt0NUIrFTI8Ylk+b+8M5q+rja5LSPj04FQCUI0ZO5dxxzQBl6fYWunXUonhLMx+Vutad5sFsR5GIz15qtrUu+9tY4pec/MFq1fBLqZLduUxknPNAHJ6rZCVgsKYQ9SRXCeLAulSLMiF0TkjNeySWsEduYkWQAevNcH418Orc6fJI2QhzwOtAHzr8QvF0/iC6SIDy7aLogrl7G6ktZ0kiJDKcg1peKLIWuqSxxBiobuKyRE3nxqVOSRQB7N4aufEXiPSjC6BYiuBIxwa3/AOhaboOoTHUbdrm4bjIPSmeCYWs7S1RZCGdR8hNRPdS2viwpMUCk8ZbNAHdTeONO8H6ZcD7FM2WLoB0z7mvlPxTqT61rt9qUoxJcStIR9a918WauX0u8hnSMptODt5FeA3GG3gDPPXFAGd17V2Pw60A32ofbbkMsEHzLxwxrE0jSLjULqOG2XeWODgdK9dNmNG0pbGFj5u35wKAOd1CUtqUk00YIBwMGkiuBKSuBH7mmW8qNcsvlszZyd1NuxJLIAqIIx1xQBJDaNI7D5SD/EBV+GOC1Q+a5b/AGarWgDzKsUxjA6jHWq2s3JilKjbj/aoAvtcRyRlk/dhehzk1Xg1B7lgjRRsFPDdzVWyjSS3aSYcdtlaum2UMi+azCPB4wKALkCPJJExUjHYcV0tvDOXV0LYHG1uM1kWdq01yhx8o4BB5rbC+WdhlMn17UAWdVuXa3jWMIkvsKw53KOPMTdJj76mrV5L5JRXYMh9ulZ+oBYJd/mZVh930oAVJIzGzxko/cmuc8QlGiKzhW39GrTtZZWlaJDtQ9Ky9RiW41HZcb1ZOgx1oA4PWNGxp7XCDGw816D+zpNLb+KLFljBV5PLJ9M8VFqGmtdaFcLJ5kCfwkrwal+BkcUHi+2spWdt0gII6daAPTP2ipd1/oVvkgMHZvTGa5b4C2AuvGmp6xcKFsdOiJDNyAfUfSrX7QWoef4lWOPY/wBnjCgN2PeuT1JDoHwflv4dTlt7vUpfKNvGcb170Acb8ZvG0njfxrcXikjT7YG3tIz2QHlvqetcFSscnJ60nrQAd6KKKALVL2pMUdDjBHtQBp+HgW1qwVRuJmTj15r64+OUjQeC9PUfKDIoOO3y9K+SPDskMWt2Mly/lwpKrO/oAea95+LXxS8HeJ/D1nZ6Td3ss8UgYK1pJGAMY5LKB+VAHC3cLNtZVGMZO5q9E+F9sbueJTIFwfu15hY6/wCG43ke91JndVwIDbyHB+oGK7L4XeNPCOkTT3fiDVDaRk4iUQSyHPuEU4HuaAPpGCFoHCyYjjx1HOaW9j3W+yDnd3rnvCHijQPFEdzeaHrKahbQMEkRo3iZCQCPlcA4564xW1bXUkLyCKD9xyQWNADYUlt5Fiwyk87weKWY3TyER/vF7se1Pt7q4mditqxP95ulJPOGUw7mMn8SIKAIIzas5iE6mX0NZ2m3X2PXGjn3BTwMdKtlcXCtBCiMvVXHJrjtV1R7TxRFcXSBoVYbo80Aelm4Z2ISPK+uKkDo8RDDBHbFVNO1OxvYxLauoJHRvlNZeseI9KsLj99K4mH90ZFAEGlQPPr0ks5k2LnaCtdDFaj7U8vmll9D2rzsfE/SP7U+zRSt57HaOOK7PS4p7krcGT5H5x6D0oAtERW0Mjhm8ncSQTnr1xVDVo4prLMMnyMMbWFat8rtD5VvGjBuCc9KqpZxKgiLrJIvIUUAfL3xG0hrfxCFAGHbgVmv4c8i7hmZNygglRXo/wAWdLuJNZinEYiKHox6iqk1hHdx27KWWbABA6UANhvLaO4tzDIY5OBhzxWV4l0+8j8S20guYQZSMEVzWtMIPEyWcs/lsGGGc4AqHX9UvbjxHbWr3ERWFgFeM5B/GgDofindy2Cw6eTvkdQSwGK8yt4WluPJJwT2NdH8Rb69vdVi8+USeWgAIrH0MsLzzZ4/MUeooA9w+EXg22s9KuNXu5kZkQlVTk5rkNZuGOrXV5ceYqAkLiu38E6leW/haeNMRxyjG0CuC8WWl2iYRWYOcnJoAxrctvluQSEbpT7FFk3yMXJz2NKbTFvHF52JG6p0xWjaWq2dhK5uUSTHRhQBXSWRpQLcKpXruNUbiOW8v8v5RPTk9Ko2epw21zJK0vnyf3ecGqN7q80155kqpFH/AHUHagDsbWzeKMiQgKegHSt7SbWKK1LyxouOmTWTomq2V9ZxwJaPI4/i3c12kOjQz2KyrOoKj/V96AMq1tXkVrhJGVB0FWoZBDatIyGTP40vkjcI2yqE49BUfizxVaaDpsVnbJDLKec45FAE9u0aQPPqQVY+qgiuLv7trm/d1XfDn5Sp6VZtdZlv7Yu+18/wdcU/SrV5Ln5bcFs5CjpQBe0mM7izhQwAwWPr7VQu4ne6kuJtzge2BXQ6r5HkCO5jaKYDgLWPOHk0orCzEBueOaAKuptK2nBIpMK3LK/QVqfB+HTxq91cyT7pLdSflXGKzRaSSQrHKmyDbyx4rG8HakNH1HULWMqyTggN1oAu+M/M1vxTFCn7yS8uBHGQctycV1X7TXh1NH+H3heKzjHlWlx5MrY5JKHk/iDWV4Ohf/hZmgp9l8zZMHyTyvPWsz9qnxJdX3jmLRBLtsNPhV/LU8NI4yWPuBxQB4eetHrS9SaQ9OKAEooHWigC4Md+PerEVxamWAXduGghVkIgxHJIScgu3cg8fTiq3/66txahdRtCytGTDC8CbkBARuo9z79qAK658s9M4rf1S1WTUr+y0eWeW2gWSdopQI1RUGZCB/s9u5qp4V0hte16x0lJRC93IIlkIyFJ6E16jq/wM8V6NbS3lzrOkMrKyzPD5okdW4YHI5z3zQB502tT/wBhaRZ2l9fW5sRMHQACMtJKzhlI5zhgDu79OKpqs1lJ5yXgj1KOdo3iUN5kZHV9+NuCcjGc8elbd54K1Ky077ZJLYum4gYZw2R36YqW38Oalc/azMbC7lutk7zzlhKGJ3EhgMjcTz60Aelfs16dc3PiLUNenspPsMdo9tLdu5IuJ2fccA99pAOOPxNfQUerQ35eExPFjucHNeG/s2eHbqw8V61dXDW4txZrEYo5HbLFic8gdga9sUI+pOIYkRVGT70APuNRaOMQxOQf7wA6VFZX67vLtoTJdNnL54qlrBXUMpgwiMclOprG0fVVS5aztUdF6Mx6mgDsJoyB5lxInmDncnOK5PxbpllPpU+orOs08QyccY/Cl1tzb6XeXFm7pKEP3jmvH9Evbu40/V5bq5kaTacYPFAGz4R8VpPqIh2NMwbGM9K9Q1nwZ/b0EcqXPkh1yU64+leT/A7wwdVv7i7kuAhjOeBk19HD/R7UZO8ouM9M0AfMFn8P54PiTDZ7pABLnca+krC0+wxC3a43nbgA151q9xPd+MIrlNkbIwxj0r062cThHZAJAOtAHLXlndwX2UkdULZI55rdWF/LWWJipUZJx1qP7BPcai7zXTGNeiAcU2e3ks4byYzu0aITsFAHm3i+VtTvJpvlYQ5+9XF6XezX1xKbgokUWdoXviu98K6YniC11ad3aNUzhfzrzzwqgHilodzeUrkbfXmgDEsvC1z4l8QST6uhgsATmfvimat4dstFvmnsJ1vbZD1deRXT/EPWL99ej022n8mz4BCjBNSWMEMCNbzAzoy/xUAcFdNZ36l47RWb+InjFWNC0uLUdRtrPTLd5JXIyM5Ga3I9MhtJZyqq0bHhT2r1v4OaLpkdtJexWwF2vAcjpn0oAq2vhS/ttT06zkjMds2PMwcj3rF+KlrYaZ4ksbayspZXdQWVTkCvaw7tflGC+WqZHrk15z4ruoU8foksbOVjUjnjpQB4v4h0K4h1rzUQozcrGDzUcXhLXdStpXvLaSKDsTkZr2Ztl5eyyPBCXB+UsucVpeNbiSHwgkSqgkYcuOMUAfPNn4YitY5Ecfv+wNU7Hwg11qI+1F4UznNel6PoX2d47xpFlLfMwcVv6zDCNrwxqrbc4I4FAHA+HNJttH19BMGmhB69q7XWvEtg10sGmwxRJxux3rOuLyK1sn8y3Vpj0cdqx9NtESZri6RJi3TtigDY17V4TZrDbBPOIwSOteV6vpt1dXRZ4mLseprvbPRvt17NdbxHEmWCjrXPW9xNqmsuJH2xwN8o+lAG34V0hbHRGDxhZnHV61tHfyQ8SkLKf46t3t7bX2grtgZJYhjd60nhCMyWk7z4Ydh6UAJqMVpa2hnIMt1/ebkVgX+qQSwwh1VSeqxDmrF0Gt7iZS3mxueA3aqLWUKW8kqDDjJoA1ZLi2bR5PKy429JDzXmEcMcd+JRNiQvwo6iuq1y9eLw2ZEAWQnGRWJ4D02PUNVS4uGztBbGM0Adx8HUl1D4orLK7eZbxEjdxnAryD4r6hcaj8RvEFxd+X5v2po/3Zyu1TgY/CvdPg8lveav4r1KZGL2kDBAp2nAB7ivmfVLlr3Urq6cYaaRpCPTJoArcUh6UA5oPrQAgHFFOHpRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A coronal T1-weighted image shows a multilobular mass in the right paravertebral sulcus (arrow) extending into the minor fissure and along the diaphragm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_8_41088=[""].join("\n");
var outline_f40_8_41088=null;
var title_f40_8_41089="Common hepatic duct mass on cholangioscopy";
var content_f40_8_41089=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cholangioscopic view of common hepatic duct mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cholangioscopy showing a mass of the common hepatic duct near the bifurcation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_8_41089=[""].join("\n");
var outline_f40_8_41089=null;
var title_f40_8_41090="Diffuse panbronchiolitis Light";
var content_f40_8_41090=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffuse panbronchiolitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 245px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD1AWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1tlV1KsAVxyCMj8qxNT8PW10krW0klrJIMMI+Eb1yvv6+1VLDxKvl41JNjH7xRCQn+9ycVtW19b3RQ2s0UqFc4Vvm/LrWHLOGotYnHQ6JevqkVndXZi2ReZmElt6g44z0OfUVo32gTRKr2k7XA3fNFKqjj1B9RXUEj3zVRr62LmMXNuXHBUSAkfhT9rJ7FOo2eba7Zanotu1xeQW8luZQgkjfJJOecEfWmWcc8xRzwVPI3dP8a0/EMhn8QTQTGR0h+aMMCVQ7RkgdPWqBXy49sZBlHzY55J68V1Jtx13N4tuKbNyNy0a4G/K84GM+9BkMe0dV54wM/WnIwFqqspVhGu5SMYpo4LMAv+17iuV6M0TuirqEDXCqEb5/vKOBuGKxreRS3lyAFeoz6963XOFJJG0DPJ5I/Dn8qwL4+RcOpjIJ5CketaU30EwuoxPbfNGrBeSPUd+tWbXxMbOxjtlt2uJl+RHL4XaBxnPPHA96qEqIzgMin8KzIYr437LJ5RtmJaNlALJ9T2puKe4mk9zct9Q1PU1jnMjWwwQsUABJwQCSScY5Hf8ACpV+1G2Wa9nL3TkmHy3IAQDLkgjB4PQiqegslrFqb3bYsxEsYPOQXPPPXtUslte3imOC7hlOFtZ0Lg7VAYsMAdeB09KlpXstiNnY1PCmqy6jbOvkeVHCAqNuBzyR+mKz9a0oSQ3M1wsaWkRMnmISZAOeF/E8/pWpKZNM8OYjjdJlQqqINxU9c/lk5rFuEljsPLG5EkCSr5hyZDjkH/a/rUR+JtaAt7oi0k3GqJJHeTSXBiIESsF2KRzhhgE9Bj9aNWaezsDDc3Rjvrlnk3MTJhduAM44PbjjrUcGpanpccW6K1gtlYbx5eGdeB0HU1pajplp9stpVja6mRjkyEsC7427vbufSreju9hvR7EWmujWq/2fCVmkx+9Y4IQDk9/lBYfL1OTVrSwbxNkdw11EZyVl2+WVjKYPH1J4962bOKIQkK4lD8Ow5BPp9O2KldrextHchIoIlLYUAAD6VjKfSxHOZmkauJrSZbyEKLc+S7Kchxg8469qyrW7v7PU/sV66T2ZjDQyD7xUnAzn0yKx7G+udVs3llubOO7ui6iNW8ooMkAMONw6Z+8a3de0lXsLcWsqW81snlxyO+3CnsTj2FXKKi7PqXZJ2ZcuYLKJZLm4iT92N7PtzjHOcfhWXdX1tHeWerQTILWZfs29kbIIOcAYyOM80sc2pT3CiSWzit3UA8gs/GGIxkeuKwr+GT7bdR2EMt1LDulLMDtQc5445z0OPxqacF1Y4ruXbuYSeIVaS63K8gEeNw2Ifukcdck/kK1tNgtdXWRJ5ZbmaIlRI42MFyR24PIOM1iC/tNMtFsZreeQy4mlmhUOHJwRznkAAAcHoasalO1rqFlZRh4rbz03ebwGgwCBn2Ocj1POatxvohu9jRm0bTbSMySiZkQffaTnnoOB6msfTp9RFyjWkzqwAEkYYbWx0zn2qz4mN6dT3fettgI2KSAOevvmqFnezWisI5I2Rm3ZY5546n8KIJuN9ylqtTdg1mO8gMGoQCRTwWXjJ9cdj9Kt3SzKkLRYmgVdjSsf3iKR1YHhxnHHBrl4GnnaXZFJO2SzeWhIyewx25rY0A3dpetb3iOgkh3pHnKcHoOeuCM0pwS1RDVti0LBCHyxgvkQ4NpI0SEdc45APbpSxy2b3dvp0PmAtCHySSDg8ZzznPOc1Hp80+naTP8AakYzK5EUbOpcggYHJ9c96t6ZHaSXH2iNomuRlm2SZwzAbuM+386yZN7XLfk3aTI8LRLgkSB3dgw9vf8A+vVK5to1kknuY7RJJOMhGO/sC2D7jtUmsXr2k1g28R2zTbJnI4GQdo9smsfxDpr3l8skBjaMJtkj3ncXJPYfUU4K+7EixbahuL2s5ng8k7ZEBDYAzwGBzjj60+aeJoFmjtpCoY5kS4ZNoxnPrnHtUV59lhvYPOgkN25X5Cu4YACnbjuA3rWja2CQQFJSZs8DechV7AegxTdkriempT0jUJLq3MyXCXNvG4R2CFTHnHHP3uvXFO1KyiNxJdTwW6wLGcypCpkH97k/4UtvZwRXzpPFGWJLwOqgHBzkHGMnAHXPWkuryQafH9nmt4bojG26OMY4OR+VN2v7otnoUbWAziOWF7N5IsFXSMoJFP8AfXbz6/jUt3PtnjSaysmjYHdIIwScfewCOMZFU1huTHKLN7CWfhgkG1SR6ZwP51FZXl3azSJfWckIJLTn7wwRhWB3H0watxTKaZpRLpcrlYLe1LoccW6jBPvtrKBW+vJraG0soIoT99rdHL9uBjjvU8t3ptrB5kUDSM52bWTMh+u7nFW7YwPButwoyMOo6g+h985qbKOtjPYwdStNLiuIxc6XaTvIdqSxwoh4G4hhx0H1rNuIoZisU+nacokkMYb7Op25xhVwPTnJrUfQzHLC9rPuCS79skhIxgDHA9qSOCaWWeG9UBlYPHJGMKRz+o+lXotUVp3K9/o2niSMraW6AnaWEKcd+mO/Sin6isAPkSSyCVxxJIeOv3QenP50VO44rTc9O8TRW6apI0aqkps5ZJT2PTacevFcZDM0d4hty+9vvSJxgH3HbpxwK6Xxr/Z95qiRIxkuY8LIQ3yqP7vueaw5IpN6QwBBGpDDnBGO3A9q66WkVccPhNWC/wBUktprCWeaRQpBIHzsAcEbgM57fSqsFouwLJHEq4wwKjr6E4zToPMd4SAkbPyT91vbv1qWSA2sg+UlQSzFx932AFDstEUlYcIQjcKAuMZPAxVSeNIlYhm3NwVBwGJ9KtxSL5bbnZnxuLP932x6f/Wqq5ZLggIu0ruyORn6f1qFcroXbW5RJfJkYCUYXzDjB9PpVp2RAFch3PdRkD3rNjkDb41B7ZZh36/jUc0QKHEkibv7o4X8P8ahxuwTsWrqR+rEKp9ePyrmZ5ZJLp3ZmDN29KsXMknlmJt0mcLvBx09R+VV/LCsxzz0OelKK5QuaNokSvbh0yoYE5PvzVnVLOIxwqq4mvH8tR1CgnliO+BVewTcioqM7hCyRjlmxUdzeXEGvq9zbFDaovlxsT867eSOevX8qp3buiX5HTpp1sliLQFzDkklThj+I+tYkTGJ/Ksba30ySH7n8SuCQo35A7gc8961prpdR0+RdLuUFw3KgttPB59x9aowaVcm6n+3XFsy3MXlsoiI3ckkdefr2xWC0vzMhPuWiL6K6i+0yLPFO2Anl7fKP17jr1rPuhf+UTqD2lrBFKwDqDlyc4YBsD9a6K2QQW6xKpSNBhcndx9ayRFNfX029ZVtJQGjl2gYwMfLk5BOTzipi9bgnbUwzYwMlw8jElMFUmAMsxycbT1AJx09TXYwRNHbBXI81lzIyDHzHqR+NVrTTLe2laUeZLMQB5k7mRgOehPTqau8jr0pVJ82wpSuU9J02PToHhilkkDOXJkIJzVHxErbrR5QJLNJl82FhkN1Gf1H5VvKO/aoLu2iu4mt51DAjp0I9x70oz967EnrdmRaada30M6XVjakrIyHbHjPv7dePaqAttLtGKmKe8WMjBciVQfxPaptQ0W4WKP7KY7kxjKl5Cv6dDVa6tr2awnF5LtYuse484jJ+YcDjqM+w61pp30NF5M254lljWNdnlnttyCP6fhVf7Mlmqi0tI2EsoEo56Hqe+ce9U53uft0U8JjS3bIDSuVRUHAO0EA5/w9qsapbXeoaMUspFimLgM3QOo6lc9j2zWajay6BbzLLW88MSiG4TanTzIwAB6cf4VPNDFKMSIrqM43DNVoLx7rzoLZIPOhIjaKXPBHfIyCD2xRf3s1jGHms9y7QPklHzN/dUYyTRZ7E6kEelmC4WSznkjiXn7OzkqTSXdn9oiDTQRI3AzEMyAZ5wxHH1xWlA5mi3tFJFzjbIMGmiWKUyCN0coxVgrA7T6H3pczuF2mctpiXbXMtzLMbe1ZGiQhdoLbtqyemcAexrShtri9t4XlldJ4WO1x8u85xhl9DgUk+n3tvbmOymFxbjKi3lABCnsr46jtms+V7y0b93cOgKhRHdRbWIA4+deM5z8xIrX4tmVvqh66Pb3U7SXCuzMRkA7GZsAAEemKyoo4YbiOZbKS2kdQ3nNIypGTjhQQc45zyO9bP9q20725kjeMFwHmdsjHP909eg5/oKz9Saae7FvY+XdMpHnqqbg6/eDN7HIHHOc1UebqWm+oviG91KGyktbm0+1I5HlzW6s3IIKk8YIptrpk9zfG7EBSRZFmZLjd8zE5Ow4BA9ua0LNY7URQ2l29pOxCmBleSJT1KjcBjvjmtK0uIWunBQR3Mp69RKFzyD7YPHFJyaVkiG7LQqanf3enXFt5sEU0MsmwSx53ID6joCeAOf8ACtC3uornd5bD5TjGRzS3lpDeQCK4Qsm4OMEqQw5BBHes6/0S0mcE+cr45dX2nPr06+9QuVqzI0ZfuhuhYkA7QSMnA/PqKzHnFzaSpGA07AhcHBdRgjkc9COlWbb7XbKwuSLiEHhwT5gHT7uOfX86o6xaR6pJm0u5Le4iX76AheR0LdjTikEd9TMmc2lxGkAxk5IQhn3dAxYjJPtwPzq+HuXuLaG4QMk6ncd534x1K42gdulVzp2qJA5mZ5I9uCkbLk+5Iwf1qTSopIY5BDZ3rSy4DzyFflwMAZY5wPoa0drFSta4yJZ4ofNtm8xWuUAwgyVwA2QOB1zx6VZngIkkaOQIzn5wVDA/Ufn+dSTxW8l2Y5kZJXG7ashw+O+AeMVE1hboS8KmKT++uc/r1rNshtEFvax2cLLCF5OSQMZrCv8AW3stzXEQkiVypaL19Ofof0rTvJrzT7VpZniuFTksIypx34HHTPNZTTx6m1yJpokt0KsCw+U5BPU98Y5/wq4rq9RpdWRW+p2Gv22EDDLEKH25Bx1GD9aKy9L0/wCyQsYJo5UU4Ux/MFPUEY9+tFaNWfuPQtJrZnu0fhoLIrERbSo3BXYEn1qrf6Q8DHbt8sEEAMTXWjlRyT6nFIRx/nmslVd9TD2kjDuLW1tdGmmESiVk+RgPm3dhnrXKGaeUFod29HAJIGAO/tXVeKHKLaFQG+c4BPAIHUisFFUsXT5GI3Eg5yPTnp1rem/duzSntcqW4jmiMIV1WFiVYZCtyehHUUqgrExhR2APJwSSe/XmrBWIDcuemTk5zj8BzSsXAI2ZYjnBx+Qps16DY5YdoZ1bJwCNvNVrgIjBcgcnjPanvAIwoilCqQcccHPPPvmk2bsP8j7+SB/DUgmUJlUr8yjK9c+vrUAickjje3PXt/nFaO5WjVpCCR97jAI96saTpRv53mlBS2HG4cNIfY9gDQ2lqwukaeiLaPbB7WEKxUBn243fj6cVS8X26yWsUm0EqdpPsf8A69dGkSRRpGi7UUYUVg+LZkWwjiJw0jhsDsB1P06VhB3ndGCd5aHIafZNLqsUNgQvy7iwYgKQQc5+nHFbV1Y6ubtJJJ1luUJaFVfoAQenA6ZHPripfDlqLq0k1CJyJJf3KqcgIoI3EYOST9a0LOWSyNwt8LuRy5ZX2GQFB6bRwBycH1Fazm7u3QuUtSOSzvLl1MjEZ3HHmYC8HbwPw6VsAYxjAAGBVHUdVt7RI1SSOWeVlRI1bu2ME+g5FSRWz42XF3M8/VjGfLH4Adq53dq7Jbui05CAvkKo6knAH1p+MjsazrvTI54JgJHa4dSqSTEyBPop4xVKK5a3l22k5nhi4ljCfImDyFdiOegAyRxRy31QjWvo99q26Xytozu3lQODySKhtNOs4rUqIUcS5Mj5LFyep3Hk9BTmkeS0laaOOWGUHAWZQoQj+93/AA/pWTYrbWYa7gFxFbzITHEZAdp6/Kn4H170KLtYpbG0EWNAqKqqB0UYFQ5CsgY4LHA9zisOa5lBddSnlh2oWSRZ0G7PI+XgcetTrdxrpoktLtzGq4ad3WTaT7EEk+w7UOmxpFfxSYY7q3a5BwkZeM84RgScn8l/Kt3SpRc6bazBt4eMYPrjgn9KwNQuLK9ltJ3c+bGAFL5KP0zldpBz26HkVt2dyy2qNLBtjOFTyQSPYbeoqpxaikN7JGQ0N/bwXIvM/YI2eUhGAyuSQOOc8d/X61raQ1pdWsV1aI21uQXzuU9COenSrcE1vdNNHHIkpj+WRBzjI6EU60tYrWERW67Ixkhey5PaolK++4m9BHByarpbxQIUgjWNSSxCjGSep/nV5lwh4wR0zTfKO8t1BA4PaoTEyts6nHtTJYknhaORA8brtdSOGFR3l/a29/DbuHaZmUZUcJu4GfbkfmKtXDR28Mtw43LEhYheTgDOB78VVmKzRyFzpk9paTxG1e4jQbovLwxX2OTkjO7jkc1a0y8tbi2dNIULd5+eMptZCT3Df0zWpHeXMs4H9lypbEf60zJwfTaD/Wn22p2kpPmM0DgcrcRmMj8+taNtrVFNvsWZE3xtG2CrDGDyDWFJYXotiEYBlLfKG+8MDGPxz6Vfv9T06aGS1SUzyOCoWBC5DduemR/SptMNxJApuFaFRwEk++w9T6fSpScVcSulcqt9ok0p0Q5vRDg7SM+Zt9u+axbO/X+z4xfzFnDo6SHngEAnPXg8HPrXVzNFBG0krLGoIyxOK5671HT423CJr35zIJk5UE8EAjvxjFVDXoNPoascsUpHlSxuDyNrA1U1PTRcHzbQrFdg53hivPbOOv41ThTRHtDewrJBDFJklCQd3HXB6dP1qW508agjG3vVkt3KhiRlwgOdoYEH35o5bO+wloPuBaymOOdGWVMEqCVLH1GOoyDVbVbXdYifT42M0Tfwn5+vIH6URyarDfBr3ykjAwuNxTr3PY0NcmbUTybSRBgTBg0U2eoIPf3600mtg13K2ibpJHllH75k+dmQqxweOoHbFX5sIkjNgKASfYVVnvg5w9xE+zDGSBvmTkDlT1X1p1xcxyLNDNFghtkgPAAPQgnqOn5jNEk2xNNu5X8621K0Y27CaE9QM84zx+OKw52hltIYZ7cQiZ22xSRhOM4x7Hn61qsbGyjaAw3ERdh+72kFz14I/p6VWvbSO4aP7GzkFd21AGUfXJHPSmkk/Ia0K0KBLR4J1MKsdqkgp79RRWhDbXAwbmYNIQd8X8OPb8+tFDeug1Y9sPOAvAAzyKhlwoLMwVV5OTwKW9u4LSPfcSKgJwB3Y+gHeuS1/V5LhZUhZY7bgZYfMfqOeKUKbnsYxi5DNWvzeXQKqDGoKxgng88k+ntWMweXh26nbhc4Udh+dPeZ22GMB1k6eg9zV22hERLM3JQBnPr9fSuq6gtDpUdLEUlksTtJAGJC4AP8R47YqG7Enls53Rl/lPONo9c9ulW3vIPJDxshbPfqT/nNUb66ja2ZNjhByAcckfjUKUimlYsyN8+MqAw4HoPWq8kchC8+Wcgsqt2HYVGVYxwwhWeaRvlB5xmuhs9GWNB9oId+Dkdj+VTKSiQ5W3KGnaX9qnW6nZvKTpGRwx989ua6Jm7AdB0pmUggy7KkcY5diAB9TXNajrtxLMiaWn7g8maROvpjnp9RWVnUZk7zehv3tzHaQNPOxCKOgHJ+grjUuf7Q1mC6mhLJI5UQbhnA4HX8z/SmTXUjtI95I0zq2Ao55PGAKlFldRie7vIjFYxpuEbgKZmA+VWHUjPY4rWMVFeZaioo6q+JW0kW0MQmZSIgGCjPTI/z2qrNd3FrHCkluZrgoXbynCrhQMtk+pPSuR0oxwapBJcQ77ZBncV4BPBwO+MiuvntrRZkO4rMrBgBIdx9B1zjPbpxWcoqGm5LjysxHd/NZvsdnp9nG6zvcyN97HIHAAJGcYyatW7yT381/p9rLNE6YDyyBBKOCNgxnA7Zx1NXb20gkuNNE0SMkRkYLgbFYjgkfnWgABwBgD0qXJWCUjBv5U1ezDWdy0MEbfvXz5ZByDtJJHTHPXrVFb3S7lEivLVXnP3hbIHQDPB3EYPbpmug/smxDo7W0bshyu/5tv0B6Vn+KdTWwsIraIeW90zQqNvAXHJ9AORVRafuxHF9EXpoVu7a3ksEtngQEpHICE7Y4wcYxjGO5pt0l3MrxyW+n7Sm0OdxK/QY9/Wnb7XR7C3hWQmFUCRBfmeTg9Mdc/lXMa3res280aeVbRJIwYhCGkCZOQfmIzgHpUwi5PQFduyLJsdM0u8MU1wXuWiDCIhVOBwDk8DsKr2FxD9vur42b/u0SLylAk2KeBwvqeR06/jUPiO9tbpEtraNI4AN7SOmTux1B57HrU32+4ubW1j1GFreNzua4Ee1nAGVII98dq2UXa76mivuyvdXkNvdSpdxyQT4XEQtdnHqMscfX2qaFpdQl83TrW7+0ooCsLhAoI+6XHXH41f8FTJcaVfyXrhp2ciZJmB+UIOuex571NqMcSadZwWDRpI0rzK8RwYxknqOxzjvRez5bahfWxo6jDMH2rHapEDvZml2Eng56eop2nyrBK8L3v2lGwUducHHI3E4P4Vyllod5d3qTXSLLZNIyySytuZQOO/v7GuhmbU/tNvYuLT7ApKvPsyMKOAeMBs+3as5RS925LS2N5cOMqwO7ng5qhLrOmxSBJL2FWzgZJ5PoD0NczbQaS2kXAaPzL3eybkJ5OcZGOMY9PetLWbq3lh0uGx+0JYpLu86CJgFVeynGc/ezgdutJUlewuQuC306+u47mO6RrpX3qCy5B7AjrjJ6VYg0xImzKgwqbGZgArAjk+341n3/h7SX869urqURuu9W84Y6ZyD1J4Pqa446LetZRXkjsIrobg8jZ3KTkcY4yKqMFJaSsNXa0Zrax4c0iaSdINUihuGUbYjOm0nAwCo7HHr71a0XUnt5F0e+tGDQR5RnO/zEHVs9/61yUa2xjdGEUbjLIrDktjI46VHYTjTdRhuJIZHKoo2nk4OQwXkcgEY5/Ot/ZXjZu5Ti+p3F1Jp+rXIhW5kgltySUA2g5H5Hj0qlcaZqcUbiC5FxljzIzKSCAPfPtT7yOznjN0ZFERUMjSN97JGML1z9BWTrPiFz5lrpcrx2+NrSOCshPoD29OQOtYRjJ6RC3Y3Lm1ubjRzDqklvCoKlpA/GAc9+/Ss5tZ0GwRYoDJcqWUFYYxtB7EkgDiuQSOSWFzIJ5n/AOmgypb3I69+9RwOwz5rZznAwvGB/nmtlR7saWljq38XEEpbabAluchkJ659ccVh6ffmzuYZ7Qsiq3+rfIBU/wB7GM47VTaKRJnJYeW5JZh0A+tOPlGDLqRIwLIeBg5x+vX1+lWqcVsNRR3UOsW+oxyxRKVvIwWjt5SMsR0I9cH8ar6bCLh7mO6VRI4b5SucNn58k9cHb+GOtcXI+y3jZWb7UhURsCcjFdP4c1Wa4iQXRMl7B2/iaE/ewM8sCAfpWM6XKm4kSjZaE72f2O+s7ezDBhIJHKLtUL3DeoxniraTRRSOnnLJBExD+YpBhPOME8Y6jj2qW+tf7ReK4sLtFK53PGw64IBBwefrx9ag1K5dLO1EhlgMjqkrAcr+POOayetkRuVLiQamrJJsSSMhlAGWjPY46kHHasiyt7i11JpmWSYEYLQDcM55Bzj07+tat3oU8k/zX04j74cB+nIyF6dO9Yl411DDLbB2bbgDdnPAIOSOvX+VXG20WVFXVkT3sn9ouYoiYpISHSTzAM5Iyue/4UVUitrnWJILlRbQqG++CV39uhz0oqrqOlwdkegXkjy3BuMfvG/jf688D2zSxQSThWY7snGcbR/jWoIoIZVaFeVOSWJJpskpLszTYYcqAtW59i0ikkf9nK+5ipIyqlcE+w9aoSXLumBEVc5468+9TanevdSkCTDhcKAOPr9aqbEijUf89GGQCc/iaaXV7hcUHdGWbBZeQqcmoy6xKxU4Gck7SfwxTHYpKEVUEjPtQDjLH1NdNpPhyG2mjuLv99cqdwGTtQ+3r3/OlKSgtROSSuHh3SpbVftd4+bp02hRwEXOfzPGfStr5jgYzUC6jayWlxcrLmGBmWRipypHUY71najqXneH/tVsHj84EKDjPRuvp0rmcZTepztuTuZ3iG8Fy3khRJCsg27Tjcw9/Qe1ZrdUZ48upONp6cVJl9iYZVQjAG3pn0NV762W7xb+eYgy7+B9/BHU9utdEUlobr3UQPeSrLHLDLGkkZO2TGQDgjI9eM0y3SUyieSUtJxyyjb69unWpFtZ7ACWRYZYpUOzf1QKOdoHT+tIPKiVFmDCOTP3f4iRnBOcgVfoPcnMH9pC5W8ieSSOLfGPMVVwCN3IGc4/CqNxbxznyNOuZWvHUYSaHJBz6rwAD1J4q5YqDfQmzd4mJ2glVwrHtj0I610EdtDoiSMWlk8+TO5m5HcDgd6zcrbCcnFmeLG40+aS4nuIyo/eLCmMuQDyc9Bz+ta8GorcRQNaxtIXK7geCoORn8MVVtonvdPe5SCETSD907sSTz3OOOKsxfZ9H0ySWdgsMZLMwUk/4k1hLXR7kSa67l98gFgpYgdF6muE1JL7Xbl/svklEYI7K3CZHK5I5IGc4zite3vrvxLHI+nsbTTozskdmxLKD2UjIXjHPP3vasm/udPuNQtFjgluLWwzCFjwnmHjAOcYUHg9zmtKcHB+Y4aFe2gs45BJql+kF5GyQxgsp2xoo+U7cjrjrzxVfVrgTXU0ccglR22Rs2FO3HXsMdeTWxfeFI5bOWa5eC0MMR8tbdMgEZJ3E8k57jHArk4UEMSyzMEXGAqjpnoPpzW0LT1RpG29y7oWmW14832u8SzeLCqkmBuHfrjv+NWvExvtOe3tZ7lJrRgJEKRgHIyMn8Md/esyUwsqozMwB2gAHg/n/wDWpTaqbjZEzsVUrtJzggZ7/lV2967Y+pNpOkRX9sJ0vUhlSYI6OOduRhgOp78D0rWKR6JqLwSvvDRrIJiCoYEe/A5rFuIp7W+jXzESMosirGSM7s9Dj5SPX6Vu+HYG1+a8s9SZ5Qlttt5N3zoA3OG+uBk0pXSu9hN21ex0Ph++jurC4t9rTbc58oZ3BgePY8H9KshbjTr2z+wpGtteSbJlkySH2khh+RGK4S21Ka2D3elCaC2LZSN5ATuwNwPHI5q0NcvjqUFze3LOIuUTbhV4znA746nn2rN0Xe62JcLu516aFAEWIyFZo1KqUP3+p3c9Op4qfT4p0smjaWEy6d+6iuQO20ZLKeOmB+tR2F0+o6jDcGIQiMFMB9xOAT/WsnxfiTUpoVO1mjRDjOGJ559cCsUpSlysSu9Gc3rtnawasY9One8t2QSMy4b5yckAj8/xrp9Dll13TEtin2e3tTtEqnJY/wAK4Pt1NcbfIYpBbxBQkiiXcjFV2+mOvb9K3fCesNpiy288BdLh/MjZCBzjH8gK6akXyK26HJaabkmueHPsbLMr+ZahgRgYYPjAz2x/jXOgI21znEkxjXcCuDgYPuMV0HiDxBNeWzxbBDGuGK8Nkgdz+XGK5+xgLyriOJSBuBI5UdgMep9emKKfNy+8Ur21GG1FrL87/Lgom0Zx09fpSy2bSuBMg8xxlCW43HrnHHpVqeONdQlilYNEkbFlbLdh61LBbNNbiUw7Y+pJfJI4wSO+abdtRmXcK4N2schUuu1/lyvHrxkcj1qoAzwkOW2xose5QCcjtj8609YmWO18p0LyyMFkcYBCgjJ/lWbp6tGGYqNoO3HUbjx/PBNOOquBTzItwY5WHznJfGFH19KmuMmNPMXfGAPunAXuMnHHWq1pJdme6S/giQBfMjC8hwNxPfjoK0G3mHzzzuO4DOTlgOvtVsZC9uXLBcHy8LtyAG5xkH/PWiCVbKW3uIv9bBJlkUF92G9enoOKTD2rFGO/LFNrnIJPHp196YS0RXzQuCSwU87ccUbgdHdXn26Zm06BdtzaOrMsmS4Vui54yOTjvVuxvY703EkkBS5liDSsuSksYx8yfT5TXM6VOZNQtbWB9zeZuzyrKQMjaRxzjFaHhfW/taPeSWmy/toi00asNjxk4Z09CAFOO+TiuecLJ2M2rHU6dNNPZ5uFAlUlTtOQe/FZ2t6XLdTpcWcixXKDB3DIYdQParF6xa7t5YZwUuVMOVBXnPLAdjgHk+nFRWEs7QzCJWlMUjQhZH+6VJ/i5JByPeuezT5kZbaoxrONZoWtLzTLyBlVuR8yDvwfy9aK0LnUsQSPI32cwIXl+XevJwo9T+FFaJTexouZ7I7tn3McqFbP93oPWqFzevG8y4Ty9vzOo5Yjt+npTtQdQrRFW3FckhzyM9Me+KyfKikjLtHtxkfOMDr/APXrSEerLfYm81IlZpM5BI4Gc+1RLIZZdqjMhIVUxyTmm2KhlnSVixdyd2ccAY49P/rVv+FrcfaJ5XVS6KFVscgVU3yptkyaSuaGmaTDaBJJFWS5HUnkKfatA8cDFKTzxTRyeQRXFKTk7swbb1ZxXiSwtpNZDRJy+GmXoPM7H64xSadd3cLukLDy3GBHtyM98A+5NQSAXepC+DoZHL/KT0zkD8eBV221GOyvwZR5m5cH5uQePyrqd+W25utrCS2jwt5dzGVVhgA9xQ0VjJbgTlipPRB/QijXNdicw7FAjBJyWGenJPoK5yS7lJMYRJi3zKhy20dMY9cYojGT1eg1drUu3IjjKmPcrMCkMcrdsgcDOPSqyLvkaUPvR8l1B4Hv7cZ6cVA1/GZLhJXC7EwJWUfMQOduT7GuZn1q71vURomgvbxWkab7ickyblHVMjsenv7dK1UWM9G8HSJqLXF6sWbOPals7DAZ+SxX17DPrkVdutMvbiKfzbnzd6NsiZvk3Hp2yAOe9crdT3l7ZWwu54pJrZmaN4IhGATzyg4GMdferd9r2pXaKiS+QY8hhGMGQ9M59OvArF05N3RDTvc2LS507QYninvPOvcYeJX3EEc4A4C9e+K5p9QGs62q61KiW4zsjYHy0Hb1GSD15p9he2Fjbwyahpzzh2GJd3TJPIHrzzz61nPqEFprTXlqj7IZzLDE5BDDocn8/pirhTs3pr3HbW5q6hosEF9BHpsUn2Egs8s+/ap74/ADsakMUt1NDb6PbraWRtRJOWCrI435HPP90kVLN4vnufLaHT9tqSBLvYs5BI+7gAdKwNS1ebU7+eSISQxzqsCxhsDYOxI/OklN/F0BJ21JpJ2v7+8vfNllhyWRpSCQo6Bh04HH51RvGnAV1CyxzEcSjrkf/WqeJoba0dJH8tWGyMIoKlsY5Jxx+vWknY/aLWIMxDOpY4BToTz6Dp+dbrQpaFcxxRAAxMLcHogLEsOwx3x9K6LStN1GxEWp3Tm3TaUZlYNKFYYGRyDk46Z61hXVxnO5DIcHjbkgeh7D8q6DU9Ze20vSbK3uPtE2xLhpUx8gXBVOO+cDnris582iXUJX6ENtLp0HhiSxnjlOqsXUSbSWUgjHzH7uBgY4rFsG8sTsrTK6KVdzk8Z5BPuKvXV3LfXbyXmZ2mIUFTs6dxjPT+lQPblAX81t67sY+8qj+HPfr3FXDT5jRHcW6wTBbdR1xC+SD7kjv7cVcVkEoWdSUb5dxwckfy/lVKOOFr0xvcfZucYYZQ5HViSMD6CpVZbW62zRiWMnEhgO1SMjofwzV+QF6yvr2xhaUzFCj4Mg24GcD6Zwaq30xu3kefdJKxO3cTx0GSQeD170yQQR3ODJ+7zuy+DvHq3Tk/lSI7TICCCcb2DnJ55x+uOnrU2W4DImTzQgJecDhApG4Y9OM+lR3AAmZVHlhAeFOMP6nvj+lPmuI/s4lZemDsQ/NnP3V/Gq7SwrNykwUDmLOSxByD16c8/SqQImkjmlBmAYr2kwoHHv9aW1bem6YxEx/ICFAK9PvYHT8+tRHzIXAl27yRyrEA+g4xgUjqZYEmKCLdgbD9/I6nGP196W4FtLk7ZJAv7wMNzBMhcnufTpUr3v+jvsIkDZI3HggHpnPXA4/Cs1wHWMeUI2Y5DKMfUkGg2yi4lUXNvEVI+9wGz+NS4oRHeMLqISzty4OxycLn0P+eoqJojHEqOQI2/eEnJJODg59Oama288qRJG6bSAw5Y/X8vWrEVrJe6jDaYXZJIiFmGc4wWbPbAzyPxp3SQ2zbtNb0iZLXT7+1WRIVSKORodyhvu/wAwvaudv4BZ3t5ZskkciSH5mXOUz6jr1BzWO0Md3Ney204t4ppyYUJ+bbuyDnJwMEdPeti51STUJbSc4D+WkVxlQBuXgEHvkEHnFRyKLuuokrPQoSAwzZDAxs+4kEMeOmO4HWrtwplt7YIpDE/KwwOTzz+FNltx5jqzpEyAqjMxAJzj8e3erV5EttpkcgaNpUXO7Hykn+f41TexRnHzLTVkexYMY8PbvJwS45I7ZHJzUIbypFmV5hcBi4dBwpOcgDH3TnBGKnt5EaV4S22Ynkk/IDjPHfpUZ82ODmNHjQfdZfy5HU0eQHa+FgU0VY8EKrsF3enX+ea0X6NtO3Pf3rjtF1W6lmtNOiuPJWZzi4MYJbgnbyfY1oP4gEFvDE6+ffyM8ShCOSp27iOo5x0HrXHVpy5jncHchdLbW0iN8cXKEoHRtqnoQPrzxxRTfCGy10dxdyJuMpYyPhQ/TGM9cUU5NxdkU5STtE65n3TvM+8DJPLcHP8Ah6UtvbXd9chrNA6ZI3EAqOMHOeOM9Kh06OS/ZrWBCxk+bOMKB6k13enWws9Ogt8KCigHaeM9zWlWpyaLccpcqMFvDkzFWa9jDqflTysqP1qzpmn3Wm3MjMUmjl4Yq2CpGecHr1rY7sxGW4pGcEjHII7VzupJqzMnNvcdn6Vn6zcC0sJZMsC3yAgEnJ46etXGICrzgk1yniuS7t9SSd5iNOVAVjB5MnIHHelCPNKwRV7GRqMsFvasCFi4woJG45HQZ6c1o+E9DR0bUNRt4pHnUbUcZ7/ePbkAEcd656B1vddggWMzzMVGeD8nBOST2GfevTX6nHatqsnFcq6mlSVkUbHS7GwZjbW6q7ZyzZZsHtk9vaqHiaS2Nstu8dw87nei2qjzB6tnoOMjnrUlxdy2mrh7uYQ6e4EabsYZ/qPqOuOlUfF0N4kX27TpDHcRqEcqSGKluBjoetZxvzJtmaV3qZuleFs2s0mpwpLK0ZEUTHuQfv8ArniuQ0eGDTLSS1RI0dOCycBiOT7V6Bp3iGxfTrfzbtTP5eZMnJBx3+vbFcU2178SMpERw3PqT39e1dNOU23zGsW7u4v2ku8ibA0rLgFQOnfp0Hrn1pJJZEglR12yLzvZQW9Mj9ePerFxJCwZ02qzYJJHIx6Drn6CqTyPLcLGyyMuBuIU4IzzitFqWRqY0mWb5ZG525UAhvTJ/EfhSvLDGMw4DEBFVIgQ3r8vYiq8csjbQZGMSuVJ5wAc9TVvbG01ruMZUH5mAwCB07e2KoC/bnz22QiSIheWkyQTg9TjGOKyXZpZ3aUHIZslOMfT3qe4lIeSDT5Psyyn5Nx2g88f4VEj7iiyfMsYz2wvf9OKVrDQ+TdMqxNIIwW+eR/mAHrgex/SqU7FUiDLIqvISrKDsYbmGSfce1dN4c0kanHqZkj3fdSIsSMHByOPwNYfiSB7HXZYFDJHCQUjBP3D0I9Rk0ozTlygmm7E0rzz6U0UkltsguWKxLw5yM/98jpj361FFJ5c/lrwSwZsgDkfQdeOKjuZ7ZZmYAHcCVCYyD2zirGn6NOdJuNRghK7FV4JM/MW3Hc47+nJ/lRdJahsQagjs4M1yUts/OijLMox82ODjHP51asUjJjNqZRAV27mOAR/eAJz+B4qO9sbm9uYbi3i8/eoaR1Gdx5zj175xREv2cbWUmRH2MAPug5+U56HrV30sMY5VSrMqlgSQGz8o9zjHvUCI+4sH3xKAPlkAGAeDjv1HUelWryEzKphidmUEYAyc+v6fpWfIZJY4vNkicAhUO35U4yB04PFCAt7kiPlrE48tsZ37iOc8+/P4U+VBjKLhOFLZyBjoPQk/T8apWkc6ylr1zJLn5pNxJHHTPWpoFy86Q4wQyxDcCVwOO/QcUAy0rb22wJvP388jAPOF49/1qHMRDwqFeeNs43cA+u7I7+gOMU/7MTOl04EsRUKz/e2tngn2AxTVtjHd2+9dpU7yHUgkegyPr0pXEMMhIRXSRlHBwo46mrDyJyyRKsrDO8TEBQAOpwe/rxSJIhVmmw8gB+dRgY9Paq7gRBvKchXcKcEnaB/D7fhT6i3JkWAXCqztHGwODyV5GTgH+majuvJQyCSPGPlWQr8zDt68c1HA1vEDI6FmTAJznOTgdT0/Sp7hoWud9rGwPzABv4OOBycevSk9xDVtzbRFrOFmlmGFUIc+nT8c1oam8eh6O1gqrHqV6mLiTdvMCN/BnHUjr+fPFT+FvM0l5tc1Mk2Lp5VmicuSTzhf+Ank9q5SSS6uUkmll8yWQSPNKCOfqfYdqj4pW6L+vwDdmZdaTqV9dwwxPtVDhmlJ3IoPv2wDxitiG2jljjhjjNvbR5KRo2dxP1xzx/hWdBEBckK8ZlRBjc4Lc7hxnmte4nXLLACgBIbOPu9h1zx/WtJX2K6lWaRgUlPmSIDlxgceh55P5024muJ4DlcWxOPkGM8ZGfQ89KW42EwmAFgp2yd+eM4J+hpwCSeWkMEm/eS5HbPC55+tLzC4yzcL5CTBXAJw25sEk4wcjt+lSTR4tW8uXByQ2R157elTNZJarIpj3HaOh3ZOT/9aq1mzb5Gustbhdu3HA/D8KTd9UBTXMYgeOVyM71kTgqQeML9eeK7DRr+yvbLUGW3itb4Rs9xsUcnH31Pp7etcrex28wL2KJ8jrtA4JHfA/OqqiGS63SRtsRBkYOQwPPTtxUzgpolrmMbRt93LdQ3EskkUJVYlcnagI3MfxNFM0Rn/tHVWJUMTGGOB0wOB+GaKu7LXU+ivAgeBdQgdQFV1KtuySMY5rp5WABDbSD2NYHhJSzXsw+4zKqjvxmt2aPf1OOK4Kr99nLP4hHYCMZDcHjH9KhI2tn5sZzjP+NSbWHBJAx60yUtuyoznH4e9RckFIMh+Xac96wfHUsK6Jh5I1l81CiMeW56AdfWtPU7sWGnSzhdzIPlU/xsTwPzqlp2jRQP9ovQLi+f53d1B2tx0zzx25q4+6+ZlLSzOei0CSz1TS0gnVkaQPJuH7yM43EDjkY4/H3rtyT/AA4zWab+CW/tTBLG7OrRkHIbaedw46ZX6VoZ9+fapqSlK1wk29zmvHEE81hC8YLRROTIM9MjANV9F1G7fVjaRGR4NhZmuHyykdeR2JIwM10Wpo0thcxxjLvEyge5Fcv4jk/sPQfLsNq3c+wkk7fugAnjHsPxrSD54qA4vSxneLrCCzvlmt3iVbhmLoFGVwBwMHuTWBGHFvsSaNsuRs5HzHBAx9BTYbe8itFuXjna3kClJJEO1wevOe+fxqnJtnmLBssGOC64Bx05yf8AJrrgrK17myVtC5vXZkyyiQA7QF+b8zyR14pHvbpsh3WL5dpVeN3r0zz6VNBJKXJbapCkhs8A4wc8+nIqDUNWghgdV8rcU2DYvLA9O/XOKtagK6QeYJA48odNw246dDnNWo1vNQSSLS4Uu1jVZHwRux0Uc8888e2aqaXouqeIElf7I9pEQChuFMasegwOp6egro766i8E+GIrOxgkm1CVN2WHBkI5ZmAGcdgOaznOzUY6sG+iKUGh6pNGQ9v9ndQMGUqqk+3Pt+tFxYWWlIx8QapDDggrDbHfIfYAdPauQv7++1RB9ummdZc7Rh9nqcAk+36VLZpAtq6NFG0xKxh1xwc9WBGSO+RVOEur+4dmaes63qeoqkVrdJYWUZHlwWrmNipHV2OCTjFbNr4lS6hC+JtFaSWFDm6RRjA6Eg4x1OcHFcbcwQsghnbzjuwGC4H4ZByefakubpYLZgqoyqCgaRcc/n2/pTdKLVrD5UbyatoQcPDpTYjxxPIIx7ZGTmrl/wCM9aTUPMtLSEWkY4hVgyuD13E4PpjHT3rldNhj2NIyru++BGwBP44PFW5kKozSlWeQA5BzjHYelJUYdVf1CyN2PX/B7RuL1NQ0uZzl4DC7eWx6lGUHj3FUdYvdJeS0FhqMt3EVLRu4b5F6FX4znPr2qo14WaVTGELHO1VIP4VHukjljliLFgOSTyP68YqowSfUFE0VknlVJfsc6WcfzyyBjjB6fNtIUcVVh1K3uwHW5Eajlod6gvjoCF43fWrmktpx01LS8na2mEjSCRUzDJkg4fvgY/Wi98LaZM4MuuafBORhDAck8Y6AZpXSdpBddSvPMtvy0zwxlCxWSULtzng4P+c1FfapaaZDG5DuCM5QNhVzxlvf8K2rTwpp2nQK13qKNIBvVjB82w+oJyD1p8dzpWnuWh064uogxZTMUKkgd1xxwO9Lnj9nX8A5kzK0/VILqGSWBrdlIJXGNxORxzwPTNSzXlq0jCTJkO3CRrnJ46Ht16/Wugs7tr3y7mLTNPRUyDIUCiMDOcnPHWptR8SNZb102S0mlH3VSByin3YEZ79B+NQ5u9kvxJu+hz8kN9GGT7Lchk+YEodh+v6/pVX7YhcuY2imHzGNUPJ/Lv1rSk1fxRLNFdpd20av0ixJtGMjoJPaobq917UJIZrnWYbC5gJ8uONZTDMo5Jch8g/geBVJvrYLspQreXUxS209yZPuDy/v/XnqBn0rXuNDs9NSOfxDqHlOFDCxg+Z5B0x6gk+nHXmo7zxT4nh0gm50+AWj/J/aEEpmXGcEkq2V9sgVhXEQghkkEtnLK0Ibekys68H5QOu7k8D1FK0pdbegasl1bVZNRlJYvFbxfLbWqvgRDABxxycD+dVivySuAF34+T7x6dMkc9u9VtburJXnZGK2z4miYQnK8ZIOOmCcfhS6Tcw/ZJTahp4gqeYwbGzPTb6ZOOvY1olaOiKWwzSJbS4e4ljsV86J/LRopJCG29yDnGM561eaL97IS8IMR3KDyx+nb2xSaBpn2HwxcPtjnumkDPJFKpWEkKMHGTnOaC4jlkDKpIPUjhjjBobu3YSdyMkITtxGcHL527B6A1e0wSOu4/MgOElA5OeT9R71RSHyj5rPGyupUbuQVPt1z0rXs5AtkMJhRgE7cfQAfjUSegypevA80ccbkknbjk/jn8aoohUtCC0kAHKscr9B+orbSNpfMkb5GI2jvgd8GqE6mMBIyrMylE3HgZHpUpgZMzMSISYnVCP3joAxzyQD3Hr/APrpsZlChY4ApJycKeV759frTkwodpBHEQflDMAhIwefT/8AXUst6rWqwwruYHLlHBA9ge45q5PoIwvB7xyfbUkeFCZlZSzbM4QcDt+FFU/D8PlT6gkoHyOhIxnIK9B70UuW+w0z6N8O31tY6dczXUixopU5J+8dvQep4qtN40SWdkskjCrkB5yqjj1+ap9T8JtvebT5U3M4cwzZwfVQw5H40h8PF1jZLKG3uRt3s07PG+OowOfxGOlc/wC63Zh7rd2Z9zqPie7ANpGFg27zLCgKkexOc/hVzwf4lbVd9rqEkH2xRlTGMKw4B/HPatlJ7mzESXiI0bFUR4AdqE8AHJzj3965/wAQeFmnk8/SMJMzHzEZ+Dk53AnP5UXhJWkrdgunozX8U7l0xSh/e+fHsA5JbdwB71X1PVX+yThFkg3PsilOAHG7bleT15wSKjktNTiW3n1a8iuhbtm3ihj2s8pBUZPTue1Xb3TY7vRks5UYhFUou4Aqyj5eeh5qE4qyeorKyE8P3az6fApwksaBHibAdD6Edu1aJzg9M159oVzcC7aGz0+SGZI5GkefcVUEZO7A45BwByc10un+I9PvoIm+0QRzMo3xmQZQ+hoqU2noEo9jQs454oWF5OJX3Eh+mF9Og6Vx9zJY6h4ri1C5Pn6PGjQmRgTEGAHP03HGfWtLxRrMEdulnBJHNNdHYyowJER++wx3wDVO71OCxS0S/kSSzukBENuNxhRR8q56sMnk9c+1OEWte4433MuTUdU1LSpSIlbTYZskqNrtHvYDqfTHTHSsBlRJI0MhR0LbSeQB15/WumaG8g0CSQSQf2PcOHWMg+YkZctyfxHuK5y6J+1mSN2BMhc8D7xrpp21saRFkee30tllYpKcswGCeuP5VPLrOpQlJdPuoywUKDNCrP3+6SuahujHK7B1WXeOdrEEt79umOlQRo4um3NHGy5YMDuzjqOMjNVZPdDXmXJPEviKQljdmM/wr5adf9oY6V0drcR+LfDsltcLC2rwpvjIG0b/AOFlJ7dj9e1cY1xNMeI1EYABYHn/APVwecVYsLt9N1OK+iCKyAhlY53g8Nj6gde351Mqat7qs0Dj2M5JzZySvd6fCyQsRIHyGVunQMOM/wBamghMq7rTHzqcxHBbZ1OPU+nJNdl4+sTqOnRanayI1u8KiRWONylgVIx3+Yn8q4S3jSFg7iQvEQVZUI8sDsc9fy/xq4T548w4u6uWHilgkZYnDRhcDCK5A69wcdTVHUkmWeF/NZGbAUEDI68cD68VoK7SIZYldlyeAp4J5zyBxVa6gn+z+Yu/qHOU+X65qyhtoUMcD5UsrADOePfitCLLzsA0aI2GPmOF3HOMZzz7CqOlXTK83mRqMtlsZIPsPQ1JOz3NlEr+YIxuK7FGAOfmyeo5xmjcEFyNtwAYfullA+hPYHBqWJ0O8xcFANxzznHTHTg4qEm381fMdAmDt2knOB0+uf50syZKXEgCRsv7ttwGVBK9O565pjGtOJyquC7SDPO35j16DrWr4enkhtLxki/0hcCEBclFJ7d8k/WsoKSpZEGxfm6E7Pc/lXTeG1fT7OfxFqKHzZUVLdDxvI5L49OmPWoqNKJL0QiaFq13KTcWqW8TZzNMwQgY6nnP6VpXEukafAg060S8lVSPtc43ozY+oz09KzLx3v8AzZbmaSYyY3qCgVuB0wMgfj261WW5EMg8pkVYlYRABiSOhI+vTnpnvWVnLcnVj7qS4nLNcMJPmB2ggJGo7Be35d6hhupFI8vYzq3lhlTIXuTj/wCtUTeY0jxvsDNl5EDDcpIzj+VMtZPsF+bZsmWVDLCxIxjOP1PTNaJKxS2LiNcht9xEino25Np9voOlNLyzIyybOAAT6j3/AK+1SLqN9LAv2q4BhzsZCqg8n2A9fWoo0bz8xoQxAXIBOFxgHHpgf/XpW7iHCefT7v7RpsnlTLkOqEBSMY5HcVp3ujWniCCS504xQ6kVCzQZCJK3qBjqRnoRzWeCkk0rRFWmC/dH3sY7AnBGPxqGSa4spor1CjLAxcMo+nHJ/p3qGm9tGDXVGEky2l7NBNF5d3nay7cHK9ie5/8Ar0RRbblJ3fy5YxiNidpTnPHv79vaus8b3BVtM1GCQTRTnfFGy/6pgF+YY685yDWT9g1PXUjv72S3VQnl+fdHycg9wBw35CrjUuuZ6Cvpc4W+1C90jxcs0bbILuQOxt1HzrvbPTvhvrzXaB4ZHWS3UeVJ/q3JBIJ988dOPxql4hB8Oww6jaXmm3gtJFcwF3DMQy9MAfX8Kv2komV5op4pPMJcCJTgdzgHkj3+tO6aug63I5J7eYtueVZVABwuQcHnnB5qaOYxssrCR0TCx8c89ciqZxcStIilWQFgXzjk9sD/ABqWRzHbRxSneJG3IE5wcYyPy71Nugxb2+kkjCZCoGC4wVO49M+1Zyb2crOpLBv4B8p9MfTqfpUlzGYnaJ1kVihG2RCjHJHH8qgd5QVZXVJByQfmz2PT61SSS0AinvHhlCeSZIZl2yfuwfx9se1U4lhLO0a4U8AuCp6npWnJH5+3AGdwYBTkKegyaz5fMgaWSLbIXLKSrA9f6U09A9DPEkMXiG5dWciW3UjcerA4opuvymGa0vVQhoCY2yQeG6dKKIq4LQ+tSMj0pjZH+NSsMkcdKYeG7YrzDjM3Wo2bSrzyyRIsbMhUchl5GPxFUdD1n+1JpI/srxeXEkjPnKksSMDj2rabGc4rnrCH+wpZopmVobmYyRbOoyQOc44Hy9PWtFZxa6lLU3mBPeoLmVIIy0jKi9AScc+lTHAJ9T1FRTxrLE0bjIYY5FZ21HfQoW9zHJbNMTEk7JvdVbOCBxmuZttB0zWbJTLGY7lSS0qYBkOSMlenb9ar6xp17pyNI2HgPHmB8YPYEevpVDT2kjv4SJzE3mKG6nnPQ4rqjCyvFmqj2Zz7yHS9TMdoyrNHI9u0iIAWXoTjPfJrZ07RYNT0m6t7WNob20mAaWTJEynOBx2HtVOdJv8AhKbryIRJcJcuyJIcfxcDPP1qndWl3pgdLhprcyLzsPJG7OeOvPT2FbtXtZ6l7jjdzzWQt5JXNuhGYycp14wPY80240xvsy3EMqSqh58s5K98n0PPeq0xSHzYpFYgHarKc9fwqyv2j/SEEaosij5g3JXC8e4Pp9aq1thsUrGLeUu7SFVyBgKM/hS+QCrQyxyGIENuC/K5HTr/AJ5FRSLIJQXaJJMgFBklgfw9uh9afKizxIJ2uUCDcGKfLgc8Z+ntQIUXCx4eFWjGMgNgYHp0/rUV15TRPKrOI85UydsjnPbA61Neyx3aMsUk5cHJFwmXHoMgn6VPpUdvea1ZWlzLtZpwQuzIZgeV7jtjPYD8KNtR7anW+K2jsfBC27OpkeKNUIxkkFBkD07156sxOWklbf1Jzz36H8/0rZ8Wao+saw8iQtHHYloVGPv/ADEZYZ+lZiSBCZJEA/hIB6Nz096mjDljZ7hBWQyXMiMshkzGGwFkOO1TRzyJC8YdmiZN7osh2gkDjHTPaoWdWLea3lxK5VhtzyMds/Wo5HE+7IZG4O8nGcEdq1KsLcWccF4wlMdwEVSrbypViM4yDzj09qAdkUbEHa69xkAHOOOhFVjAZVR8sis2doOcn0xV1SkbrcIfKMf+rJBIbI43dMd6VrANv5kmcuyIgMeNgweQDyOmDmqpWGRrePBhVk5KjkEZ569+matXV2qyO8reVz/CpAI7VoaToOp6vD56rFb2zkGOW5YqXA5yo6kflQ2orXQG7K7MmJJ7y5tbOO7kjE0kaOHJBU7gMYyc/jn6V1Wru1xrE6NxHExiRQchUUnovTAAqtb+EtMgvo7y58RvLLDIZVSGM4znIHU8A1HqBhTU5JLe4aSNjtxKhVgc52j8SazclJ6fkTdPYSfzJAQy/uVO3auduBVdHGEww2+Zsdd2GX3+nPH/ANarMEC3N5GsXmFGb5Sy5AA6jP4GjULdEunVD85csvcgEA/lz096LrYZoFI7a6lcF8gcITxjIGa5dptvi0ozeasdpkLnOR5nT8M1tbhLb4kLebKNpTf8wGOo/KsfUU8vxhal9hBs5c7VyF+ZR+PBpR0DY6C/niMBDsC+OChGBzWQqH94nyEgbtxByD7DOM9KmubmW5smcOtsUOfLO4MO3B6Hr04NQ24ZrpRKWCKSzu3QkAcAZ47dfemlZAIkhndQgmVP9ps5Pp04706/Jlty6oANp2+vfFS3Qj+2yyoQJMZK568cioZl+XyPMjVuro/B9Rj9f0p3uGxtx2UcuiaNLcuj21jHJLMoPLtkbUPYEn+RrnNRml1KMXl86S7hlYUc7U9sVf1qeC3gttKt1ZpxtWXphSADx79c+mDWc7ARpGjgL8sYCtgtgdMehz+VRCNtSIrqZ3icLJ4e1FZIUV0iIweDkdx+VP8AC8DTaZpm5njJRRuPDdM8dOKTxBsOlalDLG8BWJyCwGTwe/4U7wwfLsrIpEVm8lVUZAHQZJHYnt9K06MdjptXjRLGVcl+hOOec9Kx7e8mgCG2QI8eCrmMMQfqelXLm5hmsgCkifMQ3A5IHaslU3hxGsjKGwjAZOc5x7+nFRFaWY7dy7d67PNCya1At5ABv+Q7HUg9mA6/4VR0+ytRavfeHp5XuIyJZLWbDPjJ6BeT+PrU6yf6Nwm1tv8AFjPJ55zxx35qneiGCJjYr5d1huYeSeQQSQBt47n1ppJaL/gCt2Gz6rO/nHULWASlQVaRDEyjpkAVVefToiWJjuUC/IsijH/fQbPXNWpdcllsliubaS5cuPK3qZCW5yh+oORjuK5+8sbi0cNdWs1uh/1atGcnv14FXGPfQaXcl1+7XUbfyoLKK2hjXzDJG7MN2eOTx6UVnyO3lgD7pccP/P8AT9aKtRSBxT6H2Gc4qKTknB5p5JxgAZ96jcnnP44rxzkRGTjpWRr0NvLDBNOgeOFySAu4sGBXA/MVpnJJHH41U1fB0q83ED9y4HOOcHFXDdAtzNsvNsYpVjuGu4oyNsK/6xFzyCDzwD69q1EuI5ZHRGJeM4YenQ/1FUplKWtl5kyxXrqEDsoyxK8gjPPSo9Jgm8+6mvJopLnzGTEQwiLxgDv07n1qpJNXNHqrh4inlh0i5eDiTbw5AIT35ri/D0Bl1S2SNzlCJHY55wy8frXfaigawuQwLAxNkDqeO3vXB6DN9j1lRucKzCLkY6sOP05rSl8DsVDZlbXNNlPiLUbxom/s9J1WfYfmO9RjAyPUdDWFZbYTGZj5yAciRu3OOucAZHtXd+ItNlk1uG5tjGw8hpJIZC2yTy8cED1BxnFcvrttYW9rp1zpu8C9jMjoX8wJ04z25OMe1b053SRUXoYx8rIEisB1O7JBJ9PTrmrtsU+znaw8sMxL/eC5PH+PvVdpY5Io0WJVlVW3HPzjAxg+lOtZGCeUF3RtwGycDHPP4cfjWr1LJZIpIXkjuBGMcjuh49fbOaiigiILSkOWGcq2QPU9RyaVw24Rz3ClUYAN3we3bPPrSQeXFclYXlD/ADHdwocDnAx1Pf39KQiCUvP5aQz2sKu2ZFMwDOPQcc9fWuo8D/a21xo40ItYlLTZiA+b+EBscn6HoKwkkMtp9oM1pO4PyoxVtvJ5I289O5pHf7OrIJZDvI3RRsUi69wPx9KUouUXEbV1Y1td8JatJftcKq30cpd2EZCGPOSBjjPWsSysrq9ZorCOa4njIyqgnywBjntW94VvdZudbtokvphaK/7xJGLjaATjn6Y61vavqC+HoEtNO2fM7SyHhmXLfd+uT3rPnmnybsnma0OI1HQ9as4VlfTLhowmCygOc9SSBk1gGbbJtQnBBO3b84Prg8jivRrTxtcRMwvbZn+fCkLsbHr6H9K1ruw0zxlov2hYUSZgfLmKgSROM4zjtzyPeq9tKHxrQfO1ujy3buU7ZSSqDlMnBx7cU9AkmzJBJblmHCH3Pp0qtah4mkjkKxy252OpOMsPvDB9+xra0PT5Nf1hbF3SJG3SyvEmAsYPIwOAT0rZtRV2W9Fcv+FPDrzCHWL0xR6bbyCRN/WfaeoHpkDGan8RXsupXrrbMUjR/wB2XUDamMbVx2PtR4h1MXmpW9vblxb8pGFAMaRqcDn8D+lUpj5Y8uPHyZYMvr+HU5xWSTb5pEpO92ReRArQ7p2RcYdOeeOhGeOoq1DJaxx/JChVGAZ2BAHXHIBxz3qgCHbYq7cnh0GUH97P6/nWrBppBMkiLlQGAAyc4xgkjp6+ppy03K3HQhra5hZ1iEgTIIdSSMdsZ461Wvwn2mKSMFcHkDncfp9P50sMbuRDGY2XJUoONxz2x+HapnzDPIzqTt5+ccsOcge4xmo6gLLaPDNE6sFDAR7VXLAkcc+nSuc1befGNjGGJaSymjZlH3myCeBXoOlwolvPrEh8ySOPKducDB+tchc2cmralZ3ljgyWiSzOhGWZCoBxjPOSPyqYyu/Qm9ymoUWr+dsacNg7OuOD04qxFt2K6qsZc9ZBjd1x1/zmo2QXcaqNpj2kAquHzz79KZYp9ntlxmZshWDHJ5xzitblMeA8JHnsPJc7gWwAx5I/LP8ASrLTGFYpreFPs4IlcggsSDz2zzj1xzVWWLb84UATDKkDO0/0+vNNeBI3TYjuyjKsvXnt/SjRkkpJMs8kkS5XLh1A6nnOR6/1osJI7QF5Qu7aWVyc4GcZ9sf5zTLqbzlQRrtYcOXYPnpggYApUKujoyxF125J6g57/jStoBz3jm7RtP8AIPFzd4RAeTjcPy6mt22gNuRGZMuEKKcD5l9Rk+1c7qUb6h430yLfG8dupmbb03fMeff5B1ro7DbLdWr3HzbT/H8vGeePTk0bIL6kModUKyK+5zlQ4x8v+cUsRjSMSyeWxUMoibg7v4WHHb8M1akjLO0Nq4yAXXJ3ZHTH1x/Kqlud84W5jYmJiDv9R/jRe4yJJJPPjMqLlMFzkDPPAIFOmtNIIa41KZED5KxorsUOeDnjPAqbVo4hCpSJEZjjjjaf735ZrNlkL71llEjockuc/Tkn/Cha6rQRvTX1rpcLQ6b/AKXfkYWUnb5ak5I3Nnnvj3pdE1tL+Oa01dUP913K7XB4x255rlHkwoj+UbwW8zJwMYH9RUV06yxhGVTkFcAnGeRn3qfYpoXImaPifQLbT57KW2hMsEm5Jm3EjsR3OO/pRWDZPLby3+64McJ25Tdx0HTPeitIqVrNjSfU+tD6j9aRueuAfrUNtdR3kCzRAhW7MMEH0I7U6TO1tvDY4z0zXmNWOQjdSGPp1z6Vm3yNNqMcBdPK+zs+xieWyACQOqj0rUnISJnYZCAsc+wrl1t7hdRsp76QJFHun+0s+MhsARk+5wcfrVwXVlJGzeQ+ZDuKI00QLRMybtrY6gf0rlba/wDsweOG7U6g43yRSbgSTjJKkZU9OOQMeldENbsnmETM0cmWzvUjbt7H/ParjQpuZkijErjO8qMk49fypqXLpJFLRakbR+balHZhvTaWHB5HauF1+xuNN1ZLoRq1oZxIu0cjGCc+nemQNd6balba7kW+jJilUtleD7j1z0roNT1y0OiNOXlkVl2uICNyEqc9SPQ1pGLhLTVMqziyDxhfHTVs76JQ4BkjKE43B04H5gVxOqvpCaNYLZTXZuE4cPk4yOcL0Az6cV1kdql34avofMZ4osSQh8howo3DPHf+tcNEguI3CYRvvAgEEZP09v0rWlFW9CoK2hCImaDz1CpuXLtnk5/xNa2nXmn2WjXdrdwPJdSZMLIMnOMDnsQRVNY1cW6yqVijJZtp+Ykdvz7cVoeD4luNYmuZ5Ui+zR+aoBCgtyCcYrSe12OT0MZgLiMOzIBtPU/eOex/z3qzEoiTMkUokiH3sBgvGM89fp05qCa5eeScziNmkYchONu0Dj3zUtvPdFHjkdPKBI+Xg89Ace4HT3qtRlaCxs45X8j7Z8xDFAe/OABnGOeQKsrOkkdxIyDAOwrs6HBwP/r8U+xljkuZFfzHdVI2nOFJ4yP8feno7CLyoIiybjtyMhz0H1PFO/cbNHRdQGh292zJHLeOoMMm/KKADyc8k8nge3rWfLPNOzGVzM7nfuYksef0AP4YqvNJHHIGRwjHIZX7n/8AXSbzkF5tvTlWIYDBz+NLlSbYrdSR5GkcO3TG3DJkDv2FbHhvUZNKvS4dmsyx3xI3yc45XPU8Cs2RFij2+UzrtynmMcqMZ3Hnpkk07anknyWYqSFIcfKScE8gYzzn8KTSkrMb10Oj8TeCoNVI1HRHWCeQea8bZ2TEjOfUMeAe1JpmlSeFfD9xeXgjOq3B8rIbIROu0EY5wDnHtWRNe39qiLDePFKrgqFl+VhjjPbr2q54kvhqWrxyeaxs1gRRAR0kPLnH4gZ9qy5Z6Rb0Js9uhmwiHedrRIBnIbC7c54y3IHNV2V3mcRhSY1LfI+cjdwR1B+v07U5oma9lijiUfPhiVztAJP4cZNXU06MPHskC4O4hTywI5zx35xW1yzNhUfJEjEHOXUgAAk9Ouf1rShuZLe02yl5JGDZO7PPbGevPbvUCxBZkkQTtEZDvkI4GD3P0NaJkWNWxsUK3p83XgD/ADzUydwKKtgxeSNkvGXUcBs9z61dltWSzinYs6xEgljkN7sT6+vvWez3HnJbSRzbxgMhQg568gc5+ntWlcWWpW1vLO1o8UON7B2XZt7AjPXPJqJaWC5HHd3NxajT7VHEjt5YhX7pOOSe+P8ADNdRoXh220kCQEvctF5cjE5UgnJwD26D8Kg8D6aYrH7fcp/pU2Qjd/L4xx74z9DXSHgVzVamrjExnLojk9f8MwtA82lRmGdBnyo+A47gehP+etUpdCh1OxjvdHRbWRgVaFycMVODg9uRjP8AKuxuZlhtnll6LyQO/oB71TsEkj+1GRAiyTtJGhABCnB5x3zmkqkkhKbscHNpepRkLNpsrRgFcRjK4xjOQT7VnhGDN5Syq64BVhzkdvavV8ivO00a/OqMt2rJ9okY7wTh+uORxnp+dbUq3Ne+hpGV9zMtrSa+vkgs4QzjduxwPqSegFaw8I3zS5kmgXefm2OfXvxyR+FddpdrFZWawRKilAA+Dk556nqep61OJ4pJGjjkV3Tlgpzt+tRKvK/ukSm+h5RaaDDDrF3c2txJPKjFDI67Ez82VUckjnrnvVyBIcSs7FZQxQfIQFHfANdjrWjNKsk2nny5iCWBY4Y+o/X0rl5fLWKW6OzDMBlT1PQkDtW0anMi4u5UbzIpRJEoAPCvgAj0zz71Uui3ms7kbiQ5xkBjgjqPpnritD+ytUMBmisC0H3kV1G4k4wduen1qG/0y6t/sjXabfOQ7k6qCT054B9s+tPmVyrozJpJbglWBIXgDk7sjseKiitZGlmYxbjgBlI2kH6Ej0Na7aeEhbBbO3lXbJxnIHPasyMTIZX/AHjW6gKgILGPsCvt+dUpdhlW4SJJWWWE7AuBtO0+vAPHbn1rMOfMyI5Nw+YZGRjPUY4x71oXMz3SKbYt57Aq+7pj+99amENrEqLIMsOWLMRn3HarvbcWxzsSpJI2cYZgWV2znoB+FFbE0enwxowjk3h8gdecd/bFFVzN7Ie59K3Vu0TPcWqoJesi4x5g9TjqRTrWdLqAOhBP3WA/hYcEfnUt9G09pLEknlO6lVcDO0+uKzdK0gWErXE07T3TJsZ8BV28dvXgV5mltdzjWwh0iAoy75trD5lyMEZyR06GqfiLSX1Bo5o2RmijZBEy5U7u/XqK3ieuOlRMRTU2ncak73OKlsZdJlWe9kJxkLJvLeY23G1RjI69/Sqn26/so4isiqgIcQ+YQQCehXPH/wCquq8Q6Y+pW0AhfZJFJvGf4h3HtXN6lo9zI3mtp/lyOwBeObfuJ4Hy/lXRGSl8RtGSa1Lut2cbebrNuI5opI1E0LAcqD95ff1z6VastEsGt428uJ1+8GEa8j0PHNT+HrW5h06WHUVw0jM3pwRjBx36mqtrG2gzNEVLafJ8sRUFmT2I69z+VZtvZPYi/RMyPEPm6Y18JN4s7iPbCYwcDgDaey9Pxrn72ydNKsr4+cIJAQ/GQjZwMgeoH8673Ur64hu0hFi9xZzREs0f3t393H0pthfW1xpgltI5DGMjyiPnB3cjH1pqo4pOxSk0jziKBA6NC6pvGB7cdfr7+9RTW6IAVDMy/MS38ODgjp0PHpXWyeHLPUYorrSJfLV23OkhJx9PQjng1zd89xDI0cjfuh8hUgbgFP8AUjt610RmpfCWmnsUyEjiLsx2AfMpGM80riFIQ8U7AhidpyAQRjJ4oL3F1Lg43HAwqmrGpxQJdr5c7koMFSBxgnIHr2/Kr6jRQiIEQVC25xsJMyvkfhz2GatW0cmwyFjBEjbhg8tkevrye1TiyZb1v3m6MngqvA71XeZpGEjblRmyEYANgHg8E9aL32GSBC06MqLDFzhgvXA446mi2leO4ZwuXKktuzg+3uO3X+WKLZuDAjjMj5Le/tx0pHVWmlcq7NghQgzjJ4P0Hf60AV5B53mDMTqZCUD84XJxj/IqzbPHHbsmxTLuIVFYA+1WLHyvNxcRFiijYqkjagPU/jn86hnto5JSsZO5TuBLDIHXGMe/60X6AJBcRASCQkEglAw6g8k/n371JbF3UqoZA+MumcjHXOBVNmT7Q5lG7ndGQDge5Pp+FTwlERJIJ2wRkhgMDoOv40NAPjnmt5S4dQJwSeeMc44z7+tSaffm3uJjIF3yZwMZZ8dMHp+ZqrPGrujzSh0jJHGMj06fhU1rBKZI47O2lnecsVVCCcdCfYcjr0xS0GTSsCzujMEcjCKMk9gF9854+ldh4f8ADf2YQ3epYa6ABEOAVjI6E5zlh6jGDVvw74bXTmFzess9+DlXQkKgxgADueTkn8Ku6lqQgAS0MUlwSR8zfLGBkszEemDx1Nc1Sq5e7AxlO+iLm9PM2lkEvuRn/GsRbSPV7yWe8IaO3kaL7KcMg2ngsD69eg7VVm06yRwY4Z7q+DLKHQ7QzZDZ5+UfQ1FdQazevPaXNsGim5lcEKGA+6A3IGPTqayjHswSt1OokkWKIyOQsa9TjpUF1cLDbTzlSywhiwXrwMkCuYNlPa3YSUzIVXfGI490aHsC+CW9xj8a6CSX7ZaXCRkIw/dO0gwFyBk4+h6GpcErEtWMKTVJNR017xECFHIgjRWZmkA4BI7df0q7pa6kbGB714kkZSXQo24emTu475qrYWZ0TT4olmikuPO5ZTlY0PVjk/Xr6itsTwSwmZJVEWSNx45/HvVTaWkdhy8gjLbQWA38bsdM+1U5YJlv5JoxE6Oqrhyd0ZGRleO+RUMus2sO8gtJwTlB8p/4EcCotLujqXnSur2zg+W8Jwcjnbz68npUWaVws1uPutPBQCCYwsAQzHq3Hfpz3zVPwxGy2qOo+Ry+9ychyGIBHQ89SSOeKlM8l3aeVo5tyiZi82ViQuOOg5J4NSSy29xYy2kVyit5YRiwxkcA4zjr0696q7tZhraxNqsi/wBl3UiXJiEa5MsZyUP4c1zMdmNZuTIALeRGwSsWYpWU5LA8Hnjr+Zq/aW1tc2csTedb/u8SxrgiRcHoTnP8XQ0sVhdJH5UbgWeMkKPnYHBwuehGO/rVx93RPUE7DdRk1WxiMwltbhUy0ihWBAyB/ePHX6VEmt6dqFtHa3skayz/ACNGRld3bk/pTrHR4X+1G4ikjnYnEwyMqe2Dxnrn69ami0CyhWXCuZJFKlyxyOMcDpS9zruF11MfUfC0ymKTTbuYyofmS4k++PqB/SsKVLyxki+22zwhGIG47kk9gRXa26XtqoiYRXUag4lLbGPsRjH41z3iOa5uNPNvqemPGVbclxFKGjRhnBPfHPerhN3s9UOMnexyuqMl0cwRxqcjCAdR3xgVEbaWNQy5XIJDA9B74pIDhGVpHMh/2QWb04HbrWhBY310Axs5GCEABjs49eetdLfKrGrfcxXkMYz5oIIwGwcH1wP0orbj8PmMym6j+yWsY3MS+/cfY5ope1iJNH0dJz+NMxgc1MRyaYy88da885EQsvp+NMPJqVhwSRzUZH1NACMvfGM9qrzC4LILcJgkBiwzgfmParG0561mXs7wzyi6dILHAxKp57ZDE/d5z+nrRFXLWoyx1DzbO4mvVWAQzPExXJHBwD+NYEs9mz+W1zd3CSMcbpCOc8duDyRxitTUFtLFoC0cc0Ui7YEZS4G0ZOO3vk81Np968yIRYypuG4/JtC+3NbLTVIrzKMWtFEb7XEUCFgzbsng8dB3pmm2ul3dw2oWyEzE/NywAZuT+lPuo73Tb25uIbaa/SVB5jM3zcEnAHYDPSsy0u54prmW0ju55WIkks5YhGSPu7lPr6+op8t17oraaGlpEdxFqVyrwpFbg5VlwfNJOc4B4xz+dcHdKY5pvOOxYnaNiOoJbGOPc5rt9U1BprKObTbgwyIw3q6dQQcjB6kYPHtXO6qp1C9iL20KSOB5sy/6t/R8/h3Oe1XS0dy4XW5jxI1rPLIDmVgFGQMFux/z6VKbNkG3c/mun+tchiPUfrWtc+HbuObyra7ia2zmTchjCHblSBnnv0NRNo1pbW0M17eLcH7qpvCc4BHPXqK1509mVdGeDOY38qUuirlxgA49M/wBearPEsUA8tcEj7rYYIe5GfrWo8cpth5giWJf3kbNKCAfTg57+3NQQWyXOoR23myRpI+GaT5SyjnI7D6/4VXNYZHY2zS7msYN5GGPz4wfxrUXw7qk9tGTbqIlXKoGUZyO53Zro7TVYIT5Wn2YezVthe3ZcL2HAOT25p+p620EUrWdpNcshMbBRkI3+0Rn9K53Vm37qIcpM4rW7O706WOO4XIKjDKQMj0PJ6VmKjTXEkUbSMpHLbznrz19q7RtU1G7aeKJBCFwSgZTIxK9FB/w9KwpXguixmt/Ln3czxRsoLbc7WGOuT19hW8JtrVFJ9zGaGdh+6crI672UYAZen0HpmpbnJWJlG1WBCuD93t0/OtwaNKttbXJUC2ufkXEgUjJ6n9Tge1W9E04Xc63V2rGyjbYkfOZyo4VRnoMHJPp9apzSVx8xDpPha6v42knuXgtmO0YVWJX168HnuK7PQtHtdHgaO03ktgvJIcs2P5DrwOKzX1i6uNzWbxojtstwVGJyDj5SeSOnPA5pLH+0dQnJnMgjhkKyIH8sK4GCM8lxyD6Vyzc5bvQzd2tWQ61r1xGVhgjRYpwYxJk7lOdvH4n8KytMsJruRYrRTaLHIA7KwbaoU4kxxl2JIzzj0710J8PQyPbGaTKRZDRbRtIPYdMe/c1tCNFACKqgcYUY+lS5xirRDmSWhjrZW2lCS7RpdqncVL8cjBJ459frV/Srn7fp9vchNvnKGC5zj8ankXKMCgcEH5OPm9ueKoxWd3PKXu5TDEVA8iCU7R7Dge2T37YFZ/EtSb33M7UFfUJWl+1zQaXEA7NGcZZTnGPvVXmtZ47dIdJlJtpZdy56wqQCTlj83fr0zUt9ZafokJkml3puLLG6B2wc/KAeo4NM1O4R9QtYII4laZVZGTaGHG4huDtAA9K0XS2xXoaRsBHArXE4leMZaeSMEsoJOMDH+RWXDpC3k8/9qObhc+bB/CVDdXGD1z+VRtqNlbWItfthuDJwsSDzC5OcZIAyPYVWm1prrLzWXEbDasdwFlA6k479PwpKMug0mTRacINRbF0zwgEkSRhiuBxgn37j0qW0gsopLaFbVUmljEhIZiVJBzg9unUGoprSKwmnuIrzzVnYSLA0YkyxOcjHXOTj603TbG8kv0uJ2mtxCSGRcKso5xn1xnGaHqr3B6q5eNq9vCYNPVYounQEJk8kD8San+zQmGKJ4kZIsbFZchcdCKsNj0OR39abgYPNZXM7kU0aSQNEQAhGBjt6YrM1K9+zwypPIyzDoI/l3L3YHnBxmtU8e9VrtiCkaRNJK4IDAgbBjk5NOIIxvEN1PYWEDafMzTy4ijjk+bex6HJ6EdcmrWjQ3MWno1/K8l1L+8k3kHYT/CMdhVqBNsEXnRxCZO6r3xyRxTpGOM9abenKNvSwjjnk1Xb5wVBAyOTjNSlvl56d6jboPapJMyGyNqrMgt3lPdYRHn8jSxszkrKm1wM4znirrcAgHnp7Vku8sVwIsBrh1ws8h+XGegA75I4/Wq1kUncNStRc2kkW7bnuBRVZpZJnaGCWScrgtKoEaL7Z7n6UVcW4rctXR7ceSevPFMZTk/SpWjfcMEAZ59x6f59Kay84xWNjnRA3Ofam454HNSFDyQPwpGQ+w5p7DIunBBz6CuLmiuTrAmWzNzC7m4WbgrnkbCp5OMdOvFdx5dZV/YSxzy3EJLW7qWlgBxlsffHbdwPT61cJcrsy4tJGBBsurhp7FnOo7RL9mkkwETI/1fHGcDj0NdLY3IvLVJ1VlDdVYEEHpj9K5nWdJj2W15PbjzCpSVVwC3IO/g4/CtPQr7zG8uSQsGQFM/59xWk1eN0VJXWhrNzwPrmonTPc+1TspwcCo8YPNYXMzntZ0iR5TcWahpW4ZCQMA4yR78frWZZeFrmOzXF5JavzuRecegGCPxrtSpx71la7Z3d5CkdlefZSD85253r3X2+taRqPa5XO9jkn0mJkhuGnvrtGJ3KwAdOcDg5644z+dXbz7JFoN2NKhglZAIp2BCtEvQsRjPH+Nben2d3C5aRLfDgKyZycZ/vbcnqeKq/8I9J9k1KMyRJNdOTGwHEaHOF+nJrRTu9WNyXU4u00ueRN1rbTzMABE5iOCCf73pwK17fwle3BM95JHCyjMduvc+jnp7cZ4rtxGLe1AABCJ1HGcCsnTPENrqMssdlb3MjRffDBVx+Jbmn7Wb1SBzb2KNxYXsV9EgtUMAhEYazXBP3gSxJABwR61pXMJsZTeYkMFvHsiggGS2euR061ejvYHuBArESkZKkfXv8AgatAfN2+lYym+qE5PqcZrV5d3ltB57Q6XE7ZDO7eaByMnHTufwqkrRS3X2J7i+1AFTukcFIQDzn5skgdjitTxFbTDVC/m5FwFVFXqh6An8c0wWYvfPiEs5vsOsyOcgtyRj5sAZ2nj/EVvFpJM0TVkR6bb2lvbC4nVbho1whuCscWByAgbnt146mtqDyrjzLW3uY2lmTEwiziFD/CnpxnA/GqV3pxu4HtBFFLceWp24C+UMEZLd+eeM/pS6kLjSNMlvLq6D3ClEj2AgEBeAxxyMhjyDUyal11J3Z1EKLFEscYCooChRxgCqtpbC1NyfNeRp5mlO4/dzj5R7DFN0W+XUtIsr6MHZcQrIM8Hkf45q4w4P0rB3WjM9tCJuDR1P0pzLkk0zPb1qWxocP88Um7LA9R7UE+g/Wmn+XNAmcdqOWe7W5VpTA5jiVAcjvuyeM4J6e1WYnRdFURwbWljCusy7JCpzwq4zng9cAmty/tzdW6IrKssciurMueRVK/jnt5EuSyMI1wRnl5WOFOcehxz0zW3PdJGvNc45EtI4naOK+jtwNrXTRdc9VDDvzirGna3LLqJSPT/Nik+QJCm7YoGMdcDv1xnNda0kKXYEuFvXTB6nj+XasbU9dtrSZrWxVfP3qZQF2KoPGenJ/CqU+fS1x3b6Etro8Jv21O3mkO7gRyR/6sDjCjjb0xWxuBzgjjrg1gxebquq3i3fmxx2hXygkhAWToSCpBPRuvrU+jadBZRvPE5mec+b5zZDMDyM5J9T+dZz83qQ/M0mP5CkPJJJ9BQfpijOB65rMkaapanALq2dNoZxyueBu9M+lXW5PqahHCjPf/APXTT1BGBo6XsE0kb2m1HbfLIz9Dz90Y5Fa0gqcngg9c8e1Qvk55zTcubUbd2RfU1Geh/nT5OODUT8DnGB0pCI2Jx049qrXMUcyhZUV1ByOBxU8h6kVXZieoINPzQIaVVECxqqqOgXiioy3r1oqrlWR7gqq3OMUxlByffFFFZ9TJbDAinPHekZFBC46jPNFFJjQwKCenShlG0nHSiikN7I5fxZpqMFu1llXCeUYwxwQT9awWmk094LuFYWQ8+W8ecdDwc9feiiuyk+ZJM2hqjS1W4mnnsZoZpbdZgq7UbkZOOvTv6dutdJHFtVVc7mAwWxjJx1oorKaVkZz0sDqCSDzUDKp5xRRWZARoC+D2p7quOnUUUU+ohrIOD3xms7U7lre2kaJVDA4BPuR/jRRRHUa3RyNvezJOWjdtw6vId7Hr0JHHfgDvWjomp3VxLcO0paNEWQI4BIzkYyAOOPSiitHqbtKzKsk813feWZNskb4EpGW2jHHp1OelX5Lxk0u4uWTcEyBFvYJndgcZ6e1FFaNKy+Q7a2I/Cd1c3F3KzyLhk3yfINztnHXsOvHvUVxGmsX82mSbkiiuzK7Ft5k2heDnoKKKNpPyJ2bZ2EcccUQSKNUjAwqKMBR6CkZscYoorm7mQwtnJxTC2DRRRbUFsIWz26+9NYjuD+dFFLog6jCQSeO9MlCyJhgcdRhsEfjRRQx9TL1WWCws5Lj7OszR4Ybzk5+pBNYs1x9tCQSQwIkzKCUQAgE8c+1FFbU1pc0iuo64WWzvtWNrNtExjVQwyEJ6n36mtqzto7W2S3izsiUKCeSfc0UUpvRES2HA/MevFNdhu6cH3oorOwiMsMHA6Gs7Ub9rW8sIVQMLh2RiTyMCiinFXf8AXYqK1K+x318vLIXjjg/dpyApLHng4PAxyKvsc9u1FFVLoJkEpwM1XdvaiipSE2QTsUXANVHm2gHHUZ60UU0OOpmQO1xG12jGLJPyLggkDqfX9KKKKpuxp1P/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse panbronchiolitis involving a respiratory bronchiole which appears filled with necrotic debris and neutrophils. This small airway is surrounded by an intense lymphoplasmacytic inflammatory infiltrate (hematoxylin and eosin stain).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_8_41090=[""].join("\n");
var outline_f40_8_41090=null;
var title_f40_8_41091="Defibrotide: Drug information";
var content_f40_8_41091=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"19\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Defibrotide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F14214047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiplatelet Agent;",
"     </li>",
"     <li>",
"      Thrombolytic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F14214094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prevention of hepatic sinusoidal obstruction syndrome (SOS) in HSCT (unlabeled use):",
"     </b>",
"     I.V.: 5 mg/kg twice daily for 21 days post-transplant (Dignan, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment of hepatic SOS in HSCT (unlabeled use; begin treatment as soon as possible after SOS is suspected):",
"     </b>",
"     I.V.: 6.25 mg/kg every 6 hours for at least 21 days (Richardson, 2009; Richardson, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F14214093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prevention of hepatic sinusoidal obstruction syndrome (SOS) in hematopoietic stem cell transplant (HSCT; unlabeled use):",
"     </b>",
"     I.V.: 6.25 mg/kg every 6 hours beginning the same day as the conditioning regimen and continued for at least 14 and up to 30 days post-transplant (Corbacioglu, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment of hepatic SOS in HSCT (unlabeled use; begin treatment as soon as possible after SOS is suspected):",
"     </b>",
"     I.V.: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F14214095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F14214046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F14214044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Defibrotide is an investigational agent available for the treatment of hepatic SOS through an Expanded Access Treatment IND Protocol (protocol 2006-05). Information on access is available at  file://www.gentium.com/vod/about-vod/access-to-defibrotide.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14214096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Infuse over 2 hours (Corbacioglu, 2012; Dignan, 2007; Richardson, 2002)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F14214070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14214049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease) in hematopoietic stem cell transplant (HSCT); treatment of hepatic SOS associated with HSCT",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14214042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Defibrotide may be confused with dofetilide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F14214063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: CNS hemorrhage, fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine: Hot flashes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain, cramping, diarrhea, diarrhea (hemorrhagic), gastrointestinal bleeding, hematemesis, mouth hemorrhage, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Hemorrhage/bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Hematuria, renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Diffuse alveolar hemorrhage, epistaxis, pulmonary hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Allergic reaction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14214051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Exclusion criteria: Predominant exclusion criteria from studies were clinically significant bleeding, &gt;1 pressor agent to maintain blood pressure, neurotoxicity, intubated patients, grade B to D graft-versus-host disease (GVHD); grade B skin GVHD was allowed (Richardson, 2010; Richardson, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Concurrent medications excluded: Patients were excluded from studies if on prior or concurrent systemic tissue plasminogen activator use, concomitant anticoagulants (except when used for central line management or dialysis; patients on prior heparin were eligible if heparin was discontinued &ge;12 hours prior to enrollment); or concomitant treatment with antithrombin III, other antithrombotics, ursodiol (unless for confirmed bile sludging), or nonsteroidal anti-inflammatory agents (Richardson, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Porcine derived: Defibrotide is derived from porcine tissue.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14214098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for signs and symptoms of hepatic SOS; monitor for bleeding",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14214071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Defibrotide binds to and protects vascular hepatic endothelial cells (especially small vessels) by enhancing fibrinolysis and suppressing coagulation. Effects are local, with no significant effect on systemic coagulation. Has antithrombotic, anti-inflammatory, antiplatelet, and anti-ischemic properties.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F14214073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.04-0.05 L/kg (Palmer, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine and feces (Palmer, 1993)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Benimetskaya L, Wu S, Voskresenskiy AM, et al, &ldquo;Angiogenesis Alteration by Defibrotide: Implications for its Mechanism of Action in Severe Hepatic Veno-Occlusive Disease,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(10):4343-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41091/abstract-text/18711003/pubmed\" id=\"18711003\" target=\"_blank\">",
"        18711003",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carreras E, D&iacute;az-Bey&aacute; M, Rosi&ntilde;ol L, et al, &ldquo;The Incidence of Veno-Occlusive Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Has Diminished and the Outcome Improved Over the Last Decade,&rdquo;",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 2011, 17(11):1713-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41091/abstract-text/21708110/pubmed\" id=\"21708110\" target=\"_blank\">",
"        21708110",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chopra R, Eaton JD, Grassi A, et al, &ldquo;Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Results of the European Compassionate-Use Study,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2000, 111(4):1122-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41091/abstract-text/11167751/pubmed\" id=\"11167751\" target=\"_blank\">",
"        11167751",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Corbacioglu S, Cesaro S, Faraci M, et al, &ldquo;Defibrotide for Prophylaxis of Hepatic Veno-Occlusive Disease in Paediatric Haemopoietic Stem-Cell Transplantation: An Open-Label, Phase 3, Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2012, 379(9823):1301-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41091/abstract-text/22364685/pubmed\" id=\"22364685\" target=\"_blank\">",
"        22364685",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Corbacioglu S, Greil J, Peters C, et al, &ldquo;Defibrotide in the Treatment of Children With Veno-Occlusive Disease (VOD): A Retrospective Multicentre Study Demonstrates Therapeutic Efficacy Upon Early Intervention,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2004, 33(2):189-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41091/abstract-text/14661036/pubmed\" id=\"14661036\" target=\"_blank\">",
"        14661036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeLeve LD, Shulman HM, and McDonald GB, &ldquo;Toxic Injury to Hepatic Sinusoids: Sinusoidal Obstructions Syndrome (Veno-Occlusive Disease),&rdquo;",
"      <i>",
"       Semin Liver Dis",
"      </i>",
"      , 2002, 22(1):27-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41091/abstract-text/11928077/pubmed\" id=\"11928077\" target=\"_blank\">",
"        11928077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dignan F, Gujral D, Ethell M, et al, &ldquo;Prophylactic Defibrotide in Allogeneic Stem Cell Transplantation: Minimal Morbidity and Zero Mortality From Veno-Occlusive Disease,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2007, 40(1):79-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41091/abstract-text/17502897/pubmed\" id=\"17502897\" target=\"_blank\">",
"        17502897",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palmer KJ and Goa KL, &ldquo;Defibrotide: a Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Vascular Disorders,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1993, 45(2):259-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41091/abstract-text/7681375/pubmed\" id=\"7681375\" target=\"_blank\">",
"        7681375",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palomo M, Diaz-Ricart M, Rovira M, et al, &ldquo;Defibrotide Prevents the Activation of Macrovascular and Microvascular Endothelia Caused by Soluble Factors Released to Blood by Autologous Hematopoietic Stem Cell Transplantation,&rdquo;",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 2011, 17(4):497-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41091/abstract-text/21126597/pubmed\" id=\"21126597\" target=\"_blank\">",
"        21126597",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pegram AA and Kennedy LD, &ldquo;Prevention and Treatment of Veno-Occlusive Disease,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2001, 35(7-8):935-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41091/abstract-text/11485147/pubmed\" id=\"11485147\" target=\"_blank\">",
"        11485147",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qureshi A, Marshall L, and Lancaster D, &ldquo;Defibrotide in the Prevention and Treatment of Veno-Occlusive Disease in Autologous and Allogeneic Stem Cell Transplantation in Children,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2008, 50(4):831-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41091/abstract-text/18286502/pubmed\" id=\"18286502\" target=\"_blank\">",
"        18286502",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richardson PG, Murakami C, Jin Z, et al, &ldquo;Multi-Institutional Use of Defibrotide in 88 Patients after Stem Cell Transplantation With Severe Veno-Occlusive Disease and Multisystem Organ Failure: Response Without Significant Toxicity in a High-Risk Population and Factors Predictive of Outcome,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2002, 100(13):4337-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41091/abstract-text/12393437/pubmed\" id=\"12393437\" target=\"_blank\">",
"        12393437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richardson PG, Smith AR, Grupp, SA, et al, &ldquo;Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(21):487 [abstract #487 from 2011 ASH Annual Meeting]",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richardson PG, Soiffer RJ, Antin JH, et al, &ldquo;Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure After Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial,&rdquo;",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 2010, 16(7):1005-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41091/abstract-text/20167278/pubmed\" id=\"20167278\" target=\"_blank\">",
"        20167278",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richardson P, Tomblyn M, Kernan N, et al, &ldquo;Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) With Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 114(22):654 [abstract #654 from 2009 ASH Anual meeting].",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83451 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-0869272E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_8_41091=[""].join("\n");
var outline_f40_8_41091=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14214047\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14214094\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14214093\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14214095\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14214046\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14214044\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14214096\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14214070\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14214049\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14214042\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14214063\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14214051\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14214098\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14214071\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14214073\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83451\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83451|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_8_41092="Allergic rhinitis (seasonal allergies)";
var content_f40_8_41092=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/8/41092/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41092/contributors\" id=\"au5875\">",
"       Richard D deShazo, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41092/contributors\" id=\"au6045\">",
"       Stephen F Kemp, MD, FACP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/8/41092/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41092/contributors\" id=\"se952\">",
"       Jonathan Corren, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/8/41092/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41092/contributors\" id=\"de128\">",
"       Anna M Feldweg, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/8/41092?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ALLERGIC RHINITIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Rhinitis refers to inflammation of the nasal passages. This inflammation can cause a variety of annoying symptoms, including sneezing, itching, nasal congestion, runny nose, and post-nasal drip (the sensation that mucus is draining from the sinuses down the back of the throat).",
"    </p>",
"    <p>",
"     Brief episodes of rhinitis are usually caused by respiratory tract infections with viruses (eg, the common cold). Chronic rhinitis is usually caused by allergies, but it can also occur from overuse of certain drugs, some medical conditions, and other unidentifiable factors.",
"    </p>",
"    <p>",
"     For many people, rhinitis is a lifelong condition that waxes and wanes over time. Fortunately, the symptoms of rhinitis can usually be controlled with a combination of environmental measures, medications, and immunotherapy (also called allergy shots).",
"    </p>",
"    <p>",
"     Other forms of rhinitis are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/15/24818?source=see_link\">",
"      \"Patient information: Nonallergic rhinitis (runny or stuffy nose) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHO GETS ALLERGIC RHINITIS?",
"     </span>",
"    </p>",
"    <p>",
"     Allergic rhinitis, also known as hay fever, affects approximately 20 percent of people of all ages. The risk of developing allergic rhinitis is much higher in people with asthma or eczema and in people who have a family history of asthma or rhinitis.",
"    </p>",
"    <p>",
"     Allergic rhinitis can begin at any age, although most people first develop symptoms in childhood or young adulthood. The symptoms are often at their worst in children and in people in their 30s and 40s. However, the severity of symptoms tends to vary throughout life; many people experience periods when they have no symptoms at all.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      ALLERGIC RHINITIS CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Allergic rhinitis is caused by a nasal reaction to small airborne particles called allergens (substances that provoke an allergic reaction). In some people, these particles also cause reactions in the lungs (asthma) and eyes (allergic conjunctivitis).",
"    </p>",
"    <p>",
"     The allergic reaction is characterized by activation of two types of inflammatory cells, called mast cells and basophils. These cells produce inflammatory substances, such as histamine, which cause fluid to build up in the nasal tissues (congestion), itching, sneezing, and runny nose. Over several hours, these substances activate other inflammatory cells that can cause persistent symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Seasonal versus perennial allergic rhinitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Allergic rhinitis can be seasonal (occurring during specific seasons) or perennial (occurring year round). The allergens that most commonly cause",
"     <strong>",
"      seasonal allergic rhinitis",
"     </strong>",
"     include pollens from trees, grasses, and weeds, as well as spores from fungi and molds (",
"     <a class=\"graphic graphic_figure graphicRef77269 \" href=\"mobipreview.htm?22/59/23477\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     The allergens that most commonly cause",
"     <strong>",
"      perennial allergic rhinitis",
"     </strong>",
"     are dust mites, cockroaches, animal dander, and fungi or molds. Perennial allergic rhinitis tends to be more difficult to treat.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      ALLERGIC RHINITIS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The symptoms of allergic rhinitis vary from person to person. Although the term \"rhinitis\" refers only to the nasal symptoms, many patients also experience problems with their eyes, throat, and ears. In addition, sleep can be disrupted, so it is helpful to consider the entire spectrum of symptoms.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Nose: watery nasal discharge, blocked nasal passages, sneezing, nasal itching, post-nasal drip, loss of taste, facial pressure or pain.",
"      </li>",
"      <li>",
"       Eyes: itchy, red eyes, feeling of grittiness in the eyes, swelling and blueness of the skin below the eyes (called allergic shiners) (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/27/5553?source=see_link\">",
"        \"Patient information: Allergic conjunctivitis (Beyond the Basics)\"",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Throat and ears: sore throat, hoarse voice, congestion or popping of the ears, itching of the throat or ears.",
"      </li>",
"      <li>",
"       Sleep: mouth breathing, frequent awakening, daytime fatigue, difficulty performing work.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     When an allergen is present year round, the predominant symptoms include post-nasal drip, persistent nasal congestion, and poor-quality sleep.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      ALLERGIC RHINITIS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The diagnosis of allergic rhinitis is based upon a physical examination and the symptoms described above. Medical tests can confirm the diagnosis and identify the offending allergens.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Identify allergens and other triggers",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is often possible to identify the allergens and other triggers that provoke allergic rhinitis by:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Recalling the factors that precede symptoms",
"      </li>",
"      <li>",
"       Noting the time at which symptoms begin",
"      </li>",
"      <li>",
"       Identifying potential allergens in a person's home, work, and school environments",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Skin tests may be useful for people whose symptoms are not well controlled with medications or in whom the offending allergen is not obvious.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      ALLERGIC RHINITIS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of allergic rhinitis includes reducing exposure to allergens and other triggers, in combination with medication therapy. In most people, these measures effectively control the symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Reduce exposure to triggers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some simple measures can reduce a person's exposure to allergens and triggers that provoke allergic rhinitis. These measures are discussed in detail in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/40/5764?source=see_link\">",
"      \"Patient information: Trigger avoidance in allergic rhinitis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Several different classes of drugs counter the inflammation that causes symptoms of allergic rhinitis. The severity of symptoms and personal preferences usually guide the selection of specific drugs.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Nasal irrigation and saline sprays",
"     </span>",
"     &nbsp;&mdash;&nbsp;Rinsing the nose with a salt-water (saline) solution is called nasal irrigation or nasal lavage. Saline is also available in a standard nasal spray, although this is not as effective as using larger amounts of water in an irrigation.",
"    </p>",
"    <p>",
"     Nasal irrigation is particularly useful for treating drainage down the back of the throat, sneezing, nasal dryness, and congestion. The treatment helps by rinsing out allergens and irritants from the nose. Saline rinses also clean the nasal lining and can be used before applying sprays containing medications, to get a better effect from the medication.",
"    </p>",
"    <p>",
"     Nasal lavage with warmed saline can be performed as needed, once per day, or twice daily for increased symptoms. Nasal lavage carries few risks when performed correctly and with sterilized water. Saline nasal sprays and irrigation kits can be purchased over-the-counter. Saline mixes can also be purchased or patients can make their own solution.",
"    </p>",
"    <p>",
"     A variety of devices, including bulb syringes, Neti pots, and bottle sprayers, may be used to perform nasal lavage; instructions for nasal lavage are provided in the table (",
"     <a class=\"graphic graphic_table graphicRef71059 \" href=\"mobipreview.htm?42/33/43548\">",
"      table 1",
"     </a>",
"     ). At least 200 mL (about",
"     <span class=\"nowrap\">",
"      3/4",
"     </span>",
"     cup) of fluid (salt solution made with distilled or boiled water or sterile saline, not tap water) is recommended for each nostril.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Nasal glucocorticoids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nasal glucocorticoids (steroids delivered by a nasal spray) are the first-line treatment for the symptoms of allergic rhinitis. These drugs have few side effects and dramatically relieve symptoms in most people. Studies have shown that nasal glucocorticoids are more effective than oral antihistamines for symptom relief [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/8/41092/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     There are a number of nasal glucocorticoids available by prescription. Specific medications include fluticasone, mometasone, budesonide, flunisolide, triamcinolone, beclomethasone, fluticasone furoate, and ciclesonide. These drugs differ with regard to the frequency of doses, the spray device, and cost, but all are similarly effective for treating all the symptoms of allergic rhinitis.",
"    </p>",
"    <p>",
"     People with severe rhinitis may need to use a nasal decongestant for a few days before starting a nasal glucocorticoid to reduce nasal swelling, which will allow the nasal spray to reach more areas of the nasal passages (see",
"     <a class=\"local\" href=\"#H17\">",
"      'Decongestants'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     Some symptom relief may occur on the first day of therapy with nasal glucocorticoids, although their maximal effectiveness may not be noticeable for days to weeks. For this reason, nasal glucocorticoids are most effective when used regularly. Some people are able to use lower doses when symptoms are less severe.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      How to use a nasal spray",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nasal sprays work best when they are used properly and the medication remains in the nose rather than draining down the back of the throat. If the nose is crusted or contains mucus, it should be cleaned with a saline nasal spray before a nasal spray that contains medication.",
"    </p>",
"    <p>",
"     The head should be positioned normally or with the chin slightly tucked. The spray should be directed away from the nasal septum (the cartilage that divides the two sides of the nose). The spray is dispensed and then sniffed in slightly to pull it into the higher parts of the nose. Sniffing too hard will result in the medicine draining down the throat, and should be avoided.",
"    </p>",
"    <p>",
"     Some people find that holding one nostril closed with a finger improves their ability to draw the spray into the upper nose. Medicine that drains into the throat should be spit out, since it is not effective unless it remains in the nose.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;The side effects of nasal steroids are mild and may include a mildly unpleasant smell or taste or drying of the nasal lining. In some people, nasal steroids cause irritation, crusting, and bleeding of the nasal septum, especially during the winter. These problems can be minimized by reducing the dose of the nasal steroid, applying a moisturizing nasal gel or spray to the septum before using the spray, or switching to a water-based (rather than an alcohol-based) spray.",
"    </p>",
"    <p>",
"     Studies suggest that nasal steroids are generally safe when used for many years. However, people who use these drugs for years should have periodic nasal examinations to check for rare side effects, such as nasal infection.",
"    </p>",
"    <p>",
"     Steroids taken as a pill or inhaled into the lungs can have side effects, especially when taken for long periods of time. However, the doses used in nasal steroids are low and are NOT associated with these side effects. However, clinicians usually recommend using the lowest effective dose.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Antihistamines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antihistamines relieve the itching, sneezing, and runny nose of allergic rhinitis, but they do not relieve nasal congestion. Combined treatment with nasal steroids or decongestants may provide greater symptom relief than use of either alone.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Oral medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several antihistamines have been available for many years without a prescription, including brompheniramine (Dimetapp allergy&reg;, Nasahist B&reg;), chlorpheniramine (Chlor-Trimeton&reg;), diphenhydramine (Benadryl&reg;), and clemastine (Tavist&reg;). These drugs often cause sedation and should not be used before driving or operating machinery. Even if the person does not feel excessively drowsy, these drugs can have a sedating effect. Thus, patients should use caution.",
"    </p>",
"    <p>",
"     Less-sedating oral antihistamines include Loratadine (Claritin&reg;, Alavert&reg;), desloratadine (Clarinex&reg;), cetirizine (Zyrtec&reg;), levocetirizine (Xyzal&reg;), and fexofenadine (Allegra&reg;). Loratadine and cetirizine are available without a prescription. These drugs work as well as the sedating antihistamines for rhinitis, but they are less sedating and are available in long-acting formulas. However, they may be more expensive.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Nasal sprays",
"     </span>",
"     &nbsp;&mdash;&nbsp;Azelastine (Astelin&reg;, Astepro&reg;) and olopatadine (Patanase&reg;) are prescription nasal antihistamine sprays that can be used daily or when needed to relieve symptoms of post-nasal drip, congestion, and sneezing. These sprays start to work within minutes after use. The most common side effect with azelastine is a bad taste in the mouth immediately after use. This can be minimized by keeping the head tilted forward while spraying, to prevent the medicine from draining down the throat (see",
"     <a class=\"local\" href=\"#H12\">",
"      'How to use a nasal spray'",
"     </a>",
"     above).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Decongestants",
"     </span>",
"     &nbsp;&mdash;&nbsp;Decongestants (like pseudoephedrine or phenylephrine [Sudafed&reg;, Actifed&reg;, Drixoral&reg;]) are often combined with antihistamines in oral, over-the-counter allergy drugs. In the United States, pseudoephedrine has been used to make illegal drugs, which caused many companies to substitute phenylephrine for pseudoephedrine. However, phenylephrine is not effective for treating allergic rhinitis.",
"    </p>",
"    <p>",
"     Oral decongestants elevate blood pressure and are not appropriate for people with high blood pressure or certain cardiovascular conditions. Men with an enlarged prostate who have difficulty urinating may notice a worsening of this symptom when they take decongestants. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/51/28467?source=see_link\">",
"      \"Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Decongestants in the form of nasal sprays are also available, including oxymetazoline (Afrin&reg;) and phenylephrine (Neo-synephrine&reg;). Nasal decongestant sprays should not be used for more than two to three days at a time because they may cause a type of rhinitis called rhinitis medicamentosa, which causes the nose to be congested constantly UNLESS the medication is used repeatedly. This condition can be difficult to treat. To avoid it, do not use decongestant sprays for more than 3 days. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/15/24818?source=see_link\">",
"      \"Patient information: Nonallergic rhinitis (runny or stuffy nose) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Cromolyn sodium",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cromolyn sodium (Nasalcrom&reg;) prevents the symptoms of allergic rhinitis by interfering with the ability of allergy cells to release natural chemicals that cause inflammation. This drug is available as an over-the-counter nasal spray that must be used three to four times per day, preferably before symptoms have begun, to effectively prevent the symptoms of allergic rhinitis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Allergy shots",
"     </span>",
"     &nbsp;&mdash;&nbsp;Allergy shots, also known as allergen immunotherapy, are injections given to reduce a person's sensitivity to allergens. Allergy shots are only available for common allergens, such as pollens, cat and dog dander, dust mites, and molds. These shots contain solutions of the allergens to which a specific person is allergic, and are made up individually for each person. The process of immunotherapy changes the person's immune response to the allergens over time. As a result, being exposed to the allergen causes fewer or even no symptoms.",
"    </p>",
"    <p>",
"     Immunotherapy can help many people with allergic rhinitis. In children, immunotherapy can help prevent developing allergic asthma later in life. However, immunotherapy is relatively time-consuming and is often reserved for people who have a poor response to medication, or want to avoid taking medications long-term. Immunotherapy can be expensive, but many insurance plans cover the therapy because long-term use of allergy medications is also costly.",
"    </p>",
"    <p>",
"     Immunotherapy is usually started by an allergist. Treatment begins with several months of weekly injections of gradually increasing doses, followed by monthly maintenance injections.",
"    </p>",
"    <p>",
"     Immunotherapy is usually administered for a minimum of three to five years. If immunotherapy is discontinued, the benefits gradually diminish over time, although some patients have several more years of symptom relief [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/8/41092/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Immunotherapy injections carry a small risk of a severe allergic reaction. These reactions occur with a frequency of 6 of every 10,000 injections. The symptoms usually begin within 30 minutes of the injection. For this reason, patients are required to remain in the office after routine injections so that such a reaction could be quickly treated. Because drugs called beta-blockers may interfere with the ability to treat these reactions, people who take beta-blockers are often advised to avoid immunotherapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Other treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other drugs may be recommended for some people with allergic rhinitis.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Ipratropium &mdash; Nasal atropine is effective for the treatment of severe runny nose. This drug, available as ipratropium bromide (Atrovent&reg;), is not generally recommended for people with glaucoma or men with an enlarged prostate.",
"      </li>",
"      <li>",
"       Leukotriene modifiers &mdash; Release of substances called leukotrienes may contribute to the symptoms of allergic rhinitis. Drugs that block the actions of leukotrienes, called leukotriene modifiers, can be very useful in patients with asthma and allergic rhinitis. However, nasal steroids are more effective than leukotriene modifiers for treating allergic rhinitis; thus, leukotriene modifiers are generally reserved for patients who cannot tolerate nasal sprays (due to nose bleeds) or azelastine&nbsp;(see",
"       <a class=\"local\" href=\"#H14\">",
"        'Antihistamines'",
"       </a>",
"       above).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      PREGNANCY AND ALLERGIC RHINITIS",
"     </span>",
"    </p>",
"    <p>",
"     Women who have allergic rhinitis before pregnancy may have worsening, improvement, or no change in their symptoms during pregnancy. Most women notice some nasal congestion in the later stages of pregnancy, even if they did not have rhinitis before. This is called rhinitis of pregnancy, and is related to hormone levels. Rhinitis of pregnancy does not respond to medications and goes away after delivery. The discussion below applies only to allergic rhinitis.",
"    </p>",
"    <p>",
"     As a general rule, medications should be avoided or used at the lowest dose that controls symptoms during pregnancy. A woman should always review any medication (over-the-counter or prescription) before taking it during pregnancy. However, several of the drugs used to treat allergic rhinitis are thought to be safe.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Saline sprays and nasal irrigation &mdash; Women with mild rhinitis may be able to control symptoms using only saline nasal sprays or irrigation, which do not contain any medications. (See",
"       <a class=\"local\" href=\"#H10\">",
"        'Nasal irrigation and saline sprays'",
"       </a>",
"       above.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If medication for rhinitis is needed during pregnancy, the following are considered to be safer choices:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Nasal sprays &mdash; Certain nasal sprays are a sensible option for pregnant women, because much less drug is required to control symptoms when it is sprayed directly into the nose, compared to taking that same medication by mouth.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Cromolyn nasal sprays are safe for use during pregnancy. Only a very small amount of drug is absorbed into the blood stream with this medication and no serious side effects are known to occur. (See",
"       <a class=\"local\" href=\"#H18\">",
"        'Cromolyn sodium'",
"       </a>",
"       above.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Nasal glucocorticoids are considered safe for use in pregnancy, and women who are already taking these can simply continue during pregnancy (",
"       <a class=\"graphic graphic_table graphicRef71059 \" href=\"mobipreview.htm?42/33/43548\">",
"        table 1",
"       </a>",
"       ). Although no safety differences have been identified among the different nasal glucocorticoids, budesonide (Rhinocort Aqua&reg;) has been approved for use in pregnancy for a longer time than the others. (See",
"       <a class=\"local\" href=\"#H11\">",
"        'Nasal glucocorticoids'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Antihistamines &mdash; Chlorpheniramine (Chlor-Trimeton&reg; and others), loratadine (Claritin&reg;), or cetirizine (Zyrtec&reg;) are the antihistamines of choice during pregnancy.",
"      </li>",
"      <li>",
"       Decongestants &mdash; Pseudoephedrine should be avoided during the first trimester of pregnancy if possible, because its safety has not been confirmed. After the first trimester, it should be used only when needed and only as directed. However, it should not be used at all by women with high blood pressure or pre-eclampsia. Phenylephrine should be avoided altogether during pregnancy.",
"      </li>",
"      <li>",
"       Allergy shots &mdash; Women already taking allergy shots who have not had allergic reactions to the shots in the past may safely continue treatment through pregnancy. However, the dose should not be increased during pregnancy due to the risk of a serious allergic reaction (anaphylaxis), which could potentially reduce the blood supply to the fetus. For the same reason, allergy shots are not started during pregnancy.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498566289\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12676419\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/38/37474?source=see_link\">",
"      Patient information: Seasonal allergies in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/21/36179?source=see_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/5/42066?source=see_link\">",
"      Patient information: Allergy shots (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/24/42370?source=see_link\">",
"      Patient information: Allergy skin testing (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/18/16674?source=see_link\">",
"      Patient information: Rinsing out your nose with salt water (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/10/13475?source=see_link\">",
"      Patient information: Seasonal allergies in children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12676445\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/15/24818?source=see_link\">",
"      Patient information: Nonallergic rhinitis (runny or stuffy nose) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/27/5553?source=see_link\">",
"      Patient information: Allergic conjunctivitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/40/5764?source=see_link\">",
"      Patient information: Trigger avoidance in allergic rhinitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/51/28467?source=see_link\">",
"      Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34569?source=see_link\">",
"      Allergen avoidance in the treatment of asthma and allergic rhinitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/30999?source=see_link\">",
"      An overview of rhinitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12250?source=see_link\">",
"      Chronic nonallergic rhinitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=see_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22362?source=see_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/48/7945?source=see_link\">",
"      Occupational rhinitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6775?source=see_link\">",
"      Pathogenesis of allergic rhinitis (rhinosinusitis)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37834?source=see_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Allergy, Asthma, and Immunology Online",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.acaai.org/public/advice/rhin.htm\">",
"        www.acaai.org/public/advice/rhin.htm",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Academy of Allergy, Asthma, and Immunology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.aaaai.org/patients/publicedmat/tips/rhinitis.stm\">",
"        www.aaaai.org/patients/publicedmat/tips/rhinitis.stm",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/8/41092/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 20, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/8/41092?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41092/abstract/1\">",
"      Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998; 81:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41092/abstract/2\">",
"      van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000; 55:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41092/abstract/3\">",
"      Bousquet J, Van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108:S147.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Department of Health and Human Services. Agency for Healthcare Research and Quality. Management of allergic and nonallergic rhinitis. May 2002. AHQR publication 02:E023, Boston, MA. Summary, Evidence Report/Technology Assessment: No 54. http//www.ahqr.gov/clinic/epcsums/rhinsum.htm.",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f40_8_41092=[""].join("\n");
var outline_f40_8_41092=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ALLERGIC RHINITIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHO GETS ALLERGIC RHINITIS?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           ALLERGIC RHINITIS CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           ALLERGIC RHINITIS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           ALLERGIC RHINITIS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           ALLERGIC RHINITIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           PREGNANCY AND ALLERGIC RHINITIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/59/23477\" title=\"figure 1\">",
"           Causes of seasonal allergies PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/33/43548\" title=\"table 1\">",
"           Nasal irrigation instruct",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f40_8_41093="Ureterocele";
var content_f40_8_41093=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ureterocele",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/8/41093/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41093/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/8/41093/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41093/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/8/41093/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41093/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/8/41093/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A ureterocele is a cystic dilatation of the terminal ureter within the bladder",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the urethra (",
"    <a class=\"graphic graphic_figure graphicRef79559 \" href=\"mobipreview.htm?22/42/23201\">",
"     figure 1",
"    </a>",
"    ). It may present as an incidental finding on antenatal ultrasonography, or postnatally because of symptoms due to urinary tract infection or obstruction.",
"   </p>",
"   <p>",
"    Ureterocele, including its pathophysiology, clinical presentation, diagnosis, evaluation, and management will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;At autopsy, the incidence of ureteroceles has been reported as 1 in 500 cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/1\">",
"     1",
"    </a>",
"    ]. Ureteroceles occur four to six times more frequently in females than in males, and more commonly in Caucasians than in other races [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/2\">",
"     2",
"    </a>",
"    ]. Unilateral ureteroceles occur with similar frequency on the right and left, and in 10 percent of cases, there is bilateral involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification system adopted by the Urologic section of the American Academy of Pediatrics divides ureteroceles based on their location [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/3\">",
"     3",
"    </a>",
"    ]. According to this system, ureteroceles are classified as intravesical (ie, entirely within the bladder) or ectopic (ie, a portion extends beyond the bladder neck into the urethra) (",
"    <a class=\"graphic graphic_figure graphicRef79559 \" href=\"mobipreview.htm?22/42/23201\">",
"     figure 1",
"    </a>",
"    ). At times, differentiating between intravesical and ectopic ureteroceles may be difficult. Historically, ectopic ureteroceles that inserted beyond the bladder neck into the urethra were called cecoureteroceles.",
"   </p>",
"   <p>",
"    Ureteroceles also may be classified depending upon whether they are associated with either a single collecting system (ie, single ureter and kidney) or a duplex system (complete ureteral duplication). Approximately 80 percent of ureteroceles are associated with the upper pole of a duplex collecting system, and 60 percent of these are ectopic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/4\">",
"     4",
"    </a>",
"    ]. Whereas, intravesical ureteroceles are more common in single systems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying pathogenesis is unknown, and it appears that a single unifying theory does not explain how all the different types of ureteroceles are formed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/4\">",
"     4",
"    </a>",
"    ]. A simple explanation is that ureteroceles can be considered a diverticulum of the distal ureter within the bladder, secondary to a stenotic ureteral orifice.",
"   </p>",
"   <p>",
"    More formal proposed embryologic mechanisms resulting in ureterocele formation include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An incomplete breakdown of the ureteral membrane between the ureteral bud and mesonephric duct, resulting in an obstruction that causes the formation of a ureterocele. This mechanism explains the formation of the majority of stenotic ureteroceles but not those with patulous ureteral orifices in the urethra.",
"     </li>",
"     <li>",
"      Obstruction of the ureteral orifice by the bladder neck because of developmental delay in the timing of the ureteral bud insertion into the bladder.",
"     </li>",
"     <li>",
"      Abnormal induction of the bladder trigone development that results in the absence of trigonal musculature in the intravesical portion of ureteroceles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Antenatal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many ureteroceles are detected incidentally on antenatal ultrasonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/4\">",
"     4",
"    </a>",
"    ]. Approximately 2 percent of cases of antenatal hydronephrosis are caused by ureteroceles, which obstruct the distal end of the affected ureter (",
"    <a class=\"graphic graphic_figure graphicRef79559 \" href=\"mobipreview.htm?22/42/23201\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81543 \" href=\"mobipreview.htm?32/31/33272\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Postnatal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common postnatal presentation is during an evaluation for urinary tract infection (UTI) in the first few months after birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/59/14264?source=see_link\">",
"     \"Urinary tract infections in newborns\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other patients have a more insidious course that may include intermittent abdominal or pelvic pain, or failure to thrive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/2\">",
"     2",
"    </a>",
"    ]. In older children, stasis and infection may predispose to stone formation. Hematuria is a rare presentation.",
"   </p>",
"   <p>",
"    Some patients may present with a palpable abdominal mass due to ureterocele obstruction of the distal ureter. Most ureteroceles decompress during voiding, so bladder outlet obstruction (ie, urethral obstruction) is a rare event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/4\">",
"     4",
"    </a>",
"    ]. However, prolapse of an ectopic ureterocele can cause urethral obstruction, and may present as a vaginal mass in girls. A girl with a large intraurethral ectopic ureterocele may present with urinary incontinence due to laxity of the external urinary sphincter. A few patients, particularly older males with a single system intravesical ureterocele, may be diagnosed incidentally during imaging for other conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is generally made by ultrasonography. Further imaging by voiding cystourethrography and renal scan is used to determine whether there are associated renal and urologic abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography usually will reveal a well-defined cystic intravesical mass in the posterior portion of the bladder. A dilated proximal ureter also may be seen. In duplex systems, there is about an 80 percent chance that the other side will be duplex (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60076 \" href=\"mobipreview.htm?18/63/19455\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70773 \" href=\"mobipreview.htm?3/63/4087\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Voiding cystourethrogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;A voiding cystourethrogram (VCUG) is important to identify whether vesicoureteral reflux (VUR) is present. Reflux into the ipsilateral lower pole occurs in approximately 50 percent of patients, where it may be massive, and occurs on the contralateral side in 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The contrast material used in this procedure may obscure the ureterocele itself, so early images, as the bladder is filling, are crucial to detect a ureterocele.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Renography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A renal scan is used to evaluate the relative function of all renal segments. In particular, in patients with a duplex system, the pole that is associated with the affected ureter may contribute little or no function, and may not be worth preserving when surgery is performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, a delay in the isotope washout (especially after the administration of lasix) demonstrates impaired urinary drainage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of a ureterocele depends upon multiple considerations, including the mode and age of presentation (antenatal detection or symptomatic), the type of ureterocele (ectopic or intravesical), the function of the associated renal moiety, and whether reflux is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/4,7,8\">",
"     4,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with an antenatal diagnosis should receive antibiotic prophylaxis until the postnatal radiologic evaluation is performed and treatment is completed to relieve any associated urinary obstruction. Antibiotic treatment is continued if there is a diagnosis of vesicoureteral reflux (VUR).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical treatment is needed in most cases. Options range from endoscopic correction to complete open reconstruction. The choice of surgical intervention is dependent upon the clinical setting, particularly if there is a duplex or single system, and the presence or absence of VUR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/2,4,7,8\">",
"     2,4,7,8",
"    </a>",
"    ]. Since the introduction of endoscopic procedures in the 1980s, the most common neonatal surgical intervention has been to endoscopically incise the ureterocele (",
"    <a class=\"graphic graphic_movie graphicRef88334 \" href=\"mobipreview.htm?26/25/27037\">",
"     movie 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients who present with sepsis secondary to obstruction require immediate drainage of the kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/9\">",
"     9",
"    </a>",
"    ]. In this case, endoscopic incision of the ureterocele often relieves the obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/10\">",
"     10",
"    </a>",
"    ]. Percutaneous renal drainage rarely is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Intravesical versus ectopic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success of endoscopic decompression and the need for reoperation is dependent upon the location of the ureterocele [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravesical &mdash; With intravesical ureterocele, endoscopic decompression is the definitive procedure in about 80 to 90 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/12\">",
"       12",
"      </a>",
"      ]. The need for additional open surgery is related to the presence of lower pole reflux.",
"     </li>",
"     <li>",
"      Ectopic &mdash; In contrast, endoscopic treatment is effective in only 25 to 30 percent of ectopic ureteroceles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/9,12,13\">",
"       9,12,13",
"      </a>",
"      ]. Initial endoscopic puncture can reduce the size of an obstructed ureter, which facilitates subsequent successful open reimplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The greater the number of renal units involved with an ectopic ureterocele, the more likely a second surgical procedure will be needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/14\">",
"     14",
"    </a>",
"    ]. These cases typically need both upper tract surgery, such as upper pole nephrectomy and lower pole reconstruction, including ureteral reimplantation and excision of the ureterocele with reconstruction of the bladder neck.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Duplex system",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a duplex system, the approach selected depends upon the function of the upper pole segment associated with the ureterocele and its location. In a newborn with associated VUR in the lower pole or contralateral system, the usual approach is endoscopic puncture to decompress the ureterocele. Antibiotic prophylaxis is continued until the child reaches one year of age, when the patient is reevaluated with ultrasound and VCUG.",
"   </p>",
"   <p>",
"    If the upper pole of the kidney has minimal function and there is not associated VUR, a reasonable option is partial nephrectomy to remove the nonfunctional segment. If the upper pole is well-functioning, and reflux is not present, then the upper pole dilated ureter can be anastomosed tot he normal lower pole ureter at the level of the bladder (uretero-ureteostomy).",
"   </p>",
"   <p>",
"    Patients with a ureterocele associated with a duplex system are more likely to have a second operation than those with a ureterocele with a simple system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Single system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of reoperation after initial endoscopic decompression is lower in patients with a single system ureterocele compared to those with duplex system lesion.",
"   </p>",
"   <p>",
"    In one case series that included nine patients with a single system ureterocele, all the ureteroceles were intravesical. Only one patient required repeat puncture because of poor decompression from the initial intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/15\">",
"     15",
"    </a>",
"    ]. In another case series of 13 single system ureterocele, two of the three extravesical ureteroceles required reoperation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Age at presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcome is better with prenatal identification and early endoscopic decompression of ureteroceles in a duplex system than with treatment after postnatal presentation. This was illustrated in one retrospective study in which outcome was compared in 95 patients who had prenatal (n=40) or postnatal diagnosis (n=55) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/16\">",
"     16",
"    </a>",
"    ]. Urinary tract infection (UTI) occurred less frequently with prenatal diagnosis both before (12 versus 84 percent) and after surgery (15 versus 27 percent) compared to postnatal diagnosis. The need for secondary procedures also was less in the prenatal group (20 versus 46 percent).",
"   </p>",
"   <p>",
"    In infants and young children, endoscopic decompression is typically performed, as primary reconstruction is more challenging because of the size of the patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]. Decompression reduces the risk of UTI and facilitates later reconstruction, if it is needed.",
"   </p>",
"   <p>",
"    Patients who present when older than three to four years of age usually are managed with primary total surgical reconstruction. This approach avoids the need for endoscopic decompression with subsequent radiographic monitoring and the potential need for reoperation.",
"   </p>",
"   <p>",
"    An observational approach may be successful in the management of some prenatally detected nonobstructive ureteroceles associated with poorly or nonfunctioning renal moieties.",
"   </p>",
"   <p>",
"    In one series of 52 patients with prenatally detected duplex system ureterocele, 38 had surgical treatment, and 14 with upper pole involvement were managed expectantly with antibiotic prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/7\">",
"     7",
"    </a>",
"    ]. The latter group met criteria that included &lt;10 percent upper pole renal pole function, unobstructed lower pole, lower pole vesicoureteral reflux &le;grade III, and unobstructed bladder outflow. Through follow-up to a median of eight years, none of the expectantly managed children required surgery, had a urinary tract infection, or became symptomatic.",
"   </p>",
"   <p>",
"    In another study, infants less than two weeks of age with an ectopic ureterocele associated with a duplex system were assigned to receive either immediate endoscopic incision followed by antibiotic prophylaxis (n=32) or antibiotic prophylaxis until later surgical intervention (n=40) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/8\">",
"     8",
"    </a>",
"    ]. Febrile UTIs (three patients in each group) and progressive hydronephrosis (one versus two patients) were similar in the two groups during the first six months after birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative vesicoureteral reflux (VUR) is associated with a greater risk of reoperation after initial endoscopic incision or puncture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/11\">",
"     11",
"    </a>",
"    ]. Bladder reconstruction with excision of the ureterocele and reimplantation of the ureters is the standard approach in patients with persistent VUR in lower pole segments or new reflux into the punctured upper pole segment. In a case series of 54 patients with ectopic ureterocele who underwent total bladder reconstruction and excision of their ureterocele and ureteral reimplantation, long term follow-up (median of 9.6 years) demonstrated excellent results with continence in almost all of the patients (n=51) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41093/abstract/17\">",
"     17",
"    </a>",
"    ]. Only 10 patients required subsequent intervention for persistent VUR. Patients had minimal lower tract complications, including infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, our management depends upon a number of factors including the mode of presentation (antenatal detection or symptomatic), the type of ureterocele (ectopic or intravesical), the function of the associated renal moiety, and whether reflux is present.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With ureteroceles associated with VUR that are identified by antenatal ultrasound and evaluated postnatally, early endoscopic puncture is performed to decompress the dilated urinary tract and decrease the risk of development of pyelonephritis. Antibiotic prophylaxis is administered until re-evaulation at one year of age when definitive surgical therapy is typically performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients without VUR and a poorly functioning upper pole moiety are placed on antibiotics until definitive surgery by either open or laparoscopic heminephrectomy, which is usually performed around six months of age. Uretero-ureteostomy (anastomosis of the upper ectopic ureter to the normal lower pole ureter at the level of the bladder) is performed in patients with a well-functioning upper pole without VUR.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who present with sepsis secondary to obstruction require immediate drainage of the kidney, which is typically performed by endoscopic incision.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational data suggest good outcomes are achieved by the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upper pole heminephrectomy in patients with poorly functioning renal unit and no evidence of VUR",
"     </li>",
"     <li>",
"      Bladder level surgery with reimplantation of refluxing ureters, and removal or ureterocele with bladder neck reconstruction in patients with VUR and residual ureterocele",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A ureterocele is a cystic dilatation of the terminal ureter within the bladder",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the urethra (",
"    <a class=\"graphic graphic_figure graphicRef79559 \" href=\"mobipreview.htm?22/42/23201\">",
"     figure 1",
"    </a>",
"    ). It may present as an incidental finding on antenatal ultrasonography or postnatally because of symptoms due to urinary tract infection or obstruction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The estimated incidence of ureteroceles based upon autopsy studies is about 1 in 500 cases. It is four to six times more common in females than males, and in Caucasians than in other races. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common classification system for ureterocele is based upon whether the ureterocele is located entirely within the bladder (ie, intravesical) or if a portion extends beyond the bladder neck or urethra (ie, ectopic) (",
"      <a class=\"graphic graphic_figure graphicRef79559 \" href=\"mobipreview.htm?22/42/23201\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ureteroceles are associated with both single and duplex (double) renal collecting systems. In patients with a duplex ureterocele, the associated renal pole may either have no or poor function. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ureteroceles may present as hydroureteronephrosis by antenatal ultrasonography when the ureterocele causes obstruction of the distal portion of the affected ureter. Postnatally, the most common presentation is during an evaluation for urinary tract infection (UTI) in the first few months of life. Other less common presentations include intermittent abdominal or pelvic pain, abdominal or vaginal mass, failure to thrive, urolithiasis, urinary incontinence, and rarely hematuria. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of ureterocele is generally made by ultrasound. Further studies include a voiding cystourethrogram to detect the presence or absence of reflux, and a renal scan to evaluate the function of the renal moiety associated with the ectopic ureter and detect the presence or absence of urinary flow obstruction.",
"     </li>",
"     <li>",
"      For all patients with ureteroceles, we recommend surgery (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). The approach depends upon whether the renal system is duplex or single, age at presentation, location of the ureterocele (ie, intravesical versus ectopic), function of the involved renal moiety, presence of associated vesicoureteral reflux, and the symptoms of the patient. In general, outcome is good following surgical repair. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with sepsis and urinary obstruction, we recommend immediate drainage of the kidney (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). This is typically performed by ureterocele decompression by endoscopic incision. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41093/abstract/1\">",
"      USON AC, LATTIMER JK, MELICOW MM. Ureteroceles in infants and children: a report based on 44 cases. Pediatrics 1961; 27:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41093/abstract/2\">",
"      Shokeir AA, Nijman RJ. Ureterocele: an ongoing challenge in infancy and childhood. BJU Int 2002; 90:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41093/abstract/3\">",
"      Glassberg KI, Braren V, Duckett JW, et al. Suggested terminology for duplex systems, ectopic ureters and ureteroceles. J Urol 1984; 132:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41093/abstract/4\">",
"      Coplen DE, Duckett JW. The modern approach to ureteroceles. J Urol 1995; 153:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41093/abstract/5\">",
"      Geringer AM, Berdon WE, Seldin DW, Hensle TW. The diagnostic approach to ectopic ureterocele and the renal duplication complex. J Urol 1983; 129:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41093/abstract/6\">",
"      Jesus LE, Farhat WA, Amarante AC, et al. Clinical evolution of vesicoureteral reflux following endoscopic puncture in children with duplex system ureteroceles. J Urol 2011; 186:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41093/abstract/7\">",
"      Shankar KR, Vishwanath N, Rickwood AM. Outcome of patients with prenatally detected duplex system ureterocele; natural history of those managed expectantly. J Urol 2001; 165:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41093/abstract/8\">",
"      Rickwood AM, Reiner I, Jones M, Pournaras C. Current management of duplex-system ureteroceles: experience with 41 patients. Br J Urol 1992; 70:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41093/abstract/9\">",
"      Jayanthi VR, Koff SA. Long-term outcome of transurethral puncture of ectopic ureteroceles: initial success and late problems. J Urol 1999; 162:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41093/abstract/10\">",
"      Coplen DE. Neonatal ureterocele incision. J Urol 1998; 159:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41093/abstract/11\">",
"      Byun E, Merguerian PA. A meta-analysis of surgical practice patterns in the endoscopic management of ureteroceles. J Urol 2006; 176:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41093/abstract/12\">",
"      Cooper CS, Passerini-Glazel G, Hutcheson JC, et al. Long-term followup of endoscopic incision of ureteroceles: intravesical versus extravesical. J Urol 2000; 164:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41093/abstract/13\">",
"      Husmann DA, Strand WR, Ewalt DH, Kramer SA. Is endoscopic decompression of the neonatal extravesical upper pole ureterocele necessary for prevention of urinary tract infections or bladder neck obstruction? J Urol 2002; 167:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41093/abstract/14\">",
"      DeFoor W, Minevich E, Tackett L, et al. Ectopic ureterocele: clinical application of classification based on renal unit jeopardy. J Urol 2003; 169:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41093/abstract/15\">",
"      Hagg MJ, Mourachov PV, Snyder HM, et al. The modern endoscopic approach to ureterocele. J Urol 2000; 163:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41093/abstract/16\">",
"      Upadhyay J, Bolduc S, Braga L, et al. Impact of prenatal diagnosis on the morbidity associated with ureterocele management. J Urol 2002; 167:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41093/abstract/17\">",
"      Beganovi A, Klijn AJ, Dik P, De Jong TP. Ectopic ureterocele: long-term results of open surgical therapy in 54 patients. J Urol 2007; 178:251.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6586 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6F4C19BDB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_8_41093=[""].join("\n");
var outline_f40_8_41093=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antenatal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Postnatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Voiding cystourethrogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Renography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Intravesical versus ectopic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Duplex system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Single system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Age at presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6586\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6586|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?32/31/33272\" title=\"diagnostic image 1\">",
"      Prenatal US ureterocele bil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?18/63/19455\" title=\"diagnostic image 2\">",
"      Ureterocele cystoscopy US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6586|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/42/23201\" title=\"figure 1\">",
"      Ureterocele hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/63/4087\" title=\"figure 2\">",
"      Ureterocele US VCUG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6586|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?26/25/27037\" title=\"movie 1\">",
"      Endoscopic ureterocele decompression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/59/14264?source=related_link\">",
"      Urinary tract infections in newborns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_8_41094="Deferasirox: Pediatric drug information";
var content_f40_8_41094=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Deferasirox: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?2/19/2360?source=see_link\">",
"    see \"Deferasirox: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/16/41221?source=see_link\">",
"    see \"Deferasirox: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9935104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1987209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Exjade&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4432114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Exjade&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2738373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Chelating Agent, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F2738403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/19/2360?source=see_link\">",
"      see \"Deferasirox: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic iron overload due to blood transfusion:",
"     </b>",
"     Children &ge;2 years, Adolescents, and Adults: Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Treatment should only be initiated with evidence of chronic iron overload [ie, transfusion of &ge;100 mL/kg of packed RBCs (eg, &ge;20 units for a 40 kg individual) and serum ferritin consistently &gt;1000 mcg/L].",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: 20 mg/kg once daily; round calculated dose to the nearest whole tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance: Adjust dose every 3-6 months based on serum ferritin levels; increase by 5 or 10 mg/kg/day; calculate dose to nearest whole tablet. Usual range: 20-30 mg/kg/day; for serum ferritin levels persistently &gt;2500 mcg/L without evidence of a decreasing trend, may consider a dose of 40 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     ; doses &gt;40 mg/kg/day are not recommended.",
"     <b>",
"      Note:",
"     </b>",
"     Consider interrupting therapy for serum ferritin &lt;500 mcg/L; risk of toxicity may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment with concomitant bile acid sequestrants (eg, cholestyramine, colesevelam, colestipol) or potent UGT inducers (eg, rifampin, phenytoin, phenobarbital, ritonavir):",
"     </b>",
"     Children &ge;2 years, Adolescents, and Adults: Avoid concomitant use; if coadministration necessary, consider increasing the initial deferasirox dose by 50%; monitor serum ferritin and clinical response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Children &ge;2 years, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prior to initiation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;40 mL/minute",
"     <b>",
"      and",
"     </b>",
"     serum creatinine &lt;2 times age-appropriate ULN at baseline: No initial dosage adjustment necessary. Use caution; monitor renal function closely, particularly in patients at increased risk for renal impairment (eg, concomitant nephrotoxic therapy, dehydration, severe infection); increases in serum creatinine may require alteration or discontinuation of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute",
"     <b>",
"      or",
"     </b>",
"     serum creatinine &gt;2 times age-appropriate ULN at baseline: Do not initiate therapy; use is contraindicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     During therapy: Refer to dosage adjustment for toxicity (see below)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Children &ge;2 years, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild impairment (Child-Pugh class A): No dosage adjustment necessary; monitor closely for efficacy and for adverse reactions requiring dosage reduction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Moderate impairment (Child-Pugh class B): Initial: Reduce dose by 50%; monitor closely for efficacy and for adverse reactions requiring dosage reduction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe impairment (Child-Pugh class C): Avoid use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment for toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Bone marrow suppression:",
"     </i>",
"     Interrupt treatment; may reinitiate once cause of cytopenia has been determined; contraindicated if platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Gastrointestinal:",
"     </i>",
"     Discontinue treatment for suspected GI ulceration or hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Hearing loss or visual disturbance",
"     </i>",
"     : Consider dose reduction or treatment interruption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Severe rash:",
"     </i>",
"     Interrupt treatment; may reintroduce at a lower dose (with future dose escalation) and short-term oral corticosteroids. Permanently discontinue treatment if erythema multiforme is suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Renal impairment during therapy:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;2 years and Adolescents &lt;16 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     For increase in serum creatinine &gt;33% above the average pretreatment level and above the age-appropriate ULN, reduce daily dose by 10 mg/kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If serum creatinine &gt;2 times age-appropriate ULN or Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute: Discontinue use; contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents &ge;16 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     For increase in serum creatinine &ge;33% above the average pretreatment level for 2 consecutive weekly levels, reduce daily dose by 10 mg/kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     If serum creatinine &gt;2 times age-appropriate ULN or Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute: Discontinue use; 				contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1987300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet for suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Exjade&reg;: 125 mg, 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F1988061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F10982506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Deferasirox (Exjade&reg;) is only available through a restricted distribution program called EPASS&trade; Complete Care. Prescribers must enroll patients in this program in order to obtain the medication. For patient enrollment, contact 1-888-90-EPASS (1-888-903-7277).",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2738404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Do not chew or swallow whole tablets",
"     </b>",
"     ; administer as an oral suspension. Completely disperse tablets in water, orange juice, or apple juice; use 3.5 ounces for total doses &lt;1 g  and 7 ounces for doses &ge;1 g; stir to form suspension and drink entire contents. Rinse remaining residue with more fluid; drink. Administer at same time each day on an empty stomach, at least 30 minutes before food.  Do not administer simultaneously with aluminum-containing antacids or cholestyramine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2738380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from moisture.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2738374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic iron overload due to blood transfusions (FDA approved in children &ge;2 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4432943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Deferasirox may be confused with deferiprone, deferoxamine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F1987244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Fatigue, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: ALT increased, transaminitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Otic: Ear infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Proteinuria, serum creatinine increased (dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Acute , bronchitis, cough, nasopharyngitis, pharyngitis, pharyngolaryngeal pain, respiratory tract infection, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Influenza",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Acute renal failure, agranulocytosis, anaphylaxis, anemia (worsening), angioedema, anxiety, ascites, bilirubin increased, cataract, cholecystitis, cholelithiasis, constipation, cytopenias, dizziness, drug fever, duodenal ulcer, edema, erythema multiforme, esophagitis, Fanconi&rsquo;s syndrome, gastric ulcer, gastritis, gastrointestinal bleeding, gastrointestinal hemorrhage, glomerulonephritis, glucosuria, hearing loss (including high frequency), hematuria, Henoch-Sch&ouml;nlein purpura, hepatic dysfunction, hepatic encephalopathy, hepatic failure, hepatic transaminases increased, hepatitis, hyperactivity, hypersensitivity reaction, hypocalcemia, insomnia, intraocular pressure increased, jaundice, lens opacities, leukocytoclastic vasculitis, maculopathy, neutropenia, optic neuritis, pigment disorder, purpura, renal tubular necrosis, renal tubulopathy, retinal disorder, sleep disorder, thrombocytopenia, tubulointerstitial nephritis, visual disturbance",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2738376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to deferasirox or any component; platelet counts &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; poor performance status; high-risk myelodysplastic syndromes;  advanced malignancies; creatinine clearance &lt;40 mL/minute or serum creatinine &gt;2 times the age-appropriate ULN",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F15827022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause overchelation; treatment  should be initiated with evidence of chronic iron overload [ie, transfusion of &ge;100 mL/kg of packed RBCs (eg, &ge;20 units for a 40 kg individual) and serum ferritin consistently &gt;1000 mcg/L]. Prior to use, consider risk versus anticipated benefit with respect to individual patient&rsquo;s life expectancy, prognosis, and comorbidities. An improvement in survival or disease-related symptoms due to the therapy has not been established in clinical trials. Postmarketing experience indicates serious reactions, including fatalities, have occurred with deferasirox use, particularly when used in older patients with comorbidities or advanced disease. Overchelation of iron may increase development of toxicity; temporary interruption of treatment should be considered if serum ferritin &lt;500 mcg/L. Do not combine with other iron chelation therapies; safety of combinations has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2738377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute renal failure (including fatalities and cases requiring dialysis) may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; observed more frequently in patients with comorbid conditions and advanced hematologic malignancies; obtain serum creatinine and calculate creatinine clearance in duplicate at baseline prior to initiation, and monitor at least monthly thereafter. Use with caution in patients with renal impairment; has not been studied; in patients with underlying renal dysfunction or at risk for acute renal failure; dosage modification or treatment discontinuation may be required; use is contraindicated in patients with a creatinine clearance &lt;40 mL/minute or serum creatinine &gt;2 times age-appropriate ULN. May cause proteinuria; monitor monthly although the clinical significance of proteinuria is unknown. Renal tubular damage, including Fanconi&rsquo;s syndrome, has also been reported, primarily in pediatric/adolescent patients with &beta;-thalassemia and serum ferritin levels &lt;1500 mcg/L.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hepatotoxicity and failure (including fatalities) may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; monitor transaminases and bilirubin at baseline, every 2 weeks for 1 month, then at least monthly thereafter. Hepatitis and elevated transaminases have also been reported. Hepatotoxicity is more common in patients &gt;55 years and in patients with significant comorbidities (eg, cirrhosis, multiorgan failure). Reduce dose or temporarily interrupt treatment for severe or persistent increases in transaminases/bilirubin. Avoid use in patients with severe (Child-Pugh class C) hepatic impairment; a dose reduction is required in patients with moderate (Child-Pugh class B) hepatic impairment. Monitor patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B) impairment closely for efficacy and for adverse reactions requiring dosage reduction.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Gastrointestinal hemorrhage, including fatalities, may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; observed more frequently in elderly patients with advanced hematologic malignancies and/or low platelets; discontinue treatment for suspected GI hemorrhage or ulceration. Other GI effects including irritation and ulceration have been reported. Use caution with concurrent medications that may increase risk of adverse GI effects (eg, NSAIDs, corticosteroids, anticoagulants, oral bisphosphonates). Monitor patients closely for signs/symptoms of GI ulceration/bleeding.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Auditory disturbances of decreased hearing and high frequency hearing loss have been reported (rare) with use; perform auditory testing prior to initiation and regularly (every 12 months) during use; if abnormalities develop, monitor more closely and consider dose reduction or treatment interruption. Ocular disturbances including lens opacities, cataracts, intraocular pressure elevation, and retinal disorders have been reported (rare) with use; perform ophthalmic testing prior to initiation and regularly (every 12 months) during use; if abnormalities develop, monitor more closely and consider dose reduction or treatment interruption.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause bone marrow suppression; rare cases of peripheral cytopenias including agranulocytosis, neutropenia, and thrombocytopenia have been reported (some fatal); risk may be increased in patients with pre-existing hematologic disorders; monitor blood counts regularly. Interrupt treatment in patients who develop cytopenias; may reinitiate once cause of cytopenia has been determined; use contraindicated if platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hypersensitivity reactions including severe reactions (eg, anaphylaxis and angioedema) have been reported; usual onset is within the first month of treatment; discontinue if severe. May cause skin rash (dose-related), including erythema multiforme; mild to moderate rashes may resolve without treatment interruption; for severe rash, interrupt treatment and consider restarting at a lower dose with dose escalation in combination with a short period of oral steroid administration; if erythema multiforme suspected, discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Potent UDP-glucuronosyltransferase (UGT) inducers (eg, rifampin) or bile acid sequestrants (eg, cholestyramine) may decrease the efficacy of deferasirox; avoid concomitant use. If coadministration necessary, dosage modifications may be needed; monitor serum ferritin and clinical response.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9935524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of UGT1A1;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (moderate), CYP2C8 (moderate);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F1987249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: May diminish the therapeutic effect of Deferasirox.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Deferasirox. Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids: May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Nasal); Budesonide (Nasal); Ciclesonide (Nasal); Desonide; Dexamethasone (Ophthalmic); Difluprednate; Flunisolide (Nasal); Fluocinolone (Ophthalmic); Fluticasone (Nasal); Loteprednol; Mometasone (Nasal); PrednisoLONE (Ophthalmic); Triamcinolone (Nasal); Triamcinolone (Ophthalmic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: Deferasirox may increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: Deferasirox may increase the serum concentration of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: Deferasirox may decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Deferasirox. Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Deferasirox. Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Deferasirox. Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Deferasirox may increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Deferasirox. Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May decrease the serum concentration of Deferasirox. Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline: Deferasirox may increase the serum concentration of Theophylline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2738682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bioavailability increased variably when taken with food; administer on empty stomach",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F1987215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1987216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal reproduction studies. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2738405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum ferritin (baseline, then monthly), iron levels (baseline), CBC with differential, serum creatinine, and/or creatinine clearance [two baseline assessments, then at least monthly; for patients who are at increased risk of complications (eg, pre-existing renal conditions, elderly, comorbid conditions, or receiving other potentially nephrotoxic medications): Two baseline assessments, weekly for the first month then at least monthly thereafter]; urine protein (monthly), serum transaminases (ALT/AST) and bilirubin  at baseline, every 2 weeks for 1 month, then monthly; baseline and annual auditory and ophthalmic function (including slit lamp examinations and dilated fundoscopy); performance status (in patients with hematologic malignancies); signs and symptoms of GI ulcers or hemorrhage; cumulative number of RBC units received",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2738401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selectively binds iron with a high affinity in a 2:1 ratio, forming a complex which is excreted primarily through the feces.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2738402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Systemic exposure has been shown to be less in pediatric patients (2-16 years) compared to adults; in children 2-6 years, exposure was reduced by ~50% compared to adults; however, results of safety and efficacy trials using the same dose were similar in pediatric and adult patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: 14.4 &plusmn; 2.7 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 99% to serum albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via glucuronidation by UGT1A1 and UGT1A3; minor oxidation by CYP450; undergoes enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: 8-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: Median range: 1.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Feces (84%), urine (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clearance: Females have moderately lower clearance than males (17.5% lower)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F2738683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/16/41221?source=see_link\">",
"      see \"Deferasirox: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     My cause fever, headache, abdominal pain, nausea, diarrhea, cough, sore throat, or dizziness; may impair ability to perform activities requiring physical coordination; use caution when driving or operating machinery. Report severe skin rashes, changes in vision or hearing, swelling of extremities, decrease in urine output, shortness of breath, unusual bleeding or bruising, change in color of urine or stool, yellowing of skin or eyes, or unusual fatigue.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bacon BR, Adams PC, Kowdley KV, et al, \"Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases,\"",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2011, 54(1):328-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41094/abstract-text/21452290/pubmed\" id=\"21452290\" target=\"_blank\">",
"        21452290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cappellini MD, Bejaoui M, Agaoglu L, et al, \"Iron Chelation With Deferasirox in Adult and Pediatric Patients With Thalassemia Major: Efficacy and Safety During 5 Years' Follow-Up,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(4):884-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41094/abstract-text/21628399/pubmed\" id=\"21628399\" target=\"_blank\">",
"        21628399",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Galanello R, Piga A, Alberti D, et al, \"Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron-Chelating Agent in Patients With Transfusion-Dependent Iron Overload Due to Beta-Thalassemia,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2003,  43(6):565-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41094/abstract-text/12817519 /pubmed\" id=\"12817519 \" target=\"_blank\">",
"        12817519",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nisbet-Brown E, Oliveri NF, Giardina PJ, et al, \"Effectiveness and Safety of ICL670 in Iron-Loaded Patients With Thalassaemia: A Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 361(9369):1597-602.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41094/abstract-text/12747879/pubmed\" id=\"12747879\" target=\"_blank\">",
"        12747879",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raphael JL, Bernhardt MB, Mahoney DH, et al, \"Oral Iron Chelation and the Treatment of Iron Overload in a Pediatric Hematology Center,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2009, 52(5):616-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41094/abstract-text/19148949 /pubmed\" id=\"19148949 \" target=\"_blank\">",
"        19148949",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rund D and Rachmilewitz E, \"Beta-Thalassemia,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(11):1135-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41094/abstract-text/16162884 /pubmed\" id=\"16162884 \" target=\"_blank\">",
"        16162884",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yusuf B, McPhedran P, and Brewster UC, \"Hypocalcemia in a Dialysis Patient Treated With Deferasirox for Iron Overload,\"",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2008, 52(3):587-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/8/41094/abstract-text/18534729/pubmed\" id=\"18534729\" target=\"_blank\">",
"        18534729",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13104 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-528937E1C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_8_41094=[""].join("\n");
var outline_f40_8_41094=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9935104\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987209\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4432114\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738373\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738403\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987300\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1988061\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10982506\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738404\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738380\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738374\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4432943\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987244\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738376\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827022\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738377\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9935524\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987249\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738682\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987215\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987216\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738405\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738401\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738402\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738683\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13104\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13104|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/19/2360?source=related_link\">",
"      Deferasirox: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/16/41221?source=related_link\">",
"      Deferasirox: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_8_41095="Ross River virus infection";
var content_f40_8_41095=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ross River virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/8/41095/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41095/contributors\">",
"     Michael J Richards, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/8/41095/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41095/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/8/41095/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41095/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/8/41095/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ross River virus (RRV) is a group A arbovirus transmitted by mosquitoes that causes a disease manifest by polyarthritis and rash. The illness was first described in northern Australia in 1928 and subsequently has been observed widely through Australia and many islands of the western South Pacific. It is most the most prevalent vector borne disease in Australia. The virus can be transmitted by many mosquito species and survives in mosquito eggs in arid environments. Therefore, it has capacity to spread to other geographic areas.",
"   </p>",
"   <p>",
"    Other viruses that cause arthritis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23354?source=see_link\">",
"     \"Specific viruses that cause arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ross River virus (RRV) infection has been described in mainland Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/1\">",
"     1",
"    </a>",
"    ], Papua New Guinea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/2\">",
"     2",
"    </a>",
"    ], the Solomon Islands, the islands of eastern Indonesia, the western South Pacific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], Fiji [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/5\">",
"     5",
"    </a>",
"    ], and American Samoa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/6\">",
"     6",
"    </a>",
"    ]. As many as 500,000 people were infected in Fiji when the disease first appeared in 1979 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/5\">",
"     5",
"    </a>",
"    ]. Outbreaks have been described in American Samoa, New Caledonia, French Polynesia, the Cook Islands, and most states of Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Australia, approximately 6000 people are infected annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/9\">",
"     9",
"    </a>",
"    ]. The highest rates of infection have been reported from the Northern Territory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/10\">",
"     10",
"    </a>",
"    ]. Endemic foci also occur in more temperate eastern Australia. Infection has been observed in the outskirts of Sydney since 1997 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/11\">",
"     11",
"    </a>",
"    ]. Epidemics have increased in frequency, size, and range throughout European settlements of Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/12\">",
"     12",
"    </a>",
"    ]. The geographic range is expanding in Queensland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/13\">",
"     13",
"    </a>",
"    ] and South Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RRV infection occurs most frequently in tropical coastal regions with salt marsh habitats suitable for the principal mosquito vector species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/15\">",
"     15",
"    </a>",
"    ]. The infection is most common in spring, after summer rains, or following inundation of salt marshes by rain or tides. The virus persists in arid areas of inland Australia within desiccation-resistant mosquito eggs. Outbreaks occur after rain, when mosquitoes hatch [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Climate influences disease activity. Models predicting disease activity differ among regions; the relationships between climate, social, and environmental factors are complex. In the River Murray Valley in Southern Australia, important factors include river height, rainfall, and mosquito abundance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/17\">",
"     17",
"    </a>",
"    ]. In a Tasmanian study, a combination of high spring tides and excessive summer rainfall produced a salt marsh habitat with a high density of mosquitoes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/18\">",
"     18",
"    </a>",
"    ]. Isolation of RRV from these mosquitoes coincided with the onset of the first human cases of RRV infection. In Western Australia, climate data were moderately sensitive in predicting epidemics (64 percent); the addition of mosquito surveillance data improved sensitivity of an early warning model for epidemics (90 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dryland salinity, a substantial and expanding problem in the wheat belt of Southwestern Australia, is associated with an abundance of Aedes camptorhynchus and increased potential for zoonotic transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/20\">",
"     20",
"    </a>",
"    ], although increased human seroprevalence has not yet been demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/21\">",
"     21",
"    </a>",
"    ]. Important factors for infection in the Darwin region of tropical Northern Australia include rainfall, minimum temperature, and abundance of three mosquito species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/22\">",
"     22",
"    </a>",
"    ]. The relative importance of these environmental factors differs according to region, although rainfall is consistently associated with increased disease activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Vectors and hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mosquito species that serve as vectors for RRV vary by region. In coastal Australia, Aedes vigilax (salt marsh mosquito) and Ae. camptorhynchus are major vectors; both of these species feed during the day. In inland areas except Tasmania, Culex annulirostris predominates; this species feeds at night [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/25\">",
"     25",
"    </a>",
"    ]. Other species capable of transmitting RRV include Aedes tremulus, Aedes polynesiensis, Aedes aegypti, and many others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Aedes aegypti has the potential to considerably extend the distribution of this infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23011?source=see_link\">",
"     \"Mosquito vectors of infectious diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Native macropods (eg, kangaroos and wallabies) are the principal vertebrate hosts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/28\">",
"     28",
"    </a>",
"    ]; infection also occurs among other wild animals and livestock. Possums and horses are potential reservoirs in urban areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, vertical transmission occurs in mosquitoes, and human-mosquito-human transmission is believed to occur. Studies of RRV in northwest Victoria suggest that the density of short-lived, highly fecund hosts, such as mice, may also influence rural disease transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20298956\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ross River virus (RRV) is an enveloped RNA virus; distinct genetic types have been found in eastern and western Australia, with a mix in northern Australia. The membrane bilayer, which surrounds the nucleocapsid, is penetrated by spikes, each of which consists of glycoproteins E1 and E2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/31\">",
"     31",
"    </a>",
"    ]. E2 is thought to be involved in recognition of the cellular receptor in the host [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/32\">",
"     32",
"    </a>",
"    ]. Relapse or persistence of symptoms in many patients may be related to persistent replication within synovial macrophages despite neutralizing antibodies and antiviral cytokine responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/33\">",
"     33",
"    </a>",
"    ]. This process may be initiated by an initial IgG anti-RRV antibody response, which enhances infection in macrophages and monocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Functional polymorphisms in immune response genes, contribute to individual susceptibility and outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/35\">",
"     35",
"    </a>",
"    ]. Polymorphisms in the IFN-gamma and IL10 loci influence cytokine production and the severity and duration of illness after infection with RRV. These risk-associated cytokine genotypes may act in combination to potentiate their impact on illness severity. IL10 is a potent inhibitor of IL-1 beta and TNF-alpha production by macrophages, and these cytokines often have synergistic activities in induction of inflammation in the acute sickness response. In vitro models suggest that cellular antiviral response can direct selective pressure for viral sequence evolution that impacts on viral fitness and sensitivity to",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    interferon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The arthritis of RRV infection is believed to be mediated by local cell-mediated immune responses. In the majority of patients, inflammation is present in the absence of detectable virus, although RRV DNA has been identified in the inflamed synovium of some patients more than a month after the onset of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rash of RRV infection may be a manifestation of a cell-mediated immune response to viral antigen in the basal epidermal and eccrine duct epithelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/38\">",
"     38",
"    </a>",
"    ]. Circulating immune complexes have not been found in patients with persistent symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/39\">",
"     39",
"    </a>",
"    ]. In a mouse model, macrophages have been shown to be the primary mediators of muscle damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ross River virus (RRV) infection has been observed in individuals between 4 and 85 years of age; the disease occurs more commonly in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/41\">",
"     41",
"    </a>",
"    ]. The incubation period for acute presentations is usually 3 to 9 days, but may be as long as 21 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/15\">",
"     15",
"    </a>",
"    ]. Subclinical infection is common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic RRV infection presents in one of the three ways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute febrile illness with arthritis and rash",
"     </li>",
"     <li>",
"      Acute fever, rash, or arthritis alone",
"     </li>",
"     <li>",
"      Chronic polyarthritis or polyarthralgia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no laboratory findings specific for RRV infection. The leukocyte count is usually normal; atypical lymphocytes or a mild neutrophilia may be found in some patients. The serum C-reactive protein concentration is usually normal, but modest elevations in the erythrocyte sedimentation rate may be observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most dramatic clinical features of RRV infection are marked arthralgia and myalgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/24\">",
"     24",
"    </a>",
"    ]. Joint pains are present in more than 95 percent of patients. True arthritis occurs in 40 percent of patients (",
"    <a class=\"graphic graphic_picture graphicRef57212 \" href=\"mobipreview.htm?20/14/20704\">",
"     picture 1",
"    </a>",
"    ). The joints of the extremities are most frequently involved, especially the wrists, knees, ankles, and the metacarpophalangeal and interphalangeal joints of the fingers (",
"    <a class=\"graphic graphic_picture graphicRef72125 \" href=\"mobipreview.htm?3/27/3506\">",
"     picture 2",
"    </a>",
"    ). Joint involvement is usually symmetric, but the severity of inflammation may be asymmetric. The intensity of the pain and inflammation may resemble that of gout. Effusions are often present in joints and tendon sheaths, and Achilles tendinitis and plantar fasciitis may occur. Back pain is also common; no association between HLA-B27 or another HLA allele has been detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Synovial fluid analysis early in the disease may suggest viral arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/41\">",
"     41",
"    </a>",
"    ]. The fluid is viscous with entirely or predominantly mononuclear cells; neutrophils may comprise up to 12 percent of cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Rash and fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rash and fever are observed in approximately one-half of patients with RRV infection. Rash and arthritis usually develop within two days of one another, but may be separated by up to two weeks. The rash may occur before or after the arthritis. It is typically short-lived (1 to 10 days) but may persist for several months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/41\">",
"     41",
"    </a>",
"    ]. The palms, soles of the feet, face, and mucous membranes of the mouth may be involved. The rash usually consists of 1 to 5 mm maculopapular lesions on the limbs and trunk; it is often sparse (",
"    <a class=\"graphic graphic_picture graphicRef75678 \" href=\"mobipreview.htm?42/52/43854\">",
"     picture 3",
"    </a>",
"    ), although in some cases it is dense and can include purpuric areas or small vesicles (",
"    <a class=\"graphic graphic_figure graphicRef77070 \" href=\"mobipreview.htm?4/56/4992\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Fever, occasionally reaching 39&ordm;C, is present early in RRV infection in about 20 percent of patients and usually resolves within three days. Chills and delirium can occur; rigors are unusual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is the most frequent constitutional symptom, occurring in 90 percent of patients. It may be prominent, even in the absence of fever, and may persist after other symptoms resolve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/43\">",
"     43",
"    </a>",
"    ]. Anorexia and headache (50 percent patients) are common. Other symptoms and signs include diarrhea, neck stiffness, photophobia, splenomegaly, aseptic meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/44\">",
"     44",
"    </a>",
"    ], hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/45\">",
"     45",
"    </a>",
"    ], glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/2\">",
"     2",
"    </a>",
"    ], and superficial lymphadenopathy (usually mild; occasionally tender). Several patients with encephalitis have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]; one case of fatal encephalitis has been attributed to RRV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/46\">",
"     46",
"    </a>",
"    ]. RRV has not been associated with congenital abnormalities, although transplacental viral transmission was described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20298775\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average duration of symptoms differs considerably in different reports. Some arthralgias persist for more than three months in two-thirds of patients, but it usually steadily diminishes in severity over this time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/28,50\">",
"     28,50",
"    </a>",
"    ]. In one study, for example, nonsteroidal anti inflammatory drug use decreased from 63 percent at one month to 15 percent at three months. Early studies suggested patients can have persistent arthralgia, myalgia, and fatigue for more than a year after infection; more recent evidence suggests that symptoms usually resolve within three to six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/15,51,52\">",
"     15,51,52",
"    </a>",
"    ]. Many patients with longer duration of symptoms had other underlying comorbidities such as rheumatic disease or depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/53\">",
"     53",
"    </a>",
"    ]. Degenerative joint changes do not occur and relapses are infrequent.",
"   </p>",
"   <p>",
"    In a prospective cohort study of patients with RRV, Epstein Barr virus, or Q fever infection, 12 percent of patients had prolonged illness with disabling fatigue, musculoskeletal pains, neurocognitive difficulties, and mood disturbance at six months following initial infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/54\">",
"     54",
"    </a>",
"    ]. The outcome was predicted by severity of acute illness rather than the underlying microbiologic diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ross River virus (RRV) infection should be suspected in the setting of acute polyarthritis and rash with a history of travel or residence in endemic or epidemic areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis includes rubella, infectious mononucleosis, parvovirus B19, Henoch-Sch&ouml;nlein purpura (IgA vasculitis), serum sickness, a drug reaction, erythema multiforme, and systemic lupus erythematosus. It also includes other arboviral infections, particularly Barmah Forest virus infection and Chikungunya fever. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15576?source=see_link\">",
"     \"Chikungunya fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Barmah Forest virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barmah Forest virus (BFV) is an alphavirus transmitted by mosquitoes that causes polyarthritis. BFV causes approximately 10 percent of epidemic polyarthritis in northeastern Australia. It was first recognized as a cause of human infection in 1988 and has been increasingly reported in Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/55\">",
"     55",
"    </a>",
"    ]. Epidemics have been recognized in the Northern Territory (1992), Western Australia in (1992 to 1993) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/55,56\">",
"     55,56",
"    </a>",
"    ], coastal New South Wales (1995), Victoria (2002) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/57\">",
"     57",
"    </a>",
"    ] and Queensland (2002 to 2003) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transmission of BFV is determined by a number of environmental factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/58\">",
"     58",
"    </a>",
"    ]. Peak transmission occurs in summer and autumn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/10\">",
"     10",
"    </a>",
"    ]. Endemic activity is believed to be restricted to northern Australia. Exotic vector mosquitoes involved in past epidemics include Ae. camptorhynchus (1993), Aedes vigilax (1995) and Ochlerotatus camptorhynchus (2002). High rates of infection among brushtail possums suggest they may play a role in transmission of urban human infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of BFV are similar to those of RRV although, in general, BFV tends to cause milder disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/15\">",
"     15",
"    </a>",
"    ]. Rash is more common with BFV infection, while arthritis is more prominent in RRV infection, although these diseases cannot be reliably distinguished based on symptoms alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/51,60\">",
"     51,60",
"    </a>",
"    ]. In one series of 84 patients with BFV, the most common symptoms and signs were lethargy (89 percent), joint pain (82 percent), and rash (68 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/60\">",
"     60",
"    </a>",
"    ]. Dermatologic manifestations include urticated erythema and widespread vesiculopapular, macular, or purpuric eruptions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnosis of BFV is confirmed by a virus-specific IgM response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of RRV infection is generally established by serology; the most common serologic methods are the hemagglutination inhibition (HI) antibody test and the ELISA test. A fourfold rise in HI titer is diagnostic; levels of &ge;1:1280 indicate recent infection. RRV-specific IgM persists for months after acute infection. Thus, acute infection should be confirmed by rising IgM titers if patients live in endemic areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/15\">",
"     15",
"    </a>",
"    ]. Testing for a specific IgA response can demonstrate acute infection in patients with persistent high levels of anti-IgM and IgG antibodies although this test is rarely necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Viral culture and polymerase chain reaction (PCR) are less widely used diagnostic tools. RRV can be isolated from blood drawn early in the course of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/15,41\">",
"     15,41",
"    </a>",
"    ]. RRV has not been cultured from joint fluid, but viral antigen has been detected by immunofluorescence in joint fluid specimens collected early in the disease. A nested PCR is being developed for RRV infection, but it remains a research tool currently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20298699\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of Ross River virus (RRV) consists of supportive care; no specific antiviral therapy is available. Treatment of the arthralgias and myalgias with analgesics and nonsteroidal antiinflammatory drugs may be helpful. Some benefit from swimming, hydrotherapy, physiotherapy, or massage; others gain relief only with rest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important preventive measure is avoidance of mosquito bites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/25\">",
"     25",
"    </a>",
"    ]. In one case-controlled study, mosquito coils, repellants, and citronella candles were shown to decrease the risk of infection at least twofold; light colored clothing decreased risk threefold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/64\">",
"     64",
"    </a>",
"    ]. In contrast, camping increased the risk of Ross River virus (RRV) eightfold. Screens should be fitted to windows and doors in high risk areas. Drainage of mosquito breeding areas in endemic areas may also be helpful over the long-term to control the infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/7\">",
"     7",
"    </a>",
"    ]. Mosquito control programs affect RRV disease rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/65\">",
"     65",
"    </a>",
"    ]. Preemptive surveillance based on knowledge of disease habitats has been associated with lower RRV disease rates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/1/43031?source=see_link\">",
"     \"Prevention of arthropod and insect bites: Repellents and other measures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RRV and Barmah Forest virus are theoretically transmissible by transfusion of blood products; consideration of blood product screening may be warranted. There has been no documented transmission of RRV by transfusion; asymptomatic viremia has been documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/66\">",
"     66",
"    </a>",
"    ]. There is a theoretical possibility that transmission may occur with donors from high risk areas, especially at the time of outbreaks (even if symptomatic patients are excluded from blood donation).",
"   </p>",
"   <p>",
"    No vaccine is yet available, though experimental vaccines are under study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. An inactivated whole virus vaccine that has proven effective in mice is a promising candidate for human trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/69\">",
"     69",
"    </a>",
"    ]. It is encouraging also that the relative genetic diversity of RRV has been consistently low, so vaccination is unlikely to lead to rapid antigenic evolution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41095/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20299949\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ross River virus (RRV) is an arboviral infection transmitted by mosquitoes that causes an illness characterized by fever, polyarthritis, and rash. The illness was first described in northern Australia and subsequently has been observed widely throughout Australia and many islands of the western South Pacific. It is common in the tropical coastal regions of northern Australia. RRV can be transmitted by a variety of mosquito species, including Aedes vigilax, Aedes Camptorhynchus, and Culex annulirostris. Kangaroos and wallabies are the principal vertebrate hosts. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic RRV infection typically presents as acute illness with fever, arthritis, and rash. These symptoms frequently occur together but may occur in isolation. Arthritis in the wrists, knees, ankles, and finger joints is common and frequently symmetric. The rash is usually maculopapular and involves the limbs and trunk. Arthralgia may persist for up to three months. Fatigue is the most frequent constitutional symptom. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of RRV infection is generally established by serology; the most common serologic methods are the hemagglutination inhibition (HI) antibody test and ELISA test. A fourfold rise in HI titer is diagnostic; levels of &ge;1:1280 indicate recent infection. RRV-specific IgM persists for months after acute infection, and acute infection can be confirmed by rising IgM titers. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment consists of supportive care, analgesics, and nonsteroidal antiinflammatory drugs. (See",
"      <a class=\"local\" href=\"#H20298699\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important preventive measure is avoidance of mosquito bites. Helpful interventions include use of window and door screens, mosquito repellants, and light colored clothing. Over the long-term, drainage of mosquito breeding areas in endemic areas may be helpful to control infection. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/1\">",
"      Kelly-Hope LA, Purdie DM, Kay BH. Differences in climatic factors between Ross River virus disease outbreak and nonoutbreak years. J Med Entomol 2004; 41:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/2\">",
"      Fraser JR, Cunningham AL, Muller HK, et al. Glomerulonephritis in the acute phase of Ross River virus disease (epidemic polyarthritis). Clin Nephrol 1988; 29:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/3\">",
"      Fauran P, Donaldson M, Harper J, et al. Characterization of Ross River viruses isolated from patients with polyarthritis in New Caledonia and Wallis and Futuna Islands. Am J Trop Med Hyg 1984; 33:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/4\">",
"      Rosen L, Gubler DJ, Bennett PH. Epidemic polyarthritis (Ross River) virus infection in the Cook Islands. Am J Trop Med Hyg 1981; 30:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/5\">",
"      Aaskov JG, Mataika JU, Lawrence GW, et al. An epidemic of Ross River virus infection in Fiji, 1979. Am J Trop Med Hyg 1981; 30:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/6\">",
"      Tesh RB, McLean RG, Shroyer DA, et al. Ross River virus (Togaviridae: Alphavirus) infection (epidemic polyarthritis) in American Samoa. Trans R Soc Trop Med Hyg 1981; 75:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/7\">",
"      Tai KS, Whelan PI, Patel MS, Currie B. An outbreak of epidemic polyarthritis (Ross River virus disease) in the Northern Territory during the 1990-1991 wet season. Med J Aust 1993; 158:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/8\">",
"      Lindsay M, Oliveira N, Jasinska E, et al. An outbreak of Ross River virus disease in Southwestern Australia. Emerg Infect Dis 1996; 2:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/9\">",
"      Bi P, Hiller JE, Cameron AS, et al. Climate variability and Ross River virus infections in Riverland, South Australia, 1992-2004. Epidemiol Infect 2009; 137:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/10\">",
"      Quinn HE, Gatton ML, Hall G, et al. Analysis of Barmah Forest virus disease activity in Queensland, Australia, 1993-2003: identification of a large, isolated outbreak of disease. J Med Entomol 2005; 42:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/11\">",
"      Amin J, Hueston L, Dwyer DE, Capon A. Ross River virus infection in the north-west outskirts of the Sydney basin. Commun Dis Intell 1998; 22:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/12\">",
"      Weinstein P, Judge D, Carver S. Biological and cultural coevolution and emerging infectious disease: Ross River virus in Australia. Med Hypotheses 2011; 76:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/13\">",
"      Tong S, Hu W, McMichael AJ. Climate variability and Ross River virus transmission in Townsville Region, Australia, 1985-1996. Trop Med Int Health 2004; 9:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/14\">",
"      Selden SM, Cameron AS. Changing epidemiology of Ross River virus disease in South Australia. Med J Aust 1996; 165:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/15\">",
"      Mackenzie JS, Smith DW. Mosquito-borne viruses and epidemic polyarthritis. Med J Aust 1996; 164:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/16\">",
"      Lindsay MD, Broom AK, Wright AE, et al. Ross River virus isolations from mosquitoes in arid regions of Western Australia: implication of vertical transmission as a means of persistence of the virus. Am J Trop Med Hyg 1993; 49:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/17\">",
"      Williams CR, Fricker SR, Kokkinn MJ. Environmental and entomological factors determining Ross River virus activity in the River Murray Valley of South Australia. Aust N Z J Public Health 2009; 33:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/18\">",
"      Robertson GJ, Doggett S, Seeman O, et al. Ross River virus and its vectors in Sorell Municipal Area, south-eastern Tasmania, January to March 2002. Commun Dis Intell Q Rep 2004; 28:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/19\">",
"      Woodruff RE, Guest CS, Garner MG, et al. Early warning of Ross River virus epidemics: combining surveillance data on climate and mosquitoes. Epidemiology 2006; 17:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/20\">",
"      Carver S, Spafford H, Storey A, Weinstein P. Dryland salinity and the ecology of Ross River virus: the ecological underpinnings of the potential for transmission. Vector Borne Zoonotic Dis 2009; 9:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/21\">",
"      Jardine A, Speldewinde P, Lindsay MD, et al. Is there an association between dryland salinity and Ross River virus disease in southwestern Australia? Ecohealth 2008; 5:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/22\">",
"      Jacups SP, Whelan PI, Markey PG, et al. Predictive indicators for Ross River virus infection in the Darwin area of tropical northern Australia, using long-term mosquito trapping data. Trop Med Int Health 2008; 13:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/23\">",
"      Hu W, Nicholls N, Lindsay M, et al. Development of a predictive model for ross river virus disease in Brisbane, Australia. Am J Trop Med Hyg 2004; 71:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/24\">",
"      Suhrbier A, La Linn M. Clinical and pathologic aspects of arthritis due to Ross River virus and other alphaviruses. Curr Opin Rheumatol 2004; 16:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/25\">",
"      Wolstenholme J. Ross River virus: an Australian export? Med J Aust 1992; 156:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/26\">",
"      Gubler DJ. Transmission of Ross River virus by Aedes polynesiensis and Aedes aegypti. Am J Trop Med Hyg 1981; 30:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/27\">",
"      Harley D, Ritchie S, Phillips D, van den Hurk A. Mosquito isolates of Ross River virus from Cairns, Queensland, Australia. Am J Trop Med Hyg 2000; 62:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/28\">",
"      Mylonas AD, Brown AM, Carthew TL, et al. Natural history of Ross River virus-induced epidemic polyarthritis. Med J Aust 2002; 177:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/29\">",
"      Kay BH, Boyd AM, Ryan PA, Hall RA. Mosquito feeding patterns and natural infection of vertebrates with Ross River and Barmah Forest viruses in Brisbane, Australia. Am J Trop Med Hyg 2007; 76:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/30\">",
"      Carver S, Sakalidis V, Weinstein P. House mouse abundance and Ross River virus notifications in Victoria, Australia. Int J Infect Dis 2008; 12:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/31\">",
"      Cheng RH, Kuhn RJ, Olson NH, et al. Nucleocapsid and glycoprotein organization in an enveloped virus. Cell 1995; 80:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/32\">",
"      Smith TJ, Cheng RH, Olson NH, et al. Putative receptor binding sites on alphaviruses as visualized by cryoelectron microscopy. Proc Natl Acad Sci U S A 1995; 92:10648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/33\">",
"      Boyd AM, Hall RA, Gemmell RT, Kay BH. Experimental infection of Australian brushtail possums, Trichosurus vulpecula (Phalangeridae: Marsupialia), with Ross River and Barmah Forest viruses by use of a natural mosquito vector system. Am J Trop Med Hyg 2001; 65:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/34\">",
"      Linn ML, Aaskov JG, Suhrbier A. Antibody-dependent enhancement and persistence in macrophages of an arbovirus associated with arthritis. J Gen Virol 1996; 77 ( Pt 3):407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/35\">",
"      Vollmer-Conna U, Piraino BF, Cameron B, et al. Cytokine polymorphisms have a synergistic effect on severity of the acute sickness response to infection. Clin Infect Dis 2008; 47:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/36\">",
"      Lidbury BA, Rulli NE, Musso CM, et al. Identification and characterization of a ross river virus variant that grows persistently in macrophages, shows altered disease kinetics in a mouse model, and exhibits resistance to type I interferon. J Virol 2011; 85:5651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/37\">",
"      Soden M, Vasudevan H, Roberts B, et al. Detection of viral ribonucleic acid and histologic analysis of inflamed synovium in Ross River virus infection. Arthritis Rheum 2000; 43:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/38\">",
"      Fraser JR, Ratnamohan VM, Dowling JP, et al. The exanthem of Ross River virus infection: histology, location of virus antigen and nature of inflammatory infiltrate. J Clin Pathol 1983; 36:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/39\">",
"      Fraser JR, Cunningham AL, Mathews JD, Riglar A. Immune complexes and Ross River virus disease (epidemic polyarthritis). Rheumatol Int 1988; 8:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/40\">",
"      Lidbury BA, Simeonovic C, Maxwell GE, et al. Macrophage-induced muscle pathology results in morbidity and mortality for Ross River virus-infected mice. J Infect Dis 2000; 181:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/41\">",
"      Fraser JR. Epidemic polyarthritis and Ross River virus disease. Clin Rheum Dis 1986; 12:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/42\">",
"      Aaskov JG, Ross P, Davies CE, et al. Epidemic polyarthritis in northeastern Australia, 1978-1979. Med J Aust 1981; 2:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/43\">",
"      Bennett BK, Hickie IB, Vollmer-Conna US, et al. The relationship between fatigue, psychological and immunological variables in acute infectious illness. Aust N Z J Psychiatry 1998; 32:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/44\">",
"      Penna JE, Irving LG. Evidence for meningitis in Ross River virus infection. Med J Aust 1993; 159:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/45\">",
"      Anstey N, Currie B, Tai KS. Ross River virus disease presenting with hematuria. Southeast Asian J Trop Med Public Health 1991; 22:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/46\">",
"      Scrimgeour EM, Aaskov JG, Matz LR. Ross River virus arthritis in Papua New Guinea. Trans R Soc Trop Med Hyg 1987; 81:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/47\">",
"      Lucas RE, Qiao M. A case of encephalitis in central Australia due to Ross River virus? Aust N Z J Med 1999; 29:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/48\">",
"      Scrimgeour EM. Suspected Ross River virus encephalitis in Papua New Guinea. Aust N Z J Med 1999; 29:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/49\">",
"      Aaskov JG, Nair K, Lawrence GW, et al. Evidence for transplacental transmission of Ross River virus in humans. Med J Aust 1981; 2:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/50\">",
"      Harley D, Bossingham D, Purdie DM, et al. Ross River virus disease in tropical Queensland: evolution of rheumatic manifestations in an inception cohort followed for six months. Med J Aust 2002; 177:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/51\">",
"      Flexman JP, Smith DW, Mackenzie JS, et al. A comparison of the diseases caused by Ross River virus and Barmah Forest virus. Med J Aust 1998; 169:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/52\">",
"      Westley-Wise VJ, Beard JR, Sladden TJ, et al. Ross River virus infection on the North Coast of New South Wales. Aust N Z J Public Health 1996; 20:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/53\">",
"      Doggett SL, Russell RC, Clancy J, et al. Barmah Forest virus epidemic on the south coast of New South Wales, Australia, 1994-1995: viruses, vectors, human cases, and environmental factors. J Med Entomol 1999; 36:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/54\">",
"      Hickie I, Davenport T, Wakefield D, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ 2006; 333:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/55\">",
"      Lindsay MD, Johansen CA, Smith DW, et al. An outbreak of Barmah Forest virus disease in the south-west of Western Australia. Med J Aust 1995; 162:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/56\">",
"      Tong S, Bi P, Hayes J, et al. Geographic variation of notified Ross River virus infections in Queensland, Australia, 1985-1996. Am J Trop Med Hyg 2001; 65:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/57\">",
"      Passmore J, O'Grady KA, Moran R, Wishart E. An outbreak of Barmah Forest virus disease in Victoria. Commun Dis Intell Q Rep 2002; 26:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/58\">",
"      Naish S, Hu W, Nicholls N, et al. Socio-environmental predictors of Barmah forest virus transmission in coastal areas, Queensland, Australia. Trop Med Int Health 2009; 14:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/59\">",
"      Russell RC. Ross River virus: ecology and distribution. Annu Rev Entomol 2002; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/60\">",
"      Beard JR, Trent M, Sam GA, Delpech VC. Self-reported morbidity of Barmah Forest virus infection on the north coast of New South Wales. Med J Aust 1997; 167:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/61\">",
"      Cashman P, Hueston L, Durrheim D, et al. Barmah Forest virus serology; implications for diagnosis and public health action. Commun Dis Intell Q Rep 2008; 32:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/62\">",
"      Carter IW, Fraser JR, Cloonan MJ. Specific IgA antibody response in Ross River virus infection. Immunol Cell Biol 1987; 65 ( Pt 6):511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/63\">",
"      Sellner LN, Coelen RJ, Mackenzie JS. Sensitive detection of Ross River virus--a one-tube nested RT-PCR. J Virol Methods 1994; 49:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/64\">",
"      Harley D, Ritchie S, Bain C, Sleigh AC. Risks for Ross River virus disease in tropical Australia. Int J Epidemiol 2005; 34:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/65\">",
"      Tomerini DM, Dale PE, Sipe N. Does mosquito control have an effect on mosquito-borne disease? The case of Ross River virus disease and mosquito management in Queensland, Australia. J Am Mosq Control Assoc 2011; 27:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/66\">",
"      Dunstan RA, Seed CR, Keller AJ. Emerging viral threats to the Australian blood supply. Aust N Z J Public Health 2008; 32:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/67\">",
"      Jones A, Lowry K, Aaskov J, et al. Molecular evolutionary dynamics of Ross River virus and implications for vaccine efficacy. J Gen Virol 2010; 91:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/68\">",
"      Kistner O, Barrett N, Br&uuml;hmann A, et al. The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans. Vaccine 2007; 25:4845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/69\">",
"      Holzer GW, Coulibaly S, Aichinger G, et al. Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection. Vaccine 2011; 29:4132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41095/abstract/70\">",
"      Jones A, Lowry K, Aaskov J, et al. Molecular evolutionary dynamics of Ross River virus and implications for vaccine efficacy. J Gen Virol 2010; 91:182.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3031 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-BD74261493-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_8_41095=[""].join("\n");
var outline_f40_8_41095=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20299949\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Vectors and hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20298956\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Rash and fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20298775\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Barmah Forest virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20298699\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20299949\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3031\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3031|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/56/4992\" title=\"figure 1\">",
"      Ross River virus generalized rash",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3031|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/14/20704\" title=\"picture 1\">",
"      Arthritis in RRV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/27/3506\" title=\"picture 2\">",
"      Ross River virus small joint arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/52/43854\" title=\"picture 3\">",
"      Ross River virus rash",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15576?source=related_link\">",
"      Chikungunya fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23011?source=related_link\">",
"      Mosquito vectors of infectious diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/1/43031?source=related_link\">",
"      Prevention of arthropod and insect bites: Repellents and other measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23354?source=related_link\">",
"      Specific viruses that cause arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_8_41096="Ciguatera fish poisoning";
var content_f40_8_41096=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ciguatera fish poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/8/41096/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41096/contributors\">",
"     Erin N Marcus, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/8/41096/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41096/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41096/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41096/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/8/41096/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41096/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/8/41096/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3605976\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ciguatera fish poisoning is a foodborne illness that is caused by ingestion of reef fish (eg, barracuda, amberjack, moray eel, and certain types of grouper, snapper, or parrotfish) that are contaminated with toxins that arise from",
"    <em>",
"     Gambierdiscus toxicus",
"    </em>",
"    , a single-celled organism that grows on coral reefs. Affected patients typically experience gastrointestinal, neurologic, and less commonly, cardiovascular abnormalities soon after eating a toxic fish. Treatment is primarily supportive. Prevention consists of avoidance of fish that commonly cause ciguatera poisoning.",
"   </p>",
"   <p>",
"    This topic describes the clinical manifestations, diagnosis, and management of ciguatera poisoning. Poisoning caused by ingestion of other seafood (eg, scombroid fish, shellfish, or pufferfish) is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/41/19096?source=see_link\">",
"     \"Marine toxins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3603702\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ciguatera fish poisoning accounts for more than half of the fish-related foodborne disease outbreaks in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/1\">",
"     1",
"    </a>",
"    ], and is the most common fish food poisoning in tropical coastal regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/2\">",
"     2",
"    </a>",
"    ]. Global estimates indicate that approximately 20,000 to 50,000 people develop this poisoning annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the actual number is likely higher because of missed diagnoses and underreporting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite underreporting, estimates of lifetime prevalence in affected areas are high ranging from 7 percent in Puerto Rico [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/5\">",
"     5",
"    </a>",
"    ] to 70 percent in the Polynesian Islands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/6\">",
"     6",
"    </a>",
"    ]. Most cases originate in the tropics and subtropics, between 35 degrees north latitude and 35 degrees south latitude. However, many cases of ciguatera toxicity also occur in more temperate regions because of increasing tourism, fish exportation, and unusual fish migration. For example, Canada has an estimated 1000 cases annually, with an average medical cost of $2470 per case [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/3\">",
"     3",
"    </a>",
"    ]. Multiple cases of ciguatera fish poisoning have also been reported after ingestion of barracuda or grouper purchased at fish markets in New York City [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, two cases of ciguatera fish poisoning have been reported following consumption of fish (barracuda) caught off the coast of South Carolina, well north of the typical location for such poisoning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/8\">",
"     8",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Some experts postulate that increasing seawater temperature due to climate change may increase the frequency of ciguatera fish poisoning. However, the incidence of ciguatera poisoning has not increased in the US Virgin Islands over the past 30 years despite an overall increase in seawater temperatures there [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than 400 different fish species have been associated with ciguatera fish toxicity. Reef-dwelling tropical fish such as barracuda, moray eel, amberjack, and certain types of grouper, mackerel, parrotfish, and red snapper are the most common sources. Rare cases exist of ciguatera fish poisoning occurring after the ingestion of temperate fish, including farm-raised salmon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/10\">",
"     10",
"    </a>",
"    ]. In general, however, toxicity from nontropical fish is extremely rare.",
"   </p>",
"   <p>",
"    The overall fatality rate from ciguatera fish poisoning is about 0.1 percent, with death usually due to cardiovascular collapse or respiratory failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/3,11-14\">",
"     3,11-14",
"    </a>",
"    ]. Mortality is lowest in the Caribbean and areas of the world where the healthcare system is able to rapidly treat the rare episodes of coma, bradycardia, or hypotension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3603709\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ciguatera fish poisoning is caused by several distinct toxins, of which ciguatoxin is the best known. These toxins are formed by dinoflagellates of the genus Gambierdiscus, single-celled algae-like organisms that grow on and around coral reefs.",
"    <em>",
"     Gambierdiscus toxicus",
"    </em>",
"    , which produces ciguatoxin, tends to proliferate on denuded coral surfaces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dinoflagellates are consumed by fish that do not appear to suffer ill effects from the toxin. Large, predatory fish (eg, barracuda, amberjack, moray eel, snapper, and certain types of grouper) concentrate the toxin in their organs and flesh, and thus, are considered most risky to human health. Ciguatera toxin-containing fish do not taste, smell, or appear unusual. Cooking, marinating, freezing, and stewing fish do not destroy the toxins.",
"   </p>",
"   <p>",
"    Ciguatoxin is a lipid soluble, heat stable, acid-resistant neurotoxin. It opens voltage-dependent sodium channels in cell membranes, triggering membrane depolarization. Ciguatoxin exposure in an animal model has caused long-term disruption of cerebral function in association with upregulation of sodium channel expression in astrocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maitotoxin and scaritoxin, other ciguatera associated toxins, increase calcium ion influx through excitable membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/11\">",
"     11",
"    </a>",
"    ] and permeability of sodium channels resulting in norepinephrine and acetylcholine release, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/17\">",
"     17",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3603716\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient affected with ciguatera fish poisoning frequently develops the following constellation of clinical findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Gastrointestinal",
"      </strong>",
"      &ndash; Gastroenteritis, including vomiting, diarrhea, and abdominal cramping, typically begins three to six hours after eating contaminated fish, but can be delayed up to 30 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/12,13,18\">",
"       12,13,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Neurologic",
"      </strong>",
"      &ndash; Neurologic abnormalities usually appear 3 to 72 hours after the meal. Clinical findings include peri-oral paresthesias, pruritus without urticaria or erythema, a metallic taste in the mouth, painful dentition, a feeling that the teeth are loose, painful urination, blurred vision, and temperature-related dysesthesias (cold stimuli perceived as hot or producing an abnormal, unpleasant sensation) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. Temperature-related dysesthesias are regarded as a specific finding of ciguatera toxicity. In the South Pacific, paresis may occur in up to 10 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/20\">",
"       20",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Cardiovascular",
"      </strong>",
"      &ndash; Cardiovascular signs, including bradycardia, heart block, and hypotension, can occur within hours of consumption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The types and frequencies of presenting signs and symptoms vary according to locale and likely reflect geographic differences in the various toxins and local food habits (eg, ingestion of visceral or reproductive organs where the toxin is concentrated) that may increase toxin consumption (",
"    <a class=\"graphic graphic_table graphicRef88891 \" href=\"mobipreview.htm?15/41/16029\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/4\">",
"     4",
"    </a>",
"    ]. In Pacific and Indian Ocean regions, patients often display early neurologic, gastrointestinal, and cardiovascular findings with neurologic findings predominating [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/21\">",
"     21",
"    </a>",
"    ]. Mental status changes, such as hallucinations or giddiness, and ataxia may also be noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/22\">",
"     22",
"    </a>",
"    ]. Although infrequent, life-threatening signs including coma and respiratory distress have also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/20,23\">",
"     20,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, in the Caribbean, ciguatera fish poisoning usually presents with gastroenteritis followed by a neurologic illness",
"    <strong>",
"     without",
"    </strong>",
"    mental status changes and is usually",
"    <strong>",
"     not",
"    </strong>",
"    life-threatening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/3,4,18,24,25\">",
"     3,4,18,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of other clinical findings have been associated with ciguatera toxicity as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic neuropsychiatric illness with fatigue and malaise [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Premature labor and spontaneous abortion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Painful sexual intercourse in men and women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Painful ejaculation in an affected male, followed by dyspareunia in the previously unaffected female [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The course of ciguatera fish poisoning is variable. Gastrointestinal and, if present, cardiovascular signs frequently resolve within 24 to 48 hours and rarely persist beyond four days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/4,18\">",
"     4,18",
"    </a>",
"    ]. Neurologic abnormalities typically are more persistent, lasting from a few days to several weeks. About 20 percent of patients have neurologic signs and symptoms that persist for months; and up to 2 percent report findings, such as fatigue, weakness, headache, or depression, that last for years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/24,28\">",
"     24,28",
"    </a>",
"    ]. However, patients who continue with symptoms beyond one year warrant investigation for other potential etiologies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several case reports and series describe exacerbation or relapse of ciguatera toxicity in patients who consume alcohol, caffeine, nuts, pork, chicken, or fish, including fish that did not cause poisoning symptoms in other individuals sharing the meal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/20,29-31\">",
"     20,29-31",
"    </a>",
"    ]. In one case, a patient developed neurologic symptoms (perioral paresthesia, myalgia, and malaise) and arthralgia similar to his original ciguatera poisoning symptoms two years later after drinking one beer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/29\">",
"     29",
"    </a>",
"    ]. Excessive physical exertion or dehydration within six months of original symptoms has also been reported to cause worsening or relapsing symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3603723\">",
"    <span class=\"h2\">",
"     Pregnant and nursing mothers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perinatal transmission of ciguatera toxicity may occur. As an example, a baby born by caesarean section to a mother with ciguatera poisoning exhibited left sided facial palsy, possible hand myotonia, and respiratory distress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/15\">",
"     15",
"    </a>",
"    ]. These symptoms resolved within six weeks. &nbsp;",
"   </p>",
"   <p>",
"    Toxins can also be transmitted via breast milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, nursing mothers with ciguatera fish poisoning should be advised to stop breast feeding while symptomatic. To maintain lactation, they can pump and discard breast milk. Though evidence is lacking, resumption of breast feeding is probably safe once the mother&rsquo;s symptoms have completely resolved. However, careful monitoring of the infant is warranted in such situations. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3603730\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;No clinical test is available to diagnose ciguatera fish poisoning. The diagnosis is established clinically using the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of ingestion of a large reef fish commonly associated with ciguatera toxicity (eg, moray eel, amberjack, barracuda, red snapper, or grouper).",
"     </li>",
"     <li>",
"      Gastrointestinal and neurologic features consistent with ciguatera fish poisoning, especially temperature-related dysesthesia. (See",
"      <a class=\"local\" href=\"#H3603716\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exclusion of other potential causes. (See",
"      <a class=\"local\" href=\"#H3603737\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Confirmation of ciguatoxin in the consumed fish, if possible. If the fish is not available for analysis, ciguatera poisoning in other individuals who consumed the same fish is also supportive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fish can be tested using a mouse bioassay and an IgG immunoassay, but these tests are costly and time consuming and are not widely used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/17\">",
"     17",
"    </a>",
"    ]. Alternatively, cytotoxicity assays or liquid chromatography-mass spectrophotometry can be employed although these techniques are also not widely or rapidly available, other than through the US Food and Drug Administration or similar government agency in other countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/18,33\">",
"     18,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3603737\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ciguatera fish poisoning has a distinct clinical presentation and is often readily identified once a careful food history is obtained. However, several other illnesses may have similar features as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Neurotoxic shellfish poisoning",
"      </strong>",
"      &ndash; Ingestion of shellfish contaminated by dinoflagellate species",
"      <em>",
"       Gymnodinium breve",
"      </em>",
"      , which is associated with red tides in temperate waters, can produce gastrointestinal distress and neurologic symptoms such as paresthesias of the face, mouth, and extremities, dizziness, ataxia, and muscle aches. Patients may also experience temperature-related dysesthesia and seizures. All symptoms, including neurologic toxicity, typically resolve within three days. The development of symptoms soon after ingestion of shellfish helps to differentiate neurotoxic shellfish poisoning from ciguatera poisoning. However, the diagnosis may be clouded if the patient has also ingested reef fish. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/41/19096?source=see_link&amp;anchor=H18#H18\">",
"       \"Marine toxins\", section on 'Neurotoxic shellfish poisoning'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Paralytic shellfish poisoning",
"      </strong>",
"      &ndash; Paralytic shellfish poisoning is caused by ingestion of bivalve mollusks, such as mussels, clams, scallops, and oysters, as well as crabs and snails that are contaminated with dinoflagellates of the genus Alexandrium. These algae are also associated with red tides in temperate waters. Physical findings occur within hours of ingestion and include neurologic symptoms ranging from perioral tingling, ataxia, difficulty swallowing, dizziness, paresthesias, weakness, paralysis, brainstem dysfunction, and respiratory failure. The rapid onset of weakness and paralysis distinguishes paralytic shellfish poisoning from ciguatera fish poisoning. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/41/19096?source=see_link&amp;anchor=H17#H17\">",
"       \"Marine toxins\", section on 'Paralytic shellfish poisoning'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pufferfish poisoning",
"      </strong>",
"      &ndash; Pufferfish poisoning results in paresthesias of the face and extremities, nausea, dizziness, weakness, loss of reflexes, paralysis, and hypotension caused by tetrodotoxin, which blocks sodium channels. This poisoning is primarily encountered in Japan where &ldquo;Fugu&rdquo; or blowfish is considered a delicacy. As with paralytic shellfish poisoning, the development of weakness and paralysis differentiates pufferfish poisoning from ciguatera fish poisoning. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/41/19096?source=see_link&amp;anchor=H20#H20\">",
"       \"Marine toxins\", section on 'Pufferfish poisoning (tetrodotoxin)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Scromboid fish poisoning",
"      </strong>",
"      &ndash; Signs and symptoms of scombroid toxicity usually begin within an hour of eating contaminated fish. The symptoms resemble an IgE-mediated allergic reaction. The patient may suddenly experience flushing, a sensation of warmth, an erythematous rash, palpitations, and significant tachycardia. The rash often is especially prominent on the upper torso and face. Although the timing of symptoms after eating fish is similar to ciguatera toxicity, scromboid otherwise shares very few of its clinical features. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/41/19096?source=see_link&amp;anchor=H12#H12\">",
"       \"Marine toxins\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Foodborne botulism",
"      </strong>",
"      &ndash; Ingestion of preformed botulinum toxin, typically found in home canned foods, causes vomiting, diarrhea, abdominal pain, cranial nerve dysfunction, and descending paralysis beginning hours to days after consumption. The disease presentation can vary from mild complaints to death within the first 24 hours of symptoms. Demonstration of the toxin in the blood is diagnostic. The lack of sensory changes helps to distinguish foodborne botulism from ciguatera fish poisoning. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/36/37448?source=see_link&amp;anchor=H12#H12\">",
"       \"Botulism\", section on 'Foodborne botulism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Guillain-Barr&eacute; syndrome",
"      </strong>",
"      &ndash; The acute inflammatory demyelinating polyneuropathy variant of Guillain-Barr&eacute; syndrome produces extremity paresthesias followed by ascending weakness with associated hypo- or areflexia. In some patients, the paresthesias may precede signs of weakness and suggest the diagnosis of ciguatera fish poisoning. The diagnosis of Guillain-Barr&eacute; syndrome is based upon the clinical features of the characteristic development of weakness. Lack of pleocytosis on examination of the cerebrospinal fluid and nerve conduction studies consistent with a demyelinating polyneuropathy provide confirmation of the clinical impression. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/22/5481?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/22/5481?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\", section on 'Acute inflammatory demyelinating polyneuropathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Multiple sclerosis",
"      </strong>",
"      &ndash; Sensory symptoms of multiple sclerosis (MS) can include paroxysmal onset of extremity paresthesias, pruritus dysesthesia, ataxia, fatigue, and alteration of facial sensation that may be mistaken for early signs of ciguatera toxicity. However, unlike ciguatera fish poisoning, MS causes vertigo, bowel and bladder dysfunction, transverse myelopathy, and weakness. However, clinical findings vary significantly in patients with MS and considerable overlap with neurologic symptoms of ciguatera fish poisoning may occur. The diagnosis of MS is based upon clinical findings and demonstration of demyelinating central nervous system lesions distributed over space and time. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=see_link\">",
"       \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=see_link\">",
"       \"Diagnosis of multiple sclerosis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Eosinophilic meningitis",
"      </strong>",
"      &ndash; Similar to findings of ciguatera toxicity, patients with eosinophilic meningitis commonly have nausea, vomiting, and paresthesias. Paresthesias with residual areas of hyperesthesia can persist for several weeks, even after other symptoms have resolved. However, unlike ciguatera fish poisoning, these patients typically have suggestive features of meningitis including neck stiffness and excruciating headache, which is usually frontal, occipital, or bitemporal. The diagnosis of eosinophilic meningitis is made based upon clinical presentation and cerebral spinal fluid eosinophilia, defined as the presence of more than 10",
"      <span class=\"nowrap\">",
"       eosinophils/mm&sup3;",
"      </span>",
"      in the cerebrospinal fluid (CSF)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      eosinophils accounting for more than 10 percent of CSF leukocytes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/43/40632?source=see_link\">",
"       \"Eosinophilic meningitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Organophosphate poisoning",
"      </strong>",
"      &ndash; Organophosphate poisoning has some features in common with ciguatera toxicity including vomiting, diarrhea, and abdominal pain. It can also uncommonly cause delayed neurotoxicity consisting of &ldquo;stocking-glove&rdquo; paresthesias and ascending flaccid weakness after acute toxicity has resolved. However, unlike ciguatera fish poisoning, organophosphate toxicity also has additional cholinergic findings of salivation, bronchorrhea, and bronchospasm with accompanying nicotinic features of muscle fasciculations, weakness, and paralysis. Lack of anticholinergic response to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      challenge and decreased red blood cell acetylcholinesterase activity support the clinical diagnosis of organophosphate poisoning. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33176?source=see_link&amp;anchor=H3#H3\">",
"       \"Organophosphate and carbamate poisoning\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33176?source=see_link&amp;anchor=H7#H7\">",
"       \"Organophosphate and carbamate poisoning\", section on 'Diagnosis'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the above diagnoses, chronic fatigue syndrome or depression may develop as comorbidities after ciguatera fish poisoning. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30825?source=see_link\">",
"     \"Clinical features and diagnosis of chronic fatigue syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3603744\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3603751\">",
"    <span class=\"h2\">",
"     Gastrointestional decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some experts have suggested",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) administration to bind ciguatoxins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/18\">",
"     18",
"    </a>",
"    ], vomiting frequently prevents its use and most patients seek medical attention more than one hour after fish ingestion. Therefore, AC is",
"    <strong>",
"     not",
"    </strong>",
"    warranted for the vast majority of patients with ciguatera fish poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1020320\">",
"    <span class=\"h2\">",
"     Initial supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment of ciguatera fish poisoning is primarily supportive and consists of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/18,34\">",
"     18,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Airway and breathing",
"      </strong>",
"      &ndash; In the rare patients with respiratory distress, coma, or weakness, the airway should be assessed and if not maintainable, secured by endotracheal intubation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/18,34\">",
"       18,34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=see_link\">",
"       \"Rapid sequence intubation in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=see_link\">",
"       \"Rapid sequence intubation (RSI) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Circulation",
"      </strong>",
"      &ndash; Hemodynamic instability caused by dehydration is frequently seen in patients with ciguatera fish poisoning. Bradycardia and toxin-induced hypotension also occur infrequently in some patients. Management for these conditions is as follows [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/18\">",
"       18",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Dehydration",
"      </strong>",
"      &ndash; Dehydration from vomiting and diarrhea warrants rapid fluid repletion with isotonic saline (eg, 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      normal saline, intravenously, maximum initial volume, 1 L). Further fluid therapy should be guided by the degree of dehydration and serum electrolyte values. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=see_link\">",
"       \"Treatment of hypovolemia (dehydration) in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11018?source=see_link\">",
"       \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bradycardia",
"      </strong>",
"      &ndash; Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      , including atropine infusion has been used to treat symptomatic bradycardia. Dosing in these cases varies, but anecdotal evidence from case reports suggests that high doses may be required (eg, 0.5 mg atropine intravenously every five minutes to maintain a goal heart rate &ge;60 beats per minute with no maximum total dosage) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Management according to Advanced Cardiac Life Support and Pediatric Advanced Life Support guidelines is appropriate for patients who do not respond to atropine (",
"      <a class=\"graphic graphic_algorithm graphicRef63919 \" href=\"mobipreview.htm?1/16/1280\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef52446 \" href=\"mobipreview.htm?20/4/20545\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=see_link\">",
"       \"Temporary cardiac pacing\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hypotension",
"      </strong>",
"      &ndash; In the rare patient for whom hypotension does not respond to initial fluid resuscitation, dopamine infusion or intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      may be administered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Vomiting and diarrhea",
"      </strong>",
"      &ndash; Vomiting can be treated with antiemetics (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      ). Because diarrhea may be beneficial in removing ingested toxin and is typically self-limited, antimotility agents should be",
"      <strong>",
"       avoided",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Pruritis",
"      </strong>",
"      &ndash; Pruritus may be intense after ciguatera fish poisoning and can be treated with antihistamines (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/24/391?source=see_link\">",
"       hydroxyzine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3603765\">",
"    <span class=\"h2\">",
"     Neurologic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic symptoms of ciguatera fish poisoning can be prolonged and debilitating. Although several treatments have been proposed, evidence is limited regarding benefit of any specific medical regimen.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Paresthesias (polyneuropathy)",
"      </strong>",
"      &ndash; Ciguatoxins have complex actions on ion channels in cell membranes which may explain some of the neuropathic pain in ciguatera fish poisoning. Medications used to treat ciguatera fish poisoning are as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       Mannitol",
"      </a>",
"      &ndash; We suggest that",
"      <strong>",
"       fluid-repleted",
"      </strong>",
"      patients with significant neurologic symptoms caused by ciguatera fish poisoning receive a single dose of mannitol (1",
"      <span class=\"nowrap\">",
"       gm/kg",
"      </span>",
"      infused over one hour) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/37\">",
"       37",
"      </a>",
"      ]. Because mannitol can cause additional volume loss, it should not be given to patients with significant dehydration or signs of shock. &nbsp;",
"      <br/>",
"      <br/>",
"      The use of mannitol for the treatment of ciguatera fish poisoning is controversial. Mannitol is known to reverse prolonged opening of sodium channels and to reduce Schwann cell periaxonal edema in animal models [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/38\">",
"       38",
"      </a>",
"      ]. Multiple uncontrolled trials have found that intravenous mannitol, given at a dose of 0.5 to 1",
"      <span class=\"nowrap\">",
"       g/kg,",
"      </span>",
"      reduces neurologic symptoms when given within the first 48 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/18,39\">",
"       18,39",
"      </a>",
"      ]. In addition, case reports describe significant benefit from mannitol administration several weeks after onset of symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, the only randomized, placebo-controlled trial, conducted in 50 patients with ciguatera fish poisoning, found that treatment with a single intravenous dose of mannitol did not relieve acute signs and symptoms any better than intravenous normal saline, and was associated with increased local discomfort at the infusion site [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/42\">",
"       42",
"      </a>",
"      ]. Significant improvement (50 percent reduction on a subjective symptoms scale) was seen in both treatment groups with equal frequency at 1, 3, and 24 hours after the infusion. However, the small size of this study may have prevented detection of a clinically important difference. &nbsp;",
"      <br/>",
"      <br/>",
"      Taken together, although the evidence base is somewhat weak and contradictory, a single dose of mannitol is unlikely to be harmful if given to patients who are not dehydrated or in shock and may be beneficial.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      &ndash; Gabapentin was",
"      <strong>",
"       reported to i",
"      </strong>",
"      mprove polyneuropathic symptoms in two patients approximately one month after onset of symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/43\">",
"       43",
"      </a>",
"      ]. However, it is a relatively expensive therapy which limits its usefulness in the tropical regions where ciguatera fish poisoning is most prevalent.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"       Amitriptyline",
"      </a>",
"      <strong>",
"      </strong>",
"      &ndash; Small case series suggest that amitriptyline can provide relief for chronic paresthesias and pruritus but may not be effective for temperature-related dysesthesias [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/32,44,45\">",
"       32,44,45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Headaches",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      has been used for the treatment of headaches associated with ciguatera toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/18\">",
"       18",
"      </a>",
"      ]. Limited evidence from case reports suggest that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      also may provide benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. However, nifedipine should be avoided during the acute phase of illness as it may cause or exacerbate hypotension.",
"     </li>",
"     <li>",
"      <strong>",
"       Chronic fatigue and symptoms of depression",
"      </strong>",
"      &ndash; Although one case report suggests that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      may benefit ciguatera patients suffering from chronic fatigue, insomnia, and depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/46,47\">",
"       46,47",
"      </a>",
"      ], these conditions may reflect comorbidity rather than chronic ciguatera toxicity and warrant careful evaluation by a clinician with expertise in their diagnosis and treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30825?source=see_link\">",
"       \"Clinical features and diagnosis of chronic fatigue syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3603772\">",
"    <span class=\"h2\">",
"     Diet and activity modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should avoid all fish, alcohol, caffeine, and nuts for six months because these may trigger a recurrence of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients should understand that future attacks of ciguatera fish poisoning might be worse than the initial illness. Ciguatera is not an infectious disease, and individuals do not develop immunity to the toxin.",
"   </p>",
"   <p>",
"    <br/>",
"    Given the potential for painful sexual intercourse, including dyspareunia in previously unaffected female sexual partners, the patient should curtail sexual activity until symptoms resolve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overexertion with dehydration may also cause a relapse of ciguatera symptoms and should be avoided until toxicity has resolved. The patient should then gradually increase activity over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3603780\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best way to prevent ciguatera fish poisoning is to avoid eating all high-risk fish, such as barracuda, moray eel, and certain types of grouper, red snapper, and amberjack. Unfortunately, no accurate analytical field test for caught fish is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/48\">",
"     48",
"    </a>",
"    ]. Development of such tests is difficult because of the lack of effect of ciguatoxin on live fish and the minute amounts of ciguatoxin necessary to render a fish poisonous.",
"   </p>",
"   <p>",
"    Traditional methods of identifying toxic fish, such as excessive hemorrhage when cutting into a fish (bleeding test) and lack of rigor mortis several hours after the death of a fish (rigor mortis test), can identify some fish that contain toxic levels of ciguatoxin in selected regions (eg, French Polynesia), but have significant interobserver variability and poor discrimination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When in the tropics, it may be less risky to eat smaller fish and avoid eating fish organs where the toxin concentrates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/3\">",
"     3",
"    </a>",
"    ]. Recreational fishermen should also travel with experienced local guides who often know which reefs to avoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Community outreach and education can also help to warn travelers and increase recognition and investigation of ciguatera fish poisoning outbreaks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41096/abstract/18,50\">",
"     18,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Upon diagnosis of ciguatera fish poisoning, clinicians should contact their local health department and, if applicable, their regional poison control center so that investigation of the fish source can prevent consumption of other toxic fish from the same reef.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3603787\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of suspected poisoning. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3606002\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ciguatera fish poisoning is caused by consumption of fish contaminated with several distinct toxins (eg, ciguatoxin, saitotoxin, scaritoxin) that are formed by dinoflagellates of the genus Gambierdiscus, single-celled algae-like organisms that grow on and around coral reefs. These toxins are concentrated in the organs and flesh of large, predatory reef fish (eg, moray eel, amberjack, barracuda, red snapper, or grouper). Ciguatera toxin-containing fish do not taste, smell, or appear unusual. Cooking, marinating, freezing, and stewing fish do not destroy the toxins. (See",
"      <a class=\"local\" href=\"#H3603709\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although signs and symptoms vary according to locale (",
"      <a class=\"graphic graphic_table graphicRef88891 \" href=\"mobipreview.htm?15/41/16029\">",
"       table 1",
"      </a>",
"      ), the patient affected with ciguatera fish poisoning frequently develops the following constellation of clinical findings (see",
"      <a class=\"local\" href=\"#H3603716\">",
"       'Clinical manifestations'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Gastrointestinal",
"      </strong>",
"      &ndash; Gastroenteritis, including vomiting, diarrhea, and abdominal cramping.",
"     </li>",
"     <li>",
"      <strong>",
"       Neurologic &ndash;",
"      </strong>",
"      Neurologic abnormalities include peri-oral paresthesias, a metallic taste in the mouth, painful dentition, a feeling that the teeth are loose, painful urination, blurred vision, and temperature-related dysesthesias (cold stimuli perceived as hot or producing an abnormal, unpleasant sensation). Temperature-related dysesthesias are regarded as a specific finding of ciguatera toxicity. In the South Pacific, paralysis may occur in up to 10 percent of patients. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Cardiovascular",
"      </strong>",
"      &ndash; Less commonly bradycardia, heart block, and hypotension may occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The course of ciguatera fish poisoning is variable. Gastrointestinal and, if present, cardiovascular signs frequently resolve within 24 to 48 hours and rarely persist beyond four days. Neurologic abnormalities typically are more persistent, lasting from a few days to several weeks. Ingestion of alcohol, caffeine, nuts, or fish as well as excessive physical exertion can cause exacerbation or recurrence of ciguatera toxicity. (See",
"      <a class=\"local\" href=\"#H3603716\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of ciguatera fish poisoning is made using the following clinical criteria (see",
"      <a class=\"local\" href=\"#H3603730\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A history of ingestion of a large reef fish commonly associated with ciguatera toxicity (eg, moray eel, amberjack, barracuda, red snapper, or grouper).",
"     </li>",
"     <li>",
"      Signs and symptoms consistent with ciguatera poisoning, especially temperature-related dysesthesia. (See",
"      <a class=\"local\" href=\"#H3603716\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exclusion of other potential causes. (See",
"      <a class=\"local\" href=\"#H3603737\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Confirmation of ciguatoxin in the consumed fish, if possible. If the fish is not available for analysis, ciguatera fish poisoning in other individuals who consumed the same fish is also supportive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no clinical diagnostic test for ciguatera fish poisoning. Toxins can be detected in cooked fish, but the various techniques are costly and not widely available. (See",
"      <a class=\"local\" href=\"#H3603730\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial treatment of ciguatera fish poisoning is primarily supportive and consists of expectant management of dehydration, pruritus, and hemodynamic instability. (See",
"      <a class=\"local\" href=\"#H1020320\">",
"       'Initial supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurologic symptoms of ciguatera fish poisoning can be prolonged and debilitating. We suggest that",
"      <strong>",
"       fluid-repleted",
"      </strong>",
"      patients with significant neurologic symptoms caused by ciguatera fish poisoning receive a single dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       gm/kg",
"      </span>",
"      infused over one hour) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Agents that have been effective in the treatment of other painful neuropathic syndromes (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      ) may improve symptoms of chronic polyneuropathy. (See",
"      <a class=\"local\" href=\"#H3603765\">",
"       'Neurologic symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to excessive physical exertion, patients with ciguatera toxicity should avoid consuming all fish, alcohol, caffeine, and nuts for at least six months from onset of illness since these actions may trigger a recurrence of symptoms. Sexual activity should be curtailed to avoid painful sexual intercourse. (See",
"      <a class=\"local\" href=\"#H3603772\">",
"       'Diet and activity modification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best way to prevent ciguatera fish poisoning is to avoid eating all high-risk fish, such as barracuda, moray eel, and certain types of grouper, red snapper, and amberjack. No accurate analytical field test for caught fish is available. When in the tropics, it may be less risky to eat smaller fish and avoid eating fish organs where the toxin is concentrated. Recreational fishermen should also travel with experienced local guides who often know which reefs to avoid. (See",
"      <a class=\"local\" href=\"#H3603780\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Upon diagnosis of ciguatera fish poisoning, clinicians should contact their local health department and, if applicable, their regional poison control center so that investigation of the fish source can prevent consumption of other toxic fish from the same reef. (See",
"      <a class=\"local\" href=\"#H3603780\">",
"       'Prevention'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3603787\">",
"       'Additional resources'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/1\">",
"      Lange WR. Ciguatera toxicity. Am Fam Physician 1987; 35:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/2\">",
"      Glaziou P, Legrand AM. The epidemiology of ciguatera fish poisoning. Toxicon 1994; 32:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/3\">",
"      Whittle K, Gallacher S. Marine toxins. Br Med Bull 2000; 56:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/4\">",
"      Dickey RW, Plakas SM. Ciguatera: a public health perspective. Toxicon 2010; 56:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/5\">",
"      Holt RJ, Miro G, Del Valle A. An analysis of poison control center reports of ciguatera toxicity in Puerto Rico for one year. J Toxicol Clin Toxicol 1984; 22:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/6\">",
"      Lewis ND. Disease and development: ciguatera fish poisoning. Soc Sci Med 1986; 23:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Ciguatera fish poisoning - New York City, 2010-2011. MMWR Morb Mortal Wkly Rep 2013; 62:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Ciguatera fish poisoning--Texas, 1998, and South Carolina, 2004. MMWR Morb Mortal Wkly Rep 2006; 55:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/9\">",
"      Radke EG, Grattan LM, Cook RL, et al. Ciguatera Incidence in the US Virgin Islands Has Not Increased over a 30-Year Time Period Despite Rising Seawater Temperatures. Am J Trop Med Hyg 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/10\">",
"      DiNubile MJ, Hokama Y. The ciguatera poisoning syndrome from farm-raised salmon. Ann Intern Med 1995; 122:113.",
"     </a>",
"    </li>",
"    <li>",
"     Baden DG, Fleming LE, Bean JA. Marine Toxins. In: Handbook of Clinical Neurology, deWolff, FA (Eds), Elsevier Science B V, New York 1995. p.149.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/12\">",
"      Mines D, Stahmer S, Shepherd SM. Poisonings: food, fish, shellfish. Emerg Med Clin North Am 1997; 15:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/13\">",
"      Sobel J, Painter J. Illnesses caused by marine toxins. Clin Infect Dis 2005; 41:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/14\">",
"      Lipp EK, Rose JB. The role of seafood in foodborne diseases in the United States of America. Rev Sci Tech 1997; 16:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/15\">",
"      Lehane L. Ciguatera update. Med J Aust 2000; 172:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/16\">",
"      Zhang X, Cao B, Wang J, et al. Neurotoxicity and Reactive Astrogliosis in the Anterior Cingulate Cortex in Acute Ciguatera Poisoning. Neuromolecular Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/17\">",
"      Clark RF, Williams SR, Nordt SP, Manoguerra AS. A review of selected seafood poisonings. Undersea Hyperb Med 1999; 26:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/18\">",
"      Friedman MA, Fleming LE, Fernandez M, et al. Ciguatera fish poisoning: treatment, prevention and management. Mar Drugs 2008; 6:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/19\">",
"      Pearn J. Neurology of ciguatera. J Neurol Neurosurg Psychiatry 2001; 70:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/20\">",
"      Bagnis R, Kuberski T, Laugier S. Clinical observations on 3,009 cases of ciguatera (fish poisoning) in the South Pacific. Am J Trop Med Hyg 1979; 28:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/21\">",
"      Gatti C, Oelher E, Legrand AM. Severe seafood poisoning in French Polynesia: a retrospective analysis of 129 medical files. Toxicon 2008; 51:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/22\">",
"      Quod JP, Turquet J. Ciguatera in R&eacute;union Island (SW Indian Ocean): epidemiology and clinical patterns. Toxicon 1996; 34:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/23\">",
"      Withers NW. Ciguatera fish poisoning. Annu Rev Med 1982; 33:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/24\">",
"      Lawrence DN, Enriquez MB, Lumish RM, Maceo A. Ciguatera fish poisoning in Miami. JAMA 1980; 244:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/25\">",
"      Begier EM, Backer LC, Weisman RS, et al. Outbreak bias in illness reporting and case confirmation in ciguatera fish poisoning surveillance in south Florida. Public Health Rep 2006; 121:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/26\">",
"      Friedman MA, Arena P, Levin B, et al. Neuropsychological study of ciguatera fish poisoning: a longitudinal case-control study. Arch Clin Neuropsychol 2007; 22:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/27\">",
"      Centers for Disease Control and Prevention (CDC). Cluster of ciguatera fish poisoning--North Carolina, 2007. MMWR Morb Mortal Wkly Rep 2009; 58:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/28\">",
"      Pearn JH. Chronic fatigue syndrome: chronic ciguatera poisoning as a differential diagnosis. Med J Aust 1997; 166:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/29\">",
"      Chan TY. Lengthy persistence of ciguatoxin in the body. Trans R Soc Trop Med Hyg 1998; 92:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/30\">",
"      Gillespie NC, Lewis RJ, Pearn JH, et al. Ciguatera in Australia. Occurrence, clinical features, pathophysiology and management. Med J Aust 1986; 145:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/31\">",
"      Lewis RJ. The changing face of ciguatera. Toxicon 2001; 39:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/32\">",
"      Lange WR, Snyder FR, Fudala PJ. Travel and ciguatera fish poisoning. Arch Intern Med 1992; 152:2049.",
"     </a>",
"    </li>",
"    <li>",
"     Granade, HR. Ciguatoxin. Bad bug book-Foodborne pathogenic microorganisms and natural toxins handbook, 2nd edition, Food and Drug Administration, 2012, p. 176 . file://www.fda.gov/downloads/Food/FoodSafety/FoodborneIllness/FoodborneIllnessFoodbornePathogensNaturalToxins/BadBugBook/UCM297627.pdf (Accessed on February 03, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/34\">",
"      Isbister GK, Kiernan MC. Neurotoxic marine poisoning. Lancet Neurol 2005; 4:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/35\">",
"      Senthilkumaran S, Meenakshisundaram R, Michaels AD, et al. Cardiovascular Complications in Ciguatera Fish Poisoning: A Wake-up Call. Heart Views 2011; 12:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/36\">",
"      Hung YM, Hung SY, Chou KJ, et al. Short report: persistent bradycardia caused by ciguatoxin poisoning after barracuda fish eggs ingestion in southern Taiwan. Am J Trop Med Hyg 2005; 73:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/37\">",
"      Lawrence DT, Dobmeier SG, Bechtel LK, Holstege CP. Food poisoning. Emerg Med Clin North Am 2007; 25:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/38\">",
"      Benoit E, Juzans P, Legrand AM, Molgo J. Nodal swelling produced by ciguatoxin-induced selective activation of sodium channels in myelinated nerve fibers. Neuroscience 1996; 71:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/39\">",
"      Palafox NA, Jain LG, Pinano AZ, et al. Successful treatment of ciguatera fish poisoning with intravenous mannitol. JAMA 1988; 259:2740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/40\">",
"      Schwarz ES, Mullins ME, Brooks CB. Ciguatera poisoning successfully treated with delayed mannitol. Ann Emerg Med 2008; 52:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/41\">",
"      Eastaugh JA. Delayed use of intravenous mannitol in ciguatera (fish poisoning). Ann Emerg Med 1996; 28:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/42\">",
"      Schnorf H, Taurarii M, Cundy T. Ciguatera fish poisoning: a double-blind randomized trial of mannitol therapy. Neurology 2002; 58:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/43\">",
"      Perez CM, Vasquez PA, Perret CF. Treatment of ciguatera poisoning with gabapentin. N Engl J Med 2001; 344:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/44\">",
"      Davis RT, Villar LA. Symptomatic improvement with amitriptyline in ciguatera fish poisoning. N Engl J Med 1986; 315:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/45\">",
"      Calvert GM, Hryhorczuk DO, Leikin JB. Treatment of ciguatera fish poisoning with amitriptyline and nifedipine. J Toxicol Clin Toxicol 1987; 25:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/46\">",
"      Berlin RM, King SL, Blythe DG. Symptomatic improvement of chronic fatigue with fluoxetine in ciguatera fish poisoning. Med J Aust 1992; 157:567.",
"     </a>",
"    </li>",
"    <li>",
"     Blythe DG, Hack E, Washington G. The medical management of seafood poisonings. In: Foodborne Disease Handbook: Seafood and Environmental Toxins, Hui YH, Gorham JR, Murrell KD, et al (Eds), Marcel Dekker Inc., New York 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/48\">",
"      Darius HT, Drescher O, Ponton D, et al. Use of folk tests to detect ciguateric fish: a scientific evaluation of their effectiveness in Raivavae Island (Australes, French Polynesia). Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2013; 30:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41096/abstract/49\">",
"      Crump JA, McLay CL, Chambers ST. Ciguatera fish poisoning. Postgrad Med J 1999; 75:678.",
"     </a>",
"    </li>",
"    <li>",
"     Ciguatera  fish poisoning poster. Florida Department of Health. file://www.myfloridaeh.com/medicine/aquatic/ciguatera.htm (Accessed on February 21, 2013).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88331 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-F5F47B5EFB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_8_41096=[""].join("\n");
var outline_f40_8_41096=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3606002\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3605976\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3603702\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3603709\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3603716\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3603723\">",
"      Pregnant and nursing mothers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3603730\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3603737\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3603744\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3603751\">",
"      Gastrointestional decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1020320\">",
"      Initial supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3603765\">",
"      Neurologic symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3603772\">",
"      Diet and activity modification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3603780\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3603787\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3606002\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/88331\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/88331|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?1/16/1280\" title=\"algorithm 1\">",
"      Adult bradycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?20/4/20545\" title=\"algorithm 2\">",
"      Pediatric bradycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/88331|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/41/16029\" title=\"table 1\">",
"      Clinical findings of ciguatera fish poisoning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/36/37448?source=related_link\">",
"      Botulism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30825?source=related_link\">",
"      Clinical features and diagnosis of chronic fatigue syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=related_link\">",
"      Diagnosis of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/43/40632?source=related_link\">",
"      Eosinophilic meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/41/19096?source=related_link\">",
"      Marine toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33176?source=related_link\">",
"      Organophosphate and carbamate poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=related_link\">",
"      Temporary cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_8_41097="Treatment of primary sclerosing cholangitis";
var content_f40_8_41097=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of primary sclerosing cholangitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/8/41097/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41097/contributors\">",
"     Kris V Kowdley, MD, FACP, FACG, FASGE, AGAF",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/8/41097/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41097/contributors\">",
"     Paul Angulo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/8/41097/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41097/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/8/41097/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary sclerosing cholangitis (PSC) is a chronic progressive disorder of unknown etiology that is characterized by inflammation, fibrosis, and stricturing of medium size and large ducts in the intrahepatic and extrahepatic biliary tree. The great majority of affected patients have underlying ulcerative colitis; the incidence may be as high as 90 percent when rectal and sigmoid biopsies are routinely obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35334?source=see_link\">",
"     \"Epidemiology and pathogenesis of primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PSC is associated with numerous complications including cholestasis (with associated problems), dominant stricture formation, cholelithiasis and cholangitis, cholangiocarcinoma, and colon cancer (in patients with concurrent ulcerative colitis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, PSC may follow a progressive course, resulting in portal hypertension and liver failure.",
"   </p>",
"   <p>",
"    There are two major goals of treatment in PSC:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Retardation and reversal of the disease process",
"     </li>",
"     <li>",
"      Management of progressive disease and its complications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The medical, endoscopic, and surgical therapies aimed at managing progressive PSC will be reviewed here. As will be seen, there is",
"    <strong>",
"     no",
"    </strong>",
"    proven treatment that slows progression of the disease. However, excellent outcomes may be achieved after liver transplantation for advanced disease. The clinical manifestations and diagnosis of PSC are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22521?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DRUG THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of immunosuppressive and antiinflammatory agents have been studied in patients with PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/3\">",
"     3",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"       Ursodeoxycholic acid",
"      </a>",
"     </li>",
"     <li>",
"      Glucocorticoids",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      and 6-mercaptopurine",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       Tacrolimus",
"      </a>",
"     </li>",
"     <li>",
"      D-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfortunately,",
"    <strong>",
"     none",
"    </strong>",
"    has been conclusively proven to alter the natural history of this disorder. However, randomized trials of high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    are currently underway, in an attempt to confirm encouraging results in pilot studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ursodeoxycholic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     Ursodeoxycholic acid",
"    </a>",
"    (UDCA), a hydrophilic bile acid, is the most extensively studied of all medical treatments for PSC. UDCA, at a dose up to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, is thought to exert its effects in cholestatic conditions via protection of cholangiocytes against cytotoxic hydrophobic bile acids, stimulation of hepatobiliary secretion, protection of hepatocytes against bile-acid induced apoptosis, and induction of antioxidants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    UDCA, at a dose up to 15",
"    <span class=\"nowrap\">",
"     mg/kg/day,",
"    </span>",
"    has shown some efficacy in improving biochemical abnormalities and stabilizing hepatic inflammation, but has not resulted in a survival benefit or a delay in the need for liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/5-13\">",
"     5-13",
"    </a>",
"    ]. Three meta-analyses (all with eight randomized controlled trials, though with minor differences in which studies were included) found that UDCA significantly improved liver biochemical tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. None of the meta-analyses found a benefit on the risk of death or need for liver transplantation. One detected significant benefit in liver histology and a trend toward a reduction in histologic deterioration and improvement of cholangiographic abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/12\">",
"     12",
"    </a>",
"    ], whereas two found no benefit on histology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In addition, there was no benefit from UDCA with regard to pruritus, fatigue, or cholangiocarcinoma development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/14\">",
"     14",
"    </a>",
"    ]. Thus, the available data do not demonstrate a consistent benefit on clinically important outcomes.",
"   </p>",
"   <p>",
"    However, the majority of patients in the studies included in the meta-analyses already had significant hepatic fibrosis or cirrhosis. It is possible that use of UDCA in early stage PSC (eg, before onset of fibrosis) may be helpful, but the appropriate studies have been difficult to perform because of limited numbers of patients and significant heterogeneity in patient populations. Finally,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    has also been studied as an agent to prevent colorectal cancer in patients with PSC. This topic is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/25/40342?source=see_link&amp;anchor=H6#H6\">",
"     \"Colorectal cancer and primary sclerosing cholangitis\", section on 'Chemoprevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2010 guideline issued by the American Association for the Study of Liver Diseases recommends",
"    <strong>",
"     against",
"    </strong>",
"    use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (UDCA) in the treatment of primary sclerosing cholangitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/15\">",
"     15",
"    </a>",
"    ]. The guideline notes the lack of proven efficacy on hard endpoints such as death or liver transplantation for low- or intermediate-dose UDCA and the worse outcomes described in a randomized controlled trial of high-dose UDCA (see below). Although standard dose UDCA has not been associated with adverse outcomes, UDCA cannot be recommended routinely until further data on efficacy and safety are available.",
"   </p>",
"   <p>",
"    We suggest stopping UDCA in patients who are already taking it and offering to restart the drug at standard doses (13 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in divided doses) if any of the following occur:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The patient's bilirubin increases",
"     </li>",
"     <li>",
"      The patient has worsening pruritus",
"     </li>",
"     <li>",
"      The patient is concerned about his or her liver tests worsening and prefers to resume the drug",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A derivative of UDCA (24-norursodeoxycholic acid) has shown promise in an animal model of PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     High-dose UDCA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pilot studies suggested that UDCA given in higher than standard doses (20 to 30 versus 13 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) may increase the benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. However, a placebo-controlled trial involving 150 patients was stopped early because patients randomly assigned to UDCA at doses of 28 to 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day were significantly",
"    <strong>",
"     more likely",
"    </strong>",
"    to reach the primary endpoint of death, need for liver transplant, or development of varices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/21\">",
"     21",
"    </a>",
"    ]. A follow-up study found that the increased risk of adverse events with high-dose UDCA was limited to patients with early histologic stage disease or with normal total bilirubin levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/22\">",
"     22",
"    </a>",
"    ]. The reasons for the unexpected outcome are unclear, but based upon these data, high-dose UDCA should be avoided in patients with PSC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;No studies have demonstrated a long-term benefit from glucocorticoid therapy, either alone or in combination with other agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. In addition to lack of efficacy, patients with PSC tend to have bone loss that can lead to osteoporosis, which may be made worse by glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/26\">",
"     26",
"    </a>",
"    ]. As an example, a pilot study of 21 patients treated with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    found marginal improvement in the serum alkaline phosphatase and AST levels, but the Mayo Clinic Risk Score did not change significantly and significant femoral neck bone loss was observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22521?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cyclosporine and tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single controlled clinical trial has assessed the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in the treatment of PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/27\">",
"     27",
"    </a>",
"    ]. Aside from a decrease in serum alkaline phosphatase in treated patients, there was no effect on symptoms or disease progression. A case report noted radiologic and biochemical improvement after treatment with cyclosporine followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    ; however, the patient was also given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    concomitantly, and follow-up was unavailable after eight months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    (FK506), a macrolide antibiotic with immunosuppressive activity that is now widely used to prevent rejection in transplant recipients, has been studied in an open-label trial in patients with PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/29\">",
"     29",
"    </a>",
"    ]. After one year of therapy, serum bilirubin and alkaline phosphatase declined by over 50 percent and pruritus was improved. However, there was no significant change in ERCP findings or histology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81831103\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;There was initial enthusiasm for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    as a therapeutic modality for PSC after two small studies suggested that the drug improved liver function tests and resulted in histologic improvement when used for up to 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. However, subsequent randomized trials have had variable results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial of oral pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      versus placebo resulted only in reduction in serum alkaline phosphatase in the methotrexate treated patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/32\">",
"       32",
"      </a>",
"      ]. There was no change in histology, degree of stricturing as demonstrated by ERCP, other liver function tests, or outcomes between treated and nontreated patients.",
"     </li>",
"     <li>",
"      Another report found that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"       ursodeoxycholic acid",
"      </a>",
"      was of no benefit compared to treatment with ursodeoxycholic acid alone, and it was associated with toxicity such as pulmonary fibrosis and hair loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Azathioprine and 6-mercaptopurine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no controlled trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (or its analogue 6-mercaptopurine) for the treatment of PSC. Anecdotal reports of azathioprine have shown varying results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. However, many centers have used these agents for the treatment of concurrent inflammatory bowel disease and have noted no improvement in PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Penicillamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discovery of increased serum, urinary, and hepatic copper concentrations in patients with PSC provided the rationale for the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    in this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/37\">",
"     37",
"    </a>",
"    ]. However, a randomized trial suggested no benefit on disease progression and more frequent side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/38\">",
"     38",
"    </a>",
"    ]. Subsequent studies have shown that the hepatic copper concentration is normal in early PSC, and then increases with advancing stages of the disease, an effect that was positively correlated with the serum bilirubin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/39\">",
"     39",
"    </a>",
"    ]. These findings suggest that increased hepatic copper stores in PSC are secondary to cholestasis rather than a primary event, perhaps explaining the lack of efficacy of penicillamine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anti-TNF agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor necrosis factor (TNF), released by activated Kupffer cells in the liver, has been postulated to have a role in the hepatic injury seen in PSC. Among the anti-tumor necrosis factor (TNF) drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    was of no benefit in a pilot study of 10 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/40\">",
"     40",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    was ineffective in a placebo-controlled, double blind study in 24 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"     Pentoxifylline",
"    </a>",
"    blocks the production of TNF. Although pentoxifylline inhibited hepatic fibrosis in an experimental model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/42\">",
"     42",
"    </a>",
"    ], it was not helpful in a pilot study in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of combining one or more of the drugs discussed above is uncertain. In a series of 15 patients, combined therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    , and UDCA was associated with improvement in liver biochemical tests and liver histology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/44\">",
"     44",
"    </a>",
"    ]. Significant radiographic deterioration was seen in only 1 of 10 patients who underwent cholangiography after a median follow-up of 41 months. Adverse drug reactions led to withdrawal of study medications in two patients.",
"   </p>",
"   <p>",
"    Other pilot trials found no benefit from combining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    with UDCA and only a minor short-term effect from combining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    with UDCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/45\">",
"     45",
"    </a>",
"    ]. Combination therapy with UDCA plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    has been associated with histologic improvement in the preliminary report of a small randomized controlled trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for antibiotic therapy in PSC is based upon studies in rodents, which have shown that hepatobiliary disease resembling PSC can be seen in animals with intestinal overgrowth, perhaps due to an unspecified toxin released by enteric bacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/47\">",
"     47",
"    </a>",
"    ]. A controlled trial involving 80 patients found that the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    plus UDCA improved serum alkaline phosphatase levels and the Mayo Risk Score significantly more than UDCA plus placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/48\">",
"     48",
"    </a>",
"    ]. However, no significant effect on disease progression was observed on liver histology or ERCP.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study involving 14 children with PSC found that oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      improved liver biochemical tests and symptoms, particularly in those without cirrhosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/49\">",
"       49",
"      </a>",
"      ]. Improvement in liver histology was observed in one patient who had a repeat liver biopsy two months after beginning treatment. Improvement in serum alkaline phosphatase and the Mayo Risk Score was also observed with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      in a one-year pilot study involving 16 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/50\">",
"       50",
"      </a>",
"      ]. There was no effect on serum bilirubin or albumin and liver histology was not assessed.",
"     </li>",
"     <li>",
"      A randomized trial with 35 patients with PSC assigned patients to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (125 or 250 mg four times daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (250 or 500 mg three times daily) for 12 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/51\">",
"       51",
"      </a>",
"      ]. A decrease in alkaline phosphatase at the end of treatment was seen in patients who received vancomycin, and the Mayo Risk Score decreased in those who received low-dose vancomycin or low-dose metronidazole.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies with long-term follow-up are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1859104403\">",
"    <span class=\"h2\">",
"     Probiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probiotics were studied in a randomized, placebo-controlled, crossover study of 14 patients with PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/52\">",
"     52",
"    </a>",
"    ]. There was no effect on symptoms (fatigue, pruritus, or stool frequency) or in laboratory parameters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other agents have been used to treat PSC, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and docosahexaenoic acid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/25,53-55\">",
"     25,53-55",
"    </a>",
"    ]. None of these therapies has been shown to halt disease progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     GALLBLADDER CANCER AND CHOLANGIOCARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;PSC is associated with an increased risk of cholangiocarcinoma and gallbladder carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22521?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/43/40633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cholangiocarcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2010 guideline issued by the American Association for the Study of Liver Diseases made the following recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An annual ultrasound examination to detect mass lesions in the gallbladder.",
"     </li>",
"     <li>",
"      Cholecystectomy in patients found to have a mass lesion of any size.",
"     </li>",
"     <li>",
"      Evaluation for cholangiocarcinoma in patients with deterioration of constitutional performance status or liver biochemical tests.",
"     </li>",
"     <li>",
"      The guideline did not address the issue of screening for cholangiocarcinoma, though we suggest annual screening with either ultrasound or magnetic resonance imaging with magnetic resonance cholangiopancreatography, plus measurement of a serum CA 19-9. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Summary and recommendations'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22521?source=see_link\">",
"       \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of patients with PSC have a dominant extrahepatic biliary stricture that is potentially amenable to endoscopic therapy. The proportion of patients that fall into this category at diagnosis is not well defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. One of the largest series included 125 patients and found a dominant stricture in the common bile duct",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    right or left hepatic duct in 56 patients (45 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/59\">",
"     59",
"    </a>",
"    ]. Furthermore, patients who do not have a stricture at baseline may develop a stricture over time. In one report, for example, 43 of 106 patients (40 percent) without a stricture developed a dominant stricture during five years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether treatment of a dominant stricture improves outcomes has not been evaluated in controlled trials. Casting doubt on the efficacy of such interventions was a report involving 125 patients, 56 had of whom had a dominant stricture, none of which were treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/59\">",
"     59",
"    </a>",
"    ]. All patients were followed for up to one year with serial evaluation of measures of cholestasis. Changes in serum alkaline phosphatase and bilirubin were not significantly different in patients with and without a dominant stricture, suggesting that the dominant strictures did not contribute significantly to cholestasis. The authors concluded that endoscopic therapy of dominant strictures should",
"    <strong>",
"     not",
"    </strong>",
"    be undertaken routinely until benefit is demonstrated in controlled trials.",
"   </p>",
"   <p>",
"    Although this study did not determine whether patients with a dominant stricture improved biochemically or clinically following endoscopic measures aimed at relieving the obstruction, a number of other reports have documented clinical and radiographic improvement in such patients following endoscopic dilation with or without placement of a biliary stent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/56,57,60-64\">",
"     56,57,60-64",
"    </a>",
"    ]. An illustrative report included 32 patients, the majority of whom were treated with short-term placement of a 10 Fr polyethylene stent, which was removed after a mean of 11 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/64\">",
"     64",
"    </a>",
"    ]. Cholestatic complaints improved in 83 percent of patients after a mean of two months and the serum bilirubin concentration returned to normal in 12 of 14 patients who were initially jaundiced. Only 40 percent of patients required additional endoscopic intervention after three years of follow-up.",
"   </p>",
"   <p>",
"    Although the above findings were retrospective and uncontrolled, they suggest that short-term stenting may be beneficial for patients with a dominant extrahepatic biliary stricture. Whether dilation alone without stenting could produce similar results is currently under investigation. The following observations illustrated the range of findings in observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report included 63 patients, the majority of whom were treated with repeated balloon dilation of a dominant biliary stricture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/65\">",
"       65",
"      </a>",
"      ]. The observed five-year survival was significantly higher than predicted from the Mayo Risk Score (83 versus 65 percent).",
"     </li>",
"     <li>",
"      Another study included 71 patients, 37 of whom were treated with balloon dilation plus stenting and 34 of whom were treated with balloon dilation alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/66\">",
"       66",
"      </a>",
"      ]. Intervention-related complications and cholangitis were more common in the stent group, but there was no significant difference between the groups in measures of cholestasis.",
"     </li>",
"     <li>",
"      A third series focused on 55 patients who were treated predominantly with repeated balloon dilations (five also underwent placement of a temporary stent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/58\">",
"       58",
"      </a>",
"      ]. The proportion of patients who were free of liver transplantation at three, five, and seven years was 99, 94, and 89 percent, respectively, rates that were significantly higher than predicted by the Mayo risk model (86, 78, and 74 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these retrospective analyses are susceptible to selection bias since the choice of intervention was not randomly assigned. In addition, the following cautionary notes are advisable when considering therapeutic ERCP in patients with PSC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Therapeutic ERCP should only be performed at centers with highly experienced endoscopists.",
"     </li>",
"     <li>",
"      Efforts should be made to exclude cholangiocarcinoma, which may appear as a dominant stricture.",
"     </li>",
"     <li>",
"      Antibiotic prophylaxis should be given since patients with PSC are at increased risk for the development of cholangitis following biliary tract manipulation. However, these patients remain at some risk of cholangitis even if prophylaxis is given. In a series of 168 patients with PSC and 981 who had at least one ERCP in the prior year, the incidence of cholangitis was significantly higher in the PSC group despite routine use of antibiotics before the procedure (4.0 versus 0.2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SURGICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical options for PSC include biliary reconstructive procedures, proctocolectomy (in patients with ulcerative colitis), and liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Biliary reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies using various methods of biliary-enteric drainage, with or without intraoperative stent insertion have reported excellent outcomes (free of jaundice and cholangitis) for several years after the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. However, there may be significant morbidity and mortality, particularly in patients with cirrhosis. In addition, surgery carries a risk of postoperative infection and increases scarring in the porta hepatis, potentially complicating future liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The enthusiasm for biliary surgery declined further after a retrospective study found liver transplantation to be superior to biliary surgical procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/72\">",
"     72",
"    </a>",
"    ]. The actuarial symptom-free survival rate in 23 patients treated by nontransplantation biliary surgery was 35 percent at 10 years; the actuarial survival rate from the onset of PSC (56 percent at 10 years) was identical to that expected from the prognostic model. In comparison, the actuarial patient survival rate five years after transplantation in 28 patients was greater than that expected from prognostic models (89 versus 31 percent).",
"   </p>",
"   <p>",
"    Thus, surgical therapies other than transplantation should generally be",
"    <strong>",
"     avoided",
"    </strong>",
"    in patients with PSC. The only exception may be in patients with isolated focal extrahepatic strictures and early histologic stage disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Proctocolectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective study found that, in patients with both PSC and chronic ulcerative colitis, proctocolectomy did not result in improvement of biochemical test results, cholangiography, hepatic histology, or survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/74\">",
"     74",
"    </a>",
"    ]. Thus, this procedure should be performed only if it is indicated because of the colitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver transplantation is the treatment of choice for patients with advanced liver disease due to PSC. Outcomes for liver transplantation in PSC compare favorably to transplants for other indications, with five-year survival rates as high as 85 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. As an example, in a series of 150 patients, the actuarial 1-, 2-, 5-, and 10-year survival was 94, 92, 86, and 70 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evaluation of PSC patients for liver transplantation is inherently difficult due to the unpredictability of the disease course, and the high risk of biliary tract malignancy. Several prognostic models have been developed to assist clinicians in predicting the natural history of PSC; one of the best known is the Mayo Risk Score (",
"    <a class=\"graphic graphic_table graphicRef54210 \" href=\"mobipreview.htm?13/50/14123\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22521?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"    </a>",
"    .) A calculator for the model is available online (",
"    <a class=\"external\" href=\"file://www.mayoclinic.org/gi-rst/mayomodel3.html\">",
"     www.mayoclinic.org/gi-rst/mayomodel3.html",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, the Model for End-Stage Liver Disease (MELD) score has become the primary tool for predicting prognosis in patients with PSC and other causes of end-stage liver disease. The UNOS version of the MELD score is used to allocate prioritization for liver transplantation in the United States. A complete discussion of the MELD score and its use in liver transplantation is covered elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the indications for liver transplant in PSC patients are similar to those in other forms of end-stage liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/61/25559?source=see_link\">",
"     \"Patient selection for liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Jaundice alone, in the absence of other signs of liver failure, is not an absolute indication for transplant. There are special circumstances in which liver transplantation may be indicated despite a low priority MELD score. These may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recurrent or refractory cholangitis",
"     </li>",
"     <li>",
"      Intractable pruritus",
"     </li>",
"     <li>",
"      Peripheral or hilar cholangiocarcinoma (in the context of a clinical trial)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In these and other situations, individual transplant centers may submit a petition to a regional review board for additional MELD points to assign an appropriate level of prioritization. The merits of these cases are decided on an individual basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have described recurrent PSC following liver transplantation in 14 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/77,80-88\">",
"     77,80-88",
"    </a>",
"    ]. As an example, in one series the cumulative incidence of recurrence at 1, 5, and 10 years posttransplantation was 2, 12, and 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/86\">",
"     86",
"    </a>",
"    ]. The diagnosis of recurrence is based upon consistent findings of liver biopsy and cholangiography in the absence of other conditions that could account for the findings such as an ABO blood group incompatible liver allograft, dominant anastomotic stricture or hepatic artery thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history of recurrent disease is variable, similar to the nontransplant setting. Only about one-third of patients with recurrence develop progressive disease leading to retransplantation or death. Risk factors for recurrence, particularly the influence of the immunosuppressive regimen, remain incompletely understood, although a variety of risk factors have been reported in various series including age, sex mismatch, male sex, coexistent IBD, presence of an intact colon after transplantation, CMV infection, recurrent acute cellular rejection, steroid-resistant cellular rejection, use of OKT3, presence of cholangiocarcinoma before transplantation, use of extended donor criteria, and prolonged use of glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/87,89\">",
"     87,89",
"    </a>",
"    ]. One report found that colectomy before and during initial liver transplantation for PSC was protective against recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Ulcerative colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of ulcerative colitis following liver transplantation is variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/90-96\">",
"     90-96",
"    </a>",
"    ]. Although the disease may remain quiescent in some patients, it may become aggressive in others despite the immunosuppression used for the transplant.",
"   </p>",
"   <p>",
"    The largest series to evaluate this issue included 303 patients with inflammatory bowel disease (IBD) who underwent liver transplantation between 1981 and 1997 at the University of Pittsburgh [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/93\">",
"     93",
"    </a>",
"    ]. Progression of IBD was assessed based upon the need for colectomy and clinical features of disease activity. The influence of transplantation on the disease course was determined using multivariate statistical models that adjusted for the duration of follow-up and other covariates that might influence the course of IBD. The authors found that the only two independent risk factors for IBD progression were older age at the time of transplant (age &gt;30, hazard ratio 1.5) and liver transplantation itself (hazard ratio 3.129). The incidence rates for colectomy rose from 0.007 before liver transplantation to 0.025 after transplantation.",
"   </p>",
"   <p>",
"    A limitation of this analysis was that it did not include some potentially relevant covariates in the model such as pretransplant IBD disease activity and the extent of the disease. Furthermore, IBD disease activity was assessed retrospectively, raising the potential for misclassification since other causes of bowel disturbance may occur in the transplant setting (eg, CMV, lymphoma, post-transplant lymphoproliferative disorder). Thus, this study confirms that IBD activity may progress after transplantation in some patients, but it does not provide a profile of patient characteristics or immunosuppressive regimens associated with increased risk.",
"   </p>",
"   <p>",
"    A more recent retrospective study found a decreased risk of colectomy among patients who underwent liver transplantation. The study included 167 patients with PSC and ulcerative colitis who were followed between 1985 and 2011 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/96\">",
"     96",
"    </a>",
"    ]. A liver transplantation was performed in 86 patients, whereas 81 patients were not listed for liver transplantation (patients who were listed for liver transplantation but did not receive a transplant were excluded). The median follow-up was 11 years among those who received a liver transplant and 14 years for those who were not listed for transplantation. Patients who underwent liver transplantation had a significantly lower colectomy rate than those who were not listed (27 versus 75 percent; adjusted hazard ratio [HR] 0.43; 95% confidence interval [CI] 0.25-0.75). Other risk factors for undergoing colectomy included the revised PSC Mayo risk score (",
"    <a class=\"graphic graphic_table graphicRef54210 \" href=\"mobipreview.htm?13/50/14123\">",
"     table 1",
"    </a>",
"    ) at diagnosis (HR 0.52; 95% CI 0.37-0.72) and the development of colon cancer or dysplasia (HR 2.47; 95% CI 1.63-3.75).",
"   </p>",
"   <p>",
"    Several reports have suggested that the incidence of colon cancer is increased in patients with ulcerative colitis and PSC who undergo liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/94,97-100\">",
"     94,97-100",
"    </a>",
"    ]. The mechanism by which this might occur is unclear, but may be related to the presence of longstanding ulcerative colitis or to the use of immunosuppressive drugs. An exception to these reports is the study discussed above, in which the only identified risk factor for colon cancer following transplantation was the duration of IBD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41097/abstract/93\">",
"     93",
"    </a>",
"    ]. Considering the available data, we suggest that patients who have had a liver transplant for PSC who also have ulcerative colitis undergo routine yearly surveillance colonoscopy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/25/40342?source=see_link\">",
"     \"Colorectal cancer and primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major goals of treatment in PSC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retardation and reversal of the disease process",
"     </li>",
"     <li>",
"      Management of progressive disease and its complications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A variety of immunosuppressive and antiinflammatory agents have been studied in patients with PSC but none has shown a consistent benefit on overall or transplant-free survival. A 2010 guideline issued by the American Association for the Study of Liver Diseases recommends against use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (UDCA) at any dose in the treatment of primary sclerosing cholangitis. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Ursodeoxycholic acid'",
"    </a>",
"    above.) Thus, a role for any medical therapy is unproven.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who are already taking UDCA, we suggest stopping UDCA but reinstituting it at standard doses (13 to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in divided doses) if they develop worsening pruritus or jaundice (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Decisions should be individualized and other conditions (such as a dominant stricture or development of cholangiocarcinoma) should also be considered in such patients.",
"     </li>",
"     <li>",
"      We suggest that patients with a dominant stricture undergo endoscopic therapy to dilate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      stent the stricture, provided that the patient has access to center with considerable expertise in therapeutic biliary endoscopy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). An important potential clinical benefit is relief of jaundice and pruritus, although a benefit on disease progression has not been clearly established.",
"      <br/>",
"      <br/>",
"      If a dominant stricture is found at the time of ERCP, brush cytology",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      endobiliary biopsy should be performed to exclude cholangiocarcinoma. If these are nondiagnostic, serum CA 19-9 and CEA measurements in conjunction with abdominal CT scan and clinical factors such as weight loss may raise a clinical suspicion of cholangiocarcinoma. In patients with a high clinical suspicion of cholangiocarcinoma but nondiagnostic brush",
"      <span class=\"nowrap\">",
"       cytology/endobiliary",
"      </span>",
"      biopsy, fine-needle aspiration under endoscopic ultrasonographic or CT guidance is indicated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/43/40633?source=see_link\">",
"       \"Clinical manifestations and diagnosis of cholangiocarcinoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19816?source=see_link\">",
"       \"Endoscopic methods for the diagnosis of pancreatobiliary neoplasms\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with recurrent cholangitis despite efforts to treat a dominant stricture, a 2010 guideline from the American Association for the Study of Liver Diseases recommends prophylactic long-term antibiotics. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22521?source=see_link\">",
"       \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Given the high incidence of cholangiocarcinoma, we suggest annual screening for cholangiocarcinoma in patients with PSC (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Screening consists of either ultrasound or magnetic resonance imaging with magnetic resonance cholangiopancreatography, plus measurement of a serum CA 19-9. However no studies have been performed that demonstrate a benefit in patient outcomes with screening using serum tumor markers, imaging studies, or cholangiographic brush cytology, so forgoing screening is a reasonable alternative. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22521?source=see_link\">",
"       \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A 2010 guideline issued by the American Association for the Study of Liver Diseases recommends an annual ultrasound of the gallbladder to screen for gallbladder cancer. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Gallbladder cancer and cholangiocarcinoma'",
"      </a>",
"      above.) The guideline also suggests bone density examination at diagnosis and every two to three years thereafter. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22521?source=see_link\">",
"       \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of pruritus is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/19/23863?source=see_link\">",
"       \"Pruritus associated with cholestasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recommendations for screening colonoscopy are described separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/25/40342?source=see_link\">",
"       \"Colorectal cancer and primary sclerosing cholangitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Liver transplantation is now the treatment of choice for patients with advanced liver disease secondary to PSC.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/1\">",
"      Tung BY, Brentnall T, Kowdley KV, et al. Diagnosis and prevalence of ulcerative colitis in patients with sclerosing cholangitis (abstract). Hepatology 1996; 24:169A.",
"     </a>",
"    </li>",
"    <li>",
"     Vierling, JM. Hepatobiliary complications of ulcerative colitis and Crohn's disease. In: Hepatology: A Textbook of Liver Disease, Vol 2, Zakim, D, Boyer, TD (Eds), WB Saunders, Philadelphia 1996. p.1366.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/3\">",
"      Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology 1999; 30:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/4\">",
"      Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002; 36:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/5\">",
"      Chen W, Gluud C. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev 2003; :CD003626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/6\">",
"      Charatcharoenwitthaya P, Angulo P, Enders FB, Lindor KD. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. Hepatology 2008; 47:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/7\">",
"      Stiehl A, Walker S, Stiehl L, et al. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994; 20:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/8\">",
"      De Maria N, Colantoni A, Rosenbloom E, Van Thiel DH. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. Hepatogastroenterology 1996; 43:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/9\">",
"      Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/10\">",
"      van Hoogstraten HJ, Wolfhagen FH, van de Meeberg PC, et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol 1998; 29:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/11\">",
"      Stiehl A, Rudolph G, Sauer P, et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol 1997; 26:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/12\">",
"      Shi J, Li Z, Zeng X, et al. Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatol Res 2009; 39:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/13\">",
"      Poropat G, Giljaca V, Stimac D, Gluud C. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev 2011; :CD003626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/14\">",
"      Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther 2011; 34:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/15\">",
"      Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/16\">",
"      Fickert P, Wagner M, Marschall HU, et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006; 130:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/17\">",
"      Harnois DM, Angulo P, Jorgensen RA, et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001; 96:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/18\">",
"      Mitchell SA, Bansi DS, Hunt N, et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001; 121:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/19\">",
"      Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/20\">",
"      Cullen SN, Rust C, Fleming K, et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008; 48:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/21\">",
"      Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/22\">",
"      Imam MH, Sinakos E, Gossard AA, et al. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther 2011; 34:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/23\">",
"      Angulo P, Batts KP, Jorgensen RA, et al. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000; 95:2333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/24\">",
"      Kochhar R, Goenka MK, Das K, et al. Primary sclerosing cholangitis: an experience from India. J Gastroenterol Hepatol 1996; 11:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/25\">",
"      Lindor KD, Wiesner RH, Colwell LJ, et al. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol 1991; 86:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/26\">",
"      Hay JE, Lindor KD, Wiesner RH, et al. The metabolic bone disease of primary sclerosing cholangitis. Hepatology 1991; 14:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/27\">",
"      Wiesner RH, Steiner B, LaRusso NF, et al. A controlled clinical trial evaluating cyclosporine in the treatment of primary sclerosing cholangitis (abstract). Hepatology 1991; 14:63A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/28\">",
"      Kyokane K, Ichihara T, Horisawa M, et al. Successful treatment of primary sclerosing cholangitis with cyclosporine and corticosteroid. Hepatogastroenterology 1994; 41:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/29\">",
"      Van Thiel DH, Carroll P, Abu-Elmagd K, et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/30\">",
"      Kaplan MM, Arora S, Pincus SH. Primary sclerosing cholangitis and low-dose oral pulse methotrexate therapy. Clinical and histologic response. Ann Intern Med 1987; 106:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/31\">",
"      Knox TA, Kaplan MM. Treatment of primary sclerosing cholangitis with oral methotrexate. Am J Gastroenterol 1991; 86:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/32\">",
"      Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994; 106:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/33\">",
"      Lindor KD, Jorgensen RA, Anderson ML, et al. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol 1996; 91:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/34\">",
"      Javett SL. Azathioprine in primary sclerosing cholangitif. Lancet 1971; 1:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/35\">",
"      Wagner A. Azathioprine treatment in primary sclerosing cholangitis. Lancet 1971; 2:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/36\">",
"      Kaplan MM. Medical approaches to primary sclerosing cholangitis. Semin Liver Dis 1991; 11:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/37\">",
"      Gross JB Jr, Ludwig J, Wiesner RH, et al. Abnormalities in tests of copper metabolism in primary sclerosing cholangitis. Gastroenterology 1985; 89:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/38\">",
"      LaRusso NF, Wiesner RH, Ludwig J, et al. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988; 95:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/39\">",
"      Kowdley KV, Knox TA, Kaplan MM. Hepatic copper content is normal in early primary biliary cirrhosis and primary sclerosing cholangitis. Dig Dis Sci 1994; 39:2416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/40\">",
"      Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2004; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/41\">",
"      Hommes DW, Erkelens W, Ponsioen C, et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol 2008; 42:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/42\">",
"      Pr&eacute;aux AM, Mallat A, Rosenbaum J, et al. Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells. Hepatology 1997; 26:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/43\">",
"      Bharucha AE, Jorgensen R, Lichtman SN, et al. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000; 95:2338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/44\">",
"      Schramm C, Schirmacher P, Helmreich-Becker I, et al. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann Intern Med 1999; 131:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/45\">",
"      van Hoogstraten HJ, Vleggaar FP, Boland GJ, et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol 2000; 95:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/46\">",
"      Farkkila MA, Karkkainen P, Karvonen AL, et al. Combination of ursodeoxycholic acid (UDCA) and metronidazole (MTZ) in PSC: Reduction of inflammation in liver correlates with the decrease of the New Mayo Risk Score (abstract). Gastroenterology 2003; 124:A707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/47\">",
"      Lichtman SN, Sartor RB, Keku J, Schwab JH. Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology 1990; 98:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/48\">",
"      F&auml;rkkil&auml; M, Karvonen AL, Nurmi H, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004; 40:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/49\">",
"      Davies YK, Cox KM, Abdullah BA, et al. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 2008; 47:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/50\">",
"      Silveira MG, Torok NJ, Gossard AA, et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol 2009; 104:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/51\">",
"      Tabibian JH, Weeding E, Jorgensen RA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther 2013; 37:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/52\">",
"      Vleggaar FP, Monkelbaan JF, van Erpecum KJ. Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur J Gastroenterol Hepatol 2008; 20:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/53\">",
"      Olsson R, Broom&eacute; U, Danielsson A, et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 1995; 108:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/54\">",
"      Talwalkar JA, Angulo P, Keach JC, et al. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2005; 100:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/55\">",
"      Martin CR, Blanco PG, Keach JC, et al. The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther 2012; 35:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/56\">",
"      MacCarty RL, LaRusso NF, Wiesner RH, Ludwig J. Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology 1983; 149:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/57\">",
"      May GR, Bender CE, LaRusso NF, Wiesner RH. Nonoperative dilatation of dominant strictures in primary sclerosing cholangitis. AJR Am J Roentgenol 1985; 145:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/58\">",
"      Stiehl A, Rudolph G, Kl&ouml;ters-Plachky P, et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002; 36:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/59\">",
"      Bj&ouml;rnsson E, Lindqvist-Ottosson J, Asztely M, Olsson R. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 2004; 99:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/60\">",
"      Johnson GK, Geenen JE, Venu RP, et al. Endoscopic treatment of biliary tract strictures in sclerosing cholangitis: a larger series and recommendations for treatment. Gastrointest Endosc 1991; 37:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/61\">",
"      Lee JG, Schutz SM, England RE, et al. Endoscopic therapy of sclerosing cholangitis. Hepatology 1995; 21:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/62\">",
"      Gaing AA, Geders JM, Cohen SA, Siegel JH. Endoscopic management of primary sclerosing cholangitis: review, and report of an open series. Am J Gastroenterol 1993; 88:2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/63\">",
"      van Milligen de Wit AW, van Bracht J, Rauws EA, et al. Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 1996; 44:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/64\">",
"      Ponsioen CY, Lam K, van Milligen de Wit AW, et al. Four years experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol 1999; 94:2403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/65\">",
"      Baluyut AR, Sherman S, Lehman GA, et al. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001; 53:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/66\">",
"      Kaya M, Petersen BT, Angulo P, et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 2001; 96:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/67\">",
"      Bangarulingam SY, Gossard AA, Petersen BT, et al. Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol 2009; 104:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/68\">",
"      Eckhauser FE, Colleti LM, Knol JA. The changing role of surgery for sclerosing cholangitis. Dig Dis 1996; 14:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/69\">",
"      Cameron JL, Pitt HA, Zinner MJ, et al. Resection of hepatic duct bifurcation and transhepatic stenting for sclerosing cholangitis. Ann Surg 1988; 207:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/70\">",
"      Goldenring JR, Cahow CE. Intrahepatic cholangiojejunostomy as a palliative procedure in primary sclerosing cholangitis. Arch Surg 1989; 124:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/71\">",
"      Myburgh JA. Surgical biliary drainage in primary sclerosing cholangitis. The role of the Hepp-Couinaud approach. Arch Surg 1994; 129:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/72\">",
"      Farges O, Malassagne B, Sebagh M, Bismuth H. Primary sclerosing cholangitis: liver transplantation or biliary surgery. Surgery 1995; 117:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/73\">",
"      Pawlik TM, Olbrecht VA, Pitt HA, et al. Primary sclerosing cholangitis: role of extrahepatic biliary resection. J Am Coll Surg 2008; 206:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/74\">",
"      Cangemi JR, Wiesner RH, Beaver SJ, et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 1989; 96:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/75\">",
"      Langnas AN, Grazi GL, Stratta RJ, et al. Primary sclerosing cholangitis: the emerging role for liver transplantation. Am J Gastroenterol 1990; 85:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/76\">",
"      McEntee G, Wiesner RH, Rosen C, et al. A comparative study of patients undergoing liver transplantation for primary sclerosing cholangitis and primary biliary cirrhosis. Transplant Proc 1991; 23:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/77\">",
"      Graziadei IW, Wiesner RH, Marotta PJ, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999; 30:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/78\">",
"      Dickson ER, Murtaugh PA, Wiesner RH, et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 1992; 103:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/79\">",
"      Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/80\">",
"      Harrison RF, Davies MH, Neuberger JM, Hubscher SG. Fibrous and obliterative cholangitis in liver allografts: evidence of recurrent primary sclerosing cholangitis? Hepatology 1994; 20:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/81\">",
"      Goss JA, Shackleton CR, Farmer DG, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg 1997; 225:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/82\">",
"      Graziadei IW, Wiesner RH, Batts KP, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999; 29:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/83\">",
"      Brandsaeter B, Schrumpf E, Bentdal O, et al. Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl 2005; 11:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/84\">",
"      Cholongitas E, Shusang V, Papatheodoridis GV, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008; 14:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/85\">",
"      Alexander J, Lord JD, Yeh MM, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008; 14:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/86\">",
"      Campsen J, Zimmerman MA, Trotter JF, et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl 2008; 14:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/87\">",
"      Charatcharoenwitthaya P, Lindor KD. Recurrence of primary sclerosing cholangitis: what do we learn from several transplant centers? Liver Transpl 2008; 14:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/88\">",
"      Kugelmas M, Spiegelman P, Osgood MJ, et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2003; 9:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/89\">",
"      Alabraba E, Nightingale P, Gunson B, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009; 15:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/90\">",
"      Gavaler JS, Delemos B, Belle SH, et al. Ulcerative colitis disease activity as subjectively assessed by patient-completed questionnaires following orthotopic liver transplantation for sclerosing cholangitis. Dig Dis Sci 1991; 36:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/91\">",
"      Stephens J, Goldstein R, Crippin J, et al. Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients. Transplant Proc 1993; 25:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/92\">",
"      Papatheodoridis GV, Hamilton M, Mistry PK, et al. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998; 43:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/93\">",
"      Dvorchik I, Subotin M, Demetris AJ, et al. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology 2002; 35:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/94\">",
"      Miki C, Harrison JD, Gunson BK, et al. Inflammatory bowel disease in primary sclerosing cholangitis: an analysis of patients undergoing liver transplantation. Br J Surg 1995; 82:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/95\">",
"      Navaneethan U, Choudhary M, Venkatesh PG, et al. The effects of liver transplantation on the clinical course of colitis in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/96\">",
"      Navaneethan U, Venkatesh PG, Mukewar S, et al. Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2012; 10:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/97\">",
"      Loftus EV Jr, Aguilar HI, Sandborn WJ, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology 1998; 27:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/98\">",
"      Narumi S, Roberts JP, Emond JC, et al. Liver transplantation for sclerosing cholangitis. Hepatology 1995; 22:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/99\">",
"      Bleday R, Lee E, Jessurun J, et al. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis Colon Rectum 1993; 36:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41097/abstract/100\">",
"      Vera A, Gunson BK, Ussatoff V, et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 2003; 75:1983.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 661 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_8_41097=[""].join("\n");
var outline_f40_8_41097=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DRUG THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ursodeoxycholic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - High-dose UDCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H81831103\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Azathioprine and 6-mercaptopurine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Penicillamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anti-TNF agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1859104403\">",
"      Probiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      GALLBLADDER CANCER AND CHOLANGIOCARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ENDOSCOPIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SURGICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Biliary reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Proctocolectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/661\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/661|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/50/14123\" title=\"table 1\">",
"      Mayo model survival PSC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/43/40633?source=related_link\">",
"      Clinical manifestations and diagnosis of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22521?source=related_link\">",
"      Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/25/40342?source=related_link\">",
"      Colorectal cancer and primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19816?source=related_link\">",
"      Endoscopic methods for the diagnosis of pancreatobiliary neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35334?source=related_link\">",
"      Epidemiology and pathogenesis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/61/25559?source=related_link\">",
"      Patient selection for liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/19/23863?source=related_link\">",
"      Pruritus associated with cholestasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_8_41098="Reperfusion therapy for acute ischemic stroke";
var content_f40_8_41098=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Reperfusion therapy for acute ischemic stroke",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/8/41098/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41098/contributors\">",
"     Jamary Oliveira-Filho, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41098/contributors\">",
"     Owen B Samuels, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/8/41098/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41098/contributors\">",
"     Jose Biller, MD, FACP, FAAN, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/8/41098/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/8/41098/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/8/41098/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients who have had an ischemic stroke involves several phases. The goals in the initial phase include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Insuring medical stability",
"     </li>",
"     <li>",
"      Quickly reversing any conditions that are contributing to the symptoms",
"     </li>",
"     <li>",
"      Uncovering the pathophysiologic basis of the neurologic symptoms",
"     </li>",
"     <li>",
"      Screening for potential contraindications to thrombolysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Timely restoration of blood flow using thrombolytic therapy is the most effective maneuver for salvaging ischemic brain tissue that is not already infarcted. There is a narrow window during which this can be accomplished, since the benefit of thrombolysis decreases in a continuous fashion over time. Thus, an important aspect of the hyperacute phase of stroke assessment and management is the rapid determination of patients who are eligible for thrombolysis (",
"    <a class=\"graphic graphic_table graphicRef71462 \" href=\"mobipreview.htm?31/40/32397\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The major questions when considering thrombolytic therapy for an ischemic stroke are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What are the benefits and risks of thrombolytic therapy in patients presenting with acute ischemic stroke?",
"     </li>",
"     <li>",
"      When is treatment too late to salvage brain tissue?",
"     </li>",
"     <li>",
"      When is the use of thrombolytic agents, which increase the risk of brain hemorrhage, too dangerous?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTRAVENOUS THROMBOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results from the NINDS trial showed that intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (recombinant tissue-type plasminogen activator or tPA) improves functional outcome at three months, if given within 3 hours of symptom onset or within 3 hours of when the patient was last seen normal in cases when onset time is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/1\">",
"     1",
"    </a>",
"    ]. The ECASS 3 clinical trial found that intravenous alteplase is beneficial when given up to 4.5 hours after stroke onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of intravenous thrombolysis decreases continuously over time from symptom onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/3\">",
"     3",
"    </a>",
"    ]. Therefore, treatment must be given as soon as possible, rather than near the end of the time window.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment within 3 hours",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NINDS stroke trial included only patients presenting with an acute ischemic stroke who could be treated with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    within 3 hours of symptom onset (half were required to be treated within 90 minutes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/1\">",
"     1",
"    </a>",
"    ]. Six hundred twenty four patients were randomly assigned to treatment with either placebo or intravenous alteplase (0.9",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    up to 90 mg; 10 percent as a bolus, then a 60 minute infusion).",
"   </p>",
"   <p>",
"    The following observations were reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At three months, a complete or near complete recovery occurred in a significantly greater proportion of patients assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      (38 versus 21 percent with placebo) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Three-month mortality was not significantly different between the two groups, despite a 10-fold increase in symptomatic intracerebral hemorrhage among the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      group (6.4 versus 0.6 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Severe systemic hemorrhage occurred in less than 1 percent of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The benefit of intravenous thrombolytic therapy given within 3 hours is sustained at one year of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Patients treated within 90 minutes appear to have better outcomes than those treated 90 to 180 minutes after symptom onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment from 3 to 4.5 hours",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    for treatment beyond the conventional 3 hour time window was established by the ECASS 3 trial, which randomly assigned 821 patients (18 to 80 years old) with acute ischemic stroke to treatment with intravenous alteplase or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. In addition to the standard exclusion criteria for treatment from 0 to 3 hours, ECASS 3 added further exclusions (ie, patients &gt;80 years old, those with an NIHSS &gt;25, those with a combination of previous stroke and diabetes, and those on anticoagulants regardless of INR) to satisfy safety concerns from the European regulatory agency (",
"    <a class=\"graphic graphic_table graphicRef71462 \" href=\"mobipreview.htm?31/40/32397\">",
"     table 1",
"    </a>",
"    ). Treatment was administered between 3 and 4.5 hours (median 4 hours) after stroke onset. The primary outcome was disability at three months, assessed by the modified Rankin scale score (",
"    <a class=\"graphic graphic_table graphicRef75411 \" href=\"mobipreview.htm?22/32/23051\">",
"     table 2",
"    </a>",
"    ) as either favorable (score of 0 or 1) or unfavorable (score of 2 to 6).",
"   </p>",
"   <p>",
"    The main results of ECASS 3 were as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significantly more patients had a favorable outcome with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      than with placebo (52 versus 45 percent, odds ratio 1.34, 95% CI 1.02-1.76). The number needed to treat to achieve a favorable outcome was 14.",
"     </li>",
"     <li>",
"      There was no difference in mortality between the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      and placebo groups (7.7 and 8.4 percent).",
"     </li>",
"     <li>",
"      Symptomatic intracranial hemorrhage was significantly more likely with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      than with placebo (2.2 versus 0.2 percent). When symptomatic intracranial hemorrhage was defined according to the NINDS trial definition, the rates in ECASS 3 for the alteplase and placebo groups were 7.9 and 3.5 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results show that intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    treatment initiated at 3 to 4.5 hours after ischemic stroke onset leads to a modest improvement in three-month outcome, with a rate of symptomatic intracranial hemorrhage that is similar to the rate found in patients treated within 3 hours. Initial stroke severity was milder in the ECASS 3 than in the NINDS trial, a factor that may explain the overall better outcomes for both the treatment and placebo groups in ECASS 3 trial compared with NINDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast to ECASS 3, earlier randomized trials of intravenous thrombolysis did not show clear benefit for patients treated more than 3 hours after stroke onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. However, these earlier trials had treatment time windows of up to 6 hours and small numbers of patients treated between 3 and 4.5 hours.",
"   </p>",
"   <p>",
"    Further evidence that intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    can be used safely beyond 3 hours in clinical practice comes from the observational SITS-ISTR study of intravenous alteplase for acute ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Compared with patients treated in under 3 hours (n = 21,566), those treated from 3 to 4.5 hours (n = 2376) had similar rates of independence and mortality at three month follow-up in unadjusted analyses. The unadjusted outcomes for patients in SITS-ISTR treated from 3 to 4.5 hours were similar to or even better than those reported for patients treated within 3 hours in the major randomized controlled trials. After adjusting for baseline imbalances, the following observations were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of symptomatic intracranial hemorrhage was higher in patients treated from 3 to 4.5 hours compared with those treated within 3 hours; the difference was statistically significant using the ECASS 2 definition of symptomatic intracerebral hemorrhage (odds ratio [OR] 1.27, 95% CI 1.03&ndash;1.55) but just missed statistical significance using the NINDS definition (OR 1.18, 95% CI 0.99&ndash;1.41)",
"     </li>",
"     <li>",
"      Compared with those treated in under 3 hours, the rate of functional independence at three months for those treated from 3 to 4.5 hours was lower (OR 0.84, 95% CI 0&middot;75&ndash;0&middot;95), while the rate of mortality was higher (OR 1.26, 95% CI 1.07-1.49)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, the results of the observational SITS-ISTR study suggest that there is a modest reduction in benefit and an increase in risk with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    treatment after 3 hours. This finding is congruent with those of the major randomized trials, which show that the sooner intravenous alteplase treatment is initiated, the more likely it is to be beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264417726\">",
"    <span class=\"h2\">",
"     Treatment up to 6 hours",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    administered from 4.5 to 6 hours after stroke onset is neither established nor excluded by the available data.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest single trial experience is that of the open-label IST-3 trial, which enrolled 3035 adults within 6 hours of stroke onset [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/13\">",
"       13",
"      </a>",
"      ]. At six months in the overall analysis, there was a nonsignificant trend for a favorable outcome (defined as alive and independent) with intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      compared with control (37 versus 35 percent, adjusted odds ratio [OR] 1.13, 95% CI 0.95-1.35). In the subgroup of 1007 patients randomized from 4.5 hours to 6 hours, there was a nonsignificant trend for favorable outcome (47 versus 43 percent, adjusted OR 1.31, 95% CI 0.89-1.93). Although it is the largest trial of thrombolysis for acute ischemic stroke, IST-3 attained just over one-half of its planned enrollment and was underpowered to reliably detect subgroup effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 2012 meta-analysis of 12 trials and 7012 patients, including 3035 patients from the open-label IST-3 trial, found that intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      treatment within 6 hours led to a significant increase in the proportion of patients alive and independent (ie, a favorable outcome) at the end of follow-up (46 versus 42 percent, OR 1.17, 95% CI 1.06-1.29) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/15\">",
"       15",
"      </a>",
"      ]. However, the benefit of alteplase was driven by patients treated within 3 hours of stroke onset. In the subgroup of 4971 patients treated between 3 and 6 hours, there was a nonsignificant trend toward a favorable outcome (47 versus 46 percent, OR 1.07, 95% CI 0.96-1.20). There was no subgroup analysis presented for patients treated between 4.5 and 6 hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pooled data",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis published in 2010, prior to the publication of the IST-3 trial, analyzed individual data from 3670 patients who were allocated to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    or placebo within 6 hours in the NINDS, ATLANTIS, ECASS (1, 2, and 3) and EPITHET trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/3\">",
"     3",
"    </a>",
"    ]. The primary outcome was assessed by the modified Rankin scale score (mRS) (",
"    <a class=\"graphic graphic_table graphicRef75411 \" href=\"mobipreview.htm?22/32/23051\">",
"     table 2",
"    </a>",
"    ) as either favorable (mRS score of 0 or 1) or unfavorable (mRS score of 2 to 6). The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At three months, the odds ratios (OR) for a favorable outcome in each of the four treatment periods were as follows [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/3\">",
"       3",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      OR 2.6 (95% CI 1.4-4.5) for 0 to 90 minutes",
"     </li>",
"     <li>",
"      OR 1.6 (95% CI 1.1-2.4) for 91 to 180 minutes",
"     </li>",
"     <li>",
"      OR 1.3 (95% CI 1.1-1.7) for 181 to 270 minutes",
"     </li>",
"     <li>",
"      OR 1.2 (95% CI 0.9-1.6) for 271 to 360 minutes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The number needed to treat (NNT) to obtain one favorable outcome with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      treatment in each of the four time windows was as follows [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/3\">",
"       3",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      NNT 4.5 for 0 to 90 minutes",
"     </li>",
"     <li>",
"      NNT 9.0 for 91 to 180 minutes",
"     </li>",
"     <li>",
"      NNT 14.1 for 181 to 270 minutes",
"     </li>",
"     <li>",
"      NNT 21.4 for 271 to 360 minutes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis for overall mortality found a significant increase in the risk of death with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      treatment after 4.5 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk of large intracerebral hemorrhage (parenchymal hematoma) with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      compared with placebo (5.2 versus 1.0 percent) was similar to that seen in the NINDS trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/3\">",
"       3",
"      </a>",
"      ]. The risk of parenchymal hematoma was",
"      <strong>",
"       not",
"      </strong>",
"      associated with time to treatment. Therefore, hematoma development did not appear to account for the increase in mortality observed with later treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations show that the sooner intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    treatment is initiated, the more likely it is to be beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, they confirm that the benefit of alteplase treatment for acute ischemic stroke extends up to 270 minutes (4.5 hours). The odds of a favorable three-month outcome decrease as the interval from stroke onset to start of alteplase treatment increases (",
"    <a class=\"graphic graphic_figure graphicRef66764 \" href=\"mobipreview.htm?39/14/40175\">",
"     figure 1",
"    </a>",
"    ). Beyond 4.5 hours, harm may exceed benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H209770\">",
"    <span class=\"h2\">",
"     Practical use of intravenous alteplase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important factor in successful thrombolytic treatment of acute ischemic stroke is early treatment. Nonetheless, selection of appropriate candidates for thrombolysis demands a neurologic evaluation, a neuroimaging study, and determination of eligibility based upon inclusion and exclusion criteria (",
"    <a class=\"graphic graphic_table graphicRef71462 \" href=\"mobipreview.htm?31/40/32397\">",
"     table 1",
"    </a>",
"    ). These issues are discussed in detail separately, as are recommendations for the therapeutic use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6570?source=see_link\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States, about 22 percent of all ischemic stroke patients present to an emergency department within 3 hours, but only about 8 percent also meet all other eligibility criteria for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment with advanced neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    treatment does not achieve successful vessel recanalization in all patients with acute ischemic stroke, monitoring for recanalization with advanced neuroimaging methods is being tested. Modern imaging techniques offer the potential to identify salvageable ischemic brain tissue and the responsible vascular lesion - the target of the thrombolytic therapy. In this regard, the two DIAS trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/17,18\">",
"     17,18",
"    </a>",
"    ] and the DEDAS trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/19\">",
"     19",
"    </a>",
"    ] used screening criteria to select patients for thrombolysis based upon the presence of viable ischemic brain tissue (ie, an ischemic penumbra), defined by either",
"    <span class=\"nowrap\">",
"     diffusion/perfusion",
"    </span>",
"    MRI or by multimodal CT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17290?source=see_link&amp;anchor=H14#H14\">",
"     \"Neuroimaging of acute ischemic stroke\", section on 'Identifying reversible ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preliminary data from the DIAS-1 and DEDAS trials suggested that thrombolytic treatment with intravenous desmoteplase administered within 3 to 9 hours of ischemic stroke onset was beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. However, in the larger DIAS-2 trial, desmoteplase treatment was no better than placebo in the three to nine hour time window [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The phase II EPITHET trial compared intravenous tPA treatment with placebo in the three to six hour time window and found no significant benefit for tPA on the primary MRI outcome measure of infarct growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/20\">",
"     20",
"    </a>",
"    ]. Recanalization, however, was more common after tPA, and was associated with less infarct growth and better clinical outcomes. This finding suggests that achieving better recanalization rates in the three to six hour time window is the key to improving outcome.",
"   </p>",
"   <p>",
"    Evidence of the potential for benefit for thrombolysis up to 6 hours after stroke onset comes from a multicenter German trial that used MRI screening criteria to select 174 patients with acute ischemic stroke for intravenous tPA treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/21\">",
"     21",
"    </a>",
"    ]. The trial was not randomized, and comparisons were made with the pooled data from the NINDS, ATLANTIS, and ECASS 1 and 2 trials that evaluated ischemic stroke treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    or placebo within 6 hours.",
"   </p>",
"   <p>",
"    In the German study, 66 patients selected by MRI were treated with intravenous tPA from 3 to 6 hours after onset, and this group was more likely to have a favorable outcome than patients from the pooled trials allocated to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (odds ratio 1.65, 95% CI 1.0-2.75) or placebo (OR 1.78, 95% CI 1.07-2.96) from 3 to 6 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/21\">",
"     21",
"    </a>",
"    ]. However, caution is advised when extrapolating these data to the clinical setting, as there is no consensus regarding the ideal technique to measure the ischemic penumbra on MRI.",
"   </p>",
"   <p>",
"    Data from the observational DEFUSE trial suggest that reperfusion with intravenous tPA, even at 3 to 6 hours after stroke onset, is associated with better clinical outcomes in those patients who have a baseline",
"    <span class=\"nowrap\">",
"     diffusion/perfusion",
"    </span>",
"    mismatch than in those who do not have a mismatch [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Similarly, the nonrandomized DEFUSE 2 trial found that reperfusion with endovascular treatment is associated with better clinical outcomes in those patients who have a baseline",
"    <span class=\"nowrap\">",
"     diffusion/perfusion",
"    </span>",
"    mismatch [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/25\">",
"     25",
"    </a>",
"    ]. A possible exception to this rule involves patients with a mismatch who present with massive diffusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perfusion lesion volumes (ie, the malignant profile), in which case reperfusion seems to be associated with worse outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Recanalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clot lysis resulting in recanalization and restoration of cerebral blood flow is the desired immediate result of thrombolytic therapy; rescue of ischemic brain tissue and improvement in clinical outcome is the desired end result.",
"   </p>",
"   <p>",
"    Recanalization is associated with improved outcome and reduced mortality in acute ischemic stroke. The NINDS and other clinical trials of intravenous thrombolysis did not monitor arterial occlusion or recanalization. However, the benefit of recanalization is supported by results of a meta-analysis of 53 studies published through the end of 2002 that assessed recanalization in 2066 patients with acute ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/26\">",
"     26",
"    </a>",
"    ]. The following were the main findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recanalization compared with no recanalization was associated with good functional outcome at three months (odds ratio [OR] 4.43, 95% CI 3.32-5.91)",
"     </li>",
"     <li>",
"      Recanalization was associated with reduced mortality at three months (OR 0.24; 95% CI 0.16-0.35)",
"     </li>",
"     <li>",
"      Symptomatic intracranial hemorrhagic transformation rates were similar for recanalization compared with no recanalization (OR 1.11, 95% CI 0.71-1.74)",
"     </li>",
"     <li>",
"      Recanalization rates varied according to intervention:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Spontaneous, 24.1 percent",
"     </li>",
"     <li>",
"      Intravenous thrombolysis, 46.2 percent",
"     </li>",
"     <li>",
"      Intra-arterial thrombolysis, 63.2 percent",
"     </li>",
"     <li>",
"      Combined intravenous and intra-arterial thrombolysis, 67.5 percent",
"     </li>",
"     <li>",
"      Mechanical, 83.6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies have found that full or partial recanalization up to 24 hours after onset of acute stroke is associated with a more favorable outcome than persistent occlusion after thrombolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. In addition, persistent large vessel occlusion is associated with early neurologic deterioration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    poor functional outcome in patients with initially mild or resolving symptoms who were not treated with thrombolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early recanalization from thrombolysis can lead to dramatic early clinical recovery in some but not all patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/33\">",
"     33",
"    </a>",
"    ]; other patients with recanalization may have delayed recovery. Recanalization was studied in 120 acute stroke patients with middle cerebral artery occlusion by TCD prior to intravenous tPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/34\">",
"     34",
"    </a>",
"    ]. Early recanalization (ER) was defined as complete or partial recanalization within 2 hours of tPA treatment. Lack of early clinical improvement occurred in 27 of 73 patients (37 percent) with ER, but 10 of those 27 achieved favorable outcomes at three months. The authors suggest that ischemic stunning of brain tissue, similar to what has been described with the myocardium, may be the explanation for the delayed recovery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Factors affecting recanalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors may affect the response to thrombolytic therapy, including location of the occlusion in the arterial tree, availability of collateral blood supply, and clot-specific factors such as size, composition, and source.",
"   </p>",
"   <p>",
"    In addition, elevated hematocrit may be associated with reduced reperfusion and larger infarct size after acute ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/35\">",
"     35",
"    </a>",
"    ]. This deleterious effect of elevated hematocrit is biologically plausible because hematocrit is the principal determinant of whole blood viscosity, and because hematocrit is inversely related to cerebral blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Clot size and site",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following observations have been made regarding the size and site of the thromboembolic clot [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/38-46\">",
"     38-46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Larger clots are more resistant to thrombolysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      More proximal sites of occlusion in the cerebrovascular arterial tree are more resistant to thrombolysis than more distal sites. As an example, internal carotid artery occlusions are more resistant than middle cerebral artery occlusions to intravenous tPA treatment. This may be due at least in part to the larger size of clots that lodge in larger vessels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/28,39-43,45,46\">",
"       28,39-43,45,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clot occluding the cervical internal carotid artery may promote adjacent thrombosis extending to the intracranial internal carotid artery, resulting in a very long thrombus that is unlikely to be lysed by intravenous tPA alone.",
"     </li>",
"     <li>",
"      In large vessels, in situ thromboses associated with atherosclerotic lesions may be more resistant to recanalization than fibrin rich embolic occlusions arising from the heart. As an example, in one study, early recanalization of proximal middle cerebral artery occlusion with tPA was more likely in those with a cardioembolic source compared with those having a clot from a large vessel or undetermined source [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Clot age and composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age and composition of thromboembolic material likely affects its response to thrombolytic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The ability to recanalize in experimental embolic stroke is related to the amount of red cells in the emboli and inversely related to the volume of emboli and to the fibrin content and density of the clots [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/49\">",
"     49",
"    </a>",
"    ]. Thrombolytic drugs are unlikely to disrupt other types of embolic material, such as calcific plaque and fat.",
"   </p>",
"   <p>",
"    It is thought that thrombolytic drugs may be more effective for treatment of recent thromboemboli, and mechanical disruption may be more effective for treatment of older thromboemboli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/47\">",
"     47",
"    </a>",
"    ]. After several months, the fibrin and plasminogen content of thrombi become degraded or replaced, and therefore resistant to lysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/50\">",
"     50",
"    </a>",
"    ]. However, hyperacute thromboemboli may be platelet-rich and also less amenable to lytic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/47\">",
"     47",
"    </a>",
"    ]. Unfortunately, the age and composition of the thromboembolic material is usually uncertain when acute treatment decisions must be made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Specific arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The actual recanalization rates for specific arterial locations that result from acute stroke treatment with intravenous thrombolysis are not completely known, as the few existing studies that include data on recanalization are limited by small patient numbers, different neurovascular imaging techniques, and often conflicting results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Extracranial internal carotid occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a prospective case series, intravenous thrombolysis was associated with partial or complete recanalization of an occluded extracranial internal carotid artery in 10 of 16 patients (63 percent), but in most of these a high-grade stenosis persisted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Carotid T occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In small studies that evaluated acute occlusion of the intracranial internal carotid artery bifurcation (carotid T occlusion), intravenous tPA treatment resulted in complete or partial recanalization by 24 to 36 hours in 40 to 67 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Middle cerebral occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a retrospective study of 104 patients treated with intravenous tPA, complete recanalization of an isolated middle cerebral artery (MCA) occlusion was achieved in 39 percent of patients by 2 hours and in 9 percent of patients who had a tandem hemodynamically significant stenosis of the internal carotid artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/54\">",
"     54",
"    </a>",
"    ]. Evidence from the CLOTBUST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/55\">",
"     55",
"    </a>",
"    ] and DEFUSE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/22\">",
"     22",
"    </a>",
"    ] trials suggest that proximal MCA occlusion is opened by intravenous tPA in slightly more than 20 percent of patients, whereas a prospective case series reported complete MCA recanalization at 24 hours after intravenous thrombolysis in 53 to 68 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperdensity of the MCA on noncontrast CT scan is a highly specific but poorly sensitive sign of MCA occlusion. In a post-hoc analysis of data from the NINDS trial, a hyperdense artery sign was associated with lower rates of favorable outcome at 90 days, but was not associated with reduced benefit of intravenous tPA treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/56\">",
"     56",
"    </a>",
"    ]. This finding suggests that patients with a hyperdense MCA sign may still benefit from intravenous tPA treatment despite poorer overall prognosis, and fits with other data showing that early CT signs of infarction do not appear to modify the benefit of intravenous tPA treatment. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Early CT changes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Similarly, high susceptibility MRI sequences (ie, gradient echo or T2* weighted) may reveal hypointense signal denoting acute thrombosis and occlusion of the MCA, a finding termed the MCA susceptibility sign. This sign, which is often accompanied by internal carotid artery occlusion, is associated with failed recanalization after intravenous thrombolysis of acute ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Basilar occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data exist regarding recanalization therapy for acute basilar artery occlusion, and much of it comes from studies that evaluated intra-arterial rather than intravenous thrombolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/59\">",
"     59",
"    </a>",
"    ]. In a single-center case series, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    treatment was used in 50 patients who had clinical features of posterior circulation ischemia and basilar artery occlusion determined by MRA or digital subtraction angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/60\">",
"     60",
"    </a>",
"    ]. Alteplase treatment was permitted beyond the conventional three-hour window, and mean time to treatment for sudden onset and gradual onset patients was 9 and 17.5 hours, respectively. Basilar recanalization was achieved in 26 (52 percent) of 43 patients who had repeat angiography. At three months, independence in activities of daily living was reached by 12 patients (24 percent), and 20 (40 percent) had died.",
"   </p>",
"   <p>",
"    These outcomes for recanalization, independence, and survival with intravenous thrombolysis were comparable with those reported for intra-arterial thrombolysis of basilar artery occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/61\">",
"     61",
"    </a>",
"    ]. The authors concluded that there is no convincing reason to treat basilar artery occlusion differently from anterior circulation ischemic stroke, as both may be effectively treated with intravenous therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/60\">",
"     60",
"    </a>",
"    ]. Further support for this conclusion comes from a systematic review that analyzed case series of intravenous and intra-arterial thrombolysis for basilar artery occlusion involving a total of 420 patients, 76 treated with intravenous and 344 with intra-arterial thrombolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/62\">",
"     62",
"    </a>",
"    ]. Recanalization was more frequently achieved with intra-arterial than with intravenous thrombolysis (65 versus 53 percent, respectively), but there was no significant difference for death or dependency (78 and 76 percent) or survival (50 and 45 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other variables affecting outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although early recanalization may be the most important determinant of good outcome after thrombolysis, a number of additional variables can play a role. These include stroke severity, older age, systolic hypertension, and serum glucose levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors predictive of in-hospital mortality with the use of tPA were analyzed in observational data from a large prospective cohort study in Germany that included 1685 patients treated with tPA for ischemic stroke at 225 community and academic centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/64\">",
"     64",
"    </a>",
"    ]. Overall, 10 percent of the patients died in-hospital, similar to the results of the NINDS trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/1\">",
"     1",
"    </a>",
"    ]. Increased age and decreased level of consciousness were independently associated with increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/64\">",
"     64",
"    </a>",
"    ]. Among individual hospitals, experience with use of tPA (ie, the number of patients treated with tPA at a particular hospital) was inversely associated with in-hospital mortality.",
"   </p>",
"   <p>",
"    Variables associated with outcome at 30 days were examined in the STARS trial. This study analyzed the use of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    in clinical practice and enrolled 389 patients; the following factors emerged as predictors of a favorable outcome at 30 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/65\">",
"     65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age 85 years or younger",
"     </li>",
"     <li>",
"      Milder baseline stroke severity with NIH Stroke Scale score &le;10 (",
"      <a class=\"graphic graphic_table graphicRef61698 \" href=\"mobipreview.htm?39/33/40477\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lower mean arterial pressure at baseline",
"     </li>",
"     <li>",
"      Absence of specific abnormalities on baseline CT scan (effacement or hypodensity of &gt;33 percent of the middle cerebral artery territory or a hyperdense middle cerebral artery)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Short-term outcome after tPA may be predictive of long-term outcome. In a prospective cohort study of 216 patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    , lack of improvement at 24 hours was found in 111 patients (51 percent) and was associated with poor outcome and death at three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/66\">",
"     66",
"    </a>",
"    ]. Elevated glucose level, length of time to thrombolytic therapy, and cortical involvement on brain imaging at 24 hours were associated with early lack of improvement.",
"   </p>",
"   <p>",
"    In a subsequent analysis of this cohort, major neurologic improvement at 24 hours was found in 61 patients (28 percent) and was associated with good outcome at three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/67\">",
"     67",
"    </a>",
"    ]. Glucose levels less than 144",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    lack of cortical involvement on 24-hour CT scan, and female sex were associated with early major neurologic improvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients age 80 or older appear to benefit from intravenous thrombolysis for acute ischemic stroke despite a higher mortality rate compared with younger patients. The risk of symptomatic hemorrhage with tPA treatment may also be increased for older patients, but the evidence is conflicting. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Variables associated with intracerebral hemorrhage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the NINDS cohort, outcome was related to an interaction of age and neurologic deficit, but this interaction did not affect the likelihood of favorable response to tPA treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/68-70\">",
"       68-70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 2012 meta-analysis of controlled trials testing intravenous thrombolysis included 1711 subjects who were &gt;80 years of age and 5174 subjects who were &le;80 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/15\">",
"       15",
"      </a>",
"      ]. For thrombolysis within 3 hours of stroke onset, the odds ratios for a favorable outcome at the end of follow-up were similar for both age groups (&gt;80 years, OR 1.68, 95% CI 1.20-2.34; &le;80 years, OR 1.51, 95% CI 1.18-1.93). For thrombolysis within 6 hours, the benefit was reduced but remained similar for both age groups (&gt;80 years, OR 1.22, 95% CI 0.98-1.53; &le;80 years, OR 1.16, 95% CI 1.04-1.29).",
"     </li>",
"     <li>",
"      One of the largest nonrandomized studies compared patients treated with intravenous thrombolysis for acute stroke from the SITS-ISTR registry (n = 23,062) with control patients from neuroprotection trials enrolled in the VISTA registry (n = 6166) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/71\">",
"       71",
"      </a>",
"      ]. Altogether there were 3439 subjects older than age 80 (mean age 85) and 210 older than age 90. The odds ratios for improvement at 90 days after thrombolysis treatment were similar for patients &gt;80 years old (1.4, 95% CI 1.3-1.6) compared with those &le;80 years old (1.6, 95% CI 1.5-1.7).",
"     </li>",
"     <li>",
"      In a prospective Canadian multicenter cohort study, tPA-treated patients 80 years of age or older (n = 270) were compared with younger patients (n = 1135) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/72\">",
"       72",
"      </a>",
"      ]. At three months, older patients had a significantly higher mortality rate compared with younger patients (35 versus 18 percent) and a significantly lower rate of favorable outcome (26 versus 40 percent). At baseline, stroke severity was significantly greater in patients who were 80 years or older. In addition, old age and stroke severity were independent predictors of outcome. Since this study was not randomized and lacked a control group, the possibility of selection bias cannot be entirely excluded.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these data, there are no compelling reasons to exclude older patients from intravenous thrombolysis for acute ischemic stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data regarding whether benefit from early intravenous thrombolysis of acute ischemic stroke differs by sex.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study that analyzed a combined database of 1190 men and 988 women from the NINDS, ATLANTIS, and ECASS 2 trials, women treated with tPA up to 6 hours from symptom onset were significantly more likely to benefit than men, perhaps because women had significantly worse 90-day outcomes than men in the group treated with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 2009 systematic review of 16 observational studies found no evidence that benefit of intravenous thrombolysis differs according to gender [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/74\">",
"       74",
"      </a>",
"      ]. After adjustment for confounding factors, none of the included studies reported a significant gender difference in favorable outcome after intravenous tPA treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperglycemia before reperfusion in patients with acute ischemic stroke has been associated with diminished neurologic improvement, greater infarct size, and worse clinical outcome at three months after treatment with intravenous tPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. In addition, acute (but not chronic) hyperglycemia appears to be an independent risk factor for failure of recanalization with intravenous tPA treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/77\">",
"     77",
"    </a>",
"    ], and the detrimental effect of acute hyperglycemia is higher after early than after delayed or no reperfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/78\">",
"     78",
"    </a>",
"    ]. While these findings suggest that ultra early glycemic control before thrombolysis may improve outcomes, there is no clinical trial evidence to confirm this hypothesis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=see_link&amp;anchor=H100191613#H100191613\">",
"     \"Initial assessment and management of acute stroke\", section on 'Hyperglycemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Reocclusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NINDS trial did not systematically study the incidence of arterial reocclusion. However, 13 percent of patients deteriorated clinically after an initial improvement; some of this deterioration may be accounted for by reocclusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/79\">",
"     79",
"    </a>",
"    ]. Reocclusion documented by transcranial Doppler (TCD) within 2 hours after intravenous tPA therapy for middle cerebral artery (MCA) occlusion has been reported in up to 34 percent of patients who had any initial recanalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data are limited, it appears that high initial stroke severity and severe ipsilateral carotid disease are associated with an increased risk of early MCA reocclusion after intravenous tPA therapy. This observation is supported by data from a case series of 142 patients with a documented MCA occlusion by TCD who received intravenous tPA within 3 hours of stroke onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/81\">",
"     81",
"    </a>",
"    ]. Partial or complete MCA recanalization on TCD was achieved in 84 patients (61 percent); of these, clinical deterioration after initial improvement occurred in 21 (25 percent). Early reocclusion was seen in 17 patients (12 percent of the series) and occurred in 15 of 21 (71 percent) patients who had deterioration after initial improvement and 2 of 10 (20 percent) patients who had recanalization without clinical improvement. Independent predictors of early reocclusion were an NIHSS score &gt;16 (",
"    <a class=\"graphic graphic_table graphicRef61698 \" href=\"mobipreview.htm?39/33/40477\">",
"     table 3",
"    </a>",
"    ) at baseline (odds ratio [OR] 7.1, 95% CI 1.3-32) and severe (&ge;70 percent) ipsilateral carotid artery stenosis or occlusion (OR 13.3, 95% CI 3.2-54).",
"   </p>",
"   <p>",
"    Measures to prevent reocclusion are not well studied. In a small therapeutic pilot study, four patients with immediate thrombotic reocclusion after thrombolysis were treated with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    , a platelet glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    antagonist; flow was restored successfully in all four [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Early recurrent ischemic stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent ischemic stroke appears to be an infrequent cause of early neurologic deterioration within the first 24 hours after intravenous thrombolysis, as suggested by a retrospective analysis of prospectively collected data from 341 patients treated with intravenous thrombolysis according to the NINDS protocol at eight centers in Switzerland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/83\">",
"     83",
"    </a>",
"    ]. Early recurrent ischemic stroke was diagnosed in two patients (0.59 percent, 95% CI 0.07-2.10 percent), and occurred within 40 to 50 minutes after tPA initiation in both patients. In contrast, symptomatic intracerebral hemorrhage occurred in 15 patients (4.4 percent) at 2 to 22 hours after tPA initiation. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Variables associated with intracerebral hemorrhage'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6570?source=see_link&amp;anchor=H33561301#H33561301\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\", section on 'Intracerebral hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although based on few events, these data suggest that neurologic deterioration, particularly within the first hour, may have an ischemic cause. The recurrent ischemic lesions involved multiple cerebral vascular territories in one patient, and bilateral middle cerebral artery territories and both kidneys in the other patient, suggesting that the mechanism was disintegration and showering of cardiac or aortic thrombi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigational methods of reperfusion therapy for acute ischemic stroke include alternative fibrinolytic agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/84\">",
"     84",
"    </a>",
"    ], intra-arterial thrombolysis, angioplasty and stenting, mechanical clot disruption, combined intravenous and intra-arterial thrombolysis, and the combined use of fibrinolytics and GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    antagonists.",
"   </p>",
"   <p>",
"    For patients with acute ischemic stroke, we recommend",
"    <strong>",
"     not",
"    </strong>",
"    using the following treatments outside the setting of clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/85\">",
"     85",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intravenous ancrod, desmoteplase, urokinase, or any thrombolytic agents other than tPA",
"     </li>",
"     <li>",
"      Intravenous glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      receptor inhibitors",
"     </li>",
"     <li>",
"      Mechanical endovascular treatments; none of the mechanical methods of thrombolysis have been adequately tested to draw conclusions about effectiveness",
"     </li>",
"     <li>",
"      Combinations of interventions to restore perfusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intra-arterial thrombolysis for acute stroke has not received regulatory approval and should not preclude treatment with intravenous tPA in otherwise eligible patients. However, current guidelines note that intra-arterial thrombolysis is reasonable in patients who have contraindications to intravenous thrombolysis (eg, recent surgery) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/85,86\">",
"     85,86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Intra-arterial thrombolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intra-arterial thrombolysis has shown promise for patients with acute ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. The dose of thrombolytic drugs can be limited to that needed for recanalization, since the procedure is done under direct visualization. The total dose of intra-arterial therapy is about one-third of the intravenous dose. As noted above, intra-arterial thrombolysis is a reasonable treatment option for patients with acute ischemic stroke who have contraindications to intravenous thrombolysis (eg, recent surgery) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The potential benefit of intra-arterial thrombolysis is illustrated by the results of a 2010 meta-analysis of five randomized controlled trials with 395 subjects that compared intra-arterial thrombolysis with control (generally intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ) for the treatment of acute stroke due to large artery occlusion (mainly middle cerebral artery) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/89\">",
"     89",
"    </a>",
"    ]. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intra-arterial thrombolysis resulted in a significantly increased likelihood of both a good outcome, defined as a modified Rankin scale (mRS) (",
"      <a class=\"graphic graphic_table graphicRef75411 \" href=\"mobipreview.htm?22/32/23051\">",
"       table 2",
"      </a>",
"      ) score of 0 to 2 (43 versus 28 percent, odds ratio [OR] 2.1) and an excellent outcome, defined as a mRS score of 0 to 1 (31 versus 18 percent, OR 2.1)",
"     </li>",
"     <li>",
"      Intra-arterial thrombolysis also led to significantly higher rates of partial or complete vessel recanalization (65 versus 18 percent, OR 6.4)",
"     </li>",
"     <li>",
"      The risk of symptomatic intracerebral hemorrhage was increased with intra-arterial thrombolysis (9 versus 2 percent, OR 2.9). However, there was no increase in mortality with intra-arterial thrombolysis (21 versus 24 percent, OR 0.8, 95% CI 0.5-1.4)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The largest individual trial in the meta-analysis, and the only one that was formally positive and fully double-blind, was PROACT II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/90\">",
"     90",
"    </a>",
"    ]. In PROACT II, 180 patients with acute middle cerebral artery occlusion were randomly assigned to receive either 9 mg of intra-arterial recombinant prourokinase (r-proUK) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or heparin alone within 6 hours (median 5.3 hours) of symptom onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/90\">",
"     90",
"    </a>",
"    ]. Mechanical disruption of the clot was not allowed by study design. Patients receiving r-proUK were more likely to have recanalization (66 versus 18 percent) and to achieve functional independence at 90 days (40 versus 25 percent). Mortality was similar in the two groups (25 versus 27 percent), although the r-proUK group had a significantly higher incidence of symptomatic intracranial hemorrhage within 24 hours (10.9 versus 3.1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of intracranial hemorrhage was higher in PROACT II than that observed in trials of intravenous thrombolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/92\">",
"     92",
"    </a>",
"    ]. This may be explained in part by the greater baseline stroke severity in PROACT II compared with these other studies (median NIHSS (",
"    <a class=\"graphic graphic_table graphicRef61698 \" href=\"mobipreview.htm?39/33/40477\">",
"     table 3",
"    </a>",
"    ) of 17 in PROACT, 14 in NINDS, and 11 in ECASS 2).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H212408\">",
"    <span class=\"h3\">",
"     Middle cerebral or basilar occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected or confirmed occlusion of the middle cerebral artery or the basilar artery who cannot be treated with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    may still be considered for intra-arterial alteplase therapy at expert centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are ineligible for intravenous thrombolysis with angiographically demonstrated acute middle cerebral artery occlusion and associated stroke symptoms but no signs of major early infarction on a baseline CT or MRI scan, we suggest intra-arterial",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      therapy, provided that treatment can be started within 6 hours of clearly defined symptom onset at centers with appropriate expertise.",
"     </li>",
"     <li>",
"      For patients who are ineligible for intravenous thrombolysis with angiographically demonstrated acute basilar artery occlusion and associated stroke symptoms but no signs of major infarction on a baseline CT or MRI scan, we suggest intra-arterial thrombolytic therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      at centers with appropriate expertise. Patients with basilar artery occlusion often have progressive or fluctuating symptoms, but this subtype of stroke may have a longer treatment time limit than other ischemic stroke subtypes between initial symptom onset and successful thrombolysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/60\">",
"       60",
"      </a>",
"      ]. Although good clinical results have been reported beyond 6 hours from stroke onset, the duration of the therapeutic window for intra-arterial thrombolysis for basilar occlusion is uncertain, and it is probably variable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H472769\">",
"    <span class=\"h3\">",
"     Variables affecting outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few data are available on variables affecting outcome of intra-arterial thrombolysis. In a study that analyzed data from a trial of combined intra-arterial and intravenous thrombolysis for acute ischemic stroke, time to angiographic reperfusion and age were inversely associated with good clinical outcome (",
"    <a class=\"graphic graphic_figure graphicRef50822 \" href=\"mobipreview.htm?17/13/17630\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/94\">",
"     94",
"    </a>",
"    ]. One report found that good collateral pial circulation predicted clinical improvement with intra-arterial thrombolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective study of 201 patients treated with intra-arterial (72 percent) or intravenous (28 percent) thrombolysis within 6 hours of acute stroke onset found that hyperglycemia, failure to recanalize, and intracerebral hemorrhage were independent predictors of clinical deterioration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/96\">",
"     96",
"    </a>",
"    ]. Hyperglycemia (glucose 150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or greater) was significantly greater in patients who deteriorated despite recanalization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Mechanical clot disruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to angioplasty and stenting, techniques involving mechanical clot disruption (also called neurothrombectomy) are under investigation for the treatment of acute ischemic stroke, including lasers, ultrasonography, microcatheter or microwire clot maceration, aspiration or suction devices, and clot-retrieval or microsnare devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/87,88,97,98\">",
"     87,88,97,98",
"    </a>",
"    ]. These mechanical methods can be employed alone, in combination, or as adjuncts to intra-arterial thrombolysis. They offer the possibility of faster recanalization, higher recanalization rates, reduced total thrombolytic dose, and ultimately improved outcome. However, none has been adequately tested to draw conclusions about efficacy.",
"   </p>",
"   <p>",
"    The use of ultrasound with intravenous thrombolysis is discussed in the following section (see",
"    <a class=\"local\" href=\"#H211126\">",
"     'Ultrasound enhanced thrombolysis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    A number of mechanical thrombectomy devices (eg, the Merci Retriever, the Penumbra System, the Solitaire Flow Restoration Device, and the Trevo Retriever) are approved in the United States and Europe for clot removal within 8 hours of acute stroke symptom onset in selected patients.",
"   </p>",
"   <p>",
"    The 2012 ACCP guidelines concluded that the available data regarding mechanical thrombectomy in acute ischemic stroke are of low quality and leave considerable uncertainty regarding the impact of this intervention on survival and functional outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/93\">",
"     93",
"    </a>",
"    ]. A 2011 systematic review identified 87 studies published through November 2010 that evaluated mechanical clot disruption devices for acute ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/97\">",
"     97",
"    </a>",
"    ]. All 87 studies were uncontrolled, only 18 were prospective, and only three of those used blinded outcome assessment. Nearly half the data came from studies evaluating the Merci Retriever and the Penumbra System (40 and 9 percent, respectively). For these and other thrombectomy devices, the included studies reported widely varying outcome rates of successful recanalization, good clinical outcome, symptomatic intracranial hemorrhage, vessel injury, and mortality. The one clear finding was that successful recanalization predicted a good outcome. However, given the methodologic limitations of the available studies, the investigators concluded that randomized trials are necessary to establish whether mechanical clot disruption devices improve patient outcome.",
"   </p>",
"   <p>",
"    One of the largest studies included in the systematic review was the nonrandomized MERCI study, which enrolled 151 patients (141 were treated) who were either ineligible for intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    within the conventional three-hour window or who could be treated within 3 to 8 hours and had angiographic demonstration of thrombotic occlusion in the intracranial internal carotid, middle cerebral, basilar, or vertebral artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/99\">",
"     99",
"    </a>",
"    ]. The median baseline NIH stroke scale score was 19 (higher than PROACT II). The placebo group from the PROACT II drug trial served as controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations have been made regarding the MERCI study results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no evidence that patients treated with the Merci retriever had improved outcome at 90 days compared with PROACT II historical controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/100\">",
"       100",
"      </a>",
"      ]. However, patients in the MERCI study had a higher recanalization rate (TIMI 2 or 3 flow as reported by the local operator) than the spontaneous recanalization rate for historical controls (46 versus 18 percent).",
"     </li>",
"     <li>",
"      Overall mortality was higher in MERCI than in PROACT II historical controls (44 versus 27 percent), which may be due in part to older patients with slightly more severe strokes at baseline in MERCI compared with PROACT II. Although MERCI patients had a higher rate of symptomatic intracranial hemorrhage than the historical controls (8 versus 2 percent, respectively), the 8 percent rate in MERCI is similar to the 6.4 percent rate seen with intravenous tPA treatment in the NINDS trial (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Intravenous thrombolysis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Procedural complications in MERCI, including embolization, dissection, subarachnoid hemorrhage, vessel perforation, and groin hemorrhages, occurred in 13 percent and were considered clinically significant in 7 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, although the Merci and Penumbra devices may increase recanalization rates in carefully selected patients, their clinical utility for improving outcomes after stroke is unproven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared with the MERCI retriever in small randomized trials, the newer-generation Solitaire and Trevo neurothrombectomy devices achieved significantly higher intracranial large artery recanalization rates and better patient outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. However, neither device has been compared directly with intravenous thrombolysis or supportive medical therapy. Therefore, further study in randomized controlled trials is needed before the role of mechanical clot disruption devices is defined for the emergency management of acute ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/97,104\">",
"     97,104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H211126\">",
"    <span class=\"h2\">",
"     Ultrasound enhanced thrombolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound energy may have a biologic effect that facilitates the activity of fibrinolytic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/105\">",
"     105",
"    </a>",
"    ]. This effect has been employed to enhance thrombolysis in patients with acute stroke treated with intravenous tPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/55\">",
"     55",
"    </a>",
"    ]. The methods combine intravenous tPA treatment and high-frequency ultrasound (transcranial Doppler [TCD] or transcranial color-coded Doppler [TCCD]) or low-frequency ultrasound. Another variation combines intravenous tPA with ultrasound potentiated by administration of microbubbles, which are small microspheres filled with air or gas that are commonly used as ultrasound contrast agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2010 meta-analysis of ultrasound enhanced thrombolysis for acute stroke identified six randomized trials with 224 patients and three nonrandomized studies with 192 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/107\">",
"       107",
"      </a>",
"      ]. The following observations were made:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Rates of symptomatic intracranial hemorrhage for patients treated with tPA plus TCD, tPA plus TCCD, and tPA alone were 4 percent, 11 percent, and 3 percent, respectively. There was no significant increase in the rate of symptomatic intracranial hemorrhage with high frequency sonothrombolysis (pooled odds ratio [OR] 1.3, 95% CI 0.4-3.6). In the only trial that employed low-frequency ultrasound, symptomatic intracranial hemorrhage occurred in 5 of 14 patients (36 percent), which led to its premature discontinuation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/108\">",
"       108",
"      </a>",
"      ]. The low ultrasound frequency (with its greater tissue penetration) and larger transcranial ultrasound probe used in this study may have contributed to the high rate of hemorrhages.",
"     </li>",
"     <li>",
"      Rates of complete recanalization for patients treated with tPA plus TCD, tPA plus TCCD, and tPA alone were 37 percent, 27 percent, and 17 percent, respectively. In data from eight studies, the likelihood of complete recanalization was significantly increased with high frequency ultrasound using TCD or TCCD, with or without microspheres (odds ratio 3.0, 95% CI 1.7-5.3). Rates of complete recanalization were not available from the trial of low frequency ultrasound.",
"     </li>",
"     <li>",
"      A pooled analysis showed that high frequency thrombolysis compared with intravenous tPA alone was associated with a significantly increased likelihood of functional independence at three months (OR 2.1, 95% CI 1.2-3.7).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2012 meta-analysis identified five randomized trials with 233 patients that evaluated ultrasound enhanced thrombolysis compared with intravenous tPA or conventional treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/109\">",
"       109",
"      </a>",
"      ]. There was no significant difference at three months for the primary outcome of death or disability (OR 0.80, 95% CI 0.45-1.44) or mortality, though recanalization was significantly more likely in the ultrasound group. The ultrasound enhanced thrombolysis group had a higher rate of cerebral hemorrhage, but the difference did not reach statistical significance. The results were similar when the analysis was restricted to patients treated with tPA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The largest trial in both the 2010 and 2012 meta-analysis was CLOTBUST, which enrolled 126 patients with acute stroke due to middle cerebral artery occlusion and randomly assigned them to receive continuous 2 MHz TCD ultrasonography and tPA, or placebo and tPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/55\">",
"     55",
"    </a>",
"    ]. The rate of sustained complete recanalization at 2 hours was significantly increased for the treatment group compared with placebo (38 versus 13 percent). The treatment group showed a nonsignificant trend towards an increased rate of good clinical outcome at three months.",
"   </p>",
"   <p>",
"    In conclusion, ultrasound enhanced thrombolysis holds promise for improving recanalization rates and outcomes in acute ischemic stroke. However, the techniques remain investigational, and there are concerns regarding the risk of symptomatic hemorrhage, particularly with low-frequency ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/110-112\">",
"     110-112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Combined intravenous and intra-arterial thrombolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for combined intravenous and intra-arterial thrombolytic therapy, sometimes referred to as bridging therapy, is to unite the advantages of each: the wide availability of early rapid intravenous thrombolysis and the potentially higher recanalization rates and therefore better outcomes of intra-arterial thrombolysis. In a 2012 systematic review of 15 studies of combined intravenous and intra-arterial thrombolysis, mainly single center but also including the multi-center IMS studies discussed below, the pooled estimates for favorable outcome and recanalization following such therapy were 48.9 and 69.6 percent, respectively, while pooled estimates for mortality and symptomatic intracranial hemorrhage were 17.9 and 8.6 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/113\">",
"     113",
"    </a>",
"    ]. However, these results should be interpreted with caution given the marked limitations and heterogeneity of the underlying studies, many of which were small, observational, and retrospective.",
"   </p>",
"   <p>",
"    The open-label IMS I study treated 80 patients with low-dose (0.6",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    intravenous tPA; this was followed by intra-arterial tPA for 62 patients with major arterial occlusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/114\">",
"     114",
"    </a>",
"    ]. Since there was no placebo arm in IMS I, comparisons were made to patients in the NINDS tPA trial. The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recanalization was achieved in 56 percent of IMS patients in the combined treatment group.",
"     </li>",
"     <li>",
"      IMS I patients had an outcome similar to that of the NINDS intravenous tPA treatment group and a significantly better outcome than that of the NINDS placebo group.",
"     </li>",
"     <li>",
"      IMS I patients had a rate of symptomatic intracerebral hemorrhage similar to that of NINDS tPA treatment group (6.3 versus 6.6 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings were subsequently confirmed in the single arm, open-label IMS II study, which evaluated 81 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/115\">",
"     115",
"    </a>",
"    ]. The 2012 ACCP guidelines note that the IMS I and IMS II studies provide only low-quality evidence regarding the effect of combined intravenous and intra-arterial thrombolysis compared with intravenous therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The larger IMS III trial randomly assigned patients with acute ischemic stroke to treatment with intravenous tPA alone or to a combination of intravenous tPA and intra-arterial therapy, the latter using either tPA delivered directly at the site of the clot or using a device to remove the clot [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/116,117\">",
"     116,117",
"    </a>",
"    ]. Treatment was started within 3 hours of stroke onset. However, enrollment in IMS III was stopped early due to futility after analyzing data from 587 subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/118\">",
"     118",
"    </a>",
"    ]. No safety concerns were noted.",
"   </p>",
"   <p>",
"    The IMS III trial illustrates that the additional time from intravenous tPA to initial intra-arterial therapy is an important factor in treatment. Although the time from hospital arrival to start of intravenous tPA treatment was significantly lower in IMS III compared with IMS II, the time from hospital arrival to start of intra-arterial tPA treatment was significantly longer, due to delays in starting intra-arterial treatment. This time delay is probably one of the factors responsible for the neutral results of the trial. Despite the apparent lack of efficacy for combined treatment in IMS III, ongoing trials are assessing the use of intra-arterial methods as adjunctive treatment to standard intravenous thrombolysis for patients with acute ischemic stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Glycoprotein IIb/IIIa antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, undesirably high rates of reocclusion (34 percent) and neurologic deterioration after initial clinical improvement with intravenous tPA treatment pose a substantial roadblock to better clinical outcomes. A number of myocardial reperfusion studies have found improved coronary artery patency rates using combined treatment with fibrinolytic and glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    antagonists. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/31/19961?source=see_link&amp;anchor=H53#H53\">",
"     \"Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease\", section on 'Combined therapy with fibrinolytics and GP IIb/IIIa antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interest in improving early reperfusion and decreasing the rate of vessel reocclusion has led to preliminary studies of glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    antagonists, sometimes combined with intravenous thrombolysis, for the treatment of acute stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/119-124\">",
"     119-124",
"    </a>",
"    ]. The GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    antagonist",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    has been used in many of these studies in part because it has the advantage of a relatively short half-life (1.6 hours), which may reduce the risk of symptomatic intracranial hemorrhage. Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    has also been employed in conjunction with intravenous tPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/125\">",
"     125",
"    </a>",
"    ] and intra-arterial tPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The promising results reported for combined therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    and tPA require further validation in prospective, randomized controlled trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     VARIABLES ASSOCIATED WITH INTRACEREBRAL HEMORRHAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of variables may be associated with the risk of intracerebral hemorrhage following thrombolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/126,127\">",
"     126,127",
"    </a>",
"    ]. These variables will be discussed separately for intravenous and intra-arterial thrombolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Intravenous thrombolysis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Early CT changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain edema or mass effect on the pretreatment CT scan was one of two major variables associated with an increased risk of intracerebral hemorrhage in patients treated with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    in the NINDS trial (OR, 7.8; 95% CI 2.2-27.1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/68\">",
"     68",
"    </a>",
"    ]. In a subsequent study with the largest experience to date, the Multicenter tPA Stroke Survey, which reviewed data from 1205 patients treated in routine clinical practice with intravenous alteplase, early ischemic CT changes, especially if exceeding 33 percent of the middle cerebral artery territory, also were associated with an increased risk of symptomatic intracerebral hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to these studies, others have also suggested that the presence of early CT signs increases the risk of hemorrhage with thrombolytic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/129,130\">",
"     129,130",
"    </a>",
"    ]. However, even among experienced clinicians, there is disagreement in recognizing and quantifying early CT changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/131\">",
"     131",
"    </a>",
"    ]. Furthermore, an analysis from the NINDS trial found that while early ischemic changes correlated with stroke severity, they were not independently associated with increased risk of adverse outcome after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    treatment, and patients treated with alteplase did better whether or not they had early CT signs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, it does",
"    <strong>",
"     not",
"    </strong>",
"    appear that the presence or absence of early ischemic changes on CT scan can be used to select patients for thrombolytic therapy in the conventional three-hour time window [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/133\">",
"     133",
"    </a>",
"    ]. In the ECASS 1 study of patients treated within 6 hours of stroke onset, CT change in greater than one-third of the middle cerebral artery territory was associated with a 47 percent risk of hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Stroke severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to CT changes, the severity of neurologic deficit as measured on the NIHSS score (",
"    <a class=\"graphic graphic_table graphicRef61698 \" href=\"mobipreview.htm?39/33/40477\">",
"     table 3",
"    </a>",
"    ) was the second major variable associated with intracerebral hemorrhage in the NINDS trial (OR, 1.8; 95% CI 1.2-2.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/68\">",
"     68",
"    </a>",
"    ]. However, stroke severity alone cannot be used to select or exclude patients for intravenous thrombolysis. In NINDS, the relative benefit in patients with severe strokes was greater in terms of the combined end point of death and disability if treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    despite the increased risk of hemorrhage (adjusted OR for alteplase compared with placebo, 4.3; 95% CI 1.6-11.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of intracerebral hemorrhage with tPA treatment may be increased for older patients, but the evidence is conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/64,68,69,72,128,134,135\">",
"     64,68,69,72,128,134,135",
"    </a>",
"    ]. In the NINDS cohort, age was not an independent risk factor for intracranial hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. In addition, a prospective Canadian multicenter cohort study found that 270 tPA-treated patients 80 years or older had a similar rate of symptomatic intracranial hemorrhage compared with 1135 younger patients (4.4 versus 4.6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a prospective German cohort study of 1658 patients treated with tPA found that the risk of intracranial hemorrhage was associated with increased age, and that patients older than 75 years (n = 396) had twice the risk compared with those younger than 55 years of age (10.3 versus 4.9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Other clinical and laboratory factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to CT findings, stroke severity, and older age, the following variables have been associated with an increased risk of symptomatic intracerebral hemorrhage after intravenous or intra-arterial thrombolysis for acute ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/126-128,136-147\">",
"     126-128,136-147",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ischemic heart disease",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Atrial fibrillation",
"     </li>",
"     <li>",
"      Hyperglycemia and diabetes mellitus",
"     </li>",
"     <li>",
"      Renal impairment",
"     </li>",
"     <li>",
"      Hypertension during the first 24 hours after stroke onset",
"     </li>",
"     <li>",
"      Preceding antiplatelet therapy",
"     </li>",
"     <li>",
"      Preceding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy with subtherapeutic international normalized ratio prior to thrombolysis",
"     </li>",
"     <li>",
"      Borderline or low platelet counts",
"     </li>",
"     <li>",
"      Presence of leukoaraiosis",
"     </li>",
"     <li>",
"      Size of acute stroke lesion on diffusion-weighted MRI",
"     </li>",
"     <li>",
"      Persisting cerebral arterial occlusion at the end of tPA infusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259080990\">",
"    <span class=\"h3\">",
"     Antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior antiplatelet therapy is not a contraindication to thrombolytic therapy for acute ischemic stroke. However, antiplatelet agents should not be used within the first 24 hours after administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The absolute excess symptomatic intracerebral hemorrhage attributable to antiplatelet therapy in patients treated with intravenous tPA appears to be small, and does not worsen outcome. This conclusion comes from a study that analyzed data from the prospective SITS-ISTR registry of thrombolysis for acute ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/144\">",
"     144",
"    </a>",
"    ]. The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of symptomatic intracerebral hemorrhage (according to the NINDS definition) was higher for patients who were receiving antiplatelets at baseline compared with those who were antiplatelet naive (8.8 versus 6.5 percent).",
"     </li>",
"     <li>",
"      Patients on antiplatelet therapy were on average five years older and had more vascular risk factors compared with those who were not on antiplatelets.",
"     </li>",
"     <li>",
"      On multivariate analysis, antiplatelet treatment was not associated with a significant increase in the risk of symptomatic intracerebral hemorrhage, mortality, or poor functional outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, preceding antiplatelet therapy should not be considered as a relative contraindication to thrombolytic therapy for acute ischemic stroke. However, the results of the open-label ARTIS trial suggest that co-administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    with intravenous thrombolysis is harmful. In ARTIS, 642 adults with acute ischemic stroke were randomly assigned to intravenous aspirin (300 mg) started within 90 minutes of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    or to alteplase alone; both groups received oral antiplatelet therapy 24 hours after alteplase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/148\">",
"     148",
"    </a>",
"    ]. The trial was stopped prematurely, which might lead to under- or over-estimation of treatment effects, due to an excess of symptomatic intracranial hemorrhage in the intravenous aspirin group. At three months, the favorable outcome rate was similar for the aspirin group compared with the no aspirin group (54 versus 57 percent) and the difference was not statistically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114929807\">",
"    <span class=\"h3\">",
"     Anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, one of the exclusion criteria for intravenous thrombolysis treatment of acute ischemic stroke is an international normalized ratio (INR) &gt;1.7 in the setting of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy. In Europe, current anticoagulant treatment is an exclusion criterion regardless of the INR. However, the data regarding the risk of bleeding with thrombolysis for patients on warfarin with a subtherapeutic INR (ie, &le;1.7) are conflicting, with some studies showing an increased risk of symptomatic intracranial hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/145,146,149,150\">",
"     145,146,149,150",
"    </a>",
"    ], and others showing no increased risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/151-157\">",
"     151-157",
"    </a>",
"    ]. The range of findings is illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 2012 meta-analysis, the risk of symptomatic intracranial hemorrhage with thrombolysis was increased for those taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      with a subtherapeutic INR (odds ratio 2.6, 95% CI 1.1-5.9.) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/146\">",
"       146",
"      </a>",
"      ]. A second meta-analysis from 2012 reported similar findings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/145\">",
"       145",
"      </a>",
"      ]. However, the strength of these meta-analyses is limited by the retrospective methodology and heterogeneity of the underlying studies.",
"     </li>",
"     <li>",
"      The largest experience comes from a subsequent retrospective observational study (not included in the two meta-analyses cited above) that analyzed data from a US stroke registry of 23,437 patients with an INR &le;1.7 who were treated with intravenous tPA, including 1802 with preadmission",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      use and 21,635 with no preadmission warfarin use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/157\">",
"       157",
"      </a>",
"      ]. The rate of symptomatic intracranial hemorrhage was significantly higher for patients who received preadmission warfarin compared with those not treated with warfarin (5.7 versus 4.6 percent). However, after adjustment for baseline clinical factors (age, sex,",
"      <span class=\"nowrap\">",
"       race/ethnicity,",
"      </span>",
"      baseline National Institutes of Health Stroke Scale score, systolic blood pressure, and blood glucose levels), there was",
"      <strong>",
"       no difference",
"      </strong>",
"      between the groups in the risk of symptomatic intracranial hemorrhage (adjusted odds ratio, 1.01, 95% CI 0.82-1.25).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients receiving newer oral anticoagulants (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    ), the risk of intracranial or systemic hemorrhage with thrombolysis for acute ischemic stroke is unknown. Data are limited to a few case reports, which include some patients on dabigatran who received intravenous tPA and had no cerebral complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/158-160\">",
"     158-160",
"    </a>",
"    ] and at least one patient on dabigatran who developed fatal intracranial hemorrhage after intravenous tPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/161\">",
"     161",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Low cerebral blood flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extremely low cerebral blood flow and concomitant severe ischemic injury as observed on imaging studies may identify patients who are at increased risk for cerebral hemorrhage with thrombolytic therapy.",
"   </p>",
"   <p>",
"    Positron emission tomography (PET) is probably the most reliable method for quantifying cerebral blood flow, but it is not usually available emergently. Diffusion (DWI) and perfusion (PWI) weighted magnetic resonance imaging (MRI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/162-165\">",
"     162-165",
"    </a>",
"    ], perfusion computed tomography (CTP), single photon emission computed tomography (SPECT), and xenon CT are techniques that are more readily available and may help to distinguish necrotic tissue from tissue that is ischemic but still salvageable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/166\">",
"     166",
"    </a>",
"    ]. Larger studies are needed to establish that these methods can reliably predict which patients are at risk of intracerebral hemorrhage after thrombolysis for ischemic stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Risk versus benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the factors noted above may assist in estimating the risk of hemorrhage with thrombolytic treatment of acute stroke, they",
"    <strong>",
"     do not",
"    </strong>",
"    necessarily predict which patients will or will not benefit from intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/128\">",
"     128",
"    </a>",
"    ]. The only factor known to independently alter response to intravenous tPA is",
"    <strong>",
"     time to treatment",
"    </strong>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/3,6\">",
"     3,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We strongly advocate that whenever possible the potential risks and benefits of thrombolysis be discussed objectively with the patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    family prior to initiating treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6570?source=see_link&amp;anchor=H17846222#H17846222\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\", section on 'Informed consent'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Intra-arterial thrombolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For intra-arterial thrombolytic therapy, factors related to the risk of intracerebral hemorrhage appear to be similar to those reported for intravenous thrombolysis. In one study, the following independent predictors of hemorrhagic transformation were found on multivariate analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/137\">",
"     137",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Higher baseline NIHSS score (",
"      <a class=\"graphic graphic_table graphicRef61698 \" href=\"mobipreview.htm?39/33/40477\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Higher glucose levels",
"     </li>",
"     <li>",
"      Longer time to recanalization",
"     </li>",
"     <li>",
"      Lower platelet count",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One study found that microcatheter contrast injections during intra-arterial thrombolysis were associated with an increased risk of hemorrhagic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/167\">",
"     167",
"    </a>",
"    ]. Radiologic signs seen during or immediately after intra-arterial reperfusion may also be markers of symptomatic hemorrhage, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Extravasated contrast medium on CT scan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/168\">",
"       168",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Early venous filling on angiography during intra-arterial reperfusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/169\">",
"       169",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Cerebral microbleeds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral microbleeds are small chronic hemorrhages that are best visualized on susceptibility-weighted MRI sequences. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link&amp;anchor=H23#H23\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Microbleeds'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some investigators have questioned whether the presence of microbleeds is a contraindication to thrombolysis, based upon the possibility that microbleeds increase the risk of symptomatic intracerebral hemorrhage. However, though limited to a few small studies, the available evidence does not support this concern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/170-174\">",
"     170-174",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current guidelines from the American Heart Association state that the presence of a small number of microbleeds (&lt;5) is",
"    <strong>",
"     not",
"    </strong>",
"    a contraindication to intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/8/41098/abstract/175\">",
"     175",
"    </a>",
"    ]. There are insufficient data to determine the risk in patients with &ge;5 microbleeds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/55/24435?source=see_link\">",
"       \"Patient information: Stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/37/38484?source=see_link\">",
"       \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/53/19286?source=see_link\">",
"       \"Patient information: Ischemic stroke treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Randomized controlled trials have shown that intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      (recombinant tissue-type plasminogen activator or tPA) improves functional outcome from ischemic stroke and that the benefits outweigh the risks for patients who receive treatment within 4.5 hours of symptom onset (or within 4.5 hours of when the patient was last seen normal in cases when onset time is unknown). The benefit of intravenous thrombolysis decreases continuously over time from symptom onset. Therefore, treatment must be given as soon as possible, rather than near the end of the time window. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Intravenous thrombolysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment within 3 hours'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment from 3 to 4.5 hours'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Pooled data'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important factor in successful thrombolytic treatment of acute ischemic stroke is early treatment. Nonetheless, selection of appropriate candidates for thrombolysis demands a neurologic evaluation and a neuroimaging study. Patients with acute ischemic stroke are eligible for treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      if they meet inclusion and exclusion criteria listed in the table (",
"      <a class=\"graphic graphic_table graphicRef71462 \" href=\"mobipreview.htm?31/40/32397\">",
"       table 1",
"      </a>",
"      ). Recommendations for the use of intravenous alteplase are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6570?source=see_link\">",
"       \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Since intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      treatment does not achieve successful vessel recanalization in all patients with acute ischemic stroke, monitoring for recanalization with advanced neuroimaging methods is being tested. Modern imaging techniques offer the potential to identify both salvageable ischemic brain tissue and the responsible vascular lesion - the target of the thrombolytic therapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment with advanced neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recanalization is generally associated with improved outcome and reduced mortality in acute ischemic stroke. A number of factors may affect the response to thrombolytic therapy, including location of the occlusion in the arterial tree, availability of collateral blood supply, and clot-specific features such as size, composition, and source. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Recanalization'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Factors affecting recanalization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Investigational methods of reperfusion therapy for acute ischemic stroke include intra-arterial thrombolysis, angioplasty and stenting, mechanical clot disruption, combined intravenous and intra-arterial thrombolysis, and the combined use of fibrinolytics and GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      antagonists. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Investigational methods'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Intra-arterial thrombolysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Mechanical clot disruption'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H211126\">",
"       'Ultrasound enhanced thrombolysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Combined intravenous and intra-arterial thrombolysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29\">",
"       'Glycoprotein IIb/IIIa antagonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intra-arterial thrombolysis for acute ischemic stroke should not preclude treatment with intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      for otherwise eligible patients. However, intra-arterial thrombolysis is a reasonable treatment option for select patients who have contraindications to intravenous thrombolysis. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Intra-arterial thrombolysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who are ineligible for intravenous thrombolysis with angiographically demonstrated acute middle cerebral artery occlusion and associated stroke symptoms but no signs of major early infarction on a baseline CT or MRI scan, we suggest intra-arterial",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      therapy, provided that treatment can be started within 6 hours of clearly defined symptom onset at centers with appropriate expertise (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Intra-arterial thrombolysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H212408\">",
"       'Middle cerebral or basilar occlusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are ineligible for intravenous thrombolysis with angiographically demonstrated acute basilar artery occlusion and associated stroke symptoms but no signs of major infarction on a baseline CT or MRI scan, we suggest intra-arterial thrombolytic therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      at centers with appropriate expertise (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Although good clinical results have been reported beyond 6 hours from stroke onset, the duration of the therapeutic window for thrombolysis in patients with basilar occlusion is uncertain. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Intra-arterial thrombolysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H212408\">",
"       'Middle cerebral or basilar occlusion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The clinical utility of mechanical clot disruption and combined intravenous and intra-arterial thrombolysis to improve outcome and survival after acute ischemic stroke is uncertain. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Mechanical clot disruption'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Combined intravenous and intra-arterial thrombolysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/1\">",
"      Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/2\">",
"      Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/3\">",
"      Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/4\">",
"      Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999; 340:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/5\">",
"      Schm&uuml;lling S, Grond M, Rudolf J, Heiss WD. One-year follow-Up in acute stroke patients treated with rtPA in clinical routine. Stroke 2000; 31:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/6\">",
"      Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000; 55:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/7\">",
"      Bluhmki E, Chamorro A, D&aacute;valos A, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol 2009; 8:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/8\">",
"      Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke 2000; 31:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/9\">",
"      Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/10\">",
"      Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/11\">",
"      Wahlgren N, Ahmed N, D&aacute;valos A, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/12\">",
"      Ahmed N, Wahlgren N, Grond M, et al. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010; 9:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/13\">",
"      IST-3 collaborative group, Sandercock P, Wardlaw JM, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; 379:2352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/14\">",
"      Lyden PD. In anticipation of International Stroke Trial-3 (IST-3). Stroke 2012; 43:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/15\">",
"      Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; 379:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/16\">",
"      Kleindorfer D, Kissela B, Schneider A, et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke 2004; 35:e27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/17\">",
"      Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/18\">",
"      Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009; 8:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/19\">",
"      Furlan AJ, Eyding D, Albers GW, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006; 37:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/20\">",
"      Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008; 7:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/21\">",
"      Thomalla G, Schwark C, Sobesky J, et al. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke 2006; 37:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/22\">",
"      Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006; 60:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/23\">",
"      Olivot JM, Mlynash M, Thijs VN, et al. Relationships between infarct growth, clinical outcome, and early recanalization in diffusion and perfusion imaging for understanding stroke evolution (DEFUSE). Stroke 2008; 39:2257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/24\">",
"      Lansberg MG, Thijs VN, Bammer R, et al. The MRA-DWI mismatch identifies patients with stroke who are likely to benefit from reperfusion. Stroke 2008; 39:2491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/25\">",
"      Lansberg MG, Straka M, Kemp S, et al. MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol 2012; 11:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/26\">",
"      Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007; 38:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/27\">",
"      Neumann-Haefelin T, du Mesnil de Rochemont R, Fiebach JB, et al. Effect of incomplete (spontaneous and postthrombolytic) recanalization after middle cerebral artery occlusion: a magnetic resonance imaging study. Stroke 2004; 35:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/28\">",
"      Wunderlich MT, Goertler M, Postert T, et al. Recanalization after intravenous thrombolysis: does a recanalization time window exist? Neurology 2007; 68:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/29\">",
"      Bhatia R, Hill MD, Shobha N, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke 2010; 41:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/30\">",
"      Alexandrov AV, Felberg RA, Demchuk AM, et al. Deterioration following spontaneous improvement : sonographic findings in patients with acutely resolving symptoms of cerebral ischemia. Stroke 2000; 31:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/31\">",
"      Rajajee V, Kidwell C, Starkman S, et al. Early MRI and outcomes of untreated patients with mild or improving ischemic stroke. Neurology 2006; 67:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/32\">",
"      Nedeltchev K, Schwegler B, Haefeli T, et al. Outcome of stroke with mild or rapidly improving symptoms. Stroke 2007; 38:2531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/33\">",
"      Mazighi M, Meseguer E, Labreuche J, et al. Dramatic recovery in acute ischemic stroke is associated with arterial recanalization grade and speed. Stroke 2012; 43:2998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/34\">",
"      Alexandrov AV, Hall CE, Labiche LA, et al. Ischemic stunning of the brain: early recanalization without immediate clinical improvement in acute ischemic stroke. Stroke 2004; 35:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/35\">",
"      Allport LE, Parsons MW, Butcher KS, et al. Elevated hematocrit is associated with reduced reperfusion and tissue survival in acute stroke. Neurology 2005; 65:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/36\">",
"      Grotta J, Ackerman R, Correia J, et al. Whole blood viscosity parameters and cerebral blood flow. Stroke 1982; 13:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/37\">",
"      Thomas DJ. Whole blood viscosity and cerebral blood flow. Stroke 1982; 13:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/38\">",
"      Zivin JA, Fisher M, DeGirolami U, et al. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 1985; 230:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/39\">",
"      Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/40\">",
"      Wolpert SM, Bruckmann H, Greenlee R, et al. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol 1993; 14:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/41\">",
"      von Kummer R, Holle R, Rosin L, et al. Does arterial recanalization improve outcome in carotid territory stroke? Stroke 1995; 26:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/42\">",
"      Suarez JI, Sunshine JL, Tarr R, et al. Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ischemic stroke. Stroke 1999; 30:2094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/43\">",
"      Linfante I, Llinas RH, Selim M, et al. Clinical and vascular outcome in internal carotid artery versus middle cerebral artery occlusions after intravenous tissue plasminogen activator. Stroke 2002; 33:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/44\">",
"      Molina CA, Montaner J, Arenillas JF, et al. Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke 2004; 35:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/45\">",
"      Lee KY, Han SW, Kim SH, et al. Early recanalization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre- and post-thrombolytic angiography in acute ischemic stroke patients. Stroke 2007; 38:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/46\">",
"      Saqqur M, Uchino K, Demchuk AM, et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke 2007; 38:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/47\">",
"      Fulgham JR, Ingall TJ, Stead LG, et al. Management of acute ischemic stroke. Mayo Clin Proc 2004; 79:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/48\">",
"      Kim EY, Heo JH, Lee SK, et al. Prediction of thrombolytic efficacy in acute ischemic stroke using thin-section noncontrast CT. Neurology 2006; 67:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/49\">",
"      Overgaard K. Thrombolytic therapy in experimental embolic stroke. Cerebrovasc Brain Metab Rev 1994; 6:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/50\">",
"      Brommer EJ, van Bockel JH. Composition and susceptibility to thrombolysis of human arterial thrombi and the influence of their age. Blood Coagul Fibrinolysis 1992; 3:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/51\">",
"      Zangerle A, Kiechl S, Spiegel M, et al. Recanalization after thrombolysis in stroke patients: predictors and prognostic implications. Neurology 2007; 68:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/52\">",
"      Georgiadis D, Oehler J, Schwarz S, et al. Does acute occlusion of the carotid T invariably have a poor outcome? Neurology 2004; 63:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/53\">",
"      Wunderlich MT, Stolz E, Seidel G, et al. Conservative medical treatment and intravenous thrombolysis in acute stroke from carotid T occlusion. Cerebrovasc Dis 2005; 20:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/54\">",
"      Kim YS, Garami Z, Mikulik R, et al. Early recanalization rates and clinical outcomes in patients with tandem internal carotid artery/middle cerebral artery occlusion and isolated middle cerebral artery occlusion. Stroke 2005; 36:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/55\">",
"      Alexandrov AV, Molina CA, Grotta JC, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004; 351:2170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/56\">",
"      Qureshi AI, Ezzeddine MA, Nasar A, et al. Is IV tissue plasminogen activator beneficial in patients with hyperdense artery sign? Neurology 2006; 66:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/57\">",
"      Kimura K, Iguchi Y, Shibazaki K, et al. M1 susceptibility vessel sign on T2* as a strong predictor for no early recanalization after IV-t-PA in acute ischemic stroke. Stroke 2009; 40:3130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/58\">",
"      Kimura K, Sakamoto Y, Aoki J, et al. Clinical and MRI predictors of no early recanalization within 1 hour after tissue-type plasminogen activator administration. Stroke 2011; 42:3150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/59\">",
"      Mattle HP, Arnold M, Lindsberg PJ, et al. Basilar artery occlusion. Lancet Neurol 2011; 10:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/60\">",
"      Lindsberg PJ, Soinne L, Tatlisumak T, et al. Long-term outcome after intravenous thrombolysis of basilar artery occlusion. JAMA 2004; 292:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/61\">",
"      Levy EI, Firlik AD, Wisniewski S, et al. Factors affecting survival rates for acute vertebrobasilar artery occlusions treated with intra-arterial thrombolytic therapy: a meta-analytical approach. Neurosurgery 1999; 45:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/62\">",
"      Lindsberg PJ, Mattle HP. Therapy of basilar artery occlusion: a systematic analysis comparing intra-arterial and intravenous thrombolysis. Stroke 2006; 37:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/63\">",
"      Molina CA. Editorial comment--degree of arterial recanalization: an end point for efficacy in future intravenous thrombolytic trials. Stroke 2004; 35:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/64\">",
"      Heuschmann PU, Kolominsky-Rabas PL, Roether J, et al. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA 2004; 292:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/65\">",
"      Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/66\">",
"      Saposnik G, Young B, Silver B, et al. Lack of improvement in patients with acute stroke after treatment with thrombolytic therapy: predictors and association with outcome. JAMA 2004; 292:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/67\">",
"      Saposnik G, Di Legge S, Webster F, Hachinski V. Predictors of major neurologic improvement after thrombolysis in acute stroke. Neurology 2005; 65:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/68\">",
"      Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997; 28:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/69\">",
"      Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997; 28:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/70\">",
"      Hemphill JC 3rd, Lyden P. Stroke thrombolysis in the elderly: risk or benefit? Neurology 2005; 65:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/71\">",
"      Mishra NK, Ahmed N, Andersen G, et al. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ 2010; 341:c6046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/72\">",
"      Sylaja PN, Cote R, Buchan AM, et al. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry 2006; 77:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/73\">",
"      Kent DM, Price LL, Ringleb P, et al. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials. Stroke 2005; 36:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/74\">",
"      Meseguer E, Mazighi M, Labreuche J, et al. Outcomes of intravenous recombinant tissue plasminogen activator therapy according to gender: a clinical registry study and systematic review. Stroke 2009; 40:2104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/75\">",
"      Alvarez-Sab&iacute;n J, Molina CA, Montaner J, et al. Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients. Stroke 2003; 34:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/76\">",
"      Ahmed N, D&aacute;valos A, Eriksson N, et al. Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-ISTR). Arch Neurol 2010; 67:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/77\">",
"      Ribo M, Molina C, Montaner J, et al. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke 2005; 36:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/78\">",
"      Alvarez-Sab&iacute;n J, Molina CA, Rib&oacute; M, et al. Impact of admission hyperglycemia on stroke outcome after thrombolysis: risk stratification in relation to time to reperfusion. Stroke 2004; 35:2493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/79\">",
"      Grotta JC, Welch KM, Fagan SC, et al. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. Stroke 2001; 32:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/80\">",
"      Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002; 59:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/81\">",
"      Rubiera M, Alvarez-Sab&iacute;n J, Ribo M, et al. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke 2005; 36:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/82\">",
"      Heo JH, Lee KY, Kim SH, Kim DI. Immediate reocclusion following a successful thrombolysis in acute stroke: a pilot study. Neurology 2003; 60:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/83\">",
"      Georgiadis D, Engelter S, Tettenborn B, et al. Early recurrent ischemic stroke in stroke patients undergoing intravenous thrombolysis. Circulation 2006; 114:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/84\">",
"      Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012; 366:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/85\">",
"      Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/86\">",
"      Meyers PM, Schumacher HC, Higashida RT, et al. Indications for the performance of intracranial endovascular neurointerventional procedures: a scientific statement from the American Heart Association Council on Cardiovascular Radiology and Intervention, Stroke Council, Council on Cardiovascular Surgery and Anesthesia, Interdisciplinary Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation 2009; 119:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/87\">",
"      Khalessi AA, Natarajan SK, Orion D, et al. Acute stroke intervention. JACC Cardiovasc Interv 2011; 4:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/88\">",
"      Meyers PM, Schumacher HC, Connolly ES Jr, et al. Current status of endovascular stroke treatment. Circulation 2011; 123:2591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/89\">",
"      Lee M, Hong KS, Saver JL. Efficacy of intra-arterial fibrinolysis for acute ischemic stroke: meta-analysis of randomized controlled trials. Stroke 2010; 41:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/90\">",
"      Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/91\">",
"      Kase CS, Furlan AJ, Wechsler LR, et al. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology 2001; 57:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/92\">",
"      del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998; 29:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/93\">",
"      Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e601S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/94\">",
"      Khatri P, Abruzzo T, Yeatts SD, et al. Good clinical outcome after ischemic stroke with successful revascularization is time-dependent. Neurology 2009; 73:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/95\">",
"      Ribo M, Flores A, Rubiera M, et al. Extending the time window for endovascular procedures according to collateral pial circulation. Stroke 2011; 42:3465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/96\">",
"      Leigh R, Zaidat OO, Suri MF, et al. Predictors of hyperacute clinical worsening in ischemic stroke patients receiving thrombolytic therapy. Stroke 2004; 35:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/97\">",
"      Baker WL, Colby JA, Tongbram V, et al. Neurothrombectomy devices for the treatment of acute ischemic stroke: state of the evidence. Ann Intern Med 2011; 154:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/98\">",
"      Gralla J, Brekenfeld C, Mordasini P, Schroth G. Mechanical thrombolysis and stenting in acute ischemic stroke. Stroke 2012; 43:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/99\">",
"      Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005; 36:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/100\">",
"      Becker KJ, Brott TG. Approval of the MERCI clot retriever: a critical view. Stroke 2005; 36:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/101\">",
"      Brinjikji W, Rabinstein AA, Kallmes DF, Cloft HJ. Patient outcomes with endovascular embolectomy therapy for acute ischemic stroke: a study of the national inpatient sample: 2006 to 2008. Stroke 2011; 42:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/102\">",
"      Saver JL, Jahan R, Levy EI, et al. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet 2012; 380:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/103\">",
"      Nogueira RG, Lutsep HL, Gupta R, et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet 2012; 380:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/104\">",
"      Khatri P. Neurothrombectomy devices for acute ischemic stroke: a state of uncertainty. Ann Intern Med 2011; 154:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/105\">",
"      Polak JF. Ultrasound energy and the dissolution of thrombus. N Engl J Med 2004; 351:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/106\">",
"      Meairs S, Alonso A, Hennerici MG. Progress in sonothrombolysis for the treatment of stroke. Stroke 2012; 43:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/107\">",
"      Tsivgoulis G, Eggers J, Ribo M, et al. Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies. Stroke 2010; 41:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/108\">",
"      Daffertshofer M, Gass A, Ringleb P, et al. Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. Stroke 2005; 36:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/109\">",
"      Ricci S, Dinia L, Del Sette M, et al. Sonothrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2012; 6:CD008348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/110\">",
"      Reinhard M, Hetzel A, Kr&uuml;ger S, et al. Blood-brain barrier disruption by low-frequency ultrasound. Stroke 2006; 37:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/111\">",
"      Dinia L, Rubiera M, Ribo M, et al. Reperfusion after stroke sonothrombolysis with microbubbles may predict intracranial bleeding. Neurology 2009; 73:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/112\">",
"      Tsivgoulis G, Alexandrov A. Ultrasound-enhanced thrombolysis: from bedside to bench. Stroke 2008; 39:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/113\">",
"      Mazighi M, Meseguer E, Labreuche J, Amarenco P. Bridging therapy in acute ischemic stroke: a systematic review and meta-analysis. Stroke 2012; 43:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/114\">",
"      IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004; 35:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/115\">",
"      IMS II Trial Investigators. The Interventional Management of Stroke (IMS) II Study. Stroke 2007; 38:2127.",
"     </a>",
"    </li>",
"    <li>",
"     The Interventional Management of Stroke (IMS) III trial. www.strokecenter.org/trials/clinicalstudies/interventional-management-of-stroke-ims-iii-trial (Accessed on March 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/117\">",
"      Zaidat OO, Lazzaro MA, Gupta R, et al. Interventional Management of Stroke III Trial: establishing the foundation. J Neurointerv Surg 2012; 4:235.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute of Neurological Disorders and Stroke. Interventional Management of Stroke III Trial (IMS III). file://www.ninds.nih.gov/disorders/clinical_trials/IMS-III.htm (Accessed on October 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/119\">",
"      Gupta R, Vora NA, Horowitz MB, et al. Multimodal reperfusion therapy for acute ischemic stroke: factors predicting vessel recanalization. Stroke 2006; 37:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/120\">",
"      Molina CA, Saver JL. Extending reperfusion therapy for acute ischemic stroke: emerging pharmacological, mechanical, and imaging strategies. Stroke 2005; 36:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/121\">",
"      Seitz RJ, Hamzavi M, Junghans U, et al. Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke: preliminary observations. Stroke 2003; 34:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/122\">",
"      Straub S, Junghans U, Jovanovic V, et al. Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion. Stroke 2004; 35:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/123\">",
"      Seitz RJ, Meisel S, Moll M, et al. The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions. Neurology 2004; 62:2110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/124\">",
"      Siebler M, Hennerici MG, Schneider D, et al. Safety of Tirofiban in acute Ischemic Stroke: the SaTIS trial. Stroke 2011; 42:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/125\">",
"      Pancioli AM, Broderick J, Brott T, et al. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke 2008; 39:3268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/126\">",
"      Khatri P, Wechsler LR, Broderick JP. Intracranial hemorrhage associated with revascularization therapies. Stroke 2007; 38:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/127\">",
"      Whiteley WN, Slot KB, Fernandes P, et al. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke 2012; 43:2904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/128\">",
"      Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 2002; 105:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/129\">",
"      Jaillard A, Cornu C, Durieux A, et al. Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group. Stroke 1999; 30:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/130\">",
"      Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/131\">",
"      Grotta JC, Chiu D, Lu M, et al. Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. Stroke 1999; 30:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/132\">",
"      Patel SC, Levine SR, Tilley BC, et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 2001; 286:2830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/133\">",
"      Gilligan AK, Markus R, Read S, et al. Baseline blood pressure but not early computed tomography changes predicts major hemorrhage after streptokinase in acute ischemic stroke. Stroke 2002; 33:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/134\">",
"      Engelter ST, Reichhart M, Sekoranja L, et al. Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology 2005; 65:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/135\">",
"      Ringleb PA, Schwark Ch, K&ouml;hrmann M, et al. Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome. J Neurol Neurosurg Psychiatry 2007; 78:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/136\">",
"      Demchuk AM, Morgenstern LB, Krieger DW, et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 1999; 30:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/137\">",
"      Kidwell CS, Saver JL, Carneado J, et al. Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke 2002; 33:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/138\">",
"      Neumann-Haefelin T, Hoelig S, Berkefeld J, et al. Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke 2006; 37:2463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/139\">",
"      Palumbo V, Boulanger JM, Hill MD, et al. Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke. Neurology 2007; 68:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/140\">",
"      Singer OC, Humpich MC, Fiehler J, et al. Risk for symptomatic intracerebral hemorrhage after thrombolysis assessed by diffusion-weighted magnetic resonance imaging. Ann Neurol 2008; 63:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/141\">",
"      Saqqur M, Tsivgoulis G, Molina CA, et al. Symptomatic intracerebral hemorrhage and recanalization after IV rt-PA: a multicenter study. Neurology 2008; 71:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/142\">",
"      Derex L, Nighoghossian N. Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatry 2008; 79:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/143\">",
"      Cucchiara B, Kasner SE, Tanne D, et al. Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials. Stroke 2009; 40:3067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/144\">",
"      Diedler J, Ahmed N, Sykora M, et al. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke 2010; 41:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/145\">",
"      Ruecker M, Matosevic B, Willeit P, et al. Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis. Neurology 2012; 79:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/146\">",
"      Miedema I, Luijckx GJ, De Keyser J, et al. Thrombolytic therapy for ischaemic stroke in patients using warfarin: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2012; 83:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/147\">",
"      Mazya M, Egido JA, Ford GA, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke 2012; 43:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/148\">",
"      Zinkstok SM, Roos YB, ARTIS investigators. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet 2012; 380:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/149\">",
"      Prabhakaran S, Rivolta J, Vieira JR, et al. Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2010; 67:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/150\">",
"      Seet RC, Zhang Y, Moore SA, et al. Subtherapeutic international normalized ratio in warfarin-treated patients increases the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis. Stroke 2011; 42:2333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/151\">",
"      Meretoja A, Putaala J, Tatlisumak T, et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke 2010; 41:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/152\">",
"      Kim YD, Lee JH, Jung YH, et al. Safety and outcome after thrombolytic treatment in ischemic stroke patients with high-risk cardioembolic sources and prior subtherapeutic warfarin use. J Neurol Sci 2010; 298:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/153\">",
"      Ibrahim MM, Sebastian J, Hussain M, et al. Does current oral antiplatelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen-activator-mediated recanalization rate in patients with acute ischemic stroke? Cerebrovasc Dis 2010; 30:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/154\">",
"      Levin D, Smith DB, Cumbler E, et al. Warfarin therapy does not increase risk of symptomatic intracerebral hemorrhage in eligible patients after intravenous thrombolysis. Arch Neurol 2011; 68:135; author reply 135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/155\">",
"      Vergouwen MD, Casaubon LK, Swartz RH, et al. Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator. Stroke 2011; 42:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/156\">",
"      Brunner F, Tomandl B, Schr&ouml;ter A, et al. Hemorrhagic complications after systemic thrombolysis in acute stroke patients with abnormal baseline coagulation. Eur J Neurol 2011; 18:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/157\">",
"      Xian Y, Liang L, Smith EE, et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA 2012; 307:2600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/158\">",
"      De Smedt A, De Raedt S, Nieboer K, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis 2010; 30:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/159\">",
"      Lee VH, Conners JJ, Prabhakaran S. Intravenous thrombolysis in a stroke patient taking dabigatran. J Stroke Cerebrovasc Dis 2012; 21:916.e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/160\">",
"      Matute MC, Guill&aacute;n M, Garc&iacute;a-Caldentey J, et al. Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost 2011; 106:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/161\">",
"      Casado Naranjo I, Portilla-Cuenca JC, Jim&eacute;nez Caballero PE, et al. Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran. Cerebrovasc Dis 2011; 32:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/162\">",
"      Tong DC, Adami A, Moseley ME, Marks MP. Prediction of hemorrhagic transformation following acute stroke: role of diffusion- and perfusion-weighted magnetic resonance imaging. Arch Neurol 2001; 58:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/163\">",
"      Selim M, Fink JN, Kumar S, et al. Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume. Stroke 2002; 33:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/164\">",
"      Oppenheim C, Samson Y, Dormont D, et al. DWI prediction of symptomatic hemorrhagic transformation in acute MCA infarct. J Neuroradiol 2002; 29:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/165\">",
"      Alsop DC, Makovetskaya E, Kumar S, et al. Markedly reduced apparent blood volume on bolus contrast magnetic resonance imaging as a predictor of hemorrhage after thrombolytic therapy for acute ischemic stroke. Stroke 2005; 36:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/166\">",
"      Umemura A, Suzuka T, Yamada K. Quantitative measurement of cerebral blood flow by (99m)Tc-HMPAO SPECT in acute ischaemic stroke: usefulness in determining therapeutic options. J Neurol Neurosurg Psychiatry 2000; 69:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/167\">",
"      Khatri P, Broderick JP, Khoury JC, et al. Microcatheter contrast injections during intra-arterial thrombolysis may increase intracranial hemorrhage risk. Stroke 2008; 39:3283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/168\">",
"      Yoon W, Seo JJ, Kim JK, et al. Contrast enhancement and contrast extravasation on computed tomography after intra-arterial thrombolysis in patients with acute ischemic stroke. Stroke 2004; 35:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/169\">",
"      Ohta H, Nakano S, Yokogami K, et al. Appearance of early venous filling during intra-arterial reperfusion therapy for acute middle cerebral artery occlusion: a predictive sign for hemorrhagic complications. Stroke 2004; 35:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/170\">",
"      Kidwell CS, Saver JL, Villablanca JP, et al. Magnetic resonance imaging detection of microbleeds before thrombolysis: an emerging application. Stroke 2002; 33:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/171\">",
"      Derex L, Nighoghossian N, Hermier M, et al. Thrombolysis for ischemic stroke in patients with old microbleeds on pretreatment MRI. Cerebrovasc Dis 2004; 17:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/172\">",
"      Kakuda W, Thijs VN, Lansberg MG, et al. Clinical importance of microbleeds in patients receiving IV thrombolysis. Neurology 2005; 65:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/173\">",
"      Boulanger JM, Coutts SB, Eliasziw M, et al. Cerebral microhemorrhages predict new disabling or fatal strokes in patients with acute ischemic stroke or transient ischemic attack. Stroke 2006; 37:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/174\">",
"      Fiehler J, Albers GW, Boulanger JM, et al. Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke 2007; 38:2738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/8/41098/abstract/175\">",
"      Latchaw RE, Alberts MJ, Lev MH, et al. Recommendations for imaging of acute ischemic stroke: a scientific statement from the American Heart Association. Stroke 2009; 40:3646.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1124 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-77.94.48.4-C709B3AB8E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_8_41098=[""].join("\n");
var outline_f40_8_41098=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H57\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTRAVENOUS THROMBOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment within 3 hours",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment from 3 to 4.5 hours",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H264417726\">",
"      Treatment up to 6 hours",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pooled data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H209770\">",
"      Practical use of intravenous alteplase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment with advanced neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Recanalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Factors affecting recanalization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Clot size and site",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Clot age and composition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Specific arteries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Extracranial internal carotid occlusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Carotid T occlusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Middle cerebral occlusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Basilar occlusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other variables affecting outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Gender",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Reocclusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Early recurrent ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      INVESTIGATIONAL METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Intra-arterial thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H212408\">",
"      - Middle cerebral or basilar occlusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H472769\">",
"      - Variables affecting outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Mechanical clot disruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H211126\">",
"      Ultrasound enhanced thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Combined intravenous and intra-arterial thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Glycoprotein IIb/IIIa antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      VARIABLES ASSOCIATED WITH INTRACEREBRAL HEMORRHAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Intravenous thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Early CT changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Stroke severity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Other clinical and laboratory factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H259080990\">",
"      - Antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H114929807\">",
"      - Anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Low cerebral blood flow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Risk versus benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Intra-arterial thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Cerebral microbleeds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1124\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1124|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/14/40175\" title=\"figure 1\">",
"      Stroke treatment delay and outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/13/17630\" title=\"figure 2\">",
"      Time to reperfusion after ischemic stroke predicts outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1124|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/40/32397\" title=\"table 1\">",
"      Criteria for treating acute stroke with tPA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/32/23051\" title=\"table 2\">",
"      Modified Rankin scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/33/40477\" title=\"table 3\">",
"      NIH Stroke Scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/31/19961?source=related_link\">",
"      Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6570?source=related_link\">",
"      Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17290?source=related_link\">",
"      Neuroimaging of acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/53/19286?source=related_link\">",
"      Patient information: Ischemic stroke treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_8_41099="Steps in staging ovarian cancer";
var content_f40_8_41099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Steps in staging ovarian cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Obtain any free fluid for cytologic evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. If no free fluid is present, obtain washings by instilling saline&nbsp;and recovering the fluid. The fluid should irrigate the cul de sac, paracolic gutters, and area beneath each diaphragm.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Systematically explore all intraabdominal organs and surfaces: bowel, liver, gallbladder, diaphragms, mesentery, omentum, and the entire peritoneum should be visualized and palpated, as indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Suspicious areas or adhesions should be biopsied. If there are no suspicious areas, multiple biopsies should be obtained from the peritoneum of the cul-de-sac, paracolic gutters, bladder, and intestinal mesentery when the disease appears confined to the ovary. These biopsies are not needed if the patient has advanced disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. The diaphragm should be biopsied or scraped for cytology. A laparoscope and biopsy instrument may be used.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. The omentum should be resected from the transverse colon.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. The retroperitoneum should be explored to evaluate pelvic nodes. Suspicious nodes should be removed and sent for frozen section examination.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. The paraaortic nodes should be exposed and enlarged nodes removed. Nodes superior to the inferior mesenteric artery should also be resected.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. In the absence of suspicious nodes, pelvic and paraaortic nodes should still be sampled to exclude the possibility of microscopic stage III disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. A total abdominal hysterectomy and bilateral salpingo-ophorectomy is performed. (Fertility-conserving surgery may be an option for some women).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_8_41099=[""].join("\n");
var outline_f40_8_41099=null;
var title_f40_8_41100="Neutropenic children infections";
var content_f40_8_41100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk and types of infections in pediatric hematology patients with neutropenia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Predominant causes of fever",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low risk",
"       </td>",
"       <td>",
"        Otherwise healthy child with transient, isolated neutropenia",
"       </td>",
"       <td>",
"        Viral infection",
"       </td>",
"       <td>",
"        Appropriate treatment for age or site of localized infection; careful follow-up",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Low-moderate risk",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Chronic benign neutropenia",
"        </p>",
"        <p>",
"         (chronic autoimmune and idiopathic neutropenia)",
"        </p>",
"       </td>",
"       <td>",
"        Common &mdash; Upper respiratory tract infections, acute otitis media, skin infections, gingivitis, mouth ulcers, labial cellulitis or abscess in girls",
"       </td>",
"       <td>",
"        Oral antibiotics and close outpatient management for patients with adequate marrow reserves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Less common &mdash; Pneumonia, periorbital cellulitis, meningitis, sepsis",
"       </td>",
"       <td>",
"        Hospitalization and parenteral antibiotics for complicated febrile illnesses (eg, hemodynamic instability, skin or soft-tissue infection, pneumonia, concern for catheter-related infection); hospitalization also may be warranted in patients with prior complicated febrile illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Cyclic neutropenia",
"       </td>",
"       <td>",
"        Frequent &mdash; Oral ulcers, gingivitis, periodontitis, pharyngitis, adenopathy",
"       </td>",
"       <td>",
"        Generally do not require antibiotics for fevers or mucocutaneous inflammatory lesions that are typical during neutrophil nadirs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Less frequent &mdash; Bacteremia, cellulitis, acute otitis media, sinusitis, pneumonia, appendicitis",
"       </td>",
"       <td>",
"        Careful assessment of the need for hospitalization as well as administration of antibiotics for atypical fevers or lesions, or infections such as acute otitis media, sinusitis, and lower respiratory tract disease; hospitalization also may be warranted in patients with prior complicated febrile illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncommon &mdash;",
"        <em>",
"         Clostridium",
"        </em>",
"        -associated necrotizing enterocolitis",
"       </td>",
"       <td>",
"        Hospitalization and broad-spectrum parenteral antibiotics for complaints of abdominal pain, significant localized infection, or signs of sepsis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        High risk",
"       </td>",
"       <td>",
"        Severe congenital neutropenia (Kostmann syndrome)",
"       </td>",
"       <td>",
"        Omphalitis, cellulitis, perirectal abscess, sepsis",
"       </td>",
"       <td>",
"        Hospitalization and initiation of broad-spectrum antibiotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aplastic anemia",
"       </td>",
"       <td>",
"        Respiratory tract infections, soft tissue infections, bacteremia, invasive fungal disease, especially due to",
"        <em>",
"         Aspergillus",
"        </em>",
"        spp.",
"       </td>",
"       <td>",
"        Hospitalization and initiation of broad-spectrum antibiotics; antifungal agents may be warranted",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ill-appearing child with neutropenia",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Hospitalization and initiation of broad-spectrum antibiotics",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_8_41100=[""].join("\n");
var outline_f40_8_41100=null;
var title_f40_8_41101="Insulin and potassium load";
var content_f40_8_41101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Effect of insulin on a potassium load",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 260px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The effect of a potassium chloride infusion on the plasma potassium concentration in the control state, with somatostatin alone, or somatostatin plus insulin. The rise in the plasma potassium concentration is enhanced by somatostatin, an effect that is presumably mediated by suppression of insulin release since it can be reversed by concurrent administration of insulin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from DeFronzo, RA, Sherwin, RS, Dillingham, M, et al, J Clin Invest 1978; 61:472.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_8_41101=[""].join("\n");
var outline_f40_8_41101=null;
var title_f40_8_41102="Exercise oxygen uptake";
var content_f40_8_41102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Oxygen uptake, heart rate, and a-v O2 content difference at rest and during increasing levels of exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 530px; background-image: url(data:image/gif;base64,R0lGODlh9AESAuYAAP///wBmMwAAAICAgAAzGX+ymTMzM4Czmaqqqu7u7gAz/3d3d4iIiBEREVVVVczMzMDN//8AACIiImZmZkRERGCA/7u7u93d3ZmZmTBZ/5Cm/0Bm//9gYP/w8P/g4PDz//8QEP8gIP+goKCz/+Dm//9AQICZ/7DA/9DZ/1Bz///AwP+AgBBA/yBN/3CN/wAZDP9wcP/Q0P+QkP+wsP9QUP8wMD+MZsDAwABMJrCwsCAgIGBgYKCgoODg4PDw8MDZzUBzWVBQUDAwMBAQEAAZf9DQ0JCQkH8AAIBAQGBmgEBAQCAyfwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD0ARICAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgwYMIEypcyLChw1UTBAh48LCiRUEUBGDAKIABAAQGJBpAIIiBRAEOTllACeCBAAORHAggyWhBx0MJBDS4yFNSzpMzSzaQSHMXBgEUACRo0CDBSgMJEoS0AGABSZseSyEQsKDly5hBe4o99TMBIayQBsBimsBkyogb/wEcnUAoYtdBNikMnSCzAcWhElPmTSDB7yCXJxkgfgl45oOMSC/kbJDRLACTIrca2Lz4pkkGkzMaZloV6dCUF0QPtTy24k+Jd5lKeEmRkQBYERlMBRCytkuYJSXWFoR26IW5hGZTjTi0KCGXO012/S2ocIK5rwWwlklyq8jDOi93nCw+JeniE2V6XN1abEgM1I8mtQ1r5WwJguAKQp4Acla8N622lWBAkfTTfINcINNJbXHlFUydvUReIdx9xBIACgLVIGjhDQjAeTf1NtRf2rXXE1YXCIDfhIsAdZJaqcx2EwBPRbXbUA3EdVaA2g1oUlIVyjSbjgCo96F20nmFH/8AhV0wCIuDyLSRh0XyuCF5HoLoUW8ZkcSeiZZ0wEEEZHLQQTwIpMTbRGtacJSaLcaCmZOCgJSZII2FB+B6PaIklU4hIWDTBIQJQJUgDwxlwGpJVukYZH7q+ZyiVCbKGJLjdciSlms+8EBIi5YIZiUlkGlqCfFcIKMEcaUWGGuK3KZIDzyMSoh9tlZi6q4eLCRrIT7ksIMOEtnqHW25UrKrqQz9CsANAwjhorPJVguJCmMui6qvggww7bcu3tAtuBLB6C255pIrQLrojtsuAOeCy6687tILr7rzfpvvtPu62C9Q/75Yr74D81uwvwcDnLDA974bL8EN2/uwwRF/i8T/mRMjXDHF8cKIzq/BDjuttSQv4gEMIJQgQiG9OkStILQGMUSxJddMiAo0RMBBDK29XEgRRthccwcihBDCCme257PQTHvAQcoz2Lo00yXPUAIIHLQsNdVMdyCD0TIknezUXIMZw9MlRF0y2WWPJcLVMGi9dtu2drCC0SKIbTPbdDt0dgQ0qNA2330r9DYIcfdNeOEFebACCDWszPjijAeErc6CVw4A5ZrzI0INIKwgd+Wcd37PySlLbrogpa8uD8468+z6IK1PQ6UiEbE5eyFEG4307oTUzklGcWXkkZ0v0YTZhZ7cjshKcFLS6CLOE9KbQairDLwhwm8in1Js1fgn/1VWlfYfJ9UbstVdlUxvq9VYy759Id1vwpZbAOgnlwB0DWLXjnrhX19IFJjSUIAwhqnTS0JyQPFIRDEngYlNHlgaBzRgAQlYkASK0pnQaKcxKXFJSkKyII/I5AGaAZVZFtSceXgNbHqbX/Bw05HdXO9Bg8DMcMx3pOPwLzmGyp9OwqJAAjEgSbO5QJKS1KUJcoU7KVpScLqSHdYoR4RtWslOTriVpBgPfxWCh9OgJsNY1UdFKsqPRvbzw/5QcEd8SoCHnBiUAxXCQ9JZ0EkQkKQK2WQBaDmShnLoIBbREQFY7A15uMgSrBgpjO2AX9bKGCdYyCgr4ruRTohEHCv5CP8pVSKJkNY4CA998YeE7AoTZxJIKR3CJHSZ0I9CmciJLHIic+zIKp2DDrvhLYaUPET9NjGnUoYkeXgCyk72dCQ5+ikkDQjUoAp1KAudpH/Lm0ijJtgAjwQygydZpiD+pB09/SmajmGJIsPDSCO6EZ28LMffAmeitgByAedDBdtoxbVC0QkcYjIVBw6XOIukKZ6Q+soqfBYyYg3TIa/J0ThKtay89WQlSBlOTkaCAARUMxIZAc7yomfGQUBLWi4KZjSWRabRWUSO+LQe+yixAEUR5yozqmTG1CURcW1MYztlWFDLtTCi/lRhRxUqvoq6LqYGzKhDbWpSobrUqUo1qk//vWpVscrUI5CJq1bNqlidStaw1stjqrgAAuQIq/xI4J75bAQGcqRQ/zmIPoJo6MhUugzHQa4G2uIJZkDSP+sBBTiPWAl86urAHSbCZzGb2UP5GovLcUBwAS0TMBsiAQNscAGIHYQFOtrRjzZCj99xY04rmQigUbYYvTsaMF36kJyABAETCO0ClHjPmE6COkeSqCMm+1pbZE91uZJAbmtaWNse8zu/VWiexFnS4ioDdjsr2VEk0oB/fsQppPUoK4hrXVe8ULZCswA+vVsL8pZXFWNMG9Wq2Rb1UWAzBihsKtz7XlNIkrYlM4BHLLAZQ+QptPrsry/OGza6RQQyM8UT/6Gi0gr+KtgTZwMBDdRWOJNs8JUUIK1pT2HhC2uCoABmWm8p8Na45g66qiixiSvhyxBYlHHZiWAhNgrX8c44FvPMXOfCK2JDUEC/Pv5xKz6HuBQzjgGNQXCRorkZJJNYyfB9XORkKIHZLIqka9LxQrF8CssKeXs5MUkC+IKTqLQ1wWQeBZNFF0znLsABoZ2AYyscZ1Ac97UGcMAEmysRCsQ1xn3uBHblZ90jFkKJs2mAA0Z85URjIra/K68F6LTpQ6RJUaBBtKUr8WcFG+AuoE1EWwIl6lFH4r8XJnADOrsoKRui0/t19SMYvFnrHou7nKQRkZOsa0XEl8M/XjNo3v8siOdyl72lkDFfDzfJRGNgvYcINCAloBcwk0LaZazxjRP94gQSogE0WcCRbT0KcG8vyLrOiQMQMFcEDSKa9N5MqnNdbACguN+8SbeU6YgBCni73bp2XAgi12tLT4ACgKQAxPMpqAVQ2hTu1pyZAV4IZ8OYRk86dLQTPWcn63q0RP6ogGlUYLC8EQMyogC0hUlmv26Z44hgQG9djBTYSMIBTppKFPd3cPopGbtnxrkhnG1rD8cTEqyezQRsEmyaXxjTDVe6IFCOgG6e5Z4s9q0kMrKk5VFgz1Z/b6m1/ggDICjHH3fEAyJNEZckxcONgBglF812R+h8AREJLZFLGwn/xBigNk9RUt6Ly+u+tx0oVbdEhFIC5ULPnHuUPbbjI8F1x+pZFhkHE6w3r4kDiRzO82s86TkBaZ1Mms/vHtOGVy+KT78k1Pye3b9pTwm2luT0qyZipU0n7qzzfhGW8nrLFYFr1FcO3se3REiHohvd9haQp0d45UoefUwUeM0qQizcGev8oWUrdlpGbvelj1hQEWLw4h0z0yi6q8uu33uHH2dncRF6gbA0AiZ3f81zX1VGbDXjAf8ngJ5AYYhwYAZoLbATAoGlgJrwGIWGdg0wYcyGcSSDdZmlM8ZHgY5wAdMFbQwQYoQnf7mydoMQgCL4CBaEAVExV2D2YuQ3fKJ3/zXV9oKhcGpngWA8hn0PKBaqx4OiEGiEgGdGZmWtJhaaZ4SlYBKnBlqrJQgWhF9MOHJisXtQaAo2yIRMN4QNUXxdqAoV93Tj5Gaw9xDQV4Yf8xBc6IZvuBA2N25ymA79Rw4bd4ftkIfhwH186A5+2A11GIjxMIjawHeGeIgAgXWLOA+ISA0s+IiMuA8zkDPZRYn1EInOUISaSA+c2Fdog2yfuIn1MHqliA+hCFtfEwINlorhAD2FgBkbaHTv0IawCA7HFD1b8SWstQ5xmIvhgEWCQIKVV4szpA5kKIzlQIyEQRe+WF3mcDn0xIznQIzZJBHIyDoU4w2AaI3XyDz3Jv8qvwgOhQiO6eBsOxSNjyUOe4iOA7GKsUA0NXA0LgiP+SCPqfCBHIAy2oOPB6GPqEB/ZAICjAaQBSGQp/B/94iQ+qCQpOA0CeiQAUkNkkSQEbAtFJmQ0dB4/BiCG/mQz/CELBOSCAGRJwY3DWmSAoGSYXI3NgaSLMmRx4CLM1kRLhkJwXiTODkM58iTYpGTi/COQBmUv/CNRTkWQskyKHNzSWkiSykIiviUYCKUjkiVW0MLk4iVVTkLlxg/XGkt+uiJYZkrq0iSZSmWrICKaUkyg1hjr9iWtQUpFOcilpGHNimXDvEYZrEbpXSDobeTenkRiwIrxyJcm9MJ/AiTdjj/mDyxIFlIggJAJ/yFkSCQdI45Fq6Ubbqjd5PAkJk5FgzQP8RDHTFFglLEXxMZmj0xd4mBQ8dydrTTCRipkazJNPz1kbfJNTK2krvZlb9pYlEZnDjJU8Z5nMiZnMq5nMzZnM75nNAZndI5ndRZndZ5nRrzDsNJnC7DnQq2nd7JLeFZXuA5nidpntZVnuhJk+vJV+rZni0Jn+4pnyr1nvTpD/Z5n/yQn/opkv05P/z5n/cQoAJqigW6OwR6oPKQoAoKDwzaoIIIoavzoBK6DhRaoXhIC8D1R4Lkc6NgKZGhFMf0YaWhImiIoYygR1kxV2/0KQW0eLOwoQ7CHrOBdpzg/2hd1BIpsRTR4SDWgaI/F3SGQh0VYh3u044xqlAcuhoIBCsk9EAhZRYgZEAIZKNsFFqSCU6iJHwOZKIfEWlfYYEh2qCBskRcQR3AVY6vECEzGk6ONRW4oj/VEUTMwaV3RH0JQkKdEkpOVBSzVKPUYR3IoaBkx0PS4SFpKo2wIKNdsRpD0nETYZo3cUhKUWi486L7IyGhtKnvBymHFx6/ESHsJp+uaRhmugBoeoPC1I2qwKjNpEXe1RuSekSgFCRotBEm4RwLwj6Y0UDigUE/em5D+hXh8xVN0qCG5xtf0SVM0hRHiggo6arsYROhJatfgRXnJE38Q00sRiEu8gDZ6P9NEkGihIAZ7sei7iem4hh9H1ABCvCuFfAByzB5cgEYWeGi64qkicBP0uB1qABLJNOu76oA8ZoMGzCw77oBfXgIenWhiWABTWEKTuSr1XKwCKuwyICwA0sC7OAsJ7VXZfkBJ2ACGvuuHDsMEKABEAAAJasAC2tV4OJTYDWzW1WzDmOzEoOzEEOzN9uzOeuzO6uzHCO0QKUuS+ACCkAERItUPPuz9pIE6kIE76q0RjWHANCwQJGUEGACG8ACLJACKjsIFjuwGKsLEFABGaAAGVABYUsIAguv8tqxhxBZNGOSJDACLpC2GeACI3CyhfC2BBu3tZCyKwsAhNsIfvuyrRX/NBSZsingtRtgAoWLuIOrAWirthUwuQDhsEpGAifgAge7tiOAAsVwtnrLtpobjzOJApbbAgoQuScguMJwtyt7uNBwUPxHkSLLtQrQAmxLusaAAiaQtimQutCAUbIZcj2mguCIAiNwuRvgAieQuMRwAhXQAr57AtagVnIkKOeTUKOqfcK4tV37tW2LDBCQAmprAsBrDYOVXzuWPCnYhJR4t3mrtnxLvcRguxDQt9vQWZ8lZT74CpzbOY4LuZKbDCl7uWtrvNngXLglZRPwVkLIvGXouaCLuaOrwAyMuuSgXKeWgUt3WGJIgax7va9rArGLDKxbuLZ7DtulE9DGdfFH/7/3t7sH67sa0L7FgMO9m7nvoF4McHmxUMDJ4rzQK736i7IoDLuy2w641nxVwVvLa8ObR75eC7YOPLsj4MI7bA8DvG+Vijxxh4NsZ796m7/KILzEu8XxIGu0Fk3vB15FZsEAd8AsELluvAuAW7DWi70VoL378GubZF9YWMJ9hsGhWwEbfAxj+66umwHsCxDKpoYGRsKLIIuVWiAtsYvD5Won7LpOnAxs3LJ7rA+VV8YZaMmK4MmbDCtGeldqamI+rMM8fAx/nL0tWxBdxhhgdoJ1rAjOCBTTEaaqinkzhsRpG73Tywzpu77t+8ivSxBpph1sVgg2GL6Ikq/vgajHbP+L74XF5nvKwnC4/au/ffzE/2BnSkgIQSh2iUCMcJSq2syN2bk9aIy//rsMC3y65AwASxwQ2iYRVnZkkECMadJsbBLLEQatKoXHetwMpou55wsmjmYIV1iArQwUD6Aq4xoX+Fp04Mw46QzQn7vIjawMtCsIL2wrE5CFCi1mVtw20oy9KbzCzFDKxWsz7axqrDzTXPMBLSvIzZDLgUw1UFbF7dU3ytyyLnsMH9DFLK2+knzLQhOG/mOluSc04qzFACDNZSsMUa2+O224+0w3NExfhZZ9HFgy+by3Zy0IJR0MY60AKTAC6rw9rSdpF6eFuQLRCcwIAb0Lz3zXeR1Mtif/YNv4CUbcDIqswVatDPyL1yYWfCcaCo3Nwq1704d9DP2Muf9sOlFMxKJF2qCQ2WI9sjn8u9Aw0Wtb0XwVxlJ2RP0h0uKrEE3NzINtDPwL268Fx5shx4UgAQxQQogMEF3t2wpsuf78Y4SMmOM0E1VWz6dNEG+txs7g2h4cZ5W8gRfEFWK81fwA2KHNxbWr3HH20pcq3baN2fvw2KIb2Ws8vHZd3j/W0zjBADKIqsfdDqHM2dJg1ESNc0ldwbfCaabt3vFQy6w9Dc9c1ZuH1TJFHNTN2O6Q20rs4G17zrSX1reyKHFc4Z6A2pqQ3PaNsswN2gL409YUTpH3beVw3XEt/9buCreGoN3ozXupTH7dvdgK/g3kvQxgDQAtzNI5vn69/GWGsOP1rMn12qKujFfV0McnDdnP4NS+e+K8V81rBmZJLmmL4MpEGhQMDaPVIM0KoMKdrQwtu+YvyM5A2BHW3N7Y6CDSQc9mDg0+XLK7bQwr/dUaG9Z3ONCo9CTSfWf1TIxocagskaj6mtPPu8zSu8vNoNOFO9ePeNEdJ2gEzQh1rkpnaszU7ZnAYOKEMOTKIOCI0OdlyL1rlQiaLswXQh3MWuZSPgwyHtCYXrpUPcnw+L5M6OrbqI5PPiMh/cnBEOSPwOpmu+Ezjo4ALCizTRTwa8e3AN+MLN/ZneINbP+SEJxbhhDt4V1+tPDfo1wNOK7lwgjCzBW/twXu1t4KDP7F1mDOR26SMdxd4b5cIhzvqIDhzYzu3A7EaSnEM5fvCV7dq2Dq9d7B9w6UFbdzh2Dwa0gKuW4Nf97SeklHZSwX2NbfjoDpym4Nlh6cFddlBm5X3KXVojBZ0ry3KK3t0KDq47l88Ttv9QbyjdCygezmz/Dgvj6eNgIVzEai427GlEDpJO/szM6aHM9YEQdx6mZv5D4JqB4NDK7uofn04vctIt4Jk7XrztzEal6gbsbi8NfXt40JTV/qG07vQJoLJF4Jn93tce8Lc48IJZ3udy8MeX8IQ67xfR8Mf28ILdv/9oMv99fwx0qf+MXw90CPAlfv+MSA2uZ81mJP+YTPzwO/x4iv+Z2QYyRx7HnOxKf78KD/CmWRHM4qy4raC72t9am/CtlRzBDyzclI2J0/+8fQzY2O+7OJC3zP+8mAFXhuG6yaClHtxbJP/LWQ0Htq67OsCnVd1s7PDB6tIiAd5dNvCtVP2defoQtP1uAf/uqQh5Pt8+YvDuBW9wS//g7KCYBL0c0P/9/gXpNv/5DICYcPCACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnAKcCqKjCp6mp6ipqqusra6vsK2gmxukChuxubq7vL2+v8DAs5ofFaMVH8HKy8zN/87P0J+mJNHV1tfY2dqow9ve3+Dh4uON3eTn6Onq67Hm7O/w8fLzhe709/j5+tD2+/7/AAOe6iewoMGDCA0RTMiwocN5Cx9KnEjRW8SKGDNqFLaxo8ePuy6CHEmyZCSRJlOqXIlypcuXHVvCnEnTocyaOHMCvKmzp095PH8KHUouKNGjSLEZTcq06bKlTqNKzQV1qtWr3LBq3cqrKtevYB15DUu2LCEBaNOqXcu2rdu3cOPKnUu3rt27ePPq3cu3r9+/gAO7HRDTrOHDk8YiXnxVMePHTh1DnnxUMuXLPi1j3lxTM+fPLj2DHl1SNOnTHk2jXo1RNevXD13Dno1QNv/t2wFt497tCYEDBM508x6eyQJaCg+YCSfOvFICBAsYKG9OfdkFBM8TBK/O3RcDtAgMTNjevXwuCQYkQDdA3rx7VgkEhEcwgX2z5e/LS6i/oMH4+/kFmAoGaTVwQXsCJsiJBdEdiKCCEFqyAAUAPGAABg9GqGEkDUgHgAP2TbfhiJDEBxwAC4T4FCrfoaUeibsZcCEG/mXoyXcUwngbgWgZaKMmCFCQloo6wvZAg6Y4kJaHFqLlgFioNCCABQ8IQGSRqyXAwAJcesiJAwcaMCUAEjSgpQALlMMiWmJeieVpQg6JipgIVMmenWq+idMNA/Tp55+A+nkDOPEZgMChFpz/IqQEACAgwJN4MoKfVXwGaimggzJT6aWcZhrNAC8QIOqopJZKwAuEgWNAmqg8IIEADSSHZ6SLtJVqJJtyGqinmuraqTagmiosqag2E+ywwxZbzQAEBODss9BGGwABt3ozgQRcRtdJlVYmJ0iZZ7JaqybHIluqssaGaq6p6F7DrLTwQkutsc3GG++8y9Zrb7T4fiOmnJxwmxak/z6ZJybv7stvtcskrLC8DOf78ML0TgyxNQ5P3K83FhyKqCIy6qJYxg9v3LC+FpssscXOqvwLySVHXDHLLmdzXXYgu8nKyCjH/AzMCtf8c88+MwP0vkIrc/S9MmPTYnj/DZLA1FOH/0wVuUQj3fTLWWsNbNf2Jr3L0kxjDDa8YkeDnnopErIAWzqvwjPL027tC9lo2z0zzXrrgre0aXNNd+DOmGhofW7DLTLWg/c99tl5f0133Xun7PjdkFMMzn6r1kgI1VSHxDjfQ09OeDB/a36y6Zf3kvqzpzfDI6wOCuLx7YlencnrLbceC++9S9545Rr7/vjw4FyLpNRtxa3K3KQ7Azzl2UwfuyvWG+935heDAyIiXErgQPhRwwK95aUjj032xBf9Kfewa68MAw1k66UgJgoy4eK7wx+89P773/oCSL3VqQ8awLveMv7FJkM0wFAYsFo7Roc+ALJOeNEzYAYRGEAFKv+jYx7LHSFahBYM6Q5hHZRfK9hXPQJ6cBUsfN8BvXEz7ByCQQsQ4QT7N0OluVCFx+uh4IRotBSG42ni+ZEkEghEGP4QgxXUYBQ5SMRrrG09hJiAt3xxvuKlb4Nmu2ARxShDMGbDcPQJUXwEQIH78Q+FVcQcGd31xDHGEXVG3Bx/PCeICzDgVQ1wgA7NR0EvWvCOdjTjEBWZSEN+Y3Y+MoRvpGQABmiHkDxk5CKnGEZE5iKGVNRkNBZwIAYxoHaH0BKddghHUbqujgOcIx5leUhOXsNw4mqEBVApi0K6r5GOpCMtNxnMLxYTGw0oE3pkVD4A4AwADHCjK7r4Sykes4z/rtzeMIEZtCbygn5rUdEDpNQhAEgQk6205Sw96cNtvtKd7cwmNCZgyakVQkgGkBIDzvkI4xjMnGrJZSKo2U1jXjOU8vwdLBF60GqQMmfOnIAA0COJgg1ilY8gqNdqqU6GNpQXoDRoQbeBS0RQIERtmkSV/slAClxyXJnsKDGrubKEwiKkHKXpNZKZTBklcRAR9FYCKCqJlRpCos1EhEbthQMgHOCpUI2qVKH6gxUutJM2fQVO27fRbYBTLc6rhFEL4ah/KsJWk5ieDQrA1ra69a1stcEBrApPrnY1nlkNokytQc/QpfKlKn0U/ihwIIlK8xBLtVcBIlGAubJiqx7V/6kc2fnOvAaDlFuyXyEeECfkTIKBAkhOnARwWMT68mGLhURj6UpZYEC2spb9ZB61YTiwEuICUioQL6d5WoWl9hGrfexVa7pXvRbXtbPVBnZA+LFBOKABGJgajcz6isTG67eOCK4T68rNkVpTst+9azZuF0JCrMptYc1KTC2G3UZoVxWvzSl4QTpcu5aNpM0zr1m/d8JLTK+9jHhvKuJr3/uGV7zyRfA1wje+BexnhFbikphKK7fe7qu9bxvPd9woYFQQuLsKnmxsFdraZeQPRTkahETTklTerndi7U1AAxpAJhoXosOn+PCBw+bNHNcXxAb2xgMREMErQWcBJ3qjf/8JCGAlSVSgAMCxKXSM1+PKlrszDfE1SCgAE4oonew1hHHQssVBSNkTVF7niOH74x1HLhw4HKQyrAsvAAOUuoI4cyfSjFwsk7jE2lyzRugsLTsrQs+c4HOWtUxfP8P2oyohdLQMnQhEb0LRIrbynwWNveTGg58uBjOMGevY7QL60ZAONKdZq+lxgLqXL0YtqVnd6j6f2tSrFu6tf/HMaBYCdAl49c4srNhZ63rXqq51px3d6FznYpywks453xZOJVviv8bGtbIzneorI3vZzo4FPvU5bcX199pMzjabmb1oHhf4zdjsdjNClgCJElVqwBZdrH2r7gETsKlTDbhUq2r/XHnftM1Vni80TnpRK0nypMy0diWwrdpSr3tya4Wrxtsq12aHO9EIV7PBlxFU/N17ELlt4Lknnu6K0zrMLi+4wpM9cpkz2hr2RIR//LpySlAcuBb39+QCQGlEWFro3/Yxu2nu3W1w9jhlHgQDKFDenqe15UB/+ahjzvSmi7zmXXc3DVNOu6PaVhL+HESTBHuwJU+u6Ic4+r75zXVvf/zSIbf1toHx3OgmYLq/jnCXKuqkQYDrO1A27dyLXXek0w3uhpC70pM+5by3G97aOO8g2nbPFkNirLNyuKSIfd1+e5iARDe9Vi2/6b23fubOMMB+r/Rcn3p+EWMta4VED1NR/8u68acfOuRvHPSDL/3Yd5+8670j+AkbArTpPQToHU6rs7JFfj/PbvGVz7LhE0LylT++tsFud/IDY8Vo8TzoKDHWGoer7eh+u+rDL3/gr178F08+/Zf/iyMnuROgJSsWBX8sV39Zh3zdN39a53V6x3/g5oCtQXp1poB7hnreZ2bb94AQuH8bOH4MCBOSBi0XmGcZiGYWSIEe+IHcBnsreHMpEYLPMoJRVoIVKHwomH8dWIOUl4Ji9w27BSCLV3r2x4Ewd4Bhx1ROJXACR3A4aH7Gp3+uICOnxA8SWGg3WIVWOIQLqDAZt3Fw1XE82IOR5YLzNDD/N2dYKIJXGIRCaP+E5VeE7kWDeId/9weFrnABEcR7K8KGWeiGjpeAWoiAcBhgcpiG8YNVTvgLFnAthQeEvkd3fhh8Bqh9HgeIlBiGQSZSZPgMYrIfchYMMOgsMgh+8TeJcViJg7gIpOhzrIdqKrhlXvYMoZh6gQhyNliLTbh1l5iLr5hwvYhzZ/hlbvd4a/iIkLiLb6iLp4iJmKeJYugNjgJYwliKloiMf5iKqliI16iMhCiILOiKm/gM0UiFfDhpxTiMxIiL2/h71sh9iaiB3+gM4yiLhiiK50iN1biMR8h47UiEDwNwSriEr/eL1XABE5BzjoiO2Hho2liO5qiOkpiO/WiCQ9eFXvj/VmBYhzmYC1+lh2jokDF4jwVoit1oc8dYkrx4kigJjwQJDRLwKvmEZxwBkvYIkcZ4YSJpiyTJkN7IjhO5js94RqQlAPUmk78wi6PYkDfJjz/ZkyrJk8w4gTY5h3a4CrjEX9M4kvm4kkCJk1NJkTtZaUqJjwsplgMZjvM2PumnRJGQffqYkl4ZiRq5lVAJl0z5lluYid/ga2wJCW7JlRFJl3WZjD4JmP5YmIZpl9ICkAE5cKlRj7Qol4f5lIN5lpRpdGOplYJplk/IMhZ5kXGVmesAWomnEJCZlHl5l4mZmm2Il+7IjasZmLBZmfuAUVBCk5HZlDopkbqpmFLZm7iZ/5uuGZUPCZyflhYuRYCsGJacSZzFaZyviZi0OZlxCZ1UuZlxJ5rvgFTKeXXMiZms+ZvWCZa8GZvXiZ3ZaZmqOZ3+oHuScn3eWZ7meZ5lCZ4mWZ3zGZyo2Zn1GXnaiQ4JQFgAYFjduURYN56a2Z/+iYqz2ZxduZ7s+aDimZ/xMFoUVg+nmZPxKZ/ZyKDS6aCy2aAg6pQQap8bgZQaaqC3KJnh2YfDSZ7ouaD8KaLpWRi4uZ/OqYZfqYMcOqLUWaImypKXWaMnmqE7upzfSaSEOaQy6psu+qIS+qQdaqNLOaEUWqVWOqX72JpXSpY0qqQtqqMIWhAoeqQbGqPE56FMmv+mORqSZuqla/p9/5kbRsqiPIqmcqqm+KmlUSqlfBqmbjqmAlGmdrqbeIqBegqkTdqnzwmlIRqniEqlCvmli8qoYiqokCmcfxqdkBqpc0mpeSqpcLqnm8qppBqhJKqobOqkjdqldeqosfGqsEqfoBqqW5qlPgqjCrqqQnqqQZoRhIqpbXmCb6qfxfoI06OppcqqgTqrDRGszmqsxzqptUqCqcqlrnqj07oP0JqtSNqjuQqozeqtKpqklXqtfhquEtGty6qr1Wqt96mqtmqp40quoyqvnjposmqvw7qiwoql6fqrpoqv+Squyqqusaqt29oIyYqjS+qrYDqw2Nqujwr/sedaEeyKqoa6q/OqngQ7g+gasALbpgc7shSRsQhLqx+asvRak//qCA2bogm6shGLsftKsRv7riAbrxPLsgDbqjj7o7hqshOBskR7pxxbsDP6rqt4pkkLr59Ksxd7sjersSrbqVD7sB/btOUKrkcrsSI7tUVbtT77s5carWAbtrxasRYrtmzbs19rE2Qbt5nqsB4LtzXrrlLrtml7tkH7rHObt3qLtTt7q2rbsX3rt3+LtHuLuDarsIV6tW27tkvbuEortENLt4yLtVxLp5D7sjBLrJHbsiUruDlruZfLrC6LtrURuHwruR9buFqLt68rraO7uZObumP7uax7r7Hb/7m227vfeqhZa7AjCLz/MDLqsi6jggOfCZoFkJHwtbzMKyrOC70YOae7Q73Ve73YG5qPxb3M673fG73a63Piay7ki73SmxFKIBh2kb7M+wLwKxjyuy70W7/6mxb3iyz5u7980b/+C8CBIcDC8r9o0WN6ssAM3MAO/MAQHMESPMEUXMEWfMEYnMEavMEc3MH5IDCwEouKoCTBGA1CEnXpoCRocaHWMDuelQ5jVsJkEXo2xggkjA2OQmbwACYA9YnYMAEYQiApRg4XUCbywRh4YhzskQAq/CI00iMkFH3BoCQoPJpHPA4EUpr+4gA3vBggbADaQcIXMFHxEUkfcsXYQP/F8rAo48AtZjwODNfFiGEnVeIjZEeU6PckcnwNavwOrgIrVewNVcIo5ADC4OHFDvcd7KEkIuxMUnIBjKwNfbwO3GIAgZwNVAcAxkHIKYzGhxEpYnKQKgzIBSId0CbFvpDDjagOhmyU14B+L9zJMuzBtFzLtnzLuJzLurzLvNzLvvzLwBzMX1HGhNB+j7DHwkwcBIojADDGnJwIxKx2bAcJyJzMvCHEACAkNEYgt8c8Nbx7rpwI1WzNu5FMADBj8iFRGLJ2hFXGQkLMQsIARvXEbJdyBrNiUjLL5DwbQkIg33EtNgYuSrxGaFHGBLpSeIJ4hPAqFvAdeuzJ+7wb3/GTyEZMIXiyRtFM0D6yUgrtKOxBbeDxNtIxzhE9G2PGKCvmIQJtJRkNKx4NzgmNJsxMwgotJPpc0qzxKtIxZrnDzhfQ0jSGVPOcW+MRbLCyStpsmzi91Ezd1E791FAd1VI91VRd1VZ91Vid1Vq91Vzd1V791WAd1mI91mRd1mZ91mid1mq91mzd1m791nAd13L9y4EAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With exercise and an increase in work load, there is an increase in oxygen (O2) uptake (upper panel), heart rate (HR) (middle panel), and a-v O2 difference (lower panel). Exercise training produced an increase in the maximal oxygen uptake (VO2 max) that can be achieved (upper panel) and a decrease in maximal HR occurring at any given work load (dashed blue line, middle panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Mitchell JH, Blomqvist, G. Maximal oxygen uptake. N Engl J Med 1971; 284:1018.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_8_41102=[""].join("\n");
var outline_f40_8_41102=null;
var title_f40_8_41103="Insertion Mirena IUD3";
var content_f40_8_41103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Insertion Mirena IUD3",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    While holding the inserter steady, the slider is moved partway back along the handle until it reaches an indicator mark, thereby releasing the arms of the IUD from the insertion tube.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Berlex. Copyright &copy; Berlex.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_8_41103=[""].join("\n");
var outline_f40_8_41103=null;
